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Chapter 1
Aetiology and sequelae
Hepatitis B (HBV) and hepatitis C virus (HCV) infections mostly affect the liver and result in 
a broad spectrum of health outcomes. In rare cases, acute infection can cause liver failure 
leading to liver transplant and/or death.(1, 2) Infections can spontaneously resolve and 
lead to immunity after an acute illness with mild symptoms lasting around six months. 
Infections can also fail to resolve and progress to chronicity. Long term complications of 
chronic hepatitis B (CHB) or chronic hepatitis C (CHC) infection include extra-hepatic and 
hepatic manifestations, specifically the risk of disease progression to liver fibrosis, cirrhosis, 
liver failure and hepatocellular carcinoma (HCC). These complications develop slowly over 
a period of decades after initial infection.(3) As disease progression is mostly asymptomatic, 
people infected may be unaware of their infection.(4) Latent disease is an important 
reservoir of infection as people with chronic viral hepatitis are infectious to others. Chronic 
infection is also deadly: the Global Burden of Disease study estimated the number of deaths 
(in 2010) attributed to be 786,000 for hepatitis B and 499,000 for hepatitis C.(5, 6)
Virological markers
Chronic hepatitis B is suspected in the persistent detection of hepatitis B surface antigen 
(HBsAg) in serum samples over a period of six months, with active chronic infection further 
confirmed by the presence and level of hepatitis B DNA and unfavourable liver function 
tests.(7, 8) The presence of hepatitis B e-antigen (HBeAg) correlates with a high viral load 
and was used as a proxy to confirm chronic infection before the advent of reliable viral load 
testing.(2, 9) Chronic hepatitis C is suspected in the presence of anti-HCV in serum over a 
period of six months and further confirmed by the presence of HCV RNA.(8)
Natural history
Whilst HBV and HCV share similarities in aetiology and sequelae, there are important 
differences in the viruses themselves and in our understanding. Firstly, unlike HCV, HBV is 
vaccine preventable.(10) A second key difference relates to the risk of developing a chronic 
infection following viral exposure. The risk of failure to clear an acute HBV infection depends 
on a number of, and interaction between, virological and environmental factors, but 
most significantly the state of the host’s immune system.(11) Infants and children, whose 
immune systems are immature, are at the highest risk of developing a chronic infection 
with perinatal exposure carrying the highest risk (>90%).(12) Outcomes following exposure 
to HBV as an adult are more favourable with around 5-10% of people infected with HBV 
developing a chronic infection.(13) Virus-host immune interaction influences viral clearance 
and progression to chronicity with immuno-compromised people, for instance people living 
with systemic infectious diseases like human immunodeficiency virus (HIV) or tuberculosis 
(TB), at highest risk of developing chronic infection following exposure as adults. Outcomes 
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following exposure to HCV are less favourable with research indicating that between 55-
85% of people infected progress to chronic hepatitis C infection.(14) Factors influencing 
progression to chronic infection with HCV are not well understood, although research 
indicates a complex interaction of virus-host factors.(1)
Transmission
Both viruses are remarkably successful blood-borne infectious pathogens, and much 
more infectious than HIV. Both are transmitted parenterally through exposure to infected 
blood and, in the case of HBV, to other bodily fluids.(2) There are other differences in both 
transmission routes and individual/population risk factors when comparing HBV and HCV 
epidemiology.
For HBV infection, drivers of infection also differ in low and in high prevalence areas. In HBV 
endemic areas, most transmission is perinatal from mother to child (MTCT) and horizontal 
among infants and children in households.(9) MTCT is responsible for up to one third of all 
cases of CHB worldwide.(9) As infants and children are more likely to develop a chronic HBV 
infection, interrupting transmission via these routes through antenatal screening, maternal 
antiviral treatment (to reduce viral load) and birth dose vaccination is crucial to control the 
spread of disease.(9, 15) In low prevalence areas, most transmission is via risk behaviour 
including unprotected sexual contact and injecting drugs using unsterile/shared injecting 
equipment with HBsAg carriers.(16, 17) In these instances, risk group vaccination and harm 
reduction interventions are key primary prevention measures.(18) Prior to the introduction 
of stringent hospital and health care infection control measures, including blood/blood 
product screening, both HBV and HCV were also acquired via unscreened blood transfusions 
and contaminated percutaneous medical equipment.(19)
Some of these transmission routes also apply to HCV, notably past/current injecting drug 
use (IDU), blood transfusion prior to the introduction of blood safety screening (in the early 
1990s in most high income countries) and undergoing percutaneous medical procedures 
in health care services without adequate infection control measures.(20) In many resource-
poor countries, transmission via the use of unsafe medical tools remains a key driver of 
incident infections.(20) There is an ongoing epidemiological debate about the efficacy of 
sexual contact as a means to transmit HCV. Whilst sexually acquired HCV is described to be 
uncommon, an increased incidence of chronic HCV infection among HIV positive men who 
have sex with men (MSM) has been described over the last two decades, largely coinciding 
with the use of anti-retroviral medication for HIV in the 1990s.(21) High risk sexual activity 
has been attributed as the main risk factor in most of these non-IDU, HIV positive MSM.(22) 
Primary prevention measures for controlling the spread of HCV are therefore somewhat 
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similar for HBV, and notably include health care infection control policies and procedures, 
the continuation of stringent blood/blood product safety screening and harm reduction 
measures among people who inject drugs (PWID).(18)
Global epidemiology
Along with serious sequelae for individuals, chronic viral hepatitis is also a serious public 
health challenge in scale. Global HBsAg prevalence was recently estimated to be 3.6% (95% 
CI 3.6 – 3.6), corresponding to around 250 million people with a chronic HBV infection.
(17) Global viraemic HCV prevalence was estimated at 1.0% in 2015, corresponding to 71.1 
million people living with CHC.(23) Together, HBV/HCV caused (in 2013) an estimated 1.4 
million deaths (~687,000 deaths due to HBV and ~704,000 due to HCV) and were ranked (in 
2013) as the 7th leading cause of death globally.(24) The global statistics describe the scale 
of disease burden and can motivate resource deployment but they also blur the inequitable 
distribution of infection and ill-health worldwide. There are wide differences from Global 
Burden of Disease (GBD) region to region and from country to country in prevalence of 
chronic infection, disease burden and estimated contribution of CHB/CHC to national/
regional mortality.(24, 25)
Almost all Sub-Saharan African countries are reported to be intermediate-high endemicity 
(HBsAg prevalence >5% to 7.99%) or highly endemic (HBsAg prevalence ≥8.0%) for CHB 
infection.(17) Most countries in East Asia, South East Asia, Oceania and Central Asia are also 
intermediate to high endemicity. Countries in North and Latin America are generally of 
low (<2%) HBsAg prevalence as are most European countries although endemicity levels 
increase in Europe in an easterly and southerly direction.(16) GBD Regions with the highest 
anti-HCV/viraemic prevalence are Central and South Asia, much of Sub-Saharan Africa, and 
Eastern and Central Europe.(23, 26, 27)
Prevalence of both HBsAg and anti-HCV has decreased over time in most countries although 
the persistently high prevalence in some HBV endemic countries highlights the need for 
investment in and systematisation of primary prevention especially to prevent MTCT.(17, 28, 
29) There is also a strong birth cohort effect reported in HBsAg/anti-HCV epidemiological 
data for most countries/regions, with the generation born between 1945 and 1965 most 
affected by CHC infection.(24, 26, 28) Many countries now face a dichotomy: a declining 
incidence of new infections due to the success of primary prevention alongside a projected 
increase in chronic viral hepatitis-related mortality due to ageing and disease progression 
in the most affected birth cohort.(16, 24, 28, 30)
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Treatment
Effective antiviral therapy options exist for both CHB and CHC to control and prevent 
disease progression, and therefore reduce associated morbidity and mortality, in individuals. 
A number of well-tolerated, effective antivirals are available for the treatment of CHB.
(7) The goal of CHB therapy is to suppress viral replication (the main indication for major 
disease-related complications), induce biochemical remission and prevent liver damage, 
notably progression to cirrhosis and HCC.(31) However, CHB can only be controlled and not 
completely cured in individuals.(7)
The goal of CHC treatment is to cure infection, characterised by a sustained virological 
response (SVR) and undetectable HCV RNA 24 weeks after treatment completion.(20) In 
the five year course of the research described in these thesis, the field of CHC treatment 
was completely transformed. Up until 2011, the only treatment regimen available in 
Europe for CHC infection was peglyated interferon (PegIFN) together with ribavirin, a drug 
combination with variable efficacy in achieving SVR across the six HCV genotypes (from 
40-50% in genotype 1 and 4, and up to 80% in genotypes 2, 3, 5 and 6) and associated with 
severe side effects.(32) In 2011, telaprevir and boceprevir were licenced by the European 
Medicines Agency (EMA) for use in Europe in treating HCV genotype 1. These direct-
acting antivirals (DAAs) are protease inhibitors to be used in combination with PegIFN/
ribavirin. These triple therapy regimens (DAA plus PegIFN/ribavirin) reported relative 
efficacy in achieving SVR (29-88%) in treatment-naïve and treatment-experienced patients, 
including previous null responders to dual PegIFN/ribavirin therapy.(20) The second wave 
of DAAs (daclatasvir, ledipasvir, simeprevir and sofosbuvir) were approved by the EMA for 
use (in combination with each other and/or with ribavirin) in Europe in 2014 with a third 
generation of combination DAAs (ombitasvir/paritaprevir/ritonavir, dasabuvir, sofosbuvir/
velpatasvir and grazoprevir/elbasvir) approved in 2015-16.(8) These interferon-free oral 
treatment regimens are of short (8, 12 or 24 week) duration and have reported SVR in more 
than 95% of patients including treatment-naïve, treatment-experienced, cirrhotic and HIV/
HCV co-infected patients.(33) Unlike the previous treatment options, these third generation 
DAAs are effective across all six HCV genotypes. Further pharmacological innovations were 
submitted for EMA approval in 2017. Whilst the new DAAs have demonstrable efficacy 
in curing CHC, they also incur a high (projected) cost of between ~€30,000 to more than 
€100,000 per cure.(34)
Screening
The potential public health benefits of effective treatment can only be realised by finding 
(screening), retaining in care and treating people with a chronic hepatitis B/C infection.(35) 
As chronic infections are mostly asymptomatic, it is unlikely that people with CHB/CHC 
14
Chapter 1
will present to health care services with disease-related complaints unless they are in the 
advanced stages of fibrosis, cirrhosis or liver cancer.(3, 36, 37) Studies estimate that 65-90% 
of people chronically infected with HBV/HCV are unaware of their infection.(4, 38) As the 
goal of antiviral treatment is to prevent, halt or cure (in the case of CHC) serious disease 
as well as to prevent onward transmission (by reducing viral load), early detection before 
progression to cirrhosis and liver decompensation will deliver the most health benefits both 
for individuals and in terms of population health. Early detection (secondary prevention) 
through screening, retention in care and treatment also has the potential to deliver macro-
economic productivity gains by preventing premature morbidity and mortality in a working 
age population. Direct economic costs and productivity are reported to increase with 
disease progression, further strengthening the rationale for early detection and treatment.
(39)
The ethics, public health considerations and clinical characteristics of screening were 
seminally set out by Wilson and Jungner in 1968: “The central idea of early disease detection 
and treatment is essentially simple. However, the path to its successful achievement (on 
the one hand, bringing to treatment those with previously undetected disease, and, on the 
other, avoiding harm to those persons not in need of treatment) is far from simple though 
sometimes it may appear deceptively easy.”(40) In support of balancing the benefits and 
harms at a population level, Wilson and Jungner proposed ten criteria to guide the decision 
making process about whether to organise population-based screening for a disease (Box 1).
These classic criteria have influenced others to develop their own, with more than 50 
different sets identified by Andermann et al in a systematic review from 2008.(41) Much of 
the proliferation was driven by expanded scientific possibility through genetic sequencing 
and profiling. Equally important motivations were broader trends in Western medicine 
and the value systems that underpin these societies specifically increased consumerism 
(valuing freedom of choice), a shift away from paternalism towards informed choice and 
individualistic decision making, the development of clinical epidemiology as a field of 
science, and a focus on evidence-based health care from the joint perspectives of clinical 
efficacy, cost-effectiveness and equity.(41, 42)
Interestingly, the ‘classic’ criteria also emerged during an epidemiological transition in 
many industrial nations away from communicable disease as the most important causes 
of ill-health and death; the Wilson and Jungner criteria were indeed envisaged largely 
with non-communicable disease screening in mind with limited focus on communicable 
disease in low- and middle-income countries. These criteria also emerged just after the 
discovery of HBV (in 1965), more than two decades prior to the discovery of HCV (in 1989) 
and decades before antiviral treatment and the possibility of HBV/HCV screening became 
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available. Wilson and Jungner perhaps did not foresee the emergence in high income 
industrial nations of chronic communicable disease that could be candidates for screening: 
“measures taken to control endemic communicable disease….are now to a large extent no 
longer needed in well-developed areas.” (p.15(40)) This perhaps explains the lack of explicit 
mention of prevention of onward transmission and the ability of screening to protect public 
health as a utility consideration in the criteria.
Box 1. Wilson and Jungner classic screening criteria
1. The condition sought should be an important health problem.
2. There should be an accepted treatment for patients with recognized disease.
3. Facilities for diagnosis and treatment should be available.
4. There should be a recognizable latent or early symptomatic stage.
5. There should be a suitable test or examination.
6. The test should be acceptable to the population.
7. The natural history of the condition, including development from latent to 
declared disease, should be adequately understood.
8. There should be an agreed policy on whom to treat as patients.
9. The cost of case-finding (including diagnosis and treatment of patients 
diagnosed) should be economically balanced in relation to possible expenditure 
on medical care as a whole.
10. Case-finding should be a continuing process and not a “once and for all” project.
Key populations
Both as a consequence of the evolving treatment landscape as well as the epidemiological 
characteristics, there is significant scientific and policy interest in how to design, plan and 
implement HBV/HCV screening programmes that can effectively reach, diagnose and 
retain in care people at risk of being chronically infected with HBV/HCV. An important first 
consideration in screening design concerns the population to be targeted. It is crucial to 
understand the epidemiology of CHB/CHC to identify the population subgroups that are 
most affected. Transmission risk factors are fairly well understood and demographic and 
behavioural risk groups can be defined. Key behavioural risk groups include PWID, MSM, sex 
workers and people in prison, where the clustering of risk factors due to the criminalisation 
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of risk behaviour specifically IDU and sex work increase the prevalence.(43-46) Risk factors 
can also overlap in individuals placing some population subgroups at heightened risk of 
chronic infection.
Alongside behavioural risk groups, demographic risk groups exposed through origin in high 
endemic countries can also be defined as population subgroups in which the likelihood 
of being chronically infected is higher. Exposure risks in high endemic countries affect 
the general population, placing people born/living in these countries at risk of exposure. 
A similar logic also applies in low prevalence industrialised countries where specific birth 
cohorts exposed during a historically higher prevalence period, before primary prevention 
measures were introduced, are also more likely to be chronically infected as well as being 
broadly representative of the general population. Migrants from HBV endemic countries 
may have been exposed to HBV perinatally or parenterally as children (and therefore at high 
risk of CHB infection). Migrants from HCV endemic countries are at risk of CHC infection 
due to nosocomial/iatrogenic exposure where health care infection control practices are 
substandard.(47) In many low prevalence industrialised countries, migrants from high 
endemic countries are therefore disproportionately affected by chronic viral hepatitis 
and a key population for HBV/HCV screening and linkage to care. In the European Union/
European Economic Area (EU/EEA), migration within (from high to low prevalence Member 
States (MS)) and from outside (from higher prevalence countries to lower prevalence MS) is 
a key contributor to the burden of chronic viral hepatitis.(48-50) There is therefore interest at 
the EU level in how to reduce chronic viral hepatitis-related morbidity and mortality among 
migrants as part of the strategic policy pillars relating to cross border threats, improving the 
health of the European population and reducing inequalities in health.
The HEPscreen Project
As a result of this EU policy interest, the EU Health Programme funded the HEPscreen 
consortium project during 2011-2014 to research, evaluate and synthesize knowledge 
on screening for chronic viral hepatitis among migrants.(51) This wide-ranging project 
spanned 11 EU partners and six EU countries. The scientific work conducted as part of 
HEPscreen forms the core of this PhD thesis. Alongside the scientific output, an innovative 
online resource, the HEPscreen Toolkit, was also developed to summarise and synergise 
good practice knowledge, scientific evidence and ‘real-world’ experience about how to 
tackle the public health challenge of chronic viral hepatitis. The Toolkit was produced to 
assist national and local public health planners and intervention developers to develop 
good practice-based screening programmes/strategies focused on migrants from endemic 
countries. Box 2 describes the key features and more can be found at www.hepscreen.eu.
17
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Box 2: Key aspects of the HEPscreen Toolkit
• Videos and animations about the public health challenge of chronic viral 
hepatitis
• Epidemiological tools to assess the burden of chronic viral hepatitis among 
migrants
• ‘How-to’ guides, case studies and videos about the different ways of screening
• A repository of good practice screening projects
• A tool to create multi-lingual leaflets for people offered hepatitis B/C screening 
– with over 40 languages available
• Tools to support primary care to offer testing to their patients from endemic 
areas, including a pre-test discussion checklist
• Good practice recommendations for post-test counselling and linkage to 
specialist care.
Elimination in Europe
The successful implementation of primary prevention to halt transmission together with 
the potential of secondary prevention through screening, referral and effective antiviral 
treatment have opened up the possibility for chronic viral hepatitis to be eliminated within 
decades. The World Health Organisation (WHO) agreed in 2016 the ambitious goal of 
elimination of chronic hepatitis B and C as health threat by 2030. The journey to elimination 
is set out in a Global Sector Strategy, an Advocacy Brief and an Action Plan for the health 
system response for the WHO European Region.(19, 52, 53) The Strategy defines five 
strategic pillars of elimination:
1. Information for focused action (the “who” and the “where”)
2. Interventions for impact (the “what”)
3. Delivering for equality (“the how”)
4. Financing for sustainability (the financing) and
5. Innovation for acceleration (the future).
18
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AIMS AND OUTLINE OF THE THESIS
This thesis aims to contribute strategic information towards the elimination of chronic 
viral hepatitis in the EU/EEA. Many EU/EEA countries have successfully controlled the 
transmission of HBV/HCV and the incidence of new infections is declining.(54, 55) This 
declining incidence exists alongside a projected increase in mortality due to disease 
progression and ageing among the infected population.(30, 56) This presents a public 
health challenge to countries: how to identify and retain in care people with a chronic viral 
hepatitis infection. The research is focused around the first three strategic pillars of the WHO 
elimination strategy: the who and where; the what; and the how. There are two broad aims:
1. To understand the epidemiology of chronic viral hepatitis in the general 
population and among risk groups in the EU/EEA;
2. To understand the health system conditions and screening interventions that 
effectively reach, diagnose and retain at-risk migrants in health care for viral 
hepatitis.
 
Drawing on a range of methodological techniques from both epidemiology, public health 
and the social sciences, we strive to answer the following three research questions:
1. To what extent are migrants from endemic countries a risk group for chronic 
hepatitis B and C in Europe?
2. What can be learned from different migrant-focused models of HBV/HCV 
screening?
3. What are the key conditions to maximise the impact public health of HBV/HCV 
screening among migrants?
We examine in Part I the epidemiology of chronic viral hepatitis infection in the EU/EEA 
through a series of systematic reviews, meta-analyses and epidemiological studies 
commissioned by the European Centre for Disease Control (ECDC). In Chapter 2 we identify 
and synthesize prevalence estimates among subjects considered representative of the 
general population, pregnant women and first-time blood donors. Using a study quality 
assessment framework and an algorithmic approach to select EU/EEA Member State level 
estimates, we also estimate the prevalence and number of infections for both CHB and 
CHC at the EU/EEA level. Chapter 3 is focused on the prevalence in three key populations 
at higher risk of being chronically infected with HBV/HCV namely people who inject drugs 
(PWID), men who have sex with men (MSM) and people incarcerated in prison. Chapters 
4 and 5 are focused on people born in endemic countries that migrated to the EU/EEA. In 
these two parallel studies, we conducted an epidemiological analysis to estimate both the 
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absolute number of cases among and the relative contribution of migrants from endemic 
countries to the overall number of chronic HBV/HCV infections in each EU/EEA Member 
State and across the Union as a whole. We also seek, using systematic review techniques, to 
assess the validity and reliability of using recent country of birth prevalence estimates as a 
proxy for the prevalence among migrants.
The focus of Part II of the thesis is on screening and linkage to care for chronic viral hepatitis 
infection and includes scientific work conducted as part of the EU Health Programme-
funded HEPscreen Project.(51) Chapter 6 other describes the outcomes of six pilot studies of 
different models of screening for HBV/HCV among migrants in four European countries. This 
is the first study to compare different models of screening for both HBV and HCV that reports 
on implementation, cost outcomes, results across the cascade of care and on prevalence 
by country of birth. Chapters 7 - 12 apply systematic narrative review and DELPHI-method 
inspired semi-structured survey techniques to understand the health system conditions 
and patient pathways for screening, referral and treatment for chronic viral hepatitis in the 
six HEPscreen study countries: Germany, Hungary, Italy, the Netherlands, Spain and the 
United Kingdom (UK). We explore the availability and awareness of screening guidelines 
and training among health care professionals (Chapter 7). We examine in Chapter 8 the 
availability of language support services (translated materials and interpreters) for linguistic 
minority migrant CHB/CHC patients as well as health professionals’ perceptions about what 
role perceived language barriers play in three different scenarios: why screening is not 
offered to migrants with country of birth-related risk factors; why at-risk migrants do not 
take up the offer of screening; and why migrants diagnosed with CHB/CHC do not reach 
secondary care. Chapter 9 is focused on defining and synthesising the content and aims 
of pre-test information provided to people offered HBV/HCV screening. We use primary 
research and the wider literature to explore the concept of informed choice in HBV/HCV 
screening and attempt to frame a set of recommendations on how health professionals can 
provide pre-test information that balances the seemingly polar aims of increasing uptake 
and securing informed choice in screening. Chapter 10 examines the patient pathway 
following a CHB/CHC diagnosis to find out, using the perception of clinical professionals, 
what actually happens and in which health care services. Chapter 11 delves deeper into 
current patient pathways, by exploring the role of the General Practitioner (GP) in screening 
at-risk groups and in the clinical management of patients with evidence of a CHB/CHC 
infection.
Chapters 12 and 13 are about treatment restrictions in the six HEPscreen study countries, 
also using knowledge and perceptions gathered from practising clinicians involved in the 
care of CHB/CHC patients. We are interested in (Chapter 12) restrictions based on patient 
characteristics, such as asylum seeker patients, undocumented migrants, people without 
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health insurance and people with state insurance only, and on clinical characteristics such 
as the abuse of alcohol and injecting illicit drugs. We are also interested in restrictions in 
(Chapter 13) the actual availability in the six study countries of antiviral treatment options 
available at a European level.
We bring this all together into a General Discussion (Chapter 14) and adopt a public 
health perspective on the cascade of care to address each of the research questions in turn. 
First, findings from Chapters 1 - 5 (Part 1) are placed into a wider strategic and conceptual 
context to elucidate the extent to which migrants are a risk group for CHB/CHC infection. 
Next, the findings and experiences described in the study in Chapter 6, along with other 
studies of screening for HBV/HCV among migrants, are synthesised into an overview of 
good practices in how to design and deploy screening among migrants. The third research 
question on how to maximise the public health impact of HBV/HCV screening is addressed 
using findings gathered across all chapters and from wider literature. We synthesise findings 
into a series of Recommendations for national and European public health policy and 
practice and for scientific research.
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SUMMARY
This systematic review aimed at estimating chronic hepatitis B (HBV) and C virus (HCV) 
prevalence in the European Union (EU) and Economic Area (EEA) countries in the general 
population, blood donors and pregnant women. We searched PubMed©, Embase© 
and Cochrane Library databases for reports on HBV and HCV prevalence in the general 
population and pregnant women in EU/EEA countries published between 2005 and 2015. 
Council of Europe data were used for HBV and HCV blood donor prevalence. HBV general 
population estimates were available for 13 countries, ranging from 0·1% to 4·4%. HCV 
general population estimates were available for 13 countries, ranging from 0·1% to 5·9%. 
Based on general population and blood donor estimates, the overall HBV prevalence in the 
EU/EEA is estimated to be 0·9% (95% CI 0·7–1·2), corresponding to almost 4·7 million HBsAg-
positive cases; and the overall HCV prevalence to be 1·1% (95% CI 0·9–1·4), equalling 5·6 
million anti-HCV-positive cases. We found wide variation in HCV and HBV prevalence across 
EU/EEA countries for which estimates were available, as well as variability between groups 
often considered a proxy for the general population. Prevalence estimates are essential to 
inform policymaking and public health practice. Comparing to other regions globally, HBV 
and HCV prevalence in the EU/EEA is low.
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INTRODUCTION
Both hepatitis B (HBV) and C virus (HCV) affect the liver and can cause acute and chronic 
hepatitis. People with chronic HBV or HCV infection may transmit the virus to others and are 
at risk of developing serious liver disease such as cirrhosis or hepatocellular cancer (HCC) [1, 
2]. Transmission of HBV and HCV can occur via sexual or blood–blood contact, or vertically 
(mother-to-child) [3, 4]. In Europe, the high-risk groups for acquisition of HBV include men 
who have sex with men (MSM) and people who inject drugs (PWID). The key risk groups for 
HCV include PWID, people in prison and MSM. 
The risk of developing chronic HBV infection depends on the age at which people are 
infected, with 90% of infants infected at birth developing chronic infection, compared with 
1–10% of those infected at an older age or as adults [5, 6]. Globally 248 million people were 
estimated to be chronically infected with HBV in 2010 [7]. Approximately 780 000 people 
die each year from HBV infection, mostly from chronic HBV infection-related sequelae such 
as cirrhosis and HCC [8].
Initial infection with HCV is often asymptomatic or mild (70–90% of cases); however, the 
majority of those infected with the virus (70–80%) develop chronic infection and, over a 
period of 20–30 years, 10–20% on average will develop cirrhosis and 1–5% will develop liver 
cancer [2]. An estimated 184 million people globally have chronic HCV infection [9] and 350 
000–500 000 deaths are attributable each year to HCV-related liver diseases [8].
In 2011, the European Centre for Disease Prevention and Control (ECDC) started enhanced 
European Union (EU)-wide surveillance for HBV and HCV, based on annual data collection 
from EU and Economic Area (EEA) Member States (MS). In 2014, 22442 newly diagnosed 
HBV infection cases were reported from 30 MS, a rate of 4·2 cases/100 000 population [10]. 
In the same year, 35 321 newly diagnosed HCV infection cases were reported from 28 MS, 
a crude rate of 8·8 cases/100 000 population in the EU/EEA [11]. However, because HBV 
and HCV infections are typically asymptomatic until advanced liver disease develops [1, 2], 
notification data are known to be incomplete and reflect national screening and testing 
practices rather than the real number of infections. Supplementary information in the form 
of reliable and timely prevalence data is therefore important to describe the current burden 
of disease in the EU/EEA more accurately.
The recent development of more effective HBV and HCV treatment means that elimination 
of chronic viral hepatitis in Europe is now a possibility [12, 13]. However, 65–90% of infected 
people remain unaware of their infection and models predict that associated mortality will 
continue to increase as the current infected population ages [12, 14, 15]. Achieving potential 
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population health gains through treatment will require significant expansion of screening 
and treatment among the most affected populations. Robust strategic information will be 
of even more relevance in view of the recently approved WHO viral hepatitis global health 
sector strategy, the corresponding European regional action plan, and its monitoring needs 
[16, 17].
We updated a previous systematic review undertaken by ECDC in 2009 [18] with the aim to 
assess any changes and estimate the current prevalence of chronic HBV and HCV infection 
in EU/EEA countries in the general population, blood donors and pregnant women. As a 
secondary goal, we reviewed the availability, quality and geographical coverage of HBV and 
HCV prevalence data in the region in view of designing and monitoring future prevention 
and control initiatives.
METHODS
Search strategy and selection criteria
Original research articles were retrieved from PubMed®, Embase® and Cochrane Library 
databases in March 2015. The search strategies (Supplementary Fig. S1) combined controlled 
(MeSH/ Emtree terms) and natural vocabulary (keywords) to define disease-related (HBV/
HCV infection), outcome-related (prevalence) and geographic-related (EU/EEA) search 
parameters. The search was limited to records published from 1 January 2005 to 12 March 
2015. Articles in all EU/EEA languages were included. The results of the search were shared 
with ECDC National Focal Points (NFP) for viral hepatitis in all 31 EU/EEA MS in May 2015 for 
review and to validate the list of included references for their country.
Inclusion and exclusion criteria (Supplementary Table S2) encompassed time-related criteria 
including publishing date (2005 or later); sampling timeframe (data collection ending after 
2000 or beginning from 2000 onwards); geographical coverage (EU/EEA MS and/or any 
of their regions/districts) and disease specific markers (HBsAg/anti-HCV (and DNA/ RNA) 
prevalence). Only studies reporting original data were included, although reference lists 
of relevant reviews were consulted for any original articles not captured by the literature 
search. Articles reporting prevalence in the general population or pregnant women with 
a sample size of <100 participants were excluded. Articles reporting only self-reported 
HBsAg/anti-HCV prevalence were also excluded. 
To ensure consistent application of the inclusion criteria, two reviewers (SHIH and AMF) 
independently reviewed the title and abstract of the same random selection of retrieved 
articles (5%). The inclusion criteria were further refined and a second round of reviewing was 
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conducted to ensure consistent application (>95% agreement) of the criteria. Following 
this, title and abstract screening for all articles continued independently using Endnote. 
The full texts of all publications included after title/abstract screening were assessed for 
relevance by members of the research team where language comprehension existed 
(articles in English, Dutch, French, Italian and German) or by ECDC reviewers (other EU/EEA 
languages). In case of uncertainty about in- or exclusion, the two reviewers consulted each 
other and cases of disagreement were resolved by consultation with a third team member 
(IKV).
Definitions
Chronic HBV and HCV were defined as the presence of HBsAg and anti-HCV in serum, saliva 
or dry blood spot samples, respectively. The general population was defined as people (all 
ages or adults only) living in a defined geographical area; patients attending community/
primary health care settings; and workforce/specific professional groups (e.g. workplace 
screening) but not healthcare workers. Pregnant women were defined as those women 
undergoing antenatal care screening, and blood donors were defined as first-time blood 
donors (Supplementary Table S3).
Data extraction and quality assessment
Data extraction using a pre-defined set of variables (Supplementary Table S4) was performed 
simultaneously with full-text screening. The unit for data extraction was ‘study’, defined as a 
prevalence data report on HBsAg or anti-HCV for a defined population group, in a defined 
country, over a discrete period; one article may therefore include more than one study. 
Studies published in more than one article were extracted only once and the article with 
most details about the study used as the reference.
Each included study was evaluated for risk of selection bias using a framework developed 
ad hoc by the research team. Separate assessment frameworks were developed for the 
general population and pregnant women to account for differences in possible sources of 
selection bias. For general population studies, the domains age, gender, sampling method 
and response rate, and geographical coverage were considered as possible sources of 
selection bias (Supplementary Table S5). For pregnant women studies, potential selection 
bias sources included sampling method and geographical coverage (Supplementary Table 
S6). Points were awarded in each domain for representativeness or lower risk of bias, and a 
total score was calculated by summing the values in each domain. This resulted in a score 
between zero and six for the general population studies and between zero and three for the 
pregnant women studies. We refer to the total score as study quality score, since a higher 
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score indicates a lower risk of bias. A general population estimate was considered of high 
quality when it reached a study quality score 54. A high-quality estimate of prevalence in 
pregnant women was defined as a study quality score 52.
Data analysis
This review reports HBsAg and anti-HCV prevalence, rather than a viraemic marker of HCV 
chronic infection, since information on HCV RNA and HBV DNA prevalence was reported 
in too few studies to conduct an analysis. National weighted or standardized (e.g. for age 
and/or sex distribution) prevalence estimates, if available (Czech Republic and Belgium for 
HBV), were preferred over unweighted or crude estimates. Crude estimates for the general 
population with the highest quality (score 54) were pooled at country level, where available, 
by summing cases and sample size. Ninety-five per cent confidence intervals (95% CI) were 
then calculated using the Fisher’s exact method in Microsoft Excel©. General population 
estimates were reported separately for adults and children where available. All higher 
quality estimates of HBsAg and anti-HCV prevalence (score 54) retrieved for each country 
for the general population are presented in forest plots (Microsoft Excel©). Higher quality 
prevalence estimates from pregnant women studies (score 52) were also pooled where 
possible (using the methodology as described above) and separate forest plots prepared 
for HBV and HCV. Prevalence maps of Europe for pooled or single higher quality estimates 
were created using the ECDC Mapping and Multi-Layer Analysis (EMMA) tool [19].
Blood donor data
To assess the HBV and HCV prevalence among blood donors, data from 2014 collected 
by the Council of Europe were used [20]. The Council of Europe collects comprehensive 
national data on blood donors. For countries with no data in the 2014 Council of Europe 
report, the most recent data from previous Council of Europe reports were used. No risk of 
bias assessment was performed for data on blood donors, as no data were available other 
than the number of first-time blood donors and the number of infections. When data on 
number of cases were available, we calculated 95% CI using the Fisher’s exact method.
The burden of chronic hepatitis B and C in the EU/EEA
In order to estimate the current burden of chronic HBV and HCV in the EU/EEA, an algorithm 
combining general population and blood donor data was applied. If a pooled or single 
higher quality general population prevalence crude estimate was available for a country, 
this was used to determine the HBV and HCV prevalence in that country; if a higher quality 
estimate was not available, lower quality general population crude estimates were used 
(these were pooled when possible); if no general population estimates were available, 
35
Hepatitis B and C prevalence in the EU/EEA: the general population
2
prevalence data from blood donors were used. To determine the total number of chronic 
HBV and HCV cases in each country, total population size (based on Eurostat 2014 data) for 
each country was multiplied by the estimated HBV and HCV prevalence in each country.
RESULTS
The literature search retrieved 9379 citations. After title/abstract screening, 142 articles for 
the general population and 50 articles for pregnant women were included. Seventeen MS 
validated the search results and/or provided additional references, adding nine additional 
citations for the general population and five for pregnant women. While all 55 full texts were 
available for pregnant women, three general population articles could not be retrieved. 
Following full-text screening, 48 articles for the general population and 32 articles for 
pregnant women were finally included (Fig. 1).
General population
From the 48 articles included, 53 HBsAg prevalence estimates and 45 anti-HCV estimates 
were extracted. For HBV, multiple estimates were available for 13 of 15 countries covered, 
with the most estimates (10) available for Italy (Supplementary Table S7). For HCV, more than 
one estimate was available for nine countries of 16 countries covered, with most estimates 
(14) again available for Italy (Supplementary Table S8).
From the 53 prevalence HBsAg estimates, 18 estimates in 13 countries (Belgium, Croatia, 
Czech Republic, France, Germany, Greece, Hungary, Ireland, Italy, the Netherlands, Romania, 
Slovakia and Spain) were considered to be of higher quality (score 54, Supplementary Table 
S9). These data are presented in Figures 2 and 3. For Germany, Italy and Spain, multiple 
higher quality estimates were available and used to calculate a pooled estimate. The HBsAg 
prevalence in the general population ranged from 0·1% in Ireland [21] to 4·4% in Romania 
[22] (Fig. 3). Eleven of the 13 estimates were around or below 1%. Several higher quality 
prevalence estimates were available for Italy which, when pooled, resulted in an estimated 
HBV prevalence of 0·7%. There is, however, wide heterogeneity among these single study 
prevalence estimates from Italy, ranging from 0.5% (Apuglia, Southern Italy [23]) to 5.8% 
(Bergamo, Northern Italy [24]).
Of the 45 anti-HCV prevalence estimates, 19 higher quality (score 54, Supplementary 
Table S9) prevalence estimates from 13 countries (Belgium, Croatia, France, Germany, 
Greece, Hungary, Ireland, Italy, Latvia, the Netherlands, Romania, Slovakia and Spain) were 
available. These data are presented in Figures 2 and 4. Multiple higher quality estimates 
were available for a pooled estimate in Germany and Italy. The anti-HCV prevalence in the 
36
Chapter 2
general population ranged from 0·1% in Belgium [25], Ireland [21] and the Netherlands 
[26] to 5·9% in Italy (Fig. 4). Relatively high anti-HCV prevalence was also found in Romania 
(3·2%) [27], Greece (2·2%) [28], Latvia (2·4%) [29] and Slovakia (2·0%) [30]. The estimate for 
Greece, however, is based on a sample from the population of Crete [28]. Four estimates 
were available for Spain, of which only one was of higher quality and reported an anti-HCV 
prevalence of 1·1% [31]. The others ranged from 0·4% in Barcelona [32] and 0·6% in Murcia 
and Madrid [33] to 1·5% in multiple GP practices around Barcelona [32].
 
12,379 records retrieved prior to deduplication 
 
Medline (Pubmed): 4,541 
Embase (embase.com): 7,801 
Cochrane Library: 37 
 
9,379 records after deduplication 
Records included for full 
text screening for the 
general population 
(n = 142) 
Records included for full 
text screening for  
pregnant women  
(n = 50)  
Records excluded based 
on title and/or abstract  
(n = 9,237) 
Records excluded based 
on title and/or abstract  
(n = 9,329) 
Articles added in from 
other population groups / 
sources or Member State 
additions (n = 5) 
Articles added in from 
other population groups / 
sources or Member State 
additions (n = 9) 
Full‐text articles 
unavailable (n = 3)  
(as of 01.06.15)
Full‐text articles assessed 
for eligibility for the 
general population 
(n = 148)
Full‐text articles assessed 
for eligibility for  
pregnant women  
(n = 55)  
Full‐text articles excluded, 
with reasons (n = 100)
Full‐text articles excluded, 
with reasons (n = 23) 
Studies included in 
qualitative synthesis for 
the general population 
(n = 48)
Studies included in 
qualitative synthesis for 
pregnant women  
(n = 32)  
Figure 1. Flow chart of study selection for the general population and pregnant women; EU/EEA 
countries, 2005–2015.
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Pregnant women 
To estimate the prevalence in pregnant women, 27 HBsAg estimates from 11 countries 
(Supplementary Table S10) and 15 anti-HCV estimates from eight countries (Supplementary 
Table S11) were retrieved from 32 eligible studies. Multiple estimates were available for nine 
countries, with the highest number of estimates (six) retrieved for Greece. Pooled estimates 
were available for Denmark, Italy, the Netherlands and the United Kingdom. Higher quality 
estimates (score ≥2, Supplementary Table S12) of HBsAg prevalence were available for 
seven countries, ranging from 0·1% in Norway [34] and Spain [35] to 0·8% in France [36] and 
Italy (Fig. 3). For the Netherlands, HBsAg prevalence in pregnant women increased slightly 
from 0·3% in 2006 [37] and 2007 [37] to 0·4% in 2008 [37].
Of the 15 HCV estimates for pregnant women, higher quality estimates (score ≥2, 
Supplementary Table S12) were available for Slovenia, Spain, Italy and Norway, with 
prevalence ranging from 0·1% in Slovenia [38] to 0·9% in Norway [34] (Fig. 4). The estimate 
for Slovenia is pooled, calculated using data from 2003, 2009 and 2013, which indicates a 
slight decrease in anti-HCV prevalence from 0·2% in 2003 to 0·1% in 2009 and 2013 [38].
First-time blood donors
The prevalence of HBsAg and anti-HCV in first-time blood donors was available for 30 
countries (Table 1). For Latvia and Portugal, the absolute number of positive cases and first-
time blood donors were unavailable, thus no 95% CI could be calculated. The prevalence 
of chronic HBV infection among first-time blood donors ranged from 0·0% in Finland and 
Luxembourg to 3·2% in Bulgaria. Most countries (18/31, 58%) had an HBsAg prevalence 
that was around or below 0·1%. The prevalence of anti-HCV among first-time blood donors 
ranged from 0·0% in Iceland to 2·2% in Latvia, and 58% of countries had an HCV prevalence 
that was about or below 0·1%.
European HBV/HCV prevalence estimates
Using prevalence estimates for the general population and blood donors, the HBsAg 
prevalence in the EU/EEA as a whole is estimated to be 0·9% (95% CI 0·7–1·2), equivalent 
to almost 4·7 million chronic HBV cases. An overview of the estimated prevalence and data 
used for each country is in Supplementary Table S13. The United Kingdom has the largest 
estimated burden of chronic HBV in the EU/EEA with over a million cases, followed by 
Romania (877 682), and Spain, France and Italy (each with between 400 000 and 500 000 
cases).
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Table 1. Prevalence of HBsAg and anti-HCV in first-time blood donors, EU/EEA*
Country
Prevalence of HBsAg 
(95%CI)
Prevalence of anti-HCV 
(95%CI)
Council of 
Europe Report 
Austria 0.099% (0.072–0.132) 0.039% (0.023–0.061) 2010
Belgium 0.077% (0.055–0.104) 0.039% (0.024–0.060) 2011
Bulgaria 3.224% (3.039–3.418) 0.342% (0.282–0.410) 2011
Croatia 0.233% (0.142–0.359) 0.140% (0.072–0.244) 2011
Republic of Cyprus  0.441% (0.270 -0.681) 0.221% (0.106–0.405) 2008
Czech Republic 0.059% (0.040–0.085) 0.216% (0.177–0.261) 2011
Denmark 0.016% (0.004–0.040) 0.016% (0.004–0.040) 2011
Estonia 0.267% (0.128–0.490) 0.959% (0.673–1.326) 2011
Finland 0.000% (0.000–0.019) 0.025% (0.008–0.059) 2011
France 0.070% (0.062–0.079) 0.034% (0.028–0.040) 2011
Germany 0.116% (0.107–0.126) 0.062% (0.055–0.069) 2011
Greece 1.374% (1.280 -1.473) 1.202% (1.114–1.295) 2011
Hungary 0.009% (0.003 -0.021) 0.159% (0.128–0.195) 2011
Iceland 0.072% (0.002–0.398) 0.000% (0.000–0.264) 2011
Ireland 0.039% (0.013–0.090) 0.008% (0.000–0.043) 2011
Italy 0.168% (0.155–0.181) 0.094% (0.085–0.104) 2011
Latvia† 1.127% 2.170% 2003
Liechtenstein - - n/a
Lithuania 0.560% (0.468–0.665) 1.537% (1.382–1.704) 2011
Luxembourg 0.000% (0.000–0.406) 0.221% (0.027–0.794) 2011
Malta 0.174% (0.047–0.445) 0.043% (0.001–0.242) 2011
The Netherlands 0.034% (0.018–0.060) 0.020% (0.008–0.041) 2011
Norway 0.028% (0.009–0.065) 0.033% (0.012–0.073) 2011
Poland 0.450% (0.425–0.476) 0.742% (0.710–0.775) 2010
Portugal 0.094% 0.165% 2006
Romania 3.078% (2.965–3.195) 0.590% (0.541–0.643) 2011
Slovakia 0.072% (0.048–0.104) 0.025% (0.012–0.046) 2011
Slovenia 0.087% (0.043–0.155) 0.016% (0.002–0.057) 2009
Spain 0.168% (0.152–0.185) 0.099% (0.086–0.112) 2011
Sweden 0.043% (0.026–0.065) 0.059% (0.040–0.085) 2009
United Kingdom 0.038% (0.030–0.047) 0.037% (0.030–0.047) 2011
* Adapted from Table 1 and 7.1, Council of Europe Report 2014. [20] † Latvia: No data are available after 2003. 
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0% 1% 2% 3% 4% 5%
Belgium	0.7%ª	(0.5-0.8)	N=1830
Croatia	 0.7%	(0.4-1.2)	N=2009
Czech	Republic	 0.6%ª	N=2644
Denmark	0.3%*	(0.2-0.3)	N=201353	
France	0.7%	(0.5-0.9)	N=18230
France	0.8%	(0.6-0.7)	N=N/R
Germany	0.4%*	(0.3-0.5)	N=9303
Greece	3.3%	(2.2-4.7)	N=876
Greece	2.9%	(2.4-3.5)	N=3384
Hungary	0.4%	(0.1-1.0)	N=1066
Ireland	0.1%	(0.0-0.4)	N=1478
Italy	0.7%*	(0.4-1.0)	N=3982
Italy	0.8%*	(0.7-1.0)	N=26951
The	Netherlands	 0.2%	(0.1-0.4)	N=6246
The	Netherlands	 0.3%*	(0.3-0.4)	N=562218
Norway	 0.1%	(0.0-0.3)	N=1668
Romania	4.4%	(4.0-4.8)	N=13127
Slovakia	1.1%	(0.7-1.6)	N=1946
Spain	0.8%*	(0.6-1.1)	N=5355	
Spain	0.1%	(0.0-0.5)	N=1534
The	UK	0.5%*	(0.4-0.5)	N=167398
Fig.	3.	HBsAg	prevalence	estimates	from	studies	with	a	lower	risk	of	bias	for	the	general	population	(study	quality	score	≥4) and	for	
pregnant	women	(study	quality	score	≥2),	in	the	EU/EEA,	 2005–2015	
Figure 3. HBsAg prevalence estimates from studies with a lower risk of bias for the general 
population (study quality score ≥4) and for pregnant women (study quality score ≥2), in the EU/
EEA, 2005–2015 
Legend: country, prevalence estimate (95% CI) and sample size (N), general population estimates represented by diamond data 
points, pregnant women estimates represented in italics with triangle data points. ªStandardized estimate *Pooled estimate.
The anti-HCV prevalence in the EU/EEA is estimated at 1·1% (95% CI 0·9–1·4) equivalent 
to approximately 5·6 million anti-HCV-positive cases. Of these, an estimated 70% are 
chronically infected, i.e. viraemic replication with detectable HCV RNA [17]. France, Italy, 
Poland, Romania, Spain and the United Kingdom have the largest burden of chronic HCV 
with between 350 000 and 2·5 million anti-HCV positive people.
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0% 2% 4% 6% 8%
Belgium 0.1% (0.0-0.4) N=1830
Croatia 0.9% (0.6-1.5) N=1930
France 0.8% (0.7-1.1) N=18230
Germany 0.4%* (0.3-0.5) N=9303
Greece 2.2% (1.3-3.4) N=876
Hungary 0.5% (0.2-1.1) N=1066
Ireland 0.1% (0.0-0.4) N=1478
Italy 5.9%* (5.2-6.6) N=4826
Italy 0.4% (0.3-0.5) N=9977
Latvia 2.4% (1.7-3.3) N=1459
The Netherlands 0.1% (0.0-0.2) N=4046
Norway 0.9% (0.5-1.5) N=1668
Romania 3.2% (2.9-3.6) N=13146
Slovakia 2.0% (1.4-2.7) N=2124
Slovenia 0.1% (0.1-0.2) N=24919
Spain 1.1% (0.3-2.8) N=364
Spain 0.2% (0.1-0.3) N=8555
Figure 4. Anti-HCV prevalence estimates from studies with a lower risk of bias for the general 
population (study quality score ≥4) and for pregnant women (study quality score ≥ 2), in the EU/
EEA (2005-2015).
Legend: Country, prevalence estimate (95%CI) and sample size (N), general population estimates represented by diamond data 
points, pregnant women estimates in italics with triangle data points)*Pooled estimates.
DISCUSSION
In this review, we have compiled recent evidence available on the prevalence of chronic 
HBV and HCV infection in the general population, pregnant women and blood donors from 
EU/EEA countries to provide further information on the epidemiology of these infections 
and to identify gaps in the available evidence. The prevalence of chronic HBV and HCV in 
the general population varies widely across the 16 EU/ EEA countries for which estimates 
were available, with a higher HBsAg and anti-HCV prevalence in countries in the Eastern and 
Southern part of the EU/EEA. There is great diversity across the region and the estimated 
prevalence in the country with the highest HBsAg estimate in the EU/EEA (Romania) is 44 
times higher than in the country with the lowest estimated prevalence (Ireland). We also 
found that the highest single estimated anti-HCV prevalence (in Italy) is nearly 60 times 
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higher than estimates from countries with the lowest prevalence (Belgium, Ireland and 
the Netherlands). Differing risk factors and transmission routes might partially explain this 
variation across countries, as well as different implementation of prevention and control 
strategies.
This study updates the previous ECDC systematic review [18] and adds new estimates 
of HBsAg in the general population for six countries (Germany, Greece, Ireland, Italy, the 
Netherlands and Romania). Although we did not conduct a statistical analysis of differences 
between the reviews, there is evidence of change over time in all countries except 
Ireland. A decline in HBV prevalence was observed in Germany (0·6–0·4%) and Romania 
(5·6–4·4%). Improved primary prevention programmes including antenatal screening and 
HBV vaccination are likely explanations for this decline, especially in Romania. A decline 
in estimated prevalence is also likely for Italy, but with only regional prevalence estimates 
reported in 2009 (due to heterogeneity across North, Central and South Italy), we cannot 
compare the pooled 0·8% HBsAg prevalence estimate derived from the samples included 
in this study. This study also observed heterogeneity in the estimates for Italy derived from 
higher quality studies (0·5–5·8%). An increase in estimated prevalence was observed in 
Greece (2·1–3·3%) and the Netherlands (0·1–0·2%). Limited geographical coverage is a likely 
explanation for the increase in Greece as neither estimate is from a national sample (the 
2009 study covered the Peloponnesus [39]; the study in this review was conducted in Crete 
[28]). The slight increase in the Netherlands can be explained by the increase of the migrant 
population in the country, as was reported in the original study [40].
New high-quality anti-HCV prevalence estimates were available for five countries (France, 
Germany, Greece, the Netherlands and Spain). Again, although no statistical testing was 
conducted, results suggest that while the chronic HCV prevalence remained at 0·4% in 
Germany, it declined over time in France, the Netherlands and Spain, and increased in 
Greece. As with HBsAg prevalence, it is possible that the increase in Greece is mostly a 
reflection of the restricted geographical coverage of both the current estimate (Crete [28]) 
and the two reported in 2009 (Peloponnesus [39] and Zakynthos [41]). The new estimates 
for France and the Netherlands are derived from large-scale national random samples, 
whereas in 2009, the estimates were derived from regional/city specific estimates where 
higher risk populations are over-represented. New estimates not previously available in 
2009 were available for Hungary, Ireland, Croatia (not in the EU/EEA in 2009) and Latvia.
Both Ott et al. [42] and Schweitzer et al. [7] found that HBsAg prevalence increases eastwards 
across the EU/EEA; Schweitzer et al. reports the highest estimated prevalence found in 
Romania. While most HBsAg prevalence estimates are comparable, there are some notably 
different estimates reported by Schweitzer et al. for the 1990–2015 period, particularly for 
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Greece (0·97% vs. 3·3% in this review) and the United Kingdom (0·01% vs. 1·74% in this 
review). Methodological differences, specifically the inclusion of a wider timeframe and a 
broader definition of the general population to include blood donors, pregnant women 
and health care workers, could explain these differences.
For anti-HCV, an increase in Eastern and Southern EU countries was also reported. Similar 
to the findings from this review, Gower et al. found the highest prevalence estimates for 
Romania (3·2%), Lithuania (2·9%) and Latvia (2·4%) [43]. However, there is some divergence in 
the reported estimates for Italy. Our pooled 5·9% prevalence is considerably higher than the 
published 2·2% [43], yet the wide ‘uncertainty range’ (notably not a CI) reported by Gower et 
al. does include 5·6%, suggesting some comparability. In our study, 14 highly heterogeneous 
estimates (0·6% [44] to 27·6% [45]) met the inclusion criteria, four of which were pooled. 
Gower et al., however, selected one ‘best estimate’ to represent a country. Ultimately, our 
findings suggest that the prevalence in Gower et al. could be an underestimate; on the 
other hand, our estimate for Italy might be skewed upwards by included studies conducted 
in remote areas of the centre of the country.
HCV estimates presented in Cornberg et al. for France, Germany, Hungary and Romania 
were very similar to the estimates in this paper or the same study was identified as the 
most reliable estimate [46, 47]. Cornberg et al. suggest that the best prevalence estimate 
for Italy is 4·4% (all ages) and 5·2% for adults, similar to the 5·9% we found. Cornberg et al. 
most diverges with our findings for Spain (2·6% vs. 1·1% in this review) [31]. Although they 
also present other estimates they conclude, along with Esteban et al., that the prevalence 
in Spain is around 2·5% [48], suggesting our findings may be an underestimate of the true 
prevalence in the country.
The differences in prevalence between countries and over time are difficult to interpret, 
because comparability between studies is limited by the use of different study designs, 
probabilistic and non-probabilistic sampling strategies, and use of different laboratory tests 
and sample types. In addition, geographical representativeness is limited as most studies 
were performed at sub-national level. Representative seroprevalence studies for the general 
population are thus needed for valid comparison.
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Pregnant women
Pregnant women are commonly considered as proxy for the general population, albeit to a 
different extent for HBV and HCV. The majority of EU/EEA MS offer antenatal HBV screening. 
Estimates of HBsAg prevalence among pregnant women, although slightly higher, mostly 
align with observed general population estimates in most countries, except in Greece 
and Spain, where the prevalence among pregnant women is lower. This is consistent with 
results of the 2009 systematic review [18]. The prevalence data for pregnant women in 
Spain are more recent than the general population estimates, so the difference between 
these groups might reflect a change in prevalence over time. For Greece, the prevalence 
data for pregnant women are from a national sample, while the general population data 
are derived from a regional sample. While a lower HBV prevalence could be expected in 
pregnant women, based on gender and age differences, groups with a higher risk of chronic 
viral hepatitis, such as migrants, are often under-represented in general population studies 
and may possibly be overrepresented among samples in pregnant women.
Anti-HCV prevalence in pregnant women, where available for comparison with higher quality 
general population estimates, was found to be considerably lower. Chronic HCV infections 
in many EU/EEA countries have an age- and gender-specific prevalence distribution, with 
some studies from Southern Europe suggesting that 60% of the infected population is 
over 65 years of age [46]. Older and male populations, mostly infected through injecting 
drug use, contaminated blood or blood products, or improper infection control practices 
in health care, are not represented in studies in pregnant women [46], and our findings 
suggest that pregnant women are not a reliable proxy population to estimate prevalence 
in the general population.
First-time blood donors
HBV and HCV seroprevalence data in first-time blood donors are readily available for most 
EU/EEA countries and are the most complete population prevalence source. Although 
blood donors are often used as a proxy population, this subgroup is generally considered 
not to be a representative sample due to self-selection of blood donors and strict regulation 
by blood banks [49]. These selection biases are reflected in our findings, which show that 
prevalence in first-time blood donors is considerably lower than general population 
estimates for all countries, although some confidence intervals overlap. Latvia may be the 
notable exception with a reported anti-HCV seroprevalence of 2·2% among first-time blood 
donors in 2003 (the latest estimate available), largely comparable with the higher quality 
estimate of 2·4% in 2008 in the general population [29].
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The burden of chronic hepatitis B and C in the EU/EEA
The HBV and HCV prevalence in the EU/EEA as a whole is estimated to be around 0·9% and 
1·1%, respectively, resulting in an estimated total of 4·7 million chronic HBV cases and 5·6 
million anti-HCV positive cases. Considering that an estimated 70% of anti-HCV-positive 
cases are chronically infected [17], this corresponds with approximately 3·9 million chronic 
HCV cases.
The robustness of these figures is influenced not only by the intrinsic limitation of using 
prevalence estimates derived from an array of diverse studies, but also by the inclusion of 
prevalence estimates among blood donors as a proxy for the general population in the 
absence of other evidence. However, when taking into account both HBV and HCV data, 
general population estimates obtained from included studies accounted for approximately 
83% of the total European population, with the remaining 17% covered by blood donor 
estimates.
Other than perhaps the population size of the country, no clear distribution across the 
EU can be observed in the availability of (higher quality) estimates in any of the targeted 
population groups. For one country, Liechtenstein, no information about HBV and HCV 
prevalence was available for any of the population groups. For Cyprus, Iceland and Malta, 
only prevalence data on first-time blood donors were available, and for Austria, Estonia, 
Lithuania, Poland and Sweden, only low-quality estimates were available.
Strengths and limitations
An important strength of this review is that publications in all EU/EEA languages were 
included. In addition, consultation with MS further supplemented and validated the 
evidence retrieved. We feel that the lower sensitivity in the literature search due to the use of 
a geographical filter was effectively offset by the MS consultations. Another strength is that 
small sample studies were excluded, a risk of bias assessment was developed and applied, 
and only high-quality estimates were selected and pooled (if multiple were available) for 
the analyses, to ease inter- and intra-country comparisons. The risk of bias assessment tool, 
however, has not been previously tested. An untested assumption in the tool is the equal 
weight given to each domain to calculate a final quality rating. For first-time blood donors, 
another data source was used rather than studies identified via a systematic review and the 
source was not assessed for bias.
This systematic literature review confirms the diversity in prevalence of chronic HBV and HCV 
infections across the EU/EEA, as well as the variability between groups often considered to 
provide a good proxy for the general population. Our findings suggest that using blood 
donor or pregnant women data as a proxy for HCV and, to a certain extent, HBV prevalence 
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estimates for the general population is not desirable. Comparing to other regions globally, 
HBV and HCV prevalence in the EU/EEA is low, with some sign of decline, at least for HBV. 
The availability of studies with relatively recent data on the prevalence in the general 
population is limited, with data for around half of the 31 countries in the EU/EEA, reporting 
higher HBV and HCV prevalence in countries in the Eastern and Southern part of the region. 
The epidemiology of HBV and HCV is constantly changing, in part due to the impact of 
prevention and control programmes and changes in risk factors, but many countries lack 
recent robust epidemiological studies that provide reliable estimates of the burden of 
chronic viral hepatitis. The lack of high-quality, recent, nationwide prevalence estimates and 
the heterogeneity of available studies makes it challenging to gain an EU/EEA overview of 
the current epidemiological situation regarding chronic viral hepatitis. The need for high-
quality strategic information on the burden of HBV and HCV is compelling, not only for 
scaling up secondary prevention services appropriately, but also to inform regional and 
global activities that will shape the response to these epidemics in years to come. This could 
be achieved by complementing case-based surveillance with alternative data sources with 
adequate standardization levels across the region. A standardized seroprevalence survey 
performed across the EU/EEA, while resource intensive, may be a well-needed intervention 
to consider. 
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ABSTRACT
Background: In 2016, the World Health Organisation set a goal to eliminate viral hepatitis 
by 2030. Robust epidemiological information underpins all efforts to achieve elimination 
and this systematic review provides estimates of HBsAg and anti-HCV prevalence in the 
European Union/European Economic Area (EU/EEA) among three at-risk populations: 
people in prison, men who have sex with men (MSM), and people who inject drugs (PWID).
Methods: Estimates of the prevalence among the three risk groups included in our study 
were derived from multiple sources. A systematic search of literature published during 
2005-2015 was conducted without linguistic restrictions to identify studies among people 
in prison and HIV negative/HIV sero-status unknown MSM. National surveillance focal 
points were contacted to validate the search results. Studies were assessed for risk of bias 
and high quality estimates were pooled at country level. PWID data were extracted from the 
European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) repository.
Results: Despite gaps, we report 68 single study/pooled HBsAg/anti-HCV prevalence 
estimates covering 23/31 EU/EEA countries, 42 of which were of intermediate/high 
prevalence using the WHO endemicity threshold (of ≥2%). This includes 20 of the 23 
estimates among PWID, 20 of the 28 high quality estimates among people in prison, and 
four of the 17 estimates among MSM. In general terms, the highest HBsAg prevalence was 
found among people in prison (range of 0.3% - 25.2%) followed by PWID (0.5% - 6.1%) and 
MSM (0.0% - 1.4%). The highest prevalence of anti-HCV was also found among people in 
prison (4.3% - 86.3%) and PWID (13.8% - 84.3%) followed by MSM (0.0% - 4.7%).
Conclusions: Our results suggest prioritisation of PWID and the prison population as the 
key populations for HBV/HCV screening and treatment given their dynamic interaction and 
high prevalence. The findings of this study do not seem to strongly support the continued 
classification of MSM as a high risk group for chronic hepatitis B infection. However, we still 
consider MSM a key population for targeted action given the emerging evidence of viral 
hepatitis transmission within this risk group together with the complex interaction of HBV/
HCV and HIV.
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INTRODUCTION
Chronic infection with the hepatitis B (HBV) or hepatitis C virus (HCV) is a significant cause 
of liver disease-related morbidity and mortality in the European Union/European Economic 
Area (EU/EEA).(1) Both viruses are transmitted through contact with infected blood, blood 
products and other bodily fluids. HBV is vaccine preventable which, along with other primary 
prevention measures including health care infection control and antenatal screening, have 
led to a decrease in acute and chronic hepatitis B (CHB) incidence in many EU/EEA countries.
(2) Health care infection control together with harm reduction programmes among people 
who inject drugs (PWID) have also led to some decrease in the HCV incidence in many 
countries.(3) Many EU/EEA countries now face a dichotomy: a declining incidence of new 
HBV/HCV infections in the general population due to the success of primary prevention (2, 
4) alongside a projected increase in liver disease-related morbidity and mortality due to 
ageing of the chronically infected population.(5, 6) With the availability of antiviral treatment 
that can effectively halt disease progression in CHB, including progression to cirrhosis and 
hepatocellular carcinoma, and new direct acting antivirals for chronic hepatitis C (CHC) that 
report cure rates in more than 90% of cases (7, 8), elimination of chronic viral hepatitis is 
a possibility. Elimination requires expanded access to screening, efficient linkage to care 
and retention in treatment among risk populations. Timely, reliable prevalence data are 
needed to understand which populations are most affected to better target screening and 
treatment programmes, and to monitor the performance and impact of these activities at a 
strategic level. Indeed, for screening to have a more favourable cost-effectiveness ratio and 
lead to an overall net gain in population health, current evidence indicates that it should 
be targeted to higher prevalence populations including PWID and other risk populations, 
where the expected case yield would be highest.(9, 10) However, the prevalence threshold 
above which a favourable cost effectiveness ratio varies considerably between EU/EEA 
countries.
In terms of key at-risk populations, men who have sex with men (MSM) are considered a high 
risk population for viral hepatitis due to the efficacy of sexual contact in transmitting HBV 
and the high prevalence of other sexually transmitted infections especially Human Immuno-
Deficiency Virus (HIV). Whilst sexual contact was historically considered an ineffective route 
of HCV transmission, an increased HCV incidence among MSM who have not/do not inject 
drugs has been reported since the early 2000s. There is increasing evidence of permucosal 
transmission of HCV, especially among HIV positive MSM, although sexually acquired HCV 
infection remains rare in HIV negative, non-injecting MSM.(11, 12) Hahné et al reported 
Hepatitis B surface Antigen (HBsAg) and anti-HCV (measures of evidence of chronic HBV 
and chronic or resolved HCV infection respectively) prevalence among MSM in the EU/EEA 
ranging from <1% to 4% and from >1% to 2.9%, respectively.(13)
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People detained in prison settings are considered a high risk population for blood-borne 
virus infection due the criminalisation of high transmission risk behaviour such as injecting 
drug use and sex work, coupled with pre-detention social vulnerability (such as experience of 
domestic abuse, poverty and homelessness) among many people detained and convicted. 
Prison-acquired blood-borne virus infections may also occur due to the continuation of 
transmission risk behaviour, the limited availability of harm reduction services and the lack 
of adequate infection control practices.(14, 15) Dolan et al meta-analysed data in Global 
Burden of Disease regions: in Western Europe, HBsAg and anti-HCV prevalence among 
people in prison was reported to be 2.4% and 15.5%, respectively, while in Eastern Europe 
it was 10.4% for HBsAg and 20.2% for anti-HCV.(16) HBsAg and anti-HCV estimates are 
also available for nine and 13 EU/EEA countries, respectively, although no study quality 
assessment nor country-level metaanalysis/pooling were performed.
Of the three at-risk populations included in this study, PWID are considered at highest risk 
due to the efficacy of unsafe injecting behaviour in transmitting HBV and HCV. This together 
with clustering of social and environmental risk factors in this marginalised population such 
as a history of incarceration, poverty, homelessness and multi-morbidity compound their 
vulnerability.(17) Nelson et al conducted a global review of HBsAg and anti-HCV prevalence 
among PWID in 2010, and reported prevalence data for 30 EU/EEA countries for anti-HCV 
and for 26 EU/EEA countries for HBsAg. The prevalence of anti-HCV ranged from 21.1% in 
Finland to 90.5% in Latvia, whereas HBsAg prevalence ranged from 0.0% in Ireland and 
Cyprus to 21.3% in Estonia.(17) Wiessing et al performed a systematic review of various 
epidemiological measures of the HCV epidemic among PWID in Europe.(18) Although 
anti-HCV prevalence was not an included outcome, their findings across the cascade of 
care show that 72% of anti-HCV infected PWID are viraemic; that 49% are unaware of their 
infection; and that 9.5% of diagnosed cases are reported to be on treatment. A review 
focused on the EU/EEA in 2009, Hahné et al reported HBsAg prevalence among PWID to be 
between 0.0% and 21.3% and anti-HCV prevalence to be between 5.3% and 90%.(13) An 
updated synthesis of the prevalence in this priority population is required.
Our study is part of a larger project funded by the European Centre for Disease Prevention 
and Control (ECDC) that seeks to provide a timely update on available estimates across 
a number of low risk populations (the general population, pregnant women and first-
time blood donors) and as a comparator/contrast to collate prevalence estimates in high 
risk populations. We describe the results of the study into chronic viral hepatitis low risk 
populations and among migrants elsewhere.(19, 20) In the study reported here, we seek 
to update and expand the work of the previous ECDC systematic review (from 2009) by 
Hahné et al. (21) of prevalence estimates for markers of hepatitis B (HBsAg) and C (anti-HCV) 
in three key risk groups: MSM, people who inject drugs and people incarcerated in prison. 
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Our study seeks to contribute to the elimination of viral hepatitis in Europe by providing 
information to support the design and management of primary and secondary prevention 
strategies.
METHODS
Data sources
Estimates of the prevalence among the three risk groups included in our study were derived 
from multiple sources. A systematic literature search was conducted according to PRISMA 
guidelines (22) to retrieve, assess and synthesize available data published in the period 
2005-2015 on the prevalence of HBsAg and anti-HCV infection in MSM and people in prison. 
Data on the prevalence among PWID were retrieved from the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA).(23, 24)
Definitions
The key outcome was prevalence, which was defined as the proportion of study subjects 
with a positive finding of HBsAg or anti-HCV in serum, saliva or dry blood spot samples. 
MSM were not formally defined beyond the search term/inclusion criterion of ‘MSM’ and 
in practice this conceptualisation included men participating in studies in MSM-specific 
venues (e.g. saunas). People in prison were defined as people incarcerated in prison 
settings including prisons, remand centres, youth detention centres and psychiatric prison 
hospitals but excluding formerly incarcerated populations and other non-custodial secure 
institutions (such as secure psychiatric hospitals). PWID were defined by the EMCDDA as 
any person who has ever in their lifetime injected a drug for non-medical purposes.(25)
The prevalence in MSM and people in prison: systematic review
Search strategy
A systematic search to retrieve original research articles was conducted in PubMed®, 
Embase® and Cochrane Library bibliographic databases in March 2015. The search strategy 
(described in the online supplementary file) combined controlled (i.e. MeSH/Emtree terms) 
and natural vocabulary (i.e. keywords) to define disease-related (HBV or HCV infection), 
outcome-related (prevalence), and geographic-related search parameters (EU/EEA). To 
maximise the yield of the search, no population-specific search terms were included. 
Population relevancy was instead assessed at the title/abstract and full text assessment 
stages, as described below. The search was limited to records published from 1 January 
2005 to 12 March 2015. Articles in all EU/EEA languages were included. The results of the 
search were shared with ECDC National Focal Points (26) for viral hepatitis in all EU/EEA 
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Member States in May 2015 to review and validate the list of included references for their 
country. The data extraction, risk of bias assessment and data analysis described below were 
all performed in Microsoft Excel.
Inclusion/exclusion criteria
Inclusion/exclusion criteria included publication and data collection date ranges, 
geographical relevancy, the reporting of specific markers of hepatitis B/C infection, 
population relevancy (as outlined in the definitions section above) and study design. 
Criteria related to study design included the actual measured presence of viral markers in 
bodily fluid/dried blood spot samples (and thus the exclusion of self-reported infection) 
in human subjects, prevalence as an outcome measure, the exclusion of modelled data 
only, and the exclusion of guidelines, meta-analyses, systematic reviews and commentary/
opinion pieces. These criteria were twice piloted and refined by two reviewers (AF/SHIH) on 
a random sample of 5% of articles in order to reach >95% concordance. Following this, the 
title/abstract screening continued separately using Endnote. The full text of all publications 
included during title/abstract screening were individually assessed for relevance by 
members of the research team (for articles in Dutch, English, French, German and Italian) 
or by ECDC reviewers (for articles in other EU/EEA languages). Reviewers consulted each 
other in cases of uncertainty about in- or exclusion, and with a third team member (IV) to 
resolve further disagreement. The full search strategy, the in- and exclusion criteria and the 
PRISMA checklist are available in the supplementary information accompanying this article. 
See Figure 1 for the PRISMA flowchart (reasons for full text exclusion are detailed in the 
online supplement).
Data extraction
Data extraction using a pre-defined set of variables was performed simultaneously with full 
text screening. The unit for data extraction was study, not article. A study was defined as the 
report of prevalence data on HBsAg or anti-HCV for a defined population group, in a defined 
country, over a discrete period of time and one article may therefore include more than one 
study. Studies published in more than one article were extracted only once and the article 
with the most detail about the study used as reference. For studies retrieved reporting the 
prevalence in MSM, only data on HIV negative or unknown/unmeasured HIV sero-status 
MSM were extracted. All results reported in the study relating to MSM are therefore among 
HIV negative or unknown HIV sero-status MSM.
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Risk of bias assessment
For MSM and the prison population each study was evaluated for the risk of selection bias 
using a specifically developed assessment framework. To account for differences in sources 
of selection bias, separate assessment frameworks were developed for MSM and people in 
prison to determine the representativeness of sample for that specific target population 
and the robustness of the estimates in each study. For studies in MSM, just one domain 
was included, ‘sampling venue coverage’, where the risk of bias was considered smaller for 
studies in multiple venues or multiple venue types. For studies in the prison population, the 
domains of age, gender, proportion of PWID, sampling method and geographical coverage 
were considered as possible sources of selection bias. Points were awarded in each domain 
for representativeness or a lower risk of bias, and a total score calculated by summing the 
values in each domain. This resulted in a score of between zero and two for MSM and 
between zero and six for the prison population. We refer to the total score as study quality 
score, since a higher score indicates a lower risk of bias.
Data analysis
We recalculated 95% confidence intervals (CIs) for all crude and pooled estimates using 
the Fisher’s Exact method. All prevalence estimates retrieved for MSM, irrespective of the 
study quality score, are presented in separate (one for hepatitis B and one for hepatitis 
C) forest plots prepared using Microsoft Excel. HBsAg and anti-HCV prevalence estimates 
obtained from studies among adults in prison with a high study quality score (≥3) were 
pooled, when possible, by summing cases and sample size. Pooled or single study-derived 
high quality estimates retrieved for people in prison are presented in a forest plot, unless a 
study reported data over time whereby the most recent estimate was selected. Adult and 
juvenile (as defined by the included studies) estimates for the prison population are shown 
separately.
The prevalence in PWID: extraction from the EMCDDA data repository
The EMCDDA systematically retrieves, synthesizes and publishes comprehensive (and often 
unpublished) data on the prevalence of viral infections among PWID.(23, 24) We opted 
to draw on this repository due to its extensive scope as well as the potential to retrieve 
unpublished data that would be unavailable in scientific literature. The full data set retrieved 
for use in this study included country, year of study, geographical coverage, sample size and 
prevalence as well as limited information about study design and recruitment method/
setting. We included only national level estimates, and where multiple national estimates 
were available for a country, the most recent estimate was selected. We did not assess 
the quality of the study beyond these parameters of geographical coverage and recency. 
Number positive was back calculated using prevalence and sample size, and a 95% CI re-
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calculated using the Fisher Exact method. Samples in fewer than 10 subjects were excluded 
and multiple nationallevel estimates (if available from a specific year for an EU/EEA country) 
were pooled by summing cases and sample size.
RESULTS
Literature/database search retrievals
The literature search retrieved 9,379 citations, from which 17 citations were included for 
MSM and 57 for people in prison based on title/abstract. Seventeen MS validated our 
search results or provided additional references. For people in prison, seven publications 
were added either through a manual search of retrieved studies or through the national 
viral hepatitis ECDC focal points. An additional three citations were added for MSM. Whilst 
all 20 full texts were retrieved for MSM, three of the 64 included for people in prison were 
unavailable. Following full text screening, 13 articles were included for MSM and 32 for 
people in prison. The database search of the EMCDDA data repository retrieved seven 
national level HBsAg and 16 national level anti-HCV prevalence estimates.
The prevalence of HBsAg and anti-HCV among HIV negative/unknown 
HIV sero-status MSM
A total of 17 prevalence estimates, six for HBsAg and 11 for anti-HCV, were extracted from 
the 13 included studies about HIV negative/unknown HIV sero-status MSM. Key study details, 
including the risk of bias assessment, for all reported estimates among MSM are available in 
Annex 8 (HBV) and 9 (HCV) in the supplementary file for this article.
The six HBsAg prevalence estimates covered four countries: one each from Croatia and 
France and two each from Estonia and the United Kingdom (UK). HBsAg prevalence ranged 
from 0.0% - 0.1% in Estonia (27, 28) and the UK to 1.4% in France (Figure 2). The prevalence 
in the UK was derived from STI clinics in Scotland in 2001-2003 and ranged from 0.0% (29) to 
1.0% (30), with the sample size of the study for the latter estimate considerably larger than 
the former study (N=575 vs N=81). The estimate from France is based on a large (N=876), 
multi-centre, multi venue type study from 2009.(31)
The 11 anti-HCV estimates covered seven countries and the prevalence ranged from 0.0% in 
Italy (32) to 4.7% in Estonia (Figure 3), with eight of the 11 data points ≥1%. Single estimates 
were available for France(31), Italy(32) and Sweden(33) whereas multiple estimates were 
available for Croatia, Estonia, the Netherlands and the UK. For Estonia, the two anti-HCV 
estimates range from 4.7% (in 2013) to 1.8% (in 2014-15).(27, 28) The two estimates 
for Croatia range from 2.5%(34) to 2.9%(35) and cover broadly the same time period
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12,379 records retrieved prior to deduplication
Medline (Pubmed): 4,541
Embase (embase.com): 7,801
Cochrane Library: 37
9,379 records after deduplication
Records included for
full text screening
Prisoners
(n = 57)
Records included for
full text screening
MSM
(n = 17)
Records excluded
based on title and/or
abstract
(n = 9,322)
Records excluded
based on title and/or
abstract
(n = 9,362)
Articles added in via
manual search/MS
Focal Points
(n = 3) Articles added in by
MS Focal Points
(n = 7)
Full-text articles
unavailable
(n = 3)
Full-text articles
assessed for eligibility
Prisoners
(n = 61)
Full-text articles
assessed for eligibility
MSM
(n = 20)
Full-text articles
excluded, with
reasons (n = 29)
Full-text articles
excluded, with
reasons (n = 7)
Studies included in
qualitative synthesis
Prisoners
(n = 32)
Studies included in
qualitative synthesis
MSM
(n = 13)
Figure 1. PRISMA flowchart for studies retrieved for MSM and prisoners
(2003-2006) although the former sampled the population of Zagreb only while the latter 
covered seven cities. The two estimates from the Netherlands range from 0.7% to 1.3% 
and were derived using different study designs among the MSM population in Amsterdam; 
men attending a STI clinic opting out of HIV testing in 2007(36) and a cohort study over 
the period 1984-2003, respectively.(37) The two estimates for the UK were: 2.2%, found 
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in a multi-centre study between 2008/9 (N=1121) in London gay bars, clubs and saunas; 
and 1.6% found among STI clinic attendees in Sheffield in 2009-2011 (N=3395).(38, 39) In 
summary, prevalence among MSM ranged from 0.0% to 1.4% for HBsAg and from 0.0% to 
4.7% for anti-HCV.
The prevalence of HBsAg and anti-HCV among people in prison
Fifteen HBsAg prevalence estimates for 12 countries were extracted from the 32 included 
articles, only one of which (in Romania) scored <3 in the study quality assessment. Single 
estimates of HBsAg prevalence were retrieved for Bulgaria, Finland, France, Hungary, Ireland, 
Italy, Luxembourg, Portugal and Spain. Multiple (and therefore pooled) estimates were 
found for Croatia and the UK (Figure 4). These data show considerable heterogeneity in 
HBsAg prevalence in the prison population in the EU/EEA from <1% in the UK, Ireland(40), 
Finland(41) and France(42) to 6.7% in Italy(43), 7.0% in Luxembourg(44), 10.7% in 
Portugal(45) and 25.2% in Bulgaria(46). Two estimates for Croatia obtained over 2004-2006 
and 2005-2007 both report a HBsAg prevalence of 1.3% in adult inmates, with a third study 
from 2005-2007 reporting 1.4% among juvenile inmates. Two estimates obtained in the 
UK, one in a maximum security psychiatric hospital prison (reporting 0.0%) and the other 
in a general prison in London (reporting 2.0%), were pooled into an estimate of 1.6% (95% 
CI 0.8-2.9). Whilst diversity in sampling design was seen across the 14 high quality HBsAg 
prevalence estimates, just one study (44) was biased towards exclusive recruitment of PWID 
or use of injecting drug use as a sampling criterion. Key study details, including the risk of 
bias assessment, for all reported estimates among people in prison are available in Annex 
10 (HBV) and 11 (HCV) in the online supplementary file for this article.
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France	1.4%	(0.7-2.4)	N=876 
Estonia	1.0%	(0.0-5.6)	N=97 
The	UK	1.0%	(0.4-2.3)	N=575 
Croatia	0.6%	(0.1-2.0)	N=360
Estonia	0.0%	(0.0-8.2)	N=43 
The	UK	0.0%	(0.0-4.5)	N=81 
Figure 2. HBsAg prevalence among MSM
Legend: Country, prevalence estimate (95% CI) and sample size (N)
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0%	 2%	 4%	 6%	 8%	 10%	 12%	 14%	 16%	 18%	
Estonia	4.7%	(0.6-15.8)	N=43 
Croatia	2.9%	(1.1-6.3)	N=205
Croatia	2.5%	(1.1-4.7)	N=360
The	UK	2.1%	(0.0-3.2)	N=1121
Estonia	1.8%	(0.2-6.2)	N=113
The	UK	1.6%	(1.2-2.0)	N=3395 
The	Netherlands	1.3%	(0.8-1.9)	N=1836
France	1.0%	(0.5-1.9)	N=876 
The	Netherlands	0.7%	(0.1-1.9)	N=450
Sweden	0.6%	(0.2-1.3)	N=1008 
Italy	0.0%	(0.0-4.9%)	N=74 
Figure 3. Anti-HCV prevalence among MSM
Legend: Country, prevalence estimate (95% CI) and sample size (N)
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Figure	4:	HBsAg	prevalence	among	people	 (adults	unless	noted	as	juveniles)	in	prison
Legend:	Country,	prevalence	estimate	(95%	CIs)	and	sample	size	(N)	
Bulgaria	(juvenile)	 25.2%	(20.0-31.0)	N=258
Luxembourg	 7.0%	(3.1-13.2)	N=115
Italy	6.7%	(5.2-8.4)	N=973 
Spain	2.6%	(0.8-4.5)	N=not	reported
The	UK	(pooled)	 1.6%	(0.8-2.9)	N=640 
Hungary	1.5%	(1.2-1.8)	N=4898
Croatia	 (juvenile)	1.4%	(0.2-5.1)	N=140
Croatia	 (pooled)	1.3%	(1.0-1.6)	N=6503
Portugal	 0.7%	(0.0-3.6)	N=151
France	0.6%	(0.1-2.1)	N=347 
Finland	0.5%	(0.1-1.9)	N=383 
Ireland	0.3%	(0.0-0.9)	N=777) 
Figure 4. HBsAg prevalence among people (adults unless noted as juveniles) in prison
Legend: Country, prevalence estimate (95% CIs) and sample size (N) 
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Forty-five estimates of anti-HCV prevalence were retrieved from the included studies of 
which 37 estimates for 11 countries were considered high quality (i.e. a study quality score 
of ≥3). In 17 of the 45 anti-HCV estimates, injecting drug use was a study inclusion criterion 
or current/former PWID formed the majority of subjects. Figure 5 shows the final 16 single 
study/pooled high quality estimates included.
0%	 10%	 20%	 30%	 40%	 50%	 60%	 70%	 80%	 90%	 100%	
Luxembourg	86.3%	(79.0-91.8)	N=122
Finland	45.8%	(40.8-51.0)	N=383 
Italy	38.0%	(35.0-41.2)	N=973 
Portugal	34.4%	(26.9-42.6)	N=151
Bulgaria	(pooled)	26.3%	(23.5-29.3)	N=1156 
Spain	25.3%	(no	CI	available)	N=N/R
Spain	22.7%	(18.3-27.1)	N=N/R 
Bulgaria	(juvenile)	20.5%	(15.8-26.0)	N=258
Spain	(pooled)	20.3%	(18.9-21.7)		N=3062 
The	UK	(pooled)	17.4%	(16.4-18.4)	N=5450 
Croatia	(pooled)	13.3%	(12.5-14.2)	N=6696
Ireland	12.9%	(10.6-15.4)	N=777 
Germany	(juvenile)	8.6%	(7.0-10.4)	N=1125 
France	(pooled)	6.3%	(6.1-6.5)	N=68797 
Hungary	4.9%	(4.3-5.6)	N=4894 
Croatia	(juvenile)	4.3%	(1.6-9.1)	N=140
Figure 5. Anti-HCV prevalence among people (adults unless noted as juveniles) in prison
Legend: Country, prevalence estimate (95% CIs) and sample size (N) 
There is considerable heterogeneity in the (mostly high i.e. ≥8%) prevalence among people 
in prison across the EU/EEA; all but four estimates (from Croatia (juvenile), France, Germany 
(juvenile) and Hungary) were above 10%, with an estimate from Luxembourg as high as 
>80% prevalence.(44) Multiple high quality (and therefore pooled) estimates were available 
for Bulgaria, Croatia, France, Spain and the UK. Alongside a pooled estimate of 20.3% 
(47, 48), consecutive annual estimates report a decrease in anti-HCV prevalence in Spain 
from 44.9% in 2000 to 25.3% in 2009.(49) Two multi-centre study-derived estimates from 
Bulgaria were pooled into an estimate of 26.3% (95% CI 23.5- 29.3).(50, 51) Four estimates 
from the UK were pooled into an overall prevalence of 17.4% (95% CI 16.4-18.4) (52-55). The 
pooled prevalence of 6.3% for France is derived from seven studies screening more than 
68,000 people in prison. The three estimates among juvenile inmates show considerable 
heterogeneity, from 20.5% prevalence in Bulgaria (46) to 8.6% in Germany (56) and 4.3% 
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in Croatia (57). To summarise, prevalence extracted (and pooled where possible) from the 
high quality studies ranged from 0.3% to 25.2% (for HBsAg) and from 4.3% to 86.3% (for 
anti-HCV).
The prevalence of HBsAg and anti-HCV among PWID
The most recent, national level estimates of HBsAg and anti-HCV prevalence among PWID 
are presented in Table 1. National estimates of HBsAg prevalence were available for seven 
countries (Croatia, Cyprus, Greece, Hungary, Ireland, Latvia and Portugal), four of which were 
from studies conducted in 2013. The reported national prevalence ranges from 0.5% in 
Croatia, Hungary and Ireland, to more than 6% in Hungary and Portugal. National estimates 
of anti-HCV prevalence in the PWID population were available for 16 countries: Austria, 
Croatia, Cyprus, Czech Republic, Denmark, Finland, Greece, Hungary, Ireland, Italy, Latvia, 
Malta, Norway, Portugal, Slovenia and the UK. Anti-HCV prevalence was ≥30% in 13 of these 
countries and ≥50% in seven. In sum, the prevalence among PWID ranged from 0.5% to 
6.1% (for HBsAg) and from 13.8% to 84.3% (for anti-HCV).
DISCUSSION
This is the first review to collate, assess and compare prevalence estimates across these 
three key at-risk groups in the EU/EEA. Although gaps in evidence exist, this study reports 68 
HBsAg/anti-HCV single study/pooled prevalence estimates from 23 of 31 EU/EEA countries, 
42 of which are considered as intermediate/high prevalence using the WHO endemicity 
threshold for HBV/HCV (≥2%)(58). This includes 20 of the 23 estimates among PWID, 20 of 
the 28 high quality estimates among people in prison, and four of the 17 estimates among 
HIV negative/unknown HIV sero-status MSM. Geographical trends are difficult to determine 
due to heterogeneity of, and gaps in, evidence, although the reported data here are 
suggestive of higher prevalence among MSM (for anti-HCV) and among PWID (for both 
viruses) among countries in eastern and southern Europe.
Limitations in the estimates reported for people in prison and MSM relate to geographical 
and population coverage, study quality and heterogeneity of the included estimates. To 
retrieve estimates for people in prison and for MSM, we conducted a very broad search 
of the published literature with no language or population restrictions, and validated 
retrievals directly with countries, yet found many geographical gaps in the data. 
Indeed, only a third of EU/EEA countries are represented among the studies that met 
the inclusion criteria for people in prison and only seven countries reported estimates 
among MSM. It is unlikely we failed to identify and include all existing high quality 
data, and consider it most likely that the data just do not exist or are not published.
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In the absence of larger, more robust studies from which prevalence can be derived, we 
consider the data reported here are the best available although there may have been 
more recent estimates published since the date of our search (March 2015). Significant 
heterogeneity in study design within and between risk groups hamper the statistical 
comparison and pooling of prevalence across countries and populations. To control for 
strong sources of bias in studies among people in prison when pooling data, we developed 
and applied a study quality assessment. The five domains were considered equally 
important sources of bias and it is possible that estimates included in the analysis have 
residual selection biases. Further, our study quality assessment did not consider sample size 
and there is clearly more uncertainty in the estimates derived from smaller studies.
For pragmatic reasons, we extracted prevalence estimates for PWID from the data repository 
coordinated by EMCDDA. With limited methodological information accompanying the 
EMCDDA data sets, it is possible that this data set is not exhaustive. However, EMCDDA 
were recently identified by another wide-ranging systematic review as the source of the 
most routinely collected, European-level data on the viral hepatitis prevalence among 
PWID.(18) We adopted an algorithmic approach favouring the most recent national level 
data to select estimates, and found estimates meeting this criteria for just seven MS for 
HBsAg and 16 MS for anti-HCV. As with the retrievals from the systematic search, there 
is considerable eterogeneity in study design (intervention-related and observational), 
sampling method (single and multi-centre sampling methods) and sample size (from <50 
to >6,000 participants) across these 23 estimates. Beyond favouring the geographical and 
time-frame parameters, we did not systematically assess the quality of these studies and 
selection biases relating to study setting, population and sample size are likely to exist.
Using 2% prevalence as the endemicity threshold set out in the 2017 WHO HBV and HCV 
testing guidelines, (58) by comparing risk group prevalence with the general population 
prevalence (from previously published reviews of the literature (59-64)) and by comparing 
across risk groups, our findings generally support the continued classification of PWID and 
people in prison as the key populations for both chronic hepatitis B and C infection. Whilst 
this study does not seem to support the continued classification of HIV negative/unknown 
HIV sero-status MSM as a high (>2%) prevalence population for chronic hepatitis B infection, 
we are cautious in this conclusion given the wide confidence interval (that sometimes 
includes the 2% threshold) around the MSM-derived HBV estimates. We therefore still 
consider MSM a key population for targeted action, given that anti-HCV prevalence in MSM 
is higher than in the general population, the evidence of the ongoing transmission of viral 
hepatitis among MSM populations and the complex interaction of viral hepatitis and HIV.
(11, 12) Both infection with, and antiretroviral treatment for, HIV are suspected to increase 
progression to chronicity as well as to accelerate fibrosis.(11, 12) Global anti-HCV prevalence 
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among HIV positive MSM has been estimated as high as 6.4% (65), and end-stage liver 
disease is a leading key cause of death among co-infected HIV positive patients in some 
high income countries.(66) A cohort study found an unexpectedly high proportion of MSM 
(23% compared to the 5-10% chronicity rate expected in the general adult population(67)) 
develop a chronic hepatitis B infection following HBV exposure regardless of HIV status, with a 
younger (adult) age at infection significantly associated with an increased risk of developing 
CHB.(68) It would therefore seem an effective use of health resources to (continue to) offer 
HCV screening to HIV positive men in addition to MSM-wide HBV vaccination.(69) Specific 
cost-effectiveness analyses of offering individual or combined blood-borne virus screening 
in MSM would also greatly aid public health decision making and be a useful addition to 
the evidence.
Differences in the prevalence among people in prison between countries are related to 
the differential distribution of risk factors among the prison population together with 
differences in prison conditions, such as the availability of harm reduction interventions 
and infection control practices and infrastructure across the EU/EEA countries represented 
in this study.(16) The high prevalence of HBsAg in the prison population in some countries 
could be attributable to the incarceration of people born in intermediate or high prevalence 
countries and consequent over-representation of migrants in the incarcerated population. 
Recent estimates suggest that the proportion of the prison population that is foreign-born 
ranges from <5% in Bulgaria and Hungary, to more than 15% in France, Germany, Italy, 
Portugal and Spain, and up to 72% in Luxembourg. (70) It is possible that the incarceration 
of foreign-born migrants is a driver of the high prevalence of chronic hepatitis B and C 
infection in prisons although as there is no systematic EU-wide data collection on the 
demographic profile of the incarcerated population, our understanding of the dynamics of 
migration, incarceration and chronic infection is limited. (70)
Our study seeks to contribute to the elimination of viral hepatitis in Europe by providing 
information to support the design and management of primary and secondary prevention 
strategies. However, expected prevalence is just one of a number of factors that affects the 
cost-effectiveness of testing strategies. Programme-related factors such as ease of reaching 
the target population, uptake of screening, actual (viraemic) prevalence, linkage to care and 
treatment initiation also playing a key role.(9, 10, 13)
We see four key public health implications emerging from our experience in this study. The 
first is the indication for systematic screening and linkage to care of people in prison given 
the high prevalence, the overlap with the PWID population, and the possible continuation 
of risk behaviour. Secondly, we see significant public health benefits of providing treatment 
as prevention, especially for CHC, among populations that share risk behaviour, in line with 
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national and international clinical and public health guidelines.(58) Analyses have shown 
that treatment among high-risk dynamically interactive populations such as PWIDs, is 
costeffective, especially given the shorter and more tolerable treatment regimens.(8) Thirdly, 
the need for diagnostic testing and treatment is particularly important for PWID where the 
prevalence, and therefore risk of intra-population transmission, of hepatitis C is very high.
PWID screening in accessible locations as part of broader harm reduction measures may 
help break down barriers of stigma and among this vulnerable and high risk population.(16, 
71) The criminalisation of drug use has been suggested to be as the single most important 
determinant of the high blood-borne virus prevalence among people in prison.(16) Finally, 
the lower prevalence of CHB we found among some risk populations in some countries is 
likely a direct result of the adoption and implementation of primary prevention measures, 
especially childhood immunisation, in the general population.(72) This highlights the 
importance of adequately resourcing primary prevention measures as well as continuing to 
offer HBV vaccination to risk groups to protect public health.
The limitations of this study also provide ideas for future research, specifically the 
improvement in the design of studies and greater geographical representation to fill the 
gaps in evidence. The development and consistent application of an EU/EEA or international 
standard for the design and quality assessment of seroprevalence studies to inform pooling 
and/or statistical comparison of data across studies and populations would also greatly 
improve understanding of prevalence across countries and populations. Finally, and 
probably most importantly, there is clear and urgent need for more implementation studies 
to determine the features of screening programmes and strategies among risk populations 
that effectively reach, diagnose and link to care people infected with chronic viral hepatitis.
CONCLUSION
Our study highlights the heterogeneity in prevalence across risk groups across Europe. 
Prevalence generally increases in an Eastern and Southern direction. There are also many 
countries, especially in the Eastern and Southern part of Europe, that are not represented 
in our results, highlighting the need to build capacity for and resource the development 
of robust epidemiological studies among key risk groups. Step One of elimination action 
planning is to know your epidemic, the ‘who’ and the ‘where’,(73) and both the evidence and 
the data gaps contained in this review should contribute to this strategic aim.
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ABSTRACT
Background: Chronic hepatitis B (CHB) related morbidity and mortality can be reduced 
through risk group screening, linkage to care and anti-viral treatment. This study estimates 
the number of CHB cases among foreign-born (migrants) in the European Union and 
European Economic Area (EU/EEA) countries in order to identify the most affected migrant 
populations.
Methods: The CHB burden was estimated by combining: demographic data on migrant 
population size by country of birth in the EU/EEA, extracted from European statistical 
databases; and CHB prevalence in migrants’ countries of birth and in EU/EEA countries, 
derived from a systematic literature search. The relative contribution of migrants from 
endemic countries to the total CHB burden in each country was also estimated. The 
reliability of using country of birth prevalence as a proxy for prevalence among migrants 
was assessed by comparing it to the prevalence found in studies among migrants in Europe.
Results: An estimated 1–1.9 million CHB-infected migrants from endemic countries 
(prevalence ≥2%) reside in the EU/ EEA. Migrants from endemic countries comprise 
10.3% of the total EU/EEA population but account for 25% (15%–35%) of all CHB cases. 
Migrants born in China and Romania contribute the largest number of infections, with over 
100,000 estimated CHB cases each, followed by migrants from Turkey, Albania and Russia, 
in descending order, with over 50,000 estimated CHB cases each. The CHB prevalence 
reported in studies among migrants in EU/EEA countries was lower than the country of 
birth prevalence in 9 of 14 studies.
Conclusions: Migrants from endemic countries are disproportionately affected by CHB; 
their contribution however varies between EU/EEA countries. Migrant focused screening 
strategies would be most effective in countries with a high relative contribution of migrants 
and a low general population prevalence. In countries with a higher general population 
prevalence and a lower relative contribution of migrants, screening specific birth cohorts 
may be a more effective use of scarce resources. Quantifying the number of CHB infections 
among 50 different migrant groups residing in each of the 31 EU/EEA host countries helps 
to identify the most affected migrant communities who would benefit from targeted 
screening and linkage to care.
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INTRODUCTION
Migration flows in the first half of the twentieth century were predominantly from Europe 
towards America. Since the Second World War, economic and geopolitical factors such as 
decolonisation, labour migration, the collapse of communism, air travel, economic growth 
and political crisis have changed this and migration to Europe has increased.(1) Much of 
this migration has been from low- and middle-income countries in Asia and Africa, many 
of which have a high prevalence of hepatitis B and C.(2, 3) Existing case-based surveillance 
systems such as the European hepatitis B and C surveillance system managed by the 
European Centre for Disease Prevention and Control are unable to accurately quantify the 
number of chronic viral hepatitis cases among migrants on account of different reporting, 
testing and screening practices among member states. Additional information sources 
and epidemiologic research are needed to estimate the scale of chronic hepatitis B virus 
infection in this population.(4)
Hepatitis B virus (HBV) infection primarily affects the liver. It usually has an insidious onset 
and can remain undetected for many years. Up to 5% of HBV infections in adults (up to 90% 
in young children) can progress to become chronic and up to 30% of chronic cases may 
develop liver cirrhosis.(5)
Public health measures, including antenatal screening, childhood HBV vaccination, stringent 
testing of blood products, improved infection control practices and harm reduction 
programmes, have led to a significant reduction of viral hepatitis transmission and a decline 
in the number of acute HBV cases reported in many European Union/European Economic 
Area (EU/EEA) countries.(6) Limited or more recent implementation of these primary 
prevention measures explains the high prevalence of viral hepatitis seen in many parts 
of the world, but especially in South East Asia, Sub-Saharan Africa and Eastern Europe.(7) 
Vertical transmission from mother to child and nosocomial transmission are considered to 
be the main routes in intermediate (2–8%) and high (>8%) HBsAg prevalence countries.(5, 7)
Worldwide viral hepatitis related mortality in absolute terms increased by 63% between 
1990 and 2013, while the associated disability adjusted life years increased by 34% during 
this time.(8) This global increase is largely the result of inadequate prevention measures 
combined with population growth in hepatitis endemic areas.(8) An estimated 13 to 14 
million people in the WHO European region are chronically infected with hepatitis B (9, 
10) and about 36,000 people die every year as a consequence.(9) In Europe, chronic HBV 
infection is a major cause of liver cirrhosis and 10–15% of hepatocellular carcinoma (HCC), 
cases are attributed to chronic hepatitis B (CHB).(10)
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Antiviral treatment with nucleot(s)ides such as tenofovir or entecavir can prevent the 
development of cirrhosis and HCC and can suppress viral replication in a very high proportion 
of cases.(3) However, because of the largely asymptomatic nature of the infection until late 
stages, it is estimated that between 40% and 80% of people infected are unaware of their 
infection and many are not diagnosed until after liver damage has occurred.(10, 11) The 
population health benefits of effective treatment can only be realised by improving early 
detection of infection through targeted testing among risk groups.
The WHO recently ratified the strategic goal to eliminate chronic viral hepatitis as a health 
threat in Europe by 2030. The strategy and action plan published to support countries and 
the region to achieve this goal highlight ‘the who’ and ‘the where’ as the first two strategic 
pillars of elimination.(12, 13) Whilst it is suspected that a large proportion of migrants to 
the EU come from hepatitis B (HBsAg) intermediate (2%–8%) and high (>8%) endemicity 
countries (2, 3), little is known about the epidemiology of CHB among migrants. Specifically 
lacking are robust estimates of the number of infections among migrants and knowledge 
about which groups are most affected. Estimates of which migrant groups are most affected 
and would therefore benefit most from (linguistically/culturally/specifically) targeted 
screening programmes, early detection and treatment are required if Europe is to achieve 
this ambitious elimination goal.
The aims of this study are: 1) to estimate the number of CHB cases among the foreign-born 
population originating from intermediate and high HBV endemicity countries residing in 
the 31 countries of the EU/EEA; 2) to estimate the relative contribution of migrants to the 
overall burden of CHB in Europe; and 3) to identify the migrant groups among whom the 
largest number of cases are found so as to help direct more effective screening programmes. 
In a sister paper (INFD-D-1700468) (14), we conduct a similar analysis for chronic hepatitis C 
among migrants from endemic countries.
METHODS
The data retrieval and analysis process are described in detail below and in a schematic 
representation (Figure 1). To estimate the number of CHB cases among migrants in each 
EU/EEA country, demographic data on the number of foreign-born migrants by country 
of birth living, in EU/EEA countries were extracted from statistical databases. Country of 
birth-specific and EU/EEA countryspecific general population Hepatitis B surface antigen 
(HBsAg) prevalence estimates were derived from a systematic literature search (Part 1).
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Figure	1:	Schematic	representation	of	the	methodological	process	to	estimating	the	burden	of	
chronic	hepatitis	B	among	migrants	in	the	EU/EEA	
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Figure 1. Schematic representation of the methodological process to estimating the burden of 
chronic hepatitis B among migrants in the EU/EEA
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Definitions
Migrant (foreign-born population): includes all persons who were born outside 
their current country of residence (and listed in the demographic registration 
databases used in this study). This includes within-EU/EEA migrants, i.e. persons born 
in another EU/EEA country, as well as those born outside the EU. It does not include 
undocumented migrants.
Chronic hepatitis B (CHB): refers to a positive hepatitis B surface antigen (HBsAg) 
test.
Note: According to the WHO and EU (2012) case definition, detection of HBsAg on 
two occasions at least 6 months apart is classified as CHB. In this study, as in the 
seroprevalence and screening studies from which prevalence data for this study were 
extracted, the presence of HBsAg is taken as the standard proxy for chronic infection. 
The lack of regular screening for HBV and the reduction in incidence of acute HBV 
infections in most countries justify the assumption that the overwhelming majority 
of HBsAg positive cases are chronic.
Hepatitis B endemic country: countries with a ≥ 2% HBsAg prevalence in the general 
population. This follows from the WHO classification of low (<2%), intermediate (2% 
to 8%) and high (>8%) endemic countries.
To assess the reliability of using country of birth-derived HBsAg prevalence as a proxy for 
the prevalence among migrants, a systematic literature search was conducted to identify 
prevalence estimates among migrants in Europe and to compare these with country of 
birth-derived prevalence (Part 2).
PART 1: THE CONTRIBUTION OF MIGRANTS FROM ENDEMIC COUNTRIES 
TO THE BURDEN OF CHB IN THE EU/EEA
Demographic data
The size and country of birth of the foreign-born migrant population was obtained for 
the 31 EU/EEA countries from Eurostat for 2013, if available.(15) Where Eurostat data by 
country of birth were missing (Croatia, Cyprus, France, Germany, Malta, Portugal and the 
UK), data from the EU 2011 – Housing and Population Census were used.(16) The most 
recent demographic data for Greece (2012) and Luxembourg (2010) were only available 
from the Organisation for Economic Co-operation and Development’ (OECD) Stats website.
(17) No demographic data were available from the above sources for Lithuania. Data were 
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thus obtained from the Lithuanian National Statistics Service (2013).(18). The data source 
is indicated in footnotes in Table 1. For each EU/EEA country, the countries of birth of 
foreign-born migrants were arranged in descending order of magnitude by the number 
of migrants. The top 50 countries of birth by size of migrant population were selected for 
estimating the CHB burden.
Systematic literature search to estimate country- specific HBsAg prevalence
The online databases Medline, Embase, the Cochrane library, Web of Science, Scopus, 
PubMed publisher and Google Scholar were searched in January 2015 for reviews, systematic 
reviews and meta-analyses in English about the prevalence of hepatitis B in the general 
population at national level. The search terms (described in full in Annex 1 of the online 
supplement) consisted of a combination of disease-related (hepatitis B), outcomerelated 
(prevalence), population-related (general population, worldwide), and study design-related 
(reviews) terms. Since the aim was to identify recent reviews, the search was restricted to 
papers published between 2009 and 2014. The titles and abstracts of retrieved articles were 
assessed for relevance using exclusion criteria. Key exclusion criteria included studies about 
hepatitis other than type B; focusing on natural history, clinical features or complications 
of hepatitis; about medical treatment; focusing on high risk groups e.g. people who inject 
drugs; and single case studies and cost effectiveness analyses. Full texts of the selected 
abstracts were retrieved and assessed, decisions to exclude were recorded and a PRISMA 
flowchart (described in Annex 2 of the online supplement) was prepared.
From included reviews, country-specific HBsAg prevalence estimates and confidence 
intervals (CI) were extracted into a Microsoft Excel database. Where a country-specific 
estimate was unavailable, the relevant Global Burden of Disease region estimate was used, 
if available. If a meta-analysis reported a statistically significant time trend, the estimate 
from the most recent period was selected. When multiple estimates for a country were 
available from different reviews, the most robust or relevant review was selected based 
on the following criteria: sampling method; representativeness of population studied; 
geographical coverage; sample size; quality of included studies and data collection 
timeframe. Decisions were made jointly by two reviewers (AF and IV) with the rationale 
recorded for each decision about a chosen estimate. This rationale, together with the search 
strategy, the inclusion and exclusion criteria and the PRISMA flowchart are described in 
annexs 1, 2, 3 and 5 of the online supplement for this article.
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Estimating the number of CHB cases among foreign-born migrants from endemic 
countries in each EU/EEA country
The retrieved HBsAg general population prevalence estimate in the countries of origin were 
multiplied by the number of migrants from that respective country in each EU/EEA country. 
The number of migrants born in endemic countries (≥2%) was summed to determine 
the total and proportional contribution of migrants from intermediate/high hepatitis B 
endemicity countries to the overall number of migrants residing in the host country. The 
ten migrant populations originating from intermediate and high endemicity countries with 
the highest number of HBsAg infected cases in the EU/EEA were determined.
Relative contribution
To estimate the relative contribution of migrants born in endemic countries to the overall 
number of people infected with CHB in the respective EU host country, the estimated 
number of infected cases among migrants was divided by the number of infected persons 
in that country based on the general population prevalence. Given the uncertainty in the 
size of migrant population and the CHB prevalence estimates in the countries of birth, the 
range of the relative contribution with a lower and a higher limit was calculated using the 
Delta method (19).
EU/EEA-level estimates
The population of the EU/EEA was derived by summing up the population of all 31 EU/
EEA countries as extracted from demographic sources. To estimate the HBsAg prevalence 
in the EU/EEA, the number of estimated HBsAg positive cases in all 31 EU/EEA countries 
was summed up and divided by the total EU/EEA population. To derive the lower and 
upper prevalence range, the lower and upper estimates of the number of cases across the 
31 countries were summed up. To estimate the number of cases among migrants to and 
within the EU/EEA, the number of cases among migrants from endemic countries (≥2%) 
across all 31 countries was summed up. This was then divided by the number of cases in 
the EU/EEA to derive the relative contribution of migrants from endemic countries to the 
burden of CHB infection in the EU/EEA.
PART 2: SYSTEMATIC LITERATURE SEARCH FOR HBsAg PREVALENCE IN 
MIGRANT POPULATIONS IN EUROPE
The online databases Medline, Embase, the Cochrane library, Web of Science, Scopus, 
PubMed publisher and Google Scholar were searched in November 2014 for studies 
in English that estimate the prevalence of hepatitis B among migrants in any of the 31 
EU/EEA countries. The search consisted of a combination of disease-related (hepatitis B), 
outcome-related (prevalence), population-related (migrants) and geographical area (EU/
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EEA countries) terms and was limited to studies published between 2000 and 2014. Only 
studies about the prevalence in migrants who were considered to be representative of 
the general migrant population (i.e. not refugees or asylum seekers, hospital patients or 
other higher risk groups and not lower risk groups like pregnant women or children) were 
compared with incountry of birth derived prevalence estimates. The full search strategy, 
inclusion and exclusion criteria and PRISMA flowchart can be found in annexs 3, 4 and 6 of 
the online supplement.
Country-level HBsAg prevalence estimates among migrants residing in different European 
countries were extracted from the included studies and entered into Microsoft Excel. 
Pooled estimates for countries of birth were produced by combining the numbers tested 
and the number of cases. A 95% CI was re-calculated using the Fisher’s exact method. 
Both pooled and large single study (>25 subjects from a single country of birth) estimates 
were compared with the in-country estimates extracted in Part 1 to determine whether 
in-country estimates reflect the prevalence found in migrants. When the point estimate 
from a study in migrants (Part 2) fell within the CI of the in-country estimate (from Part 1), 
the estimate was considered to be comparable; when it fell below the lower CI limit, it was 
considered lower than the in-country prevalence; and when it was higher than the upper 
CI limit the prevalence in migrants was considered to be higher.
RESULTS
Estimated CHB prevalence and number of infected cases in 31 EU/EEA 
countries
Chronic hepatitis B (HBsAg) prevalence differs considerably among EU/EEA countries, 
ranging from 0.1% in Ireland and the Netherlands to 5.5% in Romania. The average 
prevalence in the general population of the EU/ EEA is estimated at 1.1%, corresponding 
to an estimated 5.7 million cases (range 4.0 to 7.5 million). These estimates, together with 
the total number of infected cases, are listed in Table 1. Italy and Romania are the EU/EEA 
countries with the highest estimated number of CHB cases, both above 1 million.
The distribution of migrants in the EU/EEA based on HBV endemicity in 
country of birth
The top 50 foreign-born populations in each EU/EEA country included in our analysis make 
up at least 95% of the total migrant population in 19 of 31 EU/EEA countries and at least 
90% in all but three EU/EEA countries (Denmark, Sweden and the UK where it is at least 
85%). These migrant populations account for approximately 9.5% of the population in the 
EU/EEA. The proportion, however, ranges from 0.9% in Romania and 1.3% in Bulgaria to 
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more than 40% in Luxembourg and 62% in Liechtenstein (Figure 2). Just over half of the EU/
EEA migrant population were born in HBV endemic (≥2% prevalence) countries. EU/EEA 
countries with the highest proportion of migrants from endemic countries among their 
foreign-born population are Croatia, Estonia and Latvia (>90%), and those with the lowest 
proportion are Liechtenstein, Luxembourg and Slovakia (<16%) (Figure 2). The foreign-born 
population and the number and proportion from endemic countries in the EU/EEA and by 
country are shown in Table 2.
Country-specific HBsAg prevalence estimates
The most comprehensive systematic global review of country-specific prevalence in 
the general population identified by the systematic literature search was a review by 
Kowdley et al. published in 2012.(20) This This provided CHB prevalence estimates for 102 
countries, based on studies published between 1980 and July 2010 using population-based 
surveys and studies of groups considered representative of the general population, such 
as pregnant women, school children, military recruits and healthy controls from cohort 
studies. Studies in emigrants to the United States, Europe, Australia and elsewhere were 
also included. Studies in blood donors and in higher risk populations were excluded. The 
Kowdley et al review used meta-analytic methods to estimate country- and region-specific 
pooled HBsAg seroprevalence and corresponding 95% CI.(20) Since the Kowdley review 
did not include a prevalence estimate for the United States, this was taken from the most 
recent nationally representative survey in 2011.(21) For 11 countries (China, Egypt, Ethiopia, 
Greece, Italy, Romania, Saudi Arabia, South Korea, Spain, Thailand and Turkey), Kowdley et 
al (20) reported a statistically significant decrease in prevalence over time and therefore the 
post-2000 estimate was taken. Estimates from other studies were considered more robust or 
relevant than this review for 11 countries (Albania, Algeria, Belgium, Cyprus, Finland, Ireland, 
Libya, Morocco, the Netherlands, Sweden and Tunisia). (9, 11, 22), and the reasons for this 
are listed in Annex 7 of the online supplement. For the 44 countries and territories where 
no country estimate was available, the relevant regional estimate calculated by Kowdley et 
al was used. All country-specific prevalence estimates used can be seen in Annex 8 of the 
online supplement.
Estimated prevalence and number of CHB infections among migrants
In the EU/EEA overall, between 1 million and 1.9 million migrants born in endemic countries 
are estimated to have CHB infection, which corresponds to an estimated prevalence of 
5.5%. The estimated cumulative number and range of CHB cases among the top 50 migrant 
populations from intermediate and high endemicity countries in each EU/EEA country is 
listed in Table 2. The average HBsAg prevalence among migrants from intermediate and 
high endemicity countries is also available for each EU/EEA country, and ranges from 3% in 
Estonia, Latvia, Lithuania and Poland to 9% in Portugal.
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Table 1. Chronic hepatitis B prevalence and the estimated number of infected cases in the general 
population of 31 EU/EEA countries
Country
Total 
Population
HBsAg prevalence Estimated no. of CHB cases
% Low 95% CI High 95% CI
Central 
estimate
Lower 
estimate
Upper 
estimate
Austria 8,451,149 0.55 0.34 0.71 46,481 28,734 60,003
Belgium 11,161,642 0.7 0.4 1.2 78,131 44,647 133,940
Bulgaria 7,284,552 4.25 2.80 5.70 309,593 203,967 415,219
Croatia 4,284,889# 1.47 0.84 2.10 62,988 35,993 89,983
Cyprus 840,407# 0.9 0.3 2 7,564 2,521 16,808
Czech Republic 10,516,125 0.70 0.43 0.98 73,613 45,219 103,058
Denmark 5,602,628 0.55 0.34 0.71 30,814 19,049 39,779
Estonia 1,320,174 0.58 0.42 0.74 7,657 5,545 9,769
Finland 5,426,674 0.2 0.1 0.4 10,853 5,427 21,707
France 64,932,339# 0.68 0.44 1.05 441,540 285,702 681,790
Germany 80,219,695# 0.6 0.4 0.8 481,318 320,879 641,758
Greece 11,090,000∆ 2.33 1.54 3.11 258,397 170,786 344,899
Hungary 9,908,798 1.08 0.04 2.11 107,015 3,964 209,076
Iceland 321,857 0.55 0.34 0.71 1,770 1,094 2,285
Ireland 4,591,087 0.1 0 0.3 4,591 0 13,773
Italy 59,685,227 1.89 1.26 2.52 1,128,051 752,034 1,504,068
Latvia 2,023,825 1.39 1.10 1.67 28,131 22,262 33,798
Liechtenstein 36,838 0.55 0.34 0.71 203 125 262
Lithuania 2,971,905 µ 2.03 1.37 2.69 60,330 40,715 79,944
Luxembourg 506,953∞ 0.55 0.34 0.71 2,788 1,724 3,599
Malta 417,432 0.55 0.34 0.71 2,296 1,419 2,964
Netherlands 16,779,575 0.1 0 0.2 16,780 0 33,559
Norway 5,049,223 0.55 0.34 0.71 27,771 17,167 35,849
Poland 38,533,299 1.44 1.16 1.72 554,880 446,986 662,773
Portugal 10,562,178# 1.35 0.66 2.04 142,589 69,710 215,468
Romania 20,020,074 5.49 5.24 5.73 1,099,102 1,049,052 1,147,150
Slovakia 5,410,836 0.70 0.43 0.98 37,876 23,267 53,026
Slovenia 2,058,821 3.29 2.33 4.24 67,735 47,971 87,294
Spain 46,727,890 0.66 0.34 0.97 308,404 158,875 453,261
Sweden 9,555,893 0.2 0.1 0.4 19,112 9,556 38,224
United Kingdom 63,182,180# 0.54 0.30 0.60 341,184 189,547 379,093
EU/EEAβ 509,474,165 1.12 0.79β 1.47β 5,705,260 4,003,937 7,514,179
*Source is EUROSTAT 2013 unless indicated by the following symbol: #ESS 2011 Census; ∆OECD 2012; ∞OECDC 2010;   µhttp:///
www.euras.lt (Lithuanian National Statistics Agency); β For the 31 EU/EEA countries the cumulative HBsAg prevalence and the 
upper and lower CI were estimated from the sum of the estimated number of CHB cases (central, lower and upper estimate), 
hence these should be considered as upper and lower prevalence ranges and not CI.
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Table 2. Total size and proportion of foreign-born migrant population (from endemic countries) 
in EU/EEA host countries; estimated number and range of CHB cases among migrants; estimated 
relative contribution to the total number of cases in the EU/EEA host country
Country
Population of foreign-born migrants
Estimated number of CHB cases
(from endemic countries)
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Austria 1,298,945 768,773 9.1% 33,456 25,757 41,040 4.4% 72%
Belgium 1,596,848 622,206 5.6% 42,530 32,218 54,309 6.8% 54%
Bulgaria 90,990 62,755 0.9% 2,436 1,860 3,039 3.9% 1%
Croatia 582,271 523,470 12.2% 18,673 11,966 25,376 3.6% 30%
Cyprus 190,568 139,689 16.6% 6,770 5,141 8,445 4.8% 90%
Czech 
Republic
374,296 234,291 2.2% 12,185 9,637 14,752 5.2% 17%
Denmark 484,139 224,384 4.0% 12,352 9,605 15,152 5.5% 40%
Estonia 197,744 184,642 14.0% 5,432 3,822 7,038 2.9% 71%
Finland 257,044 141,953 2.6% 8,136 6,206 10,067 5.7% 75%
France 6,775,948 3,591,002 5.5% 212,538 131,238 380,923 5.9% 48%
Germany 10,426,860 5,398,700 6.7% 234,792 180,867 288,066 4.3% 49%
Greece 713,471 615,986 5.6% 43,163 36,636 49,346 7.0% 17%
Hungary 411,403 302,781 3.1% 15,286 13,649 16,940 5.0% 14%
Iceland 32,910 7,857 2.4% 421 349 494 5.4% 24%
Ireland 687,462 205,071 4.5% 13,196 10,935 15,574 6.4% >100%
Italy 5,319,754 3,443,409 5.8% 213,063 174,632 251,539 6.2% 19%
Latvia 278,243 267,617 13.2% 7,866 5,269 10,454 2.9% 28%
Liechtenstein 22,806 2,140 5.8% 97 74 119 4.5% 48%
Lithuania 139,712 121,992 4.1% 3,765 2,469 5,057 3.1% 6%
Luxembourg 189,858 28,085 5.5% 1,450 913 2,019 5.2% 52%
Malta 33,301 9,629 2.3% 637 429 860 6.6% 28%
Netherlands 1,772,756 1,052,695 6.3% 56,650 40,335 73,016 5.4% >100%
Norway 597,316 277,047 5.5% 17,021 12,125 21,979 6.1% 61%
Poland 659,657 438,446 1.1% 11,679 7,018 16,342 2.7% 2%
Portugal 854,830 475,155 4.5% 42,688 29,595 55,795 9.0% 30%
Romania 166,973 103,740 0.5% 7,531 5,453 9,581 7.3% 1%
Slovakia 155,346 25,170 0.5% 1,073 846 1,301 4.3% 3%
Slovenia 231,276 160,220 7.8% 5,713 3,756 7,663 3.6% 8%
Spain 5,930,170 1,909,343 4.1% 118,316 92,282 148,318 6.2% 38%
Sweden 1,304,130 596,303 6.2% 33,850 23,728 44,011 5.7% >100%
UK 6,845,805 3,976,870 6.3% 244,409 195,342 294,417 6.1% 72%
EU/EEA 48,622,832 25.911.421 5.1% 1,427,174 1,074,152 1,873,032 5.5% 25%
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Figure 2. Total (%) of foreign born migrant population in each EU/EEA country and the proportion 
(of all migrants) originating from HBsAg endemic countries (≥2%)
Migrants originating from China and Romania contribute the largest number of infections, 
with over 100,000 CHB cases each, followed by migrants from Turkey, Albania and Russia, in 
descending order, with over 50,000 CHB cases each. Table 3 lists the ten migrant populations 
with the highest estimated number of CHB cases, adding up to over 680,000 cases and 
corresponding to 48% of CHB cases among migrants from endemic countries in the EU/
EEA. Table 3 lists the EU host countries with the largest populations of migrants born in 
these countries. Estimates for the 50 migrant groups in each EU/EEA country can be found 
in Annex 9 of the online supplement.
Migrants from China, Romania and Russia are among the top ten migrant populations with 
the highest estimated number of CHB cases in 28, 19 and 18 respectively of the 31 EU/EEA 
countries as listed in Table 4. At least three of the ten migrant populations most affected by 
CHB in the Czech Republic, Denmark, Finland, Hungary, Iceland, Liechtenstein, Norway, the 
Netherlands and Sweden were born in South-East or East Asian countries including China, 
Vietnam, the Philippines and Thailand. People born in Yugoslavia before 1992 or in one of 
the former Yugoslav Republics since 1992 are represented among three or more of the top 
ten migrant populations with the highest number of infected cases in Austria, Liechtenstein 
and Luxembourg as well as in Croatia and Slovenia. Similarly, people born in the Soviet 
Union before 1991 or in one of the former Soviet Republics since 1991 are represented 
among three or more of the top ten migrant populations most affected by CHB in Bulgaria, 
Cyprus, the Czech Republic, Germany, Hungary, Poland, Romania and Slovenia as well as 
in the Baltic states of Estonia, Latvia and Lithuania (see Annex 9 of the online supplement).
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Table 3. The ten migrant groups (from HBsAg endemic countries) with the highest estimated 
number of CHB cases (rounded) and the main host EU/EEA countries
Migrant 
country of 
origin 
Total migrant 
population in 
Europe
HBsAg 
prevalence
Cumulative 
number of 
CHB cases
Host countries (first 6 with largest 
populations)*
Romania 2,817,458 5.5 154,679 Italy, Spain, Germany, Hungary, UK, Austria
China 1,012,550 10.2 103,585 UK, Italy, Spain, France, Germany, Netherlands
Turkey 2,266,977 4.3 97,255
Germany, France, Netherlands, Austria, 
Belgium, UK
Albania 804,570 9.0 72,412 Italy, Greece, Belgium, Austria, Bulgaria
Russia 1,810,197 2.9 52,315 Germany, Latvia, Estonia, Italy, Spain, Lithuania
Vietnam 365,048 12.5 45,557
France, Germany, Czech Republic, UK, Sweden, 
Norway
Nigeria 336,155 13.3 44,741 UK, Italy, Spain, Ireland, Netherlands, Austria
Kazakhstan 828,526 5.0 41,013
Germany, Latvia, Czech Republic, Poland, 
Lithuania, Estonia
Algeria 1,482,465 2.6 38544 France, Spain, Belgium, Italy, Ireland
India 1,120,352 3.2 36.188 UK, Italy, Germany, France, Spain, Ireland
Total 686,289§
* if migrant population is at least 1,000; § The sum of CHB cases among the ten migrant groups with the largest number of CHB 
cases (686,289) corresponds to 48% of the total number of CHB cases among migrants from endemic countries (1,427,174)
Table 4. Countries of birth of foreign-born migrants found amongst the ten migrant groups most 
affected by chronic hepatitis B in 10 or more of the 31 EU/EEA countries*
Migrant 
country of birth
Number of EU/EEA 
countries (of 31)
EU/EEA Countries
China 28
AUT, BEL, BLG, HR,  CZ, DK, DE, FIN, FR, EE,  HU, IRL, ISL, IT, LIE, LT, 
LUX, MT, NL, NO, PL, PT, RO, SK, SI, ES, SE, UK
Romania 19
AUT, BEL, BLG, HR, CY, CZ, DK, DE, GRC, HU, IRL, ISL, IT, LUX, MT, PL, 
PT, SK, ES, 
Russia 18
AT, BLG, HR, CY, CZ, DE, FIN, EE, GRC, HU, ISL, LT, LV,  MT, PL, RO, SK, 
SI
Ukraine 14 BLG, HR, CZ, DE, EE, HU, IT, LT, LV, PL, PT, RO, SK, SI
Vietnam 14 BLG, CY, CZ, DK, DE, FIN, FR, HU, ISL, NL, NO, PL, SK, SE
Turkey 12 AUT, BEL, BLG, DK, DE, FIN, FR, GRC, LIE, NL, RO, SE 
Moldova 11 BLG, CY, CZ, EE, IRL, IT, LT, LV, PT, RO, SI
Philippines 11 AUT, CY, DK, GRC, IRL, ISL, IT, MT, NO, ES, UK
Afghanistan 10 AUT, BEL, DK, DE, FIN, HU, NL, NO, SK, SE
Bosnia and 
Herzegovina
10 AUT, HR, DK, DE, LIE, LUX, NO, PL, SI, SE
*selected from the ten largest CHB affected migrant groups from intermediate/high endemicity countries in the EU/EEA 
countries
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In the UK, migrants from India, Pakistan and Bangladesh are among the top ten migrant 
populations with the highest number of infected cases. Migrants from Maghreb countries 
such as Algeria and Tunisia are represented in the top ten in France. Across the EU/ EEA, 
African countries of origin that contribute a large number of estimated cases include Eritrea, 
Ghana, Nigeria, Senegal, Somalia and South Africa. In Belgium, France, Luxembourg, Malta, 
Portugal and the UK, four or more of the ten migrant populations most affected by CHB are 
from African countries.
Relative contribution of migrants from endemic countries to the overall 
CHB burden in EU/EEA countries
The relative proportion of infected migrants from endemic countries among the overall 
number of CHB cases in EU/EEA countries is shown in Table 2 and Figure 3. Migrants from 
intermediate and high endemicity countries contribute more than 90% and, in some 
instances, up to 100% of the total estimated number of CHB cases in Cyprus, Ireland, the 
Netherlands and Sweden. Conversely, in Bulgaria, Poland, Romania and Slovakia, migrants 
contribute less than 4% of the total.
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Figure 3. Relative contribution of migrants to the total number of CHB cases per EU/EEA country
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Comparing migrant-derived HBsAg prevalence with country of origin 
estimates
Sixteen HBsAg prevalence studies in migrants residing in Europe were identified from the 
literature search for comparison with the in-country estimates derived in Part 1 (Table 
5). Prevalence figures for migrants from Suriname and the Dutch Antilles could only be 
compared with a regional estimate, since in-country data were not available from the 
review studies in Part 1.
In nine of the remaining 14 studies in migrants, HBsAg prevalence figures were lower 
than the derived in-country estimate. Prevalence among migrants was comparable with 
the in-country or region estimate for four migrant populations. HBsAg prevalence among 
migrants from Albania was higher than the in-country estimate.
DISCUSSION
The number of CHB cases in the general population of the 31 EU/EEA countries is estimated 
at between 4 million and 7.5 million cases, with a disproportionately high number of these 
cases found among migrants. Although migrants from endemic countries make up only 
one in 20 EU/EEA citizens, they account for one in four of all CHB infections. Migrants from 
ten countries account for 48% of all CHB cases among migrants in the EU/EEA.
The data suggest that the relative contribution of migrants to the overall CHB burden is 
higher in Western and Northern European countries than in Southern and Eastern European 
countries. The relative contribution of migrants to the overall burden of CHB is lowest (<4%) 
in EU/EEA countries with a higher HBsAg prevalence and a lower proportion of migrants 
such as Romania, Bulgaria, Slovakia and Poland. Conversely, the relative contribution is very 
high (>100%) in EU/EEA countries with a very low HBsAg prevalence such as Ireland, the 
Netherlands and Sweden. The estimate of over 100% is a result of the prevalence in the 
general population of the host country likely to be underestimated (because migrants and 
other higher risk, harder to reach populations are underrepresented in the samples used to 
determine this prevalence) or because the prevalence in countries of birth of migrants is an 
over-estimation of the actual prevalence among migrants.
To assess whether the country of birth prevalence estimates used are over-estimates, we 
compared these estimates to the prevalence reported in migrant studies in Europe and 
found evidence indicating an overestimation. Based on the epidemiologic features of HBV, 
the lower than in-country prevalence among migrants from 9 of 14 countries was surprising, 
since the infection is often acquired at birth or in early childhood in countries where 
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HBV is endemic. One explanation could be an age or cohort effect, since the estimates 
of in-country prevalence include older data from the 1980s and 1990s, while most of the 
migrant studies in Europe used for comparison were conducted after 2000. A recent study 
estimating hepatitis B prevalence by region showed a decrease in most regions between 
1990 and 2005.(6) This decrease is largely explained by the widespread introduction of 
antenatal HBV screening together with risk group and infant HBV vaccination programmes 
(23) and the resulting decline in incidence. The healthy migrant effect, the hypothesis that 
migrants are often younger and healthier than the general population in their countries 
of birth, may also be a factor.(24) Study design should also be considered. The figures for 
prevalence among migrants living in EU/EEA countries tend to be based on data from 
small-scale, local studies that mostly use convenience sampling, such as screening studies 
(Table 5). These may under-estimate the true prevalence because people who have already 
been diagnosed may not participate. Nevertheless, although prevalence among migrants 
from intermediate and high endemicity countries may not be as high as in the country of 
birth, the evidence strongly suggests that it is still considerably higher than among the host 
population in EU/EEA countries and high enough for screening of affected migrant groups 
to be cost-effective.(11, 25)
This study seeks to inform national screening efforts. The results suggests that an approach 
focused solely on migrants would have limited impact in most Eastern European countries, 
specifically Bulgaria, Lithuania, Poland, Romania, Slovakia and Slovenia, where the relative 
contribution of migrants to the overall national burden of CHB is low (between 1% and 
8%) and the  proportion of migrants from endemic countries is also low (<5%). In addition, 
Bulgaria, Lithuania, Romania and Slovenia are HBV-endemic countries with an HBsAg 
prevalence of >2.0% to 5.5%. A more effective approach would be to screen sub-groups of 
the general population, i.e. birth cohorts born before antenatal screening, childhood HBV 
vaccination and the regular screening of blood/blood products were introduced. Screening 
individuals potentially exposed to HBV through transfusions, transplants and dental or 
surgical procedures may also help to identify cases.
In contrast, targeted migrant screening approaches would be of value in countries such as 
Austria, Cyprus, Estonia, Finland, Ireland, the Netherlands, Sweden and UK, where more than 
70% of CHB cases are estimated to be among migrants from endemic countries. To optimise 
cost-effectiveness, screening should target those migrant populations that are most at risk 
of chronic viral hepatitis infection where the likelihood of detecting cases is higher.
Screening and subsequent contact tracing increases the diagnosis rate and, together with 
effective linkage to and retention in care and antiviral treatment, are the key to effective 
secondary prevention. The asymptomatic nature of the disease until its late stages and 
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the lack of awareness of risk among migrants and often also among health care providers 
limit early detection. Other barriers to screening include language, health care access and 
entitlement issues, high work-load among health care staff, and the potential stigma or 
fear associated with being diagnosed positive.(26, 27) The EU-funded HEPscreen project 
describes four different screening approaches: (i) outreach screening (e.g. through awareness 
raising and screening sessions in communities or workplaces); (ii) extension of existing 
screening programmes (e.g. expanding tuberculosis screening to include other diseases); 
(iii) opportunistic screening (e.g. offering viral hepatitis screening when patients attend 
for other health care services); and (iv) invitation-based screening (e.g. using municipal or 
general practice patient registers). Summaries of screening studies conducted using these 
different methods, practical guides on how to implement different screening approaches 
among migrants and resource and logistical considerations are available on the website 
http://www.hepscreen.eu/ and present a useful resource for public health practitioners.(28)
Undocumented migrants are also an important and vulnerable group. Lack of robust 
demographic data and the diversity in size and country of birth of undocumented migrants 
(29) hinder effective planning, resourcing and evaluation of screening interventions for 
this population. In addition, undocumented migrants face specific access and entitlement 
challenges when accessing public health services. Promoting voluntary screening for this 
vulnerable group would have public health benefits, but would require national policies 
that allow undocumented migrants to receive treatment without adverse consequences.
The systematic approach to estimation of the burden of CHB among migrant populations 
in the EU/EEA overall and in each of the 31 EU/EEA countries is a strength of this study. The 
data that underpin these estimates are derived from a common demographic data source 
(Eurostat 2013) for most countries and from published meta-analytic studies. A potential 
limitation is that, for some countries, demographic data from earlier years and other sources 
had to be used. In addition, there are differences in population registration and reporting 
systems between EU/EEA countries. However, using data from 2013 or earlier has the 
advantage of limiting the effect of reporting delays with respect to accurate numbers of 
migrants and their countries of birth.
Using country of birth prevalence data to estimate the CHB burden among migrants may 
have resulted in a degree of over-estimation for some countries, because of differences in 
the age structure, risk profile and socioeconomic status between different migrant groups. 
Migrants sharing the same country of birth but residing in different EU/EEA countries may 
also differ in terms of risk profile as a result of differences in host country pull factors and 
reasons for migration. Data allowing a comparison of prevalence figures between the 
general population in the migrants’ countries of birth and from studies among migrants in 
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Europe were however only available for 14 countries. An additional strength of this study is 
that, even if the absolute number of estimated CHB cases lies closer to the lower estimate, 
it identifies which migrant populations would benefit most from targeted screening 
programs and linkage to care.
CONCLUSIONS
Today, anti-viral treatments for CHB can benefit most patients, offering the prospect 
of significant public health gains through secondary prevention. Expanded access to 
screening, linkage to care and treatment, together with the continued implementation of 
existing primary prevention measures such as vaccinaiton and antenatal screening, are the 
cornerstones of eliminating viral hepatitis as a global public health threat in the next few 
decades.
This study confirms that migrant populations are a key risk group for CHB in specific EU/EEA 
countries. It details the number of CHB cases among migrants by country of birth in each EU/
EEA country, identifies the migrant populations that would benefit most from screening and 
treatment, and highlights which EU/EEA countries would benefit from a migrant-targeted 
screening approach. The findings in this study about which migrant groups are at highest 
risk is also useful for developing linguistically-specific and culturally-sensitive screening 
programmes and raising awareness among physicians so that they offer screening. Efficient 
and innovative public health approaches to increase access to screening and to screen 
high-risk populations are needed. Experience from a migrant-specific screening project 
conducted at the EU/EEA level (28) can help to inform the design of screening programmes 
that can successfully reach migrant communities. Planners and practitioners can also use 
the results presented here and those from the HEPscreen project to develop evidencebased 
screening interventions that target the most affected migrant populations.
Further research is required to inform the development and assessment of effective and 
cost-effective screening interventions and long-term patient follow up, as well as to improve 
linkage to and retention in treatment and care among hard to reach risk populations, if we 
are to realise the vision of a world free of viral hepatitis.
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ABSTRACT
Background/aims: Increasing the proportion diagnosed with and on treatment for chronic 
hepatitis C (CHC) is key to the elimination of hepatitis C in Europe. This study contributes 
to secondary prevention planning in the European Union/European Economic Area (EU/
EEA) by estimating the number of CHC (anti-HCV positive and viraemic) cases among 
migrants living in the EU/EEA and born in endemic countries, defining the most affected 
migrant populations, and assessing whether country of birth prevalence is a reliable proxy 
for migrant prevalence.
Methods: Migrant country of birth and population size extracted from statistical databases 
and anti-HCV prevalence in countries of birth and in EU/EEA countries derived from a 
systematic literature search were used to estimate caseload among and most affected 
migrants. Reliability of country of birth prevalence as a proxy for migrant prevalence was 
assessed via a systematic literature search.
Results: Approximately 11% of the EU/EEA adult population is foreign-born, 79% of whom 
were born in endemic (anti-HCV prevalence ≥1%) countries. Anti-HCV/CHC prevalence 
in migrants from endemic countries residing in the EU/EEA is estimated at 2.3%/1.6%, 
corresponding to ~580,000 CHC infections or 14% of the CHC disease burden in the EU/
EEA.
The highest number of cases is found among migrants from Romania and Russia (50-60,000 
cases each) and migrants from Italy, Morocco, Pakistan, Poland and Ukraine (25-35,000 cases 
each). Ten studies reporting prevalence in migrants in Europe were identified; in seven of 
these estimates, prevalence was comparable with the country of birth prevalence and in 
three estimates it was lower.
Discussion: Migrants are disproportionately affected by CHC, account for a considerable 
number of CHC infections in EU/EEA countries, and are an important population for targeted 
case finding and treatment. Limited data suggest that country of birth prevalence can be 
used as a proxy for the prevalence in migrants.
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BACKGROUND
Chronic infection with the hepatitis C virus (HCV) is a global public health challenge and a 
leading cause of liver disease-related morbidity and mortality. The epidemiology remains 
poorly understood, however, and global, national and risk group-specific anti-HCV and 
viraemic prevalence estimates vary considerably. Recent studies suggest that between 
105 million and 185 million people are anti-HCV positive worldwide and that global anti-
HCV prevalence in adults could be as high as 2%.(1, 2) The Global Burden of Disease study 
estimated that chronic HCV (CHC) infection causes almost half a million deaths annually 
and is the 25th leading cause of death worldwide.(3)
Chronic HCV infection affects the liver and has a mostly asymptomatic onset, but can lead 
to cirrhosis and hepatocellular carcinoma (HCC) decades later.(4) The asymptomatic nature 
of infection and the lack of adequate screening programmes means that the majority of 
people infected with CHC are unaware of their infection and only around one third of all 
estimated CHC infections in Europe have been diagnosed.(5-7) Effective antiviral treatment 
can prevent the development of cirrhosis and HCC and, with newer direct acting antivirals 
(DAAs) reporting cure rates in more than 90% of cases, (8) the elimination of HCV infection is 
now possible in Europe.(9) This will require continued primary prevention of new infections 
in parallel with expansion of secondary prevention through effective screening, linkage to 
care and treatment.
Primary prevention measures in Europe, including a safe blood supply, improved infection 
control practices and harm reduction programmes, have led to a significant reduction of 
HCV transmission in many countries and a mathematical modelling study shows incident 
cases are declining.(10) Incident data is not systematically collected and reported in most 
EU/EEEA countries hampering a good understanding of time trends although iatrogenic 
and nosocomial transmission is reported to be rare in most EU/EEA countries.(11) However, 
models predict that the peak in the mortality is yet to be reached.(9, 10, 12) An estimated 7.4 
million people are anti-HCV positive in the European Union/European Economic area (EU/
EEA), although prevalence varies from 0.9% in Western Europe to 3.3% in Eastern Europe.(1, 
13) Deaths from viral hepatitis now exceed those from HIV and tuberculosis combined and 
latest published estimates show that 96,000 people die each year in EU/EEA countries from 
HBV and HCV-related liver disease.(3) Some populations are disproportionately affected 
and have a high prevalence of chronic infection. One such population is migrants born in 
high anti-HCV prevalence countries (10, 14-16), although estimates of the number of cases 
and the most affected migrant populations in Europe are lacking. This epidemiological 
study seeks to inform targeted screening, linkage to care and treatment in the EU/EEA by: 
providing estimates, across and within all 31 EU/EEA countries, of the number of CHC cases 
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among migrants from countries where anti-HCV prevalence is ≥1%; providing an estimate 
of the relative contribution of migrants to the overall burden of disease; and comparing the 
reported in-country of birth prevalence with that found among migrants living in European 
countries. In a sister paper to this, we conduct a similar analysis for chronic hepatitis B 
among migrants from endemic countries.
METHODS
The data retrieval and analysis process are described in detail below and in a schematic 
representation (Figure 1). Demographic data on the size of and countries of birth of migrant 
populations were extracted from statistical databases. Country of birth-specific and EU/EEA 
country general population anti-HCV prevalence estimates were derived from a systematic 
literature search. To assess the reliability of using country of birth-derived prevalence as a 
proxy for the prevalence among migrants, a systematic literature search was conducted to 
identify prevalence estimates among migrants in Europe to compare with country of birth-
derived prevalence.
Definitions
Migrant: an adult 15 years old or above, born in a country other than the current 
country of residence. Children are excluded due to the dominance of older age 
populations in sero-prevalence studies and the higher prevalence reported among 
adults than among children. (1) The use of the term ‘migrant’ in this study therefore 
refers to adult (foreign-born) migrants only. The study accounts for and includes 
migration from outside the EU/EEA and migration within the EU/EEA, but excludes 
undocumented migrants.
Anti-HCV prevalence: the common measure of exposure to HCV/endemicity used 
in seroprevalence studies. Anti-HCV prevalence can include exposed individuals with 
a resolved infection.
Chronic hepatitis C (CHC): refers to viraemic infection, i.e. anti-HCV and HCV-RNA 
positivity.
Endemic country: the anti-HCV prevalence in the general adult population is ≥1%. 
This relatively low threshold was chosen to take into account migrants from countries 
where prevalence is higher than that of the EU/EEA as a whole.
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Figure 1: Schematic representation of the methodological process to estimating the burden of 
chronic hepatitis B among (adult (>15 years) migrants in the EU/EEA 
 
 
 
Step 1: Retrieve demographic data 
from European statistical databases for 
each EU/EEA Member State (MS): 
 Total adult population  
 Size and proportion of adult foreign‐
born (migrant) population by country 
of birth 
Step 2: Retrieve country‐specific anti‐HCV prevalence:
 Via a systematic literature search of worldwide reviews and meta‐
analyses (2009 – 2014) 
Select the 50 largest (by absolute 
number) adult migrant groups (by 
country of birth) in each EU/EEA MS 
Estimate CHC cases among these top 
migrant groups in each EU/EEA MS 
 Apply 70% viraemic ratio to anti‐HCV 
prevalence in country of birth 
 For each country of birth, multiply both 
anti‐HCV and viraemic prevalence with 
the number of adult migrants in each 
EU/EEA MS 
Estimate CHC cases among the 
adult general population in each 
EU/EEA MS 
 Apply 70% viraemic ratio to MS‐
specific anti‐HCV prevalence 
 Multiply both anti‐HCV and 
viraemic prevalence by population 
size in each EU/EEA MS 
Estimate the proportion of adult 
migrants from endemic countries  
 To the total adult population in 
each EU/EEA MS  
 To the total foreign‐born adult 
population in each EU/EEA MS  
 In the EU/EEA as a whole 
Analysis:
 Sort in descending order countries of 
birth by anti‐HCV prevalence and then 
by absolute number of CHC cases in 
each EU/EEA MS  
 Identify anti‐HCV endemic (≥1% 
prevalence) countries of birth.  
 Sum adult migrant population from 
endemic countries in each EU/EEA MS  
 Sum adult migrant population from 
endemic countries across EU/EEA
Define the ten most affected 
migrant groups in each EU/EEA MS 
 The ten countries of birth with the 
highest estimated number of CHC 
cases 
Estimate EU/EEA anti‐HCV 
prevalence 
 Sum number of anti‐HCV cases 
across all EU/EEA MS  
 Divide total number of anti‐HCV 
cases  in the EU/EEA by total adult 
EU/EEA population 
Estimate total number of CHC cases and average CHC prevalence 
 Among adult migrants from endemic countries in each EU/EEA MS 
 Across the EU/EEA as a whole 
Estimate relative contribution in each EU/EEA MS
Proportional contribution (and lower/upper range) of CHC 
cases (among adult migrants from endemic countries) to the 
total number of CHC cases in the general population 
Estimate relative contribution in the EU/EEA as a whole 
Proportional contribution (and lower/upper range) of CHC 
cases (among adult migrants from endemic countries) to the 
total number of CHC cases in the general population of the 
Compare migrant‐derived with 
country of birth‐derived prevalence 
 Determine whether estimates are 
comparable (lie within the range) 
or not (outside lower/upper range) 
 Extract anti‐HCV sero‐prevalence 
estimates from large single studies  
 Pool estimates by combining cases 
and sample size among migrants 
born in the same country 
 Recalculate 95% CI using Fishers 
exact 
Identify migrant‐specific anti‐HCV 
prevalence estimates 
 In EU/EEA MS 
 Via a systematic literature search 
for studies published 2000 – 2014 
 Among subjects representative of 
the general migrant population  
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Figure 1. Schematic representation of the methodological process to estimating the burden of 
chronic hepatitis B among (adult (>15 years) migrants in the EU/EEA
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PART 1: THE CONTRIBUTION OF MIGRANTS FROM ENDEMIC 
COUNTRIES TO THE BURDEN OF CHC IN THE EU/EEA
Demographic data (Step 1)
The size and country of birth of the migrant population was obtained for all 31 EU/EEA 
countries from Eurostat for 2013, if available (17). Where data were unavailable, either 
the ‘EU 2011 – Housing and Population Census’, the most recent demographic data from 
the Organisation for Economic Co-operation and Development (OECD) Stats website or 
national statistics were used, in that order.(18-20) The data source is indicated in footnotes 
in Table 1. For each EU/EEA country, the countries of birth of migrants were sorted into 
descending order of magnitude of the number of migrants, and the top 50 countries of 
birth by migrant population size were then selected for estimating the CHC burden.
Country-specific anti-HCV prevalence (Step 2)
The online databases Medline, Embase, the Cochrane library, Web of Science, Scopus, 
PubMed publisher and Google Scholar were searched in January 2015 for reviews, 
systematic reviews and meta-analyses in English about the prevalence of hepatitis C in 
the general population at country level. The search (described in full in Annex 1 of the 
online supplement) used a combination of disease-related (hepatitis C), outcome-related 
(prevalence), population-related (general population, worldwide) and study design-related 
(reviews) terms. Note that the search also included terms related to hepatitis B since we 
conducted a similar analysis for chronic hepatitis B among migrants from endemic countries 
(to be published in this journal). Since the aim was to identify recent reviews, the search was 
restricted to papers published after 2009 to the date of the search. The titles and abstracts, 
then the full text, of retrieved citations were assessed for relevancy by one reviewer (AF). Key 
exclusion criteria included studies focused on: hepatitis other than type C; natural history, 
clinical features or complications of hepatitis; medical treatment; other high risk groups e.g. 
people who inject drugs (PWID); and single case studies and cost effectiveness analyses. 
High quality systematic reviews/meta-analyses were selected given the recent publication 
of robust systematic reviews/meta-analyses of national level prevalence estimates globally.
Country-level anti-HCV prevalence estimates and uncertainty ranges/confidence intervals 
(CIs) were extracted from the included reviews and entered into a Microsoft Excel database 
of all countries. Where a country-specific estimate was unavailable, the relevant Global 
Burden of Disease region estimate was used. If a meta-analysis reported a statistically 
significant time trend, the estimate from the most recent period was selected. Where 
multiple estimates for a country were available from different reviews, the most robust was 
selected based on the assessed risk of selection bias. Risk of selection bias was assessed 
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based on: sampling method (random favoured over convenience); sampling population (the 
general population was favoured over more specifically defined (risk) groups); geographical 
coverage (national favoured over regional; regional favoured over local); sample size (larger 
studies preferred over smaller one); and data collection timeframe (favouring recency). 
Decisions were made jointly by two reviewers (AF and IV) based on these criteria (rather 
than a pre-defined algorithm) with a detailed rationale recorded for each selected estimate. 
This rationale, together with search strategy, the inclusion/exclusion criteria and a PRISMA 
flowchart are available in the online supplement.
Estimating the CHC burden among migrants from endemic countries
Anti-HCV prevalence was multiplied by the number of migrants from the top 50 countries 
of birth of migrants in each EU/EEA country. The countries of birth were then sorted in 
descending order of magnitude by anti-HCV prevalence to identify all endemic (≥1% 
anti-HCV prevalence) countries. The total number of migrants born in anti-HCV endemic 
countries was used to determine both the total and proportional contribution of migrants 
from these countries to the overall number of migrants residing in each of the 31 EU/EEA 
countries. To estimate the proportion of CHC (viraemic) cases among the anti-HCV positive 
migrant population, the worldwide average viraemic proportion of 70% found in a recent 
global meta-analysis was applied.(1)
Relative contribution
For each EU/EEA country, the estimated number of infected cases among migrants from 
endemic countries was divided by the total number of infected persons (based on the 
general population CHC prevalence estimate and the total population) to estimate the 
relative contribution of migrants from endemic countries to the overall number of people 
infected with CHC. Given uncertainty in both the size of the migrant population and CHC 
prevalence estimates in countries of birth, a range in the relative contribution (a lower limit 
and a higher limit) was also calculated using the Delta method.(21)
PART 2: ANTI-HCV PREVALENCE IN MIGRANT POPULATIONS IN 
EUROPE
The online databases Medline, Embase, the Cochrane library, Web of Science, Scopus, 
PubMed publisher and Google Scholar were searched in November 2014 for studies in 
English that estimate the prevalence of hepatitis C in migrants in any of the 31 EU/EEA 
countries. The search used a combination of disease-related (hepatitis C), outcome-related 
(prevalence), population-related (migrants) and geographical area (EU/EEA countries) 
terms and was limited to studies published between 2000 and 2014. We expected a limited 
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retrieval from this search and therefore included only selection bias (how representative 
the study population was of the general population) as a key parameter in the risk of bias 
assessment. This operationalised through the exclusion of studies sampled from higher risk 
migrant groups such as refugees/asylum seeker and higher risk (general) populations such 
as STI clinic attendees, outpatient clinics, international health centres etc. The full search 
strategy, inclusion/exclusion criteria and PRISMA flowchart are available in the online 
supplement.
Data from the included studies were entered into Microsoft Excel. Pooled estimates for 
countries of birth were produced by combining the numbers tested and the number of 
cases. A 95% CI was re-calculated using the Fisher’s exact method. Prevalence estimates 
pooled from multiple studies or extracted from large single studies (>25 subjects from 
a single country) were compared with the in-country estimates to determine whether 
in-country estimates reflect the prevalence found among migrants. When the point 
prevalence from a study in migrants (Part 2) fell within the CI/uncertainty range of the in-
country estimate (from Part 1), this estimate was considered to be comparable; when it fell 
below the lower CI/uncertainty range, it was considered to be lower than the in-country 
prevalence; and when it was higher than the upper CI/uncertainty range, it was considered 
to be higher.
RESULTS
Estimated CHC prevalence and number of infected cases in 31 EU/EEA 
countries (Table 1)
The anti-HCV prevalence in the general population in the EU/EEA is estimated at 1.4% 
(range of 0.7-2.2%). However, prevalence estimates range from 0.2% in the Netherlands to 
4.4% in Italy and 14 EU/EEA countries are considered endemic by the definition adopted in 
our study (≥1% anti-HCV prevalence). Table 1 lists the estimated number and range of CHC 
cases among adults in EU/EEA countries. An estimated 4.2 million (range 2.0-6.6 million) 
adults in the EU/EEA have CHC infection. Italy has the highest absolute number, with an 
estimated 1.6 million CHC cases. Other EU/EEA countries with a high absolute number of 
CHC cases among adults are Romania, with 380,000, and Spain, with 470,000.
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5
The distribution of migrants in the EU/EEA based on HCV endemicity in 
country of birth
The top 50 migrant populations in each EU/EEA country included in the analysis make up 
at least 95% of the total migrant population in 19 countries and at least 90% in all but three 
EU/EEA countries (Denmark, Sweden and the United Kingdom, where the proportion is at 
least 85%). These migrant populations account for approximately 10.7% of the total adult 
population in the EU/EEA although the proportion in each country varies, ranging from 
0.7% in Romania, 1.1% in Bulgaria and 1.7% in Poland to 42.0% in Luxembourg and 65.2% 
in Liechtenstein (Figure 2).
Nearly 80% of the total migrant population were born in HCV endemic countries. Other 
than in Slovakia, where 23% of the total migrant population are from endemic countries, 
over half of all migrants in the other 30 EU/EEA countries were born in countries where the 
anti-HCV prevalence is ≥1%. In Croatia, Estonia, Latvia, Lithuania, Romania and Slovenia, 
more than 90% of all migrants are from endemic countries (Figure 2). The number and 
proportion of all migrants that from endemic countries, at country level and in the EU/EEA 
as a whole are shown in Table 1.
Country-specific anti-HCV prevalence estimates
The most comprehensive review with country-specific estimates of anti-HCV prevalence 
identified by the search was published in 2014 by Gower et al.(1) This review includes 
studies published after the year 2000 and provides estimates for 87 countries and for each 
of the 21 Global Burden of Disease regions. The country-level estimates from Gower do not 
have 95% CIs but a lower and upper uncertainty range; the lower range is based on studies 
among populations considered representative of ‘healthy adults’ (such as blood donors), 
but the methodology applied to derive the upper limit is unclear. For nine countries, 
Gower’s regional or in-country estimate was replaced with estimates from other systematic 
reviews deemed more robust according to the criteria described in the methods. (2, 22-26) 
The 224 country-level prevalence estimates and the source, together with an overview of 
decision rationale where an estimate other than Gower was available, are listed in the online 
supplement.
Estimated prevalence and number of CHC infections among migrants
Across the EU/EEA, the overall anti-HCV prevalence among migrants from endemic 
countries is estimated at 2.3%, which corresponds to a CHC prevalence of 1.6% and an 
estimated 580,000 CHC infections (Table 2). The estimated prevalence of CHC infection 
among migrants from endemic countries ranges from 0.9% in Croatia to 2.4% in Estonia. 
Table 2 lists the ten migrant populations with the highest estimated number of CHC cases 
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and the host EU/EEA countries with the largest populations of migrants born in these 
countries. Based on cumulative analysis of the CHC burden among the different migrant 
populations from endemic countries to or within the EU, migrants from Romania, Russia, 
Italy and Poland contribute most, in descending order, to the overall number of CHC cases. 
An estimated 50,000-60,000 CHC cases are found among migrants from Romania and from 
Russia.
Table 2. The ten migrant groups (adults from endemic countries) accounting for the highest 
number of CHC cases
Migrant 
country of 
birth
Total 
migrant 
population
Anti-HCV 
prevalence
Number# 
of CHC 
cases
Host countries (first 6 with largest 
populations)*
Romania 2,646,392 3.2 59,000 Italy, Spain, Germany, Hungary, UK, Austria
Russia 1,713,636 4.1 49,000 Germany, Latvia, Estonia, Italy, Lithuania, Spain
Italy 1,114,683 4.4 34,000
France, Germany, UK, Belgium, Spain, 
Netherlands
Poland 4,103,409 1.1 32,000 Germany, UK, Italy, France, Ireland, Netherlands
Morocco 2,418,072 1.6 27,000
France, Spain, Italy, Belgium, The Netherlands, 
Germany
Pakistan 756,170 5.0 27,000 UK, Italy, Spain, Germany, Greece, France
Ukraine 993,459 3.6 25,000
Poland, Germany, Italy, Czech Republic, Spain, 
Latvia
Egypt 194,852 15.7 21,000 Italy, UK, France, The Netherlands, Austria, Greece
Kazakhstan 807,781 3.3 19,000
Germany, Latvia, Czech Republic, Poland, 
Lithuania, Estonia
Nigeria 313,212 8.4 18,000 UK, Italy, Spain, Ireland, Austria, Netherlands
# rounded to nearest 1,000;  * if migrant population is at least 1,000
Some countries of birth of migrants are common across EU/EEA countries. Adult migrants 
from Russia, a high CHC prevalence country (2.9%), are represented among the top ten 
migrant populations in 25 of 31 EU/EEA countries. Migrants from Romania and Italy are 
among the top ten migrant groups in 20 EU/EEA countries. Although small in number, 
migrants from Egypt are among the top ten CHC-infected migrant populations in 16 of 
31 EU/EEA countries due the very high anti-HCV prevalence (15.7%) in Egypt. In Estonia, 
Lithuania and Latvia, the top ten migrant populations with the highest number of infected 
cases are all from countries of the former Soviet Union. This is also the case in five to six of 
the top ten migrant populations with the highest number of infected cases in Bulgaria, 
the Czech Republic and Poland. People born either in Yugoslavia before 1992 or in one of 
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the countries that emerged from the fall of Yugoslavia since 1992are represented in six of 
the top ten migrant populations with the largest of number of CHC cases in Croatia and 
Slovenia and three of the top ten in Austria. Migrants from the Algeria, Morocco and Tunisia 
are represented among the ten most CHC-affected migrant populations in France. EU/EEA 
countries with three to five African countries represented among the top ten CHC-affected 
migrant groups include Belgium, France, Luxembourg, Portugal and the UK. Prevalence, 
population size and number and range of CHC infections among, for all 50 countries of birth 
of migrants in each EU/EEA country can be found in the online supplement.
Relative contribution of migrants to the CHC burden in EU/EEA countries
The relative proportion (and range) of infected migrants from endemic countries within 
the overall CHC burden in EU/EEA countries is shown in Table 1 and Figure 3. The relative 
contribution is low (<4%) in Bulgaria, Poland, Romania and Slovakia and much higher (64%-
92%) in Cyprus, Liechtenstein, Luxembourg and the Netherlands.
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Figure 3. Estimated relative contribution (and range) of migrants to the total number of CHC cases
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Comparing migrant-derived anti-HCV prevalence with country of birth 
estimates
The literature search identified thirteen anti-HCV prevalence estimates from studies in 
migrants in the EU/EEA for comparison with the in-country estimates derived in Part 1. 
Two of the thirteen estimates, from studies among migrants from the former Dutch Antilles 
and Suriname, were higher than the comparator regional prevalence.(1) One estimate, from 
a study among migrants from the former Soviet Union, could not be compared with in-
country anti-HCV prevalence since this nation state is now dissolved. Of the remaining ten 
estimates, seven were comparable with the in-country estimate and three, among migrants 
from Egypt, Pakistan and Turkey, were lower than the in-country prevalence (Egypt: 2.4% in 
migrants vs. 15.7% in-country; Pakistan: 2.8% in migrants vs. 5.5% in-country; and Turkey: 
0.2% in migrants vs. 1.0% in-country), although for Turkey the two confidence intervals 
overlap. See Table 3 for details.
Table 3. Comparing migrant study-derived prevalence to country of birth-derived prevalence
Country of 
birth
Migrants In-country
ComparisonN. 
tested
Prevalence 
(95% CI)
Reference
Prevalence
(95% CI)
Reference
Afghanistan 293 1.0 (0.2 – 3.0) (32) 1.1 (0.6 – 1.9) (1) Comparable
Bangladesh 934 0.4 (0.1 – 1.1) (52, 53) 1.3 (0.2 – 2.2) (1) Comparable
Dutch Antilles 38 2.6 (0.1 – 13.8) (15, 45) 0.8$  (0.2 – 1.3) (1) Higher
Egypt 465 2.4 (1.2 – 4.2) (54) 15.7 (13.9 – 17.5) (25) Lower
Former USSR 65 3.1 (0.4 – 10.7) (32) 3.3* (1.6 – 4.5) (1) Comparable
India 1334 0.4 (0.2 – 1.0) (52, 53) 0.8 (0.4 – 1.0) (1) Comparable
Iran 153 0.7 (0 – 3.6) (32) 0.5 (0.2 – 1*) (1) Comparable
Iraq 290 0.3 (0 – 1.9) (32) 3.2 (0.3 – 3.2*) (1) Comparable
Morocco 331 0.9 (0.2 – 2.6) (15, 45) 1.6 (0.6 – 1.9*) (1) Comparable
Pakistan 3562 2.8 (2.3 – 3.4) (30, 52, 53) 5.5 (4.4 – 5.5) (26) Lower
Suriname 225 2.4 (0.5 – 7.0) (15, 45) 0.8$  (0.2 – 1.3) (1) Higher
Turkey 965 0.2 (0 – 0.8) (15, 45, 46) 1.0 (0.7 – 1.1) (22) Lower
Vietnam 126 1.6 (0.2 – 5.6) (32) 1.0 (0.8-1.8) (1) Comparable
*Regional estimate from GBD Eastern European region; $ Caribbean GBD Regional estimate
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DISCUSSION
This is the first study we know of that attempts to systematically estimate the overall 
number of CHC cases among migrants, as well as the relative contribution of cases among 
migrants to the overall burden of CHC in EU/EEA countries. Migrants from endemic 
countries account for one in 12 EU/EEA adult citizens and for one in seven of all CHC cases 
in the EU/EEA. As the contribution of migrants to the overall burden of CHC varies between 
EU/EEA countries, effective approaches to secondary prevention will, therefore, also differ. 
Screening programmes targeting migrant populations will be most effective in EU/EEA 
countries such as Austria, France, Germany, the Netherlands and the UK where migrants 
account for a large proportion of the disease burden (32%-92%, see Figure 3) and a small 
proportion of the total population (7%-15%, see Figure 2).
In contrast, in countries where HCV prevalence is high in the general population and the 
contribution of migrants is low, it may be more cost-effective to implement population-
based screening. (27) (28) Examples of such countries include Bulgaria, Poland, Romania 
and Slovakia where less than 4% of the CHC burden is attributable to migrants from 
endemic countries. The differences in general population prevalence between EU/EEA 
countries, together with the contribution of migrants moving within the EU/EEA from high 
to low prevalence countries, suggests that there may also be value in allocating EU health 
funding to scale up and systematise screening and treatment efforts in EU/EEA countries 
with a high general population prevalence, to strengthen efforts to reduce cross-border 
health threats and to improve overall population health in the EU. A recent modelling study 
estimated that only around a third of all CHC cases across Europe have been diagnosed 
and that there are wide differences in both the proportion diagnosed and the proportion 
on treatment comparing EU/EEA countries.(6) There is however no data on the estimated 
proportion of migrants from endemic countries that are diagnosed. The data reported, as 
well as the strategies and interventions suggested, in this study can contribute to increasing 
the proportion of cases of CHC diagnosed and on treatment.
Previous studies of hepatitis B/C screening implemented among migrant populations 
describe different models. These include: outreach offering awareness raising and/or on-
site screening by public health teams in social, civic or cultural locations familiar to the 
target community (29-31); invitation-based screening where municipal, population or 
patient registries are used to send postal invitations to attend screening to people born in 
higher prevalence countries (32, 33); opportunistic offering of screening to patients with 
country of birth-related risk factors who attend health care services for other health issues 
(34, 35); and adding viral hepatitis screening to an existing screening programme, such 
as for tuberculosis, that targets people from high prevalence countries (36). Each of these 
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models differs in terms of logistical and resource requirements, uptake and case yield, but 
few studies have compared the characteristics and effectiveness of different models (37). 
The characteristics of screening programmes that have demonstrated success in uptake 
and yield include: involvement of the community in planning and raising awareness; 
provision of screening in suitable and accessible locations for the target community; 
provision of language support, for example, translated materials and interpreters; planning 
and provision for people without health insurance coverage; cultural sensitivity about 
and efforts to reduce or eliminate stigma; and availability of follow-up and care in the 
community. Retention within a follow-up care and treatment pathway is crucial to ensure 
that the public health benefits of screening are realised (38). A summary of migrant-specific 
screening programmes, an appraisal of factors contributing to success, and a range of other 
scientific and practical resources are available as part of the HEPscreen Toolkit, produced 
by the EU-funded HEPscreen project, which focused on screening for chronic viral hepatitis 
among migrants (39).
In four countries, (Cyprus, Lichtenstein, Luxembourg and the Netherlands) the upper range 
of the estimated relative contribution of migrants as a proportion of the total number 
of estimated cases was found to be over 100%. This reflects unmeasured correlation 
between the input parameters (prevalence in countries of birth and the size of the migrant 
population) for the Delta method as well as the strong skew in the distribution of cases 
in the general population in these countries. It is also possible that the prevalence in the 
general population in these EU/EEA countries is under-estimated, due to unrepresentative 
sampling or low participation of risk populations who are harder to reach, such as PWID 
and ethnic minorities as well as migrants. Under-representation of migrants and ethnic 
minorities is a widely recognised phenomenon in clinical trial and health survey research, 
(40, 41) although literature specifically focused on sero-prevalence sampling and uptake is 
very limited. (23) In addition, it is possible that estimates based on prevalence in countries of 
birth results in over-estimation of the prevalence among migrants. For example, it is probable 
that no longer living in a high prevalence country would reduce the risk of transmission of 
HCV, especially since much of the transmission in higher prevalence countries is nosocomial 
(42) and most EU/EEA countries have successfully controlled nosocomial transmission 
through health care infection control procedures. Over-estimation may also be due to the 
characteristics of migrants to the EU/EEA, who may be younger and healthier, and so less 
likely to have experienced hospitalisation or serious medical intervention and more likely 
to have benefited from improved primary prevention in the last two decades. Migrants to 
the EU may also be from higher socio-economic groups in their countries of birth and able 
to afford better, safer health care (43).  We sought to test out this theory of over-estimation 
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and found that, for just three of the ten countries of birth for which we retrieved estimates 
for, (15, 29, 30, 44-47) the prevalence in migrants was lower than the reported in-country 
prevalence.
Despite the systematic nature of data retrieval, there are some data limitations. Detailed 
demographic data was available from Eurostat for only 21 EU/EEA countries. There is also 
heterogeneity in the parameters and methods used by the different demographic databases 
and in the way that demographic data on migration is collected and reported by EU/EEA 
countries. From other literature, we know that countries such as Germany, France and the 
Netherlands require municipal registration upon arrival in a new area and collect country 
of birth data as part of registration. Other countries, like the UK, rely on population census 
data to systematically collect population size and origin.(48) However, there is very limited 
information in the literature on the methods used by each database or on the heterogeneity 
of demographic data collection methods across the EU/EEA. Despite these differences, the 
demographic data used in this study are derived from databases that in turn derive data 
from national statistical institutes. We believe it to be the best and most reputable available. 
These analyses do not include undocumented migrants, partly because the size and origin 
of this population is very dynamic, but mostly because of the imprecision and unreliability 
of the data.(49) The use of systematic reviews and meta-analyses for the country of birth 
prevalence input has reduced the reliance on less reliable single study estimates, and whilst 
we critically appraised the quality of the systematic reviews and meta-analyses, which 
all applied quality criteria to select studies, we did not directly assess the quality of the 
estimates included in these reviews. A further note of caution relates to the studies retrieved 
on prevalence in migrants, as just ten countries of birth were represented in the estimates 
and few studies had the specific aim of estimating the prevalence in migrants. The use of 
convenience sampling in many of these studies increases the chance of selection bias and, 
specifically, that people already diagnosed may not present for screening.
CONCLUSIONS
Advances in antiviral treatment open up the possibility of eliminating hepatitis C 
infection in Europe, but achieving this will require countries to scale up and better target 
screening, linkage to care and treatment. This study provides strategic, timely and detailed 
epidemiological intelligence for EU/EEA countries on the hepatitis C burden among 
migrant populations, a key population group affected by this infection in Europe. It also 
provides prevalence estimates for 224 countries and territories, which should serve as 
a useful resource for other countries and regions wishing to understand the relative 
contribution of migrants to the burden of hepatitis C. This intelligence, together with the 
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learning from previous migrant-specific screening projects in the EU/EEA (39), can help to 
inform the design of screening programmes to reach migrant populations most affected by 
chronic hepatitis C infection. A targeted approach in higher risk populations makes more 
effective use of health care resources and contributes to reducing health inequalities. The 
World Health Organisation’s Global Strategy for Viral Hepatitis (50) and the European Action 
Plan (51) both share the ambitious goal of elimination of viral hepatitis by 2030. If this goal 
is to be realised, it will be essential to dramatically increase the proportion of people who 
are diagnosed, aware of their infection and on treatment.  Future research can contribute 
by focussing on improving the evidence base on effective strategies to reach and retain 
migrant and other risk populations in screening and treatment and on cost-effectiveness 
across the treatment cascade.
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ABSTRACT
Background: Migrants born in endemic countries are a key risk group for chronic hepatitis B 
and C virus (HBV/HCV) infection in many EU countries. In the EU-funded HEPscreen project 
(2011-2014) we compared costs and outcomes of six different screening models targeting 
migrants in the UK, Spain and Hungary.
Methods: Two outreach screening models (one in communities, one in workplaces), an 
opportunistic and an invitation-based model in primary care, and two extension models 
(adding hepatitis B/C to university-based tuberculosis screening and antenatal screening) 
were implemented. Outcome data collected included: screening uptake, cascade of care 
retention, HBsAg and anti-HCV prevalence and costs.
Results: Five of the six screening models were completed, screening 1203 people. Uptake 
varied from 33% in workplace outreach screening to 78% in opportunistic screening. The 
invitation-based model ceased prematurely due to low uptake (2.3%). The multi-stage 
screening pathway in the community outreach led to attrition of 49% of participants. Overall, 
the highest HBsAg prevalence (12.9%) was detected among South-East Asian migrants. 
Overall, the highest anti-HCV prevalence was found in migrants from Central (10.3%) and 
South (8.3%) Asia, and Eastern Europe (5.3%). Costs per person screened ranged from €48 
(tuberculosis screening extension model) to €111 (community outreach model). 
Conclusions: Migrants can be effectively reached via screening in health care and 
community settings. Uptake and cost per person screened in community-based outreach 
screening may be improved by offering testing at the first point of contact. To maximise 
impact and improve cost favourability, chronic viral hepatitis screening should prioritise 
migrants born in intermediate to high endemic countries.
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INTRODUCTION
Advances in treatment for chronic infection with the hepatitis B (HBV) and hepatitis C (HCV) 
viruses, especially the cure of chronic HCV infection with interferon-free, virtually side effect-
free regimens, have increased the scope for secondary prevention of liver disease-related 
morbidity and mortality.(1-3) The World Health Organisation (WHO) recently agreed the 
ambitious goal of the elimination of chronic hepatitis B (CHB) and C (CHC) as a health threat 
in Europe by 2030.(4) The journey to elimination is set out in the action plan for the health 
system response in the European region.(5) Alongside the continuation (and expansion 
for some countries) of primary prevention measures to halt transmission, the scale up of 
screening and treatment for people with chronic viral hepatitis is crucial for elimination.
(6-11) 
In Europe, migrants from countries where HBV/HCV is endemic are an important risk group 
for CHB and CHC infection.(12-15) Two recent studies, funded by the European Centre for 
Disease Prevention and Control (ECDC), estimated that 14% of the burden of CHC (viraemic) 
and 25% of the burden of CHB in the EU/EEA is attributable to migrants from endemic 
countries.(16-18) These studies also highlight the differences across the EU in prevalence in 
the general population and in demographic characteristics related to migration. Migrants 
from endemic countries account for a much larger proportion of estimated cases of chronic 
viral hepatitis in low CHB/CHC prevalence countries in Northern and Western Europe than 
in higher prevalence countries in the Eastern and Southern part of Europe. Migration flows 
are dynamically driven by economic circumstances, conflict, geography, linguistic affinity 
and immigration policy, although countries in Northern and Western Europe have tended 
to experience much higher net migration from endemic countries (from within and outside 
the EU).(19) 
Health planners and service providers in countries experiencing high net migration (where 
migrants are disproportionately affected and account for a large proportion of CHB/CHC 
cases) can make use of scientific work on how to engage, reach, screen and retain at risk 
migrants in a cascade of care for chronic viral hepatitis. Various models of screening among 
migrants have been described in literature. These include: outreach offering awareness 
raising and/or on-site screening in social, civic or cultural locations accessible for the 
target community (20-24); invitation-based using municipal or patient registries (25-27); 
opportunistic screening of migrant patients who attend health care services for other 
health issues (28-30); and adding viral hepatitis screening to an existing migrant-specific 
screening programme, such as for tuberculosis (TB).(31) 
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In addition to evidence on effectiveness, public health decision makers increasingly demand 
economic assessments in order to make rational, sustainable and equitable decisions about 
the use of scarce health care resources. Most cost-effectiveness studies of the secondary 
prevention of chronic viral hepatitis either begin with a cohort of diagnosed patients (32) 
or make assumptions about the costs and characteristics (uptake of screening, retention in 
a cascade of care) of hypothetical opportunistic or invitation-based case finding.(33-36) In 
a systematic review, Geue et al (37) conclude that most cost-effectiveness studies neglect 
to include costs associated with actual screening efforts, such as recruiting patients from 
(harder to reach) populations.(36) Yet screening intervention costs were found to account 
for 43% of the variation in costs per QALY in a study modelling cost outcomes of HCV case 
finding and treatment among migrants from South Asia.(35) Few cost-effectiveness analyses 
include model parameters based on ‘real world’ experience of screening strategies.(38) Fewer 
still are studies that seek to compare the relative effectiveness and costs across different 
models of screening among migrants. One study from the US compared five models of HBV 
screening including three unique models (a community outreach, a community clinic and a 
partnership model) and two hybrid models (incorporating elements of the unique models) 
to determine effectiveness and cost-effectiveness (39). There are no studies that compare 
the costs and outcomes of different models of screening among migrants that include both 
HBV and HCV.
We report on the planning, implementation, effectiveness and costs of six migrant HBV/HCV 
screening models carried out between October 2011 and October 2014 in Hungary, Spain 
and the United Kingdom (UK) (England and Scotland). We report key outcomes including 
uptake of screening, cost per person screened, cost per case identified and prevalence in 
order to inform policy making and research on chronic viral hepatitis. 
METHODS
We aimed to plan, implement and evaluate the six models of screening described below. 
In each model, local data were used to select the target migrant communities for HBV/HCV 
screening. Our study is part of HEPscreen (40), co-funded by the Health Programme of the 
European Union in 2011-2014.
Implementation of screening models
Workplace-based outreach model in Grampian
From August to November 2013, this model combined awareness-raising with confidential 
on-site blood-borne virus (BBV) (HBV, HCV and HIV) screening in six food processing 
businesses employing a significant proportion of migrants (64% of the workforce on 
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average, range of 32%-85%). One of three models of awareness-raising was used. In the 
simplest model, posters and written briefs were available in English and other employees’ 
languages (Bulgarian, Latvian, Lithuanian-Russian, Polish and Portuguese) regarding 
times/locations of screening sessions and the rationale for testing. In the second model, 
in addition to the above, a Public Health doctor provided a verbal briefing to employees 
at lunch. In the third model, information materials were used together with staff briefings 
given by team managers, following discussion with the Public Health doctor. Companies 
chose a drop-in screening and released employees from shifts, an appointment system 
or a combination, whichever was least disruptive to the business. To avoid stigmatisation, 
screening was offered to all 1,465 (935 migrants and 530 UK-born) employees of these six 
businesses. Everyone with a chronic HBV/HCV infection was given their results by the study-
specific liver nurse. A joint target to screen 500 people was set for this and the University-
based TB extension described below. This pilot and the TB extension pilot both operated 
a centralised regional system with co-ordinated referrals between primary and secondary 
care.
Community-based outreach model in Barcelona
Between December 2012 and July 2014, the local Public Health Agency in Barcelona, 
Spain developed a community outreach model where community health workers (CHWs) 
organised educational sessions about viral hepatitis (symptoms, transmission, prevention, 
treatment and prognosis) for migrants from Latin America and Central/Eastern Europe in a 
range of social, civic and cultural locations. These regions of origin were selected because 
they account for the largest migrant populations in Spain, excluding Western European-
born migrants. After the educational session, participants were offered an appointment 
with a physician at an international health centre, where a questionnaire on socio-
demographic variables and HBV/HCV risk factors was completed. Testing was completed 
at a third appointment and results provided in a fourth. A 10-journey metro card was given 
to educational session participants to financially compensate for health centre visits. In 
both Barcelona pilots, an agreement was in place to provide health care coverage if HBsAg/
anti-HCV infection was detected in a study participant without legal access to the health 
care system (due to undocumented status or social vulnerability). This model set a target to 
invite 450 migrants to educational sessions.
Opportunistic screening in primary care and an international health centre in 
Barcelona
An opportunistic approach was developed in Barcelona whereby migrants from Latin 
America and Central/Eastern Europe who visited an international health centre or a primary 
care centre between October 2012 and July 2014 were offered a return appointment for HBV/
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HCV screening. The two health centres are located in an area with a large (>40%) migrant 
population. Patients consenting to the offer of screening completed a questionnaire and 
underwent testing at a second appointment. Results were given in a third visit. This model 
set a target to offer screening to 300 migrants. 
TB screening extension model in Grampian, Scotland
Existing new entrant TB screening for students arriving from countries of high TB prevalence 
was extended in the academic year 2012/2013 to include an offer of confidential on-site BBV 
screening in Aberdeen and Robert Gordon Universities. At one university, a brief presentation 
and written BBV information was provided by a TB nurse at the welcome session for foreign 
students. Students completed a questionnaire, and those from high TB prevalence were 
sent an email invitation for TB screening. The second university publicised TB screening to 
all students by email and at general welcome sessions, allowing students to self-select. For 
those accepting the offer at either university, a Mantoux skin test was performed for TB 
screening and viral hepatitis screening information was provided. Students returned two 
days later for the Mantoux reading and those with a negative response were offered BBV 
screening after a pre-test discussion with a nurse. BBV screening is part of routine TB follow-
up care for those with a positive Mantoux reading and BBV results are not reported here. 
Translation was not provided since students were expected to have a good command of 
English. Everyone with a chronic HBV/HCV infection was given results via email or telephone 
by the study-specific liver nurse. 
Antenatal extension model in Budapest/Pest Country 
From April 2013 and to March 2014, antenatal infectious disease screening was extended 
to include HCV for first and second generation migrant pregnant women. Subjects were 
provided with pre-test information about viral hepatitis and the study and offered HCV 
screening at a later antenatal visit with a Health Visitor. As well as Hungarian, information 
was available in Arabic, English, Chinese, Romanian, Russian, Serbian, Vietnamese and 
Turkish. Women who agreed to HCV screening signed an informed consent declaration 
and completed a questionnaire. The blood sample was taken at a later appointment with 
an obstetrician/gynaecologist. Results were given by the same obstetrician/gynaecologist. 
A screening target of 500 pregnant women was set.
Invitation-based model in primary care in London
From January to September 2014, patient registries from two London GP practices were 
used for postal invitations to adults (aged 18 and over) of Black African, South Asian or 
Turkish ethnicity without a known CHB/CHC infection. This model was designed as a 
randomised control trial where half of the target population received an invitation to make 
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an appointment for HBV/HCV testing and the other half for BBV (HBV, HCV and HIV) testing. 
The pilot set a target of 500 people to be invited. Invitations included information about 
viral hepatitis (and HIV, if applicable) and the study. The invitation and information were 
translated into Turkish for invitees from the Turkish community. Results were to be given 
by the GP.
Ethical approval
Each study site followed locally specific medical ethical regulations. In Grampian, specific 
ethical research approval was not required since the pilot was planned as a service 
improvement. In Barcelona, the study protocol was licensed by the Research Ethics 
Committee of the Hospital del Mar in September 2012. In London, the RCT protocol was 
licensed under consent number ETT/TUKEB 150/2013 (7157/2013/EKU) by a Research 
Ethics Committee in April 2013 and by the University Research & Development Department 
in September 2013. In Budapest, the study protocol was licensed by the national ethical 
committee under the consent number ETT/TUKEB 150/2013 (7157/2013/EKU). 
Definitions
A first generation migrant (FGM) was defined by birth outside the current country of 
residence. A second generation migrant (SGM) was defined by at least one parent born 
outside the current country of residence. 
Laboratory testing methods 
CHB infection was suspected in the presence of HBsAg and confirmed by the presence of 
HBV DNA. CHC infection was suspected in the presence of anti-HCV and confirmed by the 
presence of HCV RNA. 
In Grampian, both dry blood spot (DBS) and venous sampling were used. HBV testing was 
performed using the Biokit Bioelisa anti-HBc followed by Beckman Coulter Access HBsAg 
for reactive samples with further neutralisation test confirmation; viral load testing was 
completed with ABBOTT Realtime HBV Assay. HCV testing was performed using Bio-Rad 
Access HCV Ab Plus with reactive samples re-tested with Ortho HCV 3.0 assay. HCV viral load 
was determined with ARTUS HCV QS-RGQ on a QIAsymphony platform. In Barcelona, HBsAg 
and anti-HCV were detected by ELISA and HBV DNA/HCV RNA confirmed (in specialist care) 
via PCR. In Hungary, all serum samples were tested for HBsAg and anti-HCV using an ELISA. 
Every reactive serum sample was re-tested using an ELISA, and repeatedly reactive samples 
were confirmed using an ELISA (for HBsAg) and an INNO-LIA HCV Score kit (for anti-HCV). 
HCV RNA was determined by nested-RT-PCR. In London, an ELISA was used to detect HBsAg 
and anti-HCV with HBV DNA/HCV RNA further confirmed with PCR.
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Cost data collection
To coordinate cost data collection, a data sheet listing activities, time spent on these activities 
and costs was agreed among the different sites. Each site then entered the observed 
hours of work and salaries for different staff involved in the planning, implementation and 
running of the screening model. Consumable costs (e.g. blood tests, leaflets) were then 
added to obtain total cost for each model. A (hypothetical) routine implementation cost 
was then estimated for each model by excluding the start-up/planning costs and assuming 
the same uptake and prevalence. Purchasing Power Parities (PPP) were extracted from the 
Organisation for Economic Cooperation and Development (OECD) and used to convert 
local cost data into 2013 US$.(41) US$ costs were converted into 2013 Euros.
Data analysis
Anonymised data from all sites were aggregated and analysed in Microsoft Excel to compare 
costs and outcomes. Cascade of care indicators included: total number of migrants exposed 
to some aspect of pre-test information and/or offered screening; total number of migrants 
screened; uptake (the proportion of migrants offered screening that were actually screened); 
total number (and proportion of those screened) found HBsAg and/or anti-HCV (and HBV 
DNA/HCV RNA) positive (and number of newly diagnosed infections); total number of 
(combined) HBsAg or anti-HCV positive people who reached secondary care; total number 
with an indication for treatment (according to local treatment guidelines); and total number 
who started treatment. Cost data included: total cost of each screening model in the pilot 
phase and in (hypothetical) routine implementation; cost per person screened; cost per 
HBsAg case detected; cost per anti-HCV case detected; and cost per (combined) HBsAg or 
anti-HCV case identified. In Hungary, we report cascade of care and cost data only for anti-
HCV, since the innovation tested was the extension of routine antenatal HBsAg screening to 
include anti-HCV. HBsAg and anti-HCV prevalence was measured by the number of people 
with positive serology divided by number screened (n/N) by country of birth (if N screened 
is >10 per country). Countries were grouped into Global Burden of Disease (GBD) regions 
(42) and the regional HBsAg and anti-HCV prevalence calculated. Country and region-level 
95% CIs were calculated using Fisher’s Exact method.
RESULTS
All screening models except the invitation-based model in primary care were implemented 
and completed. In the invitation-based model, 560 invitation letters from two GP practices 
were sent out but uptake of testing was unexpectedly low (2.3%) and the trial was 
discontinued prematurely. 
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Overall uptake and prevalence
In total 2531 migrants were given the opportunity to participate in the five screening 
models, 2374 of whom received pre-test information. The five pilots screened 1203 people 
(48% of the total target population), 94% (N=1133) of whom were FGM born outside 
Western Europe or North America. Around two thirds of those screened were female. 
Excluding the antenatal data decreases the proportion female to 58%. Excluding the HBsAg 
cases diagnosed through the antenatal model (since HBsAg screening is routine), 14 cases 
of HBsAg and 18 cases of anti-HCV cases were identified of which 10 and 15 (respectively) 
were new diagnoses. Eight anti-HCV cases were RNA positive, two were negative, and eight 
were lost to follow up and RNA testing was not performed. Table 1 summarises the uptake 
and cascade of care data. Prevalence among FGM across the five pilots was 2.7% for HBsAg 
and 1.6% for anti-HCV. The community outreach model and the opportunistic screening 
model reached socially vulnerable migrants including (respectively): 37 (21.6%) and 28 
(12.0%) undocumented migrants; 21 (12.3%) and 9 (3.9%) people without access to the 
health care system; and 97 (56.7%) and 92 (39.3%) people who were unemployed. 
Prevalence demographics
HBsAg prevalence was highest among migrants from East/South East Asia (12.7%) (Table 2, 
Figure 1). A high prevalence was also found among migrants from South and Central Asia 
(7.7% and 6.9%, respectively), Sub-Saharan Africa (3.3%), and Central Europe (2.7%). Anti-
HCV prevalence was highest among migrants born in Central and South Asia (10.3% and 
8.3%, respectively), followed by Eastern Europe (5.3%). Prevalence among migrants from 
Latin America/the Caribbean was low (HBsAg: 0.6%; anti-HCV: 0.3%). 
Cascade of care (Table 1)
In both the workplace-based outreach and the TB extension model, screening was 
successfully completed in everyone consenting to screening, and all diagnosed cases 
successfully reached secondary care for treatment assessment. Treatment was indicated in 
none (of eight) HBsAg cases and in five (of seven) anti-HCV cases, with all five CHC (viraemic) 
cases successfully starting treatment. There was however some attrition across the cascade 
of care in the other models. In the community outreach model, 337 people attended 45 
education sessions, 316 of whom agreed to participate and 210 of these attended the 
GP appointment. HBV/HCV screening was completed in 171. Just one of the nine HBsAg/
anti-HCV cases identified by this model successfully reached secondary care. Treatment 
was indicated in this one case of CHC (viraemic) infection. In the opportunistic screening 
model, 247 of the target sample of 300 people consented. Screening was completed in 234 
people. Just one (of four) anti-HCV case and two (of three) HBsAg cases successfully reached 
secondary care. Treatment was not indicated in both CHB cases. In Hungary, 331 women 
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consented to screening although 51 samples were lost to follow up due to unfamiliar 
laboratory arrangements or insufficient blood taken. The one case of CHC successfully 
reached secondary care, and treatment was indicated. 
Table 1. Screening and treatment cascade across the five pilot models
Screening model
TotalWorkplace 
outreach
(Grampian)
Community 
Outreach
(Barcelona)
Opportunistic
(Barcelona)
TB 
extension
(Grampian)
Antenatal 
extension◊
(Budapest) 
Number of 
migrants offered 
screening
935∆ 450 300 455 401 2531
Number of 
migrants screened
305# 171 234 156 280 1146
Uptake 33% 38% 80% 34% 69% 45%
Number HBsAg 
positive
(% of screened)
4
(1.3%)
3
(1.8%)
3
(1.3%)
4
(2.6%)
N/A
14
(1.2%) 
Number new 
HBsAg positive
4 2 2 2 N/A 10
Number anti-HCV 
positive
(% of screened)
7
(2.1%)
6
(3.5%)
4
(1.7%)
0
(0%)
1
(0.4%)
18
(1.6%)
Number new anti-
HCV positive
7 4 3 0 1 15
Number HCV-RNA 
positive
5 1* 1* n/a 1 8
Number new HCV-
RNA positive
5 1 1 n/a 1 8
Number HBsAg or 
anti-HCV positive
(% of screened) 
11 (3.6%) 9 (5.3%) 7 (3.0%) 4 (2.6%) 1 (0.4%)
32
(2.8%)
◊ Anti-HCV screening reported only  ∆Excludes 530 UK-born employees. #Excludes 57 UK-born employees that were screened. 
*The remaining anti-HCV cases were lost to follow up
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Table 2. Number positive (n), number screened (N) and prevalence (95% CI) for HBsAg and anti-
HCV by country of birth#∆: first generation migrants (across all models)
Country/GBD Region
HBsAg Anti-HCV
n N
Prevalence
(95% CI)
n N
Prevalence 
(95% CI)
Ghana 1 12 8.3 (5.6 - 13.6) 0 12 0.0 (0.0 - 5.6)
Nigeria 3 95 3.2 (2.8 - 3.9) 0 95 0.0 (0.0 - 0.7)
Other Sub-Saharan African countries* 0 13 0.0 (0.0 - 5.2) 0 13 0.0 (0.0 - 50.0)
Sub-Saharan Africa Total 4 120 3.3 (3.1 - 3.9) 0 120 0.0 (0.0 - 0.6)
*N<10 each from Cameroon, Kenya, South Africa, Sudan, Tanzania and Uganda
South Asia* Total 1 13 7.7 (5.2 - 12.6) 1 12 8.3 (5.6 - 13.6)
*N<10 each from Afghanistan, India and Pakistan
Georgia 1 16 6.3 (4.2 - 10.3) 3 16 18.8 (16.4 - 22.5)
Other Central Asian countries* 1 13 7.7 (5.2 - 12.6) 0 13 0.0 (0.0 - 5.2)
Central Asia Total 2 29 6.9 (5.7 - 9.1) 3 29 10.3 (9.1 - 12.5)
*N<10 each from Armenia, Azerbaijan, Kazakhstan, Mongolia, Uzbekistan
China (incl. Taiwan) 4 42 9.5 (8.7 - 11.0) 0 40 0.0 (0.0 - 1.8)
Viet Nam 4 20 20.0 (18.1 - 23.0) 0 19 0.0 (0.0 - 3.6)
Other East/South East Asian countries* 1 9 11.1 (7.4 - 18.0) 0 9 0.0 (0.0 - 7.4)
East/South East Asia Total 9 71 12.7 (12.2 - 13.6) 0 68 0.0 (0.0 - 1.0)
*N<10 each from Indonesia, Malaysia, Philippines, Thailand
North Africa/Middle East* Total 0 7 0.0 (0.0 - 9.4) 0 6 0.0 (0.0 - 10.9)
*N<10 each from Egypt, Kuwait, Libya, Syria and Turkey
Bolivia 1 174 0.6 (0.4 - 1.0) 0 174 0.0 (0.0 - 0.4)
Colombia 0 31 0.0 (0.0 - 2.2) 0 31 0.0 (0.0 - 2.2)
Dominican Republic 0 13 0.0 (0.0 - 5.2) 0 13 0.0 (0.0 - 5.2)
Ecuador 1 49 2.0 (1.4 - 3.4) 0 49 0.0 (0.0 - 1.4)
Peru 0 14 0.0 (0.0 - 4.8) 1 14 7.1 (4.8 - 11.7)
Other Latin American/Caribbean countries* 0 47 0.0 (0.0 - 1.5) 0 17 0.0 (0.0 - 4.0)
Total Latin America/Caribbean 2 328 0.6 (0.5 - 0.8) 1 328 0.3 (0.2 - 0.5)
*N<10 each from Argentina, Brazil, Chile, Cuba, El Salvador, Honduras, Mexico, Nicaragua, Paraguay,  Uruguay and Venezuela
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Table 2. (continued)
Country/GBD Region
HBsAg Anti-HCV
n N
Prevalence
(95% CI)
n N
Prevalence 
(95% CI)
Poland 3 163 1.8 (1.6 - 2.2) 0 162 0.0 (0.0 - 0.4)
Romania 7 210 3.3 (3.2 - 3.6) 1 189 0.5 (0.4 - 0.9)
Slovakia 0 14 0.0 (0.0 - 4.8) 0 12 0.0 (0.0 - 5.6)
Other Central European countries* 1 27 3.7 (2.5 - 6.1) 2 17 8.0 (6.6 - 10.6)
Central Europe Total 10 407 2.5 (2.4 - 2.6) 3 380 0.8 (0.7 – 1.0)
*N<10 each from Albania, Bulgaria, Croatia, Czech Republic, Hungary, Serbia and Slovenia
Latvia 0 54 0.0 (0.0 - 1.3) 6 54 11.1 (10.4 - 12.3)
Lithuania 1 84 1.2 (0.8 - 2.0) 1 84 1.2 (0.8 - 2.0)
Russian Federation 1 19 5.3 (3.6 - 8.7) 2 17 11.8 (9.7 - 15.4)
Ukraine 1 34 2.9 (2.0 - 4.9) 1 31 3.2 (2.2 - 5.4)
Other Eastern European countries* 0 4 0.0 (0.0 - 15.9) 0 4 0.0 (0.0 - 15.9)
Eastern Europe Total 3 195 1.5 (1.4 - 1.9) 10 190 5.3 (5.1 - 5.6)
*N<10 each from Estonia and Moldova
Total∆ 31 1170 2.6 (2.6 - 2.7) 18 1133 1.6 (1.6 - 1.7)
Countries were grouped into Global Burden of Disease (GBD) supra-regions.(25) #If N<10 at the country of birth level, the data 
were suppressed into regions. ∆Excluding migrants from GBD regions of Western Europe and North America.
Cost comparison
Costs per person screened in the pilot phase ranged from €58 in the TB screening extension 
model to €193 in the community outreach model (Table 3). Costs per HBsAg case detected 
ranged from €2,254 in the TB extension model to €10,976 in the community outreach 
model. Costs per anti-HCV case detected ranged from €4,158 in the workplace-based 
outreach model to €40,405 in the antenatal extension model. Costs per (combined) HBsAg 
or anti-HCV case detected ranged from €2,254 in the TB extension model to €40,405 in the 
antenatal extension model. Costs per person screened if the models were to (hypothetically) 
continue as routine implementation (without the set up/planning costs) were estimated to 
range from €48 in the TB extension model to €111 in the community outreach model (Table 
3).
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Figure1. GBD Regional HBsAg or anti-HCV prevalence and 95%CI
Figure 2. Cost per person screened and number screened during pilot and (hypothetical) routine 
implementation phases
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DISCUSSION
This is the first study to plan, implement and compare costs and outcomes from different 
models of HBV and HCV screening among migrants. Our study does not permit conclusions 
on the cost-effectiveness of the different screening models, as final health outcomes 
were not incorporated. However, our study can significantly contribute to future cost-
effectiveness studies through the provision of data to recalibrate key model parameters, 
specifically: data on the actual costs (across the cascade of care) for various models of 
screening, in both a pilot phase and as (hypothetical) routine implementation; uptake 
of screening; and the measured HBsAg/anti-HCV prevalence in 1133 FGM. The scope of 
intervention costs included here are in line with similar studies.(39, 43, 44) 
Prevalence
Prevalence in the target population is a key consideration in weighing the potential 
population health benefits and harms of screening.(45) It is also a key parameter in cost-
effectiveness assessment.(36, 38) This study was not designed as a sero-prevalence study 
and the subjects included may not be representative of the general (migrant) population. 
We are therefore cautious in general (migrant) population extrapolation. Our results 
along with other studies in migrants (24, 39, 46, 47) and countries of birth (48) suggest an 
intermediate/high HBsAg prevalence among people born in East/South East Asia. The high 
anti-HCV prevalence among migrants from Eastern/Central Europe and from Central/South 
Asia found reflects that reported in countries of birth.(49) However, the case yield from 
offering screening among migrants from low prevalence areas, for example Latin America, 
appears to be low. These findings reinforce the evidence to specifically target screening for 
people born in HBV/HCV intermediate to high endemic countries. 
Anti-HCV prevalence in the extended antenatal model was 0.4%, despite more than half of 
subjects being born in Romania where the anti-HCV prevalence is estimated to be 3.2%.
(49) This finding is possibly explained by the relatively young age (for CHC infection (50)) of 
participants (median age of 29) and by living in low HCV prevalence country (Hungary) for 
most of their lives. This low prevalence, the high cost per case together with findings from 
another study (51) suggest there is limited value in including HCV in antenatal screening. 
University-based TB screening extended to include BBV detected 2.6% HBsAg prevalence, 
suggesting that this model could be an effective way of identifying cases among migrant 
students. No cases of HCV were found, probably explained by the relatively young age 
(mean of 28 years) of this student population. 
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Screening uptake
Screening uptake is an important parameter in assessing cost-effectiveness, which is 
why we endeavoured to measure it in our study. Screening uptake is however difficult to 
compare between models and is arguably most accurate in models that offer screening on 
a one-to-one basis, since the target population offered and accepting testing is easier to 
define than in outreach models where, for instance, an entire workforce, anyone attending a 
civic or social centre or an entire local population (24) could be considered part of the target 
population. Indeed, no studies of outreach screening among migrants report screening 
uptake.(21, 24, 39, 52-54) 
In our study, models with a larger target population reported a lower screening uptake. 
Furthermore, a higher screening uptake was observed in models offering screening in 
health care by health care workers i.e. opportunistically in primary care (78% uptake) and 
antenatal screening by health visitors (69% uptake). Brady et al (in a study during 2012-
2014) also found a higher screening uptake in opportunistic models, 32% among patients 
in internal medicine clinics and 20% via electronic patient record prompted testing in 
primary care (compared to 10% in an invitation-based model).(44) The higher uptake of 
screening reported in individually-focused models raising awareness and offering testing 
in confidential, one-to-one clinical encounters suggests that these models could be more 
conducive to a higher acceptance of the offer of testing.(47) However, our findings do not 
support the inclusion of 100% screening uptake in opportunistic screening in primary care 
as assumed in a cost-effectiveness study by Wong et al (36), although the 70% included in 
Hutton et al seems realistic.(34) 
The relatively low screening uptake in the workplace-based outreach (33%) and the TB 
extension model (34%) could be due to an inability to take up screening among students/
workers (due to shift work or study priorities). Time pressures/priorities for individuals 
reached at work and in educational settings are important explanations, as priorities may 
be different than for individuals approached in health care services. The TB extension model 
was offered in two universities and screening uptake was higher (42% compared to 28%) 
where the offer of TB screening was targeted to students born in high prevalence countries. 
The relatively low screening uptake in the community outreach model (38%) is partly 
explained by the number of steps (and potential for attrition between appointments) in 
the screening pathway as well as other factors such as low local language skills (especially 
among migrants from Central and Eastern Europe) and being female carers with significant 
family responsibilities (according to a local analysis, data not shown). 
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Retention in the treatment cascade
The success of referral to secondary care was highest in the TB extension and workplace 
outreach models where a specialist liver nurse and a centralised regional system with co-
ordinated referrals were in place. Partnership between primary and secondary care services 
has been shown elsewhere to be successful in other outreach screening models.(21, 23, 24) 
Loss to follow up in the community outreach model and the opportunistic model can partly 
be explained by a complex referral pathway as well as by participant characteristics: labour 
mobility or socio-economic vulnerability (e.g. undocumented status, unemployment). 
Our experience suggests that appointing case workers (such as health or social workers) 
for socially vulnerable, linguistically marginalised migrants with evidence of chronic viral 
hepatitis may improve retention in a cascade of care. Offering testing at the first point 
of contact (and simplifying the testing cascade) may also improve uptake and retention. 
We found translation provision (via for instance migrant-language proficient CHWs in 
the community outreach or the use of telephone interpretation in the workplace-based 
outreach) overcame language barriers and seemed to partially improve retention. Other 
studies have found that language barriers are perceived to be a principal barrier in onward 
care and that immigration status is associated with not receiving viral hepatitis treatment.
(55-57) Whilst none of the ten HBsAg cases that reached secondary care were eligible for 
treatment according to existing clinical guidelines, the monitoring of liver function and 
disease progression/activation in HBsAg patients is recommended.(24, 58, 59)
Cost data
Our cost data findings can be compared with one US-based study. In this study, Rein et 
al compared five screening models (in 2008) and whilst the costs per person screened 
were broadly in the same range ($40-280 US$ compared to $49-239 in our study (US$ data 
available from the corresponding author)), costs per HBsAg case identified were generally 
much lower (at $609-$4,657 compared with $2,885-$12,942 in our study).(39) Rein et al also 
found that integrating screening into existing clinical care (the community clinic model) 
was the least costly model but reached the fewest people. It also found that the community 
outreach model was the most costly but reached the highest number of people. We did not 
see the same linear relationship between costs per person screened and number of people 
screened (Figure 2), although it is unlikely that our study would have since all five models 
set a target for the number of people to be screened over a fixed time period. 
No studies reporting costs per HCV case identified by a recent systematic review focus on 
migrants.(60) In a randomised trial of three models of HCV screening among people born 
during 1945-1965, Brady et al found costs per person screened of US$ $19-25 and costs per 
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HCV case identified of US$ $4,230-7,005.(44) Aside from the antenatal extension model, the 
cost per anti-HCV case is broadly comparable with the routine implementation costs in our 
study. 
Future research should focus on three priority areas. More studies of combined HBV/HCV 
screening focused on migrants born in endemic countries that report on and investigate 
four key indicators: uptake; costs per person screened/cost per case identified; prevalence 
by country/region of birth; and retention across the treatment cascade. Future screening 
studies should also evaluate enabling factors and barriers in securing a high uptake and 
in successful referral/retention.(47) Finally, cost-effectiveness studies should base model 
parameters on ‘real world’ measures of screening uptake and costs such as those reported 
here and elsewhere.(39, 60)
CONCLUSIONS
Results from the workplace-based outreach show that there is support among employers to 
run (health) screening interventions on-site during work time, that this model of screening is 
acceptable to the target population and that migrant workers (here workers born in higher 
prevalence countries in Eastern/Central Europe) are a key population for HCV case finding 
(2.3% anti-HCV prevalence). Experience from the two primary care-based models suggests 
that offering HBV/HCV screening in clinical encounters leads to a high screening uptake 
although it does not reach people who are not engaged with health care. Conversely, 
the community outreach model successfully reached at-risk migrants who were not yet 
integrated into the health care system. Short-term migrants, whether for work or study, 
may not remain in the country long enough for screening to be judged cost-effective from 
the host country perspective. However, taking a global health view, diagnosis may lead to 
future treatment and support informed lifestyle choices that aim to decrease the risk of 
disease complications and onward transmission. Finally, to maximise the population health 
impact, minimise costs and maximise the effective use of resources, HBV/HCV screening 
should focus on migrants born in endemic countries.
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ABSTRACT
Background: As part of the EU funded project ‘HEPScreen’, the aim of this study is to identify 
hepatitis B and C screening and patient management guidelines, to assess the awareness 
of these among health professionals (HPs) and to explore the availability of hepatitis B/C 
training programmes for HPS in Germany, Italy, the Netherlands, the UK, Spain and Hungary.
Methods: A comprehensive literature search through the main scientific databases was 
performed to retrieve guidelines, following which an online survey was developed and 
sent to HPs in six areas of health care, including public health, to verify whether HPs are 
aware of these guidelines, to retrieve additional guidelines and to find out whether specific 
professional training is available.
Results: Twelve national guidelines were identified through the literature search. Of the 268 
respondents, 80% were aware of hepatitis B guidelines and 73% were aware of hepatitis C 
guidelines in their country. The national guidelines identified through the literature search 
were mentioned by 1/3 of HP in the UK and Germany, 13% of HPs in the Netherlands, 14% 
in Italy and 4% in Spain. An additional 41 hepatitis B/C related guidance documents were 
retrieved through the online survey: 15 in the UK, seven in Hungary, six in Italy, five in the 
Netherlands, four in Germany and four in Spain. Availability of training programmes to 
improve skills and knowledge in viral hepatitis was most often reported in the Netherlands, 
with 82% indicating availability and just 10% indicating no availability, and least commonly 
in Italy, with 42% indicating yes but 40% indicating no. Availability was also reported by the 
majority in the UK, Hungary and Spain, while in Germany the majority selected unsure.
Conclusions: Results suggest that the scientific databases are not the most important 
information source of best clinical practice for many HPs. Implementation of best practices 
requires that guidelines are specifically designed and actively promoted among those 
who are to follow them. Training can disseminate these best practice recommendations 
and raise awareness of guidelines. It is therefore encouraging that diverse training about 
hepatitis B/C is available to the different professional groups.
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BACKGROUND
Chronic hepatitis B and C are leading causes of liver cancer and are both important public 
health issues in Europe. In the European Union (EU), some segments of the population, 
such as migrants from areas where HBV or HCV are endemic and people who inject drugs 
(PWID), are disproportionately affected by these diseases (1–4). The prevalence in the 
general population varies from 0.4 to 5.2% for anti-HCV and from 0.1 to 5.6% for HBsAg (5). 
However, also due to the largely silent nature of these infections, reliable epidemiological 
data in Europe are lacking both on HBV and HCV (6, 7) and it has been estimated that 
up to 90% of infected individuals are undiagnosed (8). Therefore, despite the existence of 
effective antiviral treatment that slows disease progression and prevents the development 
of cirrhosis and liver cancer, many patients who might benefit from treatment remain 
undetected (9, 10). Studies also allude to ineffective counselling and referral of diagnosed 
patients, as well as to the failure of chronically infected patients to reach secondary care, 
leading to eligible viral hepatitis patients being under-treated (11–16).
Informing health professionals (HPs) of evidence-based recommendations on the prevention 
of hepatitis B and C, the targeted screening of at-risk individuals, and the diagnostics and 
clinical management of patients with chronic viral hepatitis, is crucial to obtain the best 
possible health outcomes. The provision of comprehensive high quality guidelines, as well 
as advanced training programmes to improve the skills and knowledge of HPs on viral 
hepatitis management, are ways to achieve this purpose. Numerous studies, however, 
demonstrate little familiarity or low compliance of HPs with guidelines summarising the 
best available evidence in their specialties (17–21). National and European hepatitis B and 
C management guidelines exist, however little is known about the extent to which HPs 
who are to actually implement them are aware of their existence. Similarly, little is known 
about the availability of in-service training on chronic viral hepatitis prevention, diagnosis, 
management and treatment.
This study, conducted as part of EU HEPscreen, a project co-funded by the EU Health 
Programme (www.hepscreen.eu), has four specific aims. First, to provide an overview of 
published hepatitis B and C clinical practice guidelines available in Europe and in particular 
in six EU countries with large migrant communities and representation of migrant health 
and patient platform, i.e. the UK, Germany, the Netherlands, Hungary, Italy and Spain. 
Second, to assess the awareness of guidelines among HPs working in these six countries 
in six fields: public health, antenatal care, primary care, care for asylum seekers/refugees, 
sexual health, and gastroenterology/hepatology. Third, to measure the availability of viral 
hepatitis specific training programmes for HPs in these fields. Finally, to investigate HPs’ 
opinion on the existence of barriers such as limited guidance available to primary health 
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care professionals about onward referral, counselling and patient management of hepatitis 
B/C patients and low training uptake among professionals as explanations of why hepatitis 
B/C cases do not reach specialized care for further investigation and treatment.
METHODS
First, a comprehensive literature search was conducted to retrieve published national and 
European hepatitis B and C clinical guidelines. A modified version of the “PICO” method 
(22) was applied, using a search syntax comprising of four categories: (1) Population: 
“general population” OR migrants OR “sex workers” OR “Intravenous drug users” OR IDUs; (2) 
Disease: “hepatitis B” OR “hepatitis C”; (3) Intervention: screening OR counselling OR referral 
OR treatment OR therapies OR “clinical management”; (4) Setting: Germany OR Hungary 
OR Italy OR Spain OR the Netherlands OR the UK OR Europe. These four categories were 
combined with “AND” to build the final syntax. MEDLINE, EMBASE and the Cochrane Library 
databases were searched. In addition, websites of the National Institute for Health and 
Clinical Excellence, the Scottish Intercollegiate Guidelines Network, the Italian National 
Guidelines System, the European Association for the Study of the Liver (EASL), the European 
Centre for Disease Prevention and Control (ECDC), the Robert-Koch-Institute, the World 
Health Organization, the World Hepatitis Alliance, the European Liver Patients Association 
and the Italian Liver Patient Association, were searched. The literature search encompassed 
guidelines published between January 2000 to March 2012 in English, Spanish, Italian, 
Dutch, Hungarian or German and it was conducted between November 2011 and February 
2012. Titles, abstracts and full-texts of relevant documents were screened by two reviewers, 
independently. Disagreements about eligibility were resolved through discussion. A list of 
all guidelines retrieved was developed and categorised by country and type of hepatitis.
To identify further professional guidelines missed by the literature search and to assess 
awareness about existing guidelines among different groups of HPs involved in screening 
for or caring for chronic viral hepatitis, six semi-quantitative online surveys were developed. 
The surveys were sent to HPs in their respective field i.e. to public health professionals (PHPs); 
to general practitioners (GPs); to sexual health service providers (SHS) and/or genitourinary 
medicine (GUM) specialists; to antenatal care (ANC) providers; to asylum seeker care (ASC) 
providers and to specialists (SP) in the field of gastroenterology/hepatology and infectious 
diseases. Each survey was pilot tested, translated into the national language of the respective 
study countries, uploaded into the open source online software package LimeSurvey, 
and sent by e-mail to HPs in the six areas, who were identified by board membership of 
clinical associations, professional networks, ECDC focal points, scientific literature and other 
means. Rather than to reach a large representative sample of practising clinicians, the aim 
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in each professional group was to reach 5– 10 HPs deemed able to reflect on the practice 
within their specialism in general. Data were collected between July and September 2012. 
Respondents agreed to participate by answering the questionnaire.
We measured whether official national guidelines were available, both general guidelines 
(the question was included in all six surveys), with a request to provide the title and publisher 
in a text field in case of a positive response, and guidelines specifically developed for 
professionals in their field. We also asked public health specialists whether specific guidelines 
for migrants from endemic areas exist. The responses were exported into SPSS 19.2 and a 
descriptive analysis was performed to evaluate which hepatitis B/C guidelines are known 
to HPs, how many professionals mentioned the main guidelines identified through the 
literature search and how many additional guidelines were retrieved. In all surveys, except 
the survey aimed at public health professionals, a question about the provision of hepatitis 
B/C-related training for HPs in their respective medical specialties was also included. The 
identification of general hepatitis guidelines by respondents was analysed in connection 
with their opinion on the existence of professional training to improve knowledge and skills 
about viral hepatitis. Finally, all professional groups were asked to indicate on a five-point 
Likert scale, from “strongly agree” to “strongly disagree", to which extent they agree that 
the given statements are explanations of why hepatitis B/C cases do not reach specialized 
health care for further management: i) There is limited guidance available to primary health 
care professionals about onward referral, counselling and patient management of hepatitis 
B/C patients; ii) Although training on viral hepatitis management is available for health 
care providers, uptake is generally low among professionals. The study complied with the 
Helsinki Declaration (23).
RESULTS
Literature search results: clinical practice guidelines
The literature search retrieved eight international guidelines: two from EASL (24, 25); two 
from the Association for the Study of Liver Diseases (26, 27); the “European Guideline for 
the Management of Hepatitis B and C Virus Infections” by the International Union against 
Sexually Transmitted Infections (28); the “Best Practice in the Treatment of Chronic Hepatitis 
B” published by the European Viral Hepatitis Educational Initiative (29); and two National 
Institute of Health Consensus Statements on the management of hepatitis C and B from 
the US (30, 31). Twelve major national guidelines were retrieved: six in the UK (32–37), two 
in Italy (38, 39), two in Germany (40, 41) and two in the Netherlands (42, 43).
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Since the date of the search (March 2012), several guidelines have been revised, mostly due 
to treatment advances. In such cases, the updated guidelines are cited as references.
Survey results
We received a total of 268 responses to the survey, not evenly distributed across the six 
professional groups or across the six countries (Table 1).
Table 1. Number of health professionals completing the questionnaire by country and by survey
Survey
(% of health 
professionals for 
each survey by 
country)
Country
Total
UK DE NL HU IT ES
Public health 9 (20%) 13 (29%) 7 (16%) 2 (4%) 8 (18%) 6 (13%) 45 (100%)
Antenatal care 8 (10%) 33 (40%) 6 (7%) 4 (5%) 23 (28%) 8 (10%) 82 (100%)
GP 8 (21%) 4 (11%) 9 (24%) 1 (3%) 14 (37%) 2 (5%) 38 (100%)
Care for asylum 
seekers
4 (22%) 3 (17%) 4 (22%) 3 (17%) 3 (17%) 1 (6%) 18 (100%)
SHS 9 (35%) 4 (15%) 7 (27%) 3 (11%) 1 (4%) 2 (8%) 26 (100%)
Specialist care 9 (15%) 7 (12%) 22 (37%) 8 (14%) 9 (15%) 4 (7%) 59 (100%)
Total 47 (18%) 64 (24%) 55 (21%) 21 (8%) 58 (22%) 23 (9%) 268 (100%)
Identification of HBV and HCV guidelines through the online survey
National or international guidelines already identified through the literature search were 
mentioned by one third of respondents in the UK and Germany, and only by a minority 
of HPs in Italy (14%) and the Netherlands (13%) and by just 4% in Spain. An additional 41 
hepatitis B/C-related national guidance documents were identified by HPs through the 
online survey: 15 in the UK, seven in Hungary, six in Italy, five in the Netherlands, four in 
Germany and four in Spain. Table S1 online compiles all hepatitis B/C related guidelines and 
guidance documents retrieved through the literature search and/or identified by HPs.
National general HBV and HCV screening and management guidelines
The existence of official national general hepatitis B or C screening and patient management 
guidelines in the study countries, was reported by 61% and 56%, respectively (Table 2). 
Among these, only about 40% provided the title and publisher of the guideline. Around 
two thirds to three quarters of HPs in the Netherlands and in Hungary reported availability 
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of general guidelines compared to just over half in the UK and Italy. Conversely, the majority 
of HPs in Spain and, for hepatitis C guidelines, in Germany, reported uncertainty or that no 
general guideline is available.
Table 2. Health professionals reporting the existence of national general hepatitis B and C guidelines 
in their country
Hepatitis B guidelines
UK
(n = 47)
DE
(n = 64)
NL
(n = 55)
HU
(n = 21)
IT
(n = 58)
ES
(n = 23)
Total
(n = 268)
Proportion of health 
professionals reporting the 
existence
57% 56% 78% 67% 57% 43% 61%
Provided name and 
publishera
41% 31% 44% 36% 45% 50% 40%
Hepatitis C guidelines
UK
(n = 47)
DE
(n = 64)
NL
(n = 55)
HU
(n = 21)
IT
(n = 58)
ES
(n = 23)
Total
(n = 268)
Proportion of health 
professionals reporting the 
existence
60% 47% 67% 67% 57% 39% 56%
Provided name and 
publisherb
39% 37% 51% 29% 45% 44% 42%
a Percent of the respondents who reported the existence of general hepatitis B guidelines; b Percent of the respondents who 
reported the existence of general hepatitis C guidelines
Professional group-specific national HBV and HCV guidelines
Overall 80% (n = 215) of respondents are aware of hepatitis B guidelines and 73% (n = 196) 
of hepatitis C guidelines in their country. Among the 45 PHPs, around two thirds mentioned 
the existence of general Hepatitis B and hepatitis C guidelines. Among the 38 GPs, 29% 
mentioned specific HBV guidelines for GPs and 21% the existence of HCV guidelines for 
GPs. Interestingly, among PHPs, 47% mentioned the existence of HBV guidelines specifically 
for GPs and 40% the existence of GP-specific HCV guidelines. Of the 82 ANC experts, 52% 
mentioned HBV and 26% HCV guidelines for antenatal services. Among the 59 secondary 
care specialists, 61% mentioned HBV guidelines and 56% mentioned HCV guidelines. None 
of the 18 ASC experts identified the existence of HBV/HCV guidelines for the care of asylum 
seekers. Just 22% (for HBV) and 13% (for HCV) of PHPs reported the existence of specific 
guidelines for migrants from endemic areas. Detailed results are displayed in Table 3.
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Table 3. Health professionals identifying hepatitis general or specific guidelines by professional 
group and by country
HBV GUIDELINES UK DE NL IT ES HU Total
General Hepatitis B guidelines (Public health 
professionals)
56% 77% 71% 50% 67% 100% 67%
Antenatal care experts 50% 33% 67% 44% 13% 50% 39%
General Practitioners 38% 50% 78% 71% 100% 100% 66%
Asylum seekers Experts 100% 100% 50% 100% 0% 100% 83%
SHS Experts 56% 75% 86% 100% 0% 67% 65%
Specialists 67% 100% 86% 56% 75% 50% 75%
GP guidelines (Public health professionals) 67% 31% 100% 25% 33% 0% 47%
General Practitioners 13% 0% 78% 21% 0% 0% 29%
Antenatal guidelines (Public health professionals) 78% 8% 71% 25% 67% 50% 44%
Antenatal care Experts 75% 40% 67% 39% 88% 100% 52%
Asylum seekers guidelines (Public health 
professionals)
33% 0% 14% 13% 0% 0% 11%
Asylum seekers Experts 0% 0% 0% 0% 0% 0% 0%
Specialists guidelines (Public health professionals) 78% 38% 57% 25% 33% 50% 47%
Specialists 44% 43% 86% 33% 75% 50% 61%
Migrant care guidelines (Public health professionals) 33% 0% 14% 25% 67% 0% 22%
HCV GUIDELINES UK DE NL IT ES HU Total
General HCV guidelines (Public health professionals) 56% 77% 57% 50% 67% 100% 64%
Antenatal care experts 38% 18% 67% 44% 25% 25% 32%
General Practitioners 38% 50% 67% 71% 50% 100% 61%
Asylum seekers Experts 100% 100% 50% 100% 0% 100% 83%
SHS Experts 67% 75% 71% 100% 0% 67% 65%
Specialists 78% 86% 73% 56% 50% 63% 70%
GP guidelines (Public health professionals) 67% 23% 57% 38% 33% 0% 40%
General Practitioners 0% 0% 56% 21% 0% 0% 21%
Antenatal guidelines (Public health professionals) 33% 0% 14% 25% 0% 0% 13%
Antenatal care experts 25% 13% 0% 35% 75% 25% 26%
Asylum seekers guidelines (Public health 
professionals)
11% 0% 0% 13% 0% 0% 4%
Asylum seekers Experts 0% 0% 0% 0% 0% 0% 0%
Specialists guidelines (Public health professionals) 56% 23% 29% 25% 0% 0% 27%
Specialists 44% 43% 73% 44% 50% 50% 56%
Migrant care guidelines (Public health professionals) 33% 0% 0% 13% 33% 0% 13%
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Reported availability of hepatitis B/C training for health care 
professionals
Table 4 shows the reported availability of training in the six countries. Among secondary 
care specialists, availability of training was reported by 84% (although only by 44% in Italy), 
among GPs by two thirds (although only by half of them in Germany and Spain and by 40% 
in the UK) and by 55% among SHS experts. Most HPs working in antenatal care indicated 
that training is not available or selected unsure. The majority opinion among those providing 
care to asylum seeker is that training is not available for professionals in their field.
Table 4. Availability of training to improve knowledge and skills in viral hepatitis in the six countries
UK GP (n = 10) Antenatal (n = 8) Asylum (n = 4) SHS (n = 10) Specialist (n = 10)
Yes 40% 50% 25% 70% 100%
No 10% 13% 75% 0% 0%
Unsure 50% 38% 0% 30% 0%
DE GP (n = 4) Antenatal (n = 36) Asylum (n = 3) SHS (n = 5) Specialist (n = 9)
Yes 50% 11% 67% 60% 67%
No 0% 25% 33% 0% 0%
Unsure 50% 64% 0% 40% 33%
NL GP (n = 9) Antenatal (n = 6) Asylum (n = 4) SHS (n = 8) Specialist (n = 22)
Yes 89% 33% 75% 63% 100%
No 0% 50% 25% 13% 0%
Unsure 11% 17% 0% 25% 0%
HU GP (n = 1) Antenatal (n = 4) Asylum (n = 3) SHS (n = 3) Specialist (n = 10)
Yes 100% 50% 33% 0% 80%
No 0% 25% 33% 100% 0%
Unsure 0% 25% 33% 0% 20%
IT GP (n = 14) Antenatal (n = 25) Asylum (n = 3) SHS (n = 1) Specialist (n = 9)
Yes 79% 28% 0% 0% 44%
No 7% 52% 100% 100% 33%
Unsure 14% 20% 0% 0% 22%
ES GP (n = 2) Antenatal (n = 8) Asylum (n = 1) SHS (n = 2) Specialist (n = 4)
Yes 50% 75% 0% 50% 100%
No 50% 25% 100% 0% 0%
Unsure 0% 0% 0% 50% 0%
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Availability of general national guidelines was most commonly mentioned by HPs who 
reported the existence of professional training (Table 5). Over two thirds of those who 
indicated that professional training is available also indicated the existence of general 
guidelines for hepatitis B (69%) and hepatitis C (64%), whereas among those who indicated 
that training is not available, just 47% for HBV and 42% for HCV reported the existence of 
general national guidelines. Surprisingly, in Hungary, general hepatitis B guidelines were 
identified more often by HPs reporting a lack of, or uncertainty about, available training for 
professionals.
Perceived barriers to inadequate referral of hepatitis B/C cases
Limited guidance available to primary health care professionals about onward referral, 
counselling and patient management of hepatitis B/C patients was perceived as a reason of 
why hepatitis B/C patients do not reach specialized health care for further investigation and 
treatment according to nearly half of the respondents in Italy (43% answered they “agree” or 
“strongly agree”), around a third of respondents in Spain, a quarter in the UK and in Germany 
and a fifth in the Netherlands, but not in Hungary (Table 6). Low training uptake among 
professionals as a possible explanation was reported by more than half of the respondents 
in Italy (54% agreed or strongly agreed with such a statement), by 38% of those in the UK, a 
third in the Netherlands, along with a sixth in Germany in Hungary and 9% in Spain (Table 
6).
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DISCUSSION
It has been estimated that in Europe only a minority of hepatitis B or C cases are diagnosed, 
and that less than 20% of infected individuals receive treatment (44). The reasons for the 
low treatment rate include on one hand the largely silent nature of the disease, described 
accordingly as “the silent epidemic”, which often prevents patients to seek care until the 
disease has progressed to end-stage liver disease or hepatocellular carcinoma. On the other 
hand, patients’ lack of knowledge about the disease, language difficulties, lack of social 
support and lack of understanding of the healthcare system contribute to the exclusion 
from health care of migrants from endemic areas, despite current evidence showing that 
they account for one of the largest HBV- or HCV infected group in Europe (45). Legal, 
administrative, financial barriers and the stigmatization of certain at-risk groups, such as sex 
workers or PWID, also represent major obstacles to an effective clinical management of this 
condition (46, 47). Models show that, with treatment at current levels, mortality related to 
HCV is expected to rise and to peak around 2030 (48). Cohen et al. recently introduced the 
concept of “under-treatment” to refer to the disparity between the number of chronically 
infected individuals and the number of patients receiving treatment (12). In order for chronic 
viral hepatitis-related morbidity and mortality to stop to rise in Europe, large increases in 
early detection and treatment of patients are urgently needed.
Our study set out to measure availability and awareness of two important means through 
which evidence-based recommendations can influence clinical practice and HPs’ action 
towards effective clinical management, i.e. guidelines and training. Availability of general 
hepatitis guidelines was most commonly reported by HPs for whom professional training is 
also available in their country. Encouragingly, we identified a total of 53 national hepatitis B 
or C guidelines and guidance documents, with examples across the six countries. However, 
just twelve of these were retrieved via the literature search. For Hungary, the search failed 
to retrieve any guidelines published in English, however seven guidelines, all in Hungarian, 
were retrieved via the online survey. Moreover, in accordance with prior studies (17–21), few 
HPs themselves identified guidelines published in the scientific literature. These findings 
suggest that the scientific databases are not the most important information source of best 
clinical practice for many HPs. Interestingly, more public health officials identified specific 
guidelines for GPs than GPs themselves. Limited guidance available was perceived as a 
reason for inadequate referral of patients according to sizeable proportions of HPs in all 
countries, with the exception of Hungary. More comprehensive guidelines, tailored to the 
needs of specific professional groups like GPs, sexual health or maternity services, may be 
an alternative to increase awareness and improve implementation of recommendations. 
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Our findings also indicate that there is either scarcity or complete lack of guidance for HPs 
about screening practices and disease management of migrants and asylum seekers from 
endemic areas.
Results on the availability of specific hepatitis B/C training programmes suggest that, for 
many professionals, in the Netherlands, the UK, Hungary and Spain training is available. 
However there are differences between professional groups within countries. Results in the 
UK suggest that training is lacking or unknown for GPs and professionals in health care for 
asylum seekers. In Germany, training is similarly neither widespread nor well known across all 
professional groups. In Hungary, training is not widely available, especially for professionals 
working in the area of sexual health. In Italy, a lack of availability was reported by over half 
of the antenatal care providers and by all respondents to the asylum seeker and SHS survey; 
training seems to be more available to GPs. The low numbers of respondents among some 
professional groups in Hungary and Spain limit the generalizability of findings, although in 
Spain, training seems to be available for antenatal care providers and specialists.
That training is most commonly available to secondary care specialists is perhaps not 
surprising; what is more surprising is that less than half in Italy and only two thirds of 
specialists in Germany reported the availability of training. Given the role of the specialists 
and the rapidly advancing knowledge of viral hepatitis, especially the new treatment 
options for hepatitis C, this finding is particularly concerning. Results suggest that, except 
for Spain, training for antenatal care providers is rather limited, but especially so in Germany, 
Netherlands and Italy. The implications of this could be sub-optimal care and ineffective 
referral of pregnant women testing positive, as well as a lack of contact tracing. It would 
be particularly interesting to know how this lack of training has an impact on the care of 
hepatitis B positive pregnant women. Low training uptake as a possible explanation of 
why hepatitis B/C cases do not reach specialized health care was reported by relevant 
proportions of HPs in Italy, in the UK, and in the Netherlands.
The findings from our study highlighted that the awareness of screening and patient 
management guidelines and in-service training courses among HPs are presently insufficient. 
Improving results, as supported by key stakeholders (49), would imply a strong involvement 
of national health authorities with the implementation of specific national action plans, 
an effective disease surveillance to develop effective policies and the establishment of 
specialized centres. In this respect, the undeniable success of the experiences developed in 
Scotland and in France provide a working model for other countries to follow. Among the 
strategic actions of the Hepatitis C Action Plan for Scotland (50), a document was produced 
(51), with the aim to support NHS Boards build action plans for facilitating, delivering and 
evaluating workforce education development for staff. Complements this a workbook (52), 
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published to provide staff with a structured approach to assessing, demonstrating and 
developing their ability to carry out their role in delivering Hepatitis C services. Scaling 
up HPs training and evaluating the compliance to clinical practice guidelines were also 
objectives of the French National Plan for hepatitis B and C 2009–2012, following which the 
management of hepatitis B and C was set as a priority topic in continuing medical education 
(53). Subsequently, guidelines for the management of patients with hepatitis B and C were 
developed (54), with recommendations aimed at HPs and the other key stakeholders.
CONCLUSIONS
Our results suggest that not only are there few examples of guidelines for the professional 
groups most able to implement the recommendations, but also that there is low awareness 
of those that do exist among primary care professionals most often representing patients' 
first points of contact. Without short, precise and feasible guidelines, there are likely to 
be wide inconsistencies in screening, referral and patient management. Results from our 
survey also suggest that scientific databases are not the most important information 
source of best clinical practice for many HPs. Implementation of best practices at both 
national and European level requires not only the availability of high quality guidelines 
tailored to the needs of the different professional groups, but also that their existence is 
actively promoted among those who are to follow them, especially when we consider that 
availability of research evidence alone does not necessarily coincide with the adoption 
of recommended practices by physicians. The availability of relevant summaries within 
guidelines, as well as target dissemination to less experienced clinicians, along with the 
provision of clear and concise information to patients, are possible solutions to enhance 
guidelines implementation among clinicians. Given the growing interest in knowledge 
translation and research dissemination, our findings could prompt key decision making 
bodies to improve physicians’ awareness, agreement, adoption and adherence to clinical 
practice guidelines, for example through professional associations and training. Our results 
show that knowledge and availability of hepatitis B/C training could also be improved. 
Further studies assessing the impact of existing training and guidelines on the care, health 
literacy and onward referral of patients would be very valuable.
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ABSTRACT
Background: Language support for linguistic minorities can improve patient safety, clinical 
outcomes and the quality of health care. Most chronic hepatitis B/C infections in Europe 
are detected among people born in endemic countries mostly in Africa, Asia and Central/
Eastern Europe, groups that may experience language barriers when accessing health care 
services in their host countries. We investigated availability of interpreters and translated 
materials for linguistic minority hepatitis B/C patients. We also investigated clinicians’ 
agreement that language barriers are explanations of three scenarios: the low screening 
uptake of hepatitis B/C screening, the lack of screening in primary care, and why cases do 
not reach specialist care.
Methods: An online survey was developed, translated and sent to experts in five health care 
services involved in screening or treating viral hepatitis in six European countries: Germany, 
Hungary, Italy, the Netherlands, Spain and the United Kingdom (UK). The five areas of health 
care were: general practice/family medicine, antenatal care, health care for asylum seekers, 
sexual health and specialist secondary care. We measured availability using a three-point 
ordinal scale (‘very common’, ‘variable or not routine’ and ‘rarely or never’). We measured 
agreement using a five-point Likert scale.
Results: We received 238 responses (23% response rate, N = 1026) from representatives in 
each health care field in each country. Interpreters are common in the UK, the Netherlands 
and Spain but variable or rare in Germany, Hungary and Italy. Translated materials are 
rarely/never available in Hungary, Italy and Spain but commonly or variably available in 
the Netherlands, Germany and the UK. Differing levels of agreement that language barriers 
explain the three scenarios are seen across the countries. Professionals in countries with 
most infrequent availability (Hungary and Italy) disagree strongest that language barriers 
are explanations.
Conclusions: Our findings show pronounced differences between countries in availability 
of interpreters, differences that mirror socio-cultural value systems of ‘difference-sensitive’ 
and ‘difference-blindness’. Improved language support is needed given the complex 
natural history of hepatitis B/C, the recognised barriers to screening and care, and the large 
undiagnosed burden among (potentially) linguistic minority migrant groups.
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BACKGROUND
Most chronic viral hepatitis infections in Europe are detected among migrants born 
in countries with a medium to high prevalence of hepatitis B and/or C (1). This includes 
most of Africa and Asia, Central/Eastern Europe and the countries of the former Soviet 
Union (2, 3). Chronic viral hepatitis B (CHB) and C (CHC) infections have a complex natural 
history and could require lifelong clinical monitoring and antiviral treatment (4). People 
chronically infected with hepatitis B or C can also remain infectious to others and should 
modify or avoid certain behaviours that have a high risk of transmission (5). These features 
underline the need to provide patients with information and advice about the implications 
of a diagnosis such as referral to specialist secondary care, diagnostic tests required, the 
availability of antiviral treatment, how to prevent onward transmission, contact tracing 
and HBV vaccination. However, research suggests that many diagnosed patients do not 
reach secondary care for clinical monitoring and antiviral treatment (6, 7), that language 
barriers are perceived to be the primary barrier to health care for viral hepatitis (8), and 
that immigration status is associated with not receiving treatment (9). The asymptomatic 
nature as well as a lack of screening and suboptimal referral strategies means that more 
than 60% of people infected are unaware of their infection, undiagnosed and not in 
treatment (1, 10, 11). Effective antiviral treatment for both chronic hepatitis B/C that can 
prevent the development of cirrhosis and hepatocellular carcinoma, and with newer direct 
acting anti-virals (DAAs) reporting cure rates in up to 90% of cases of chronic hepatitis C, 
(12) the elimination of chronic viral hepatitis a possibility in Europe (13). This will require 
the continued primary prevention of new infections alongside the expansion of secondary 
prevention through screening and treatment.
Language barriers between linguistic minority migrants (migrants who face language 
barriers because they do not speak the local language) and health care professionals are 
reported to increase inequalities in health care via adverse effects on accessibility, quality of 
care, patient satisfaction, patient safety and patient health outcomes (14). A systematic review 
of medical interpreter services in the United States (US) showed negative health outcomes 
as well as poor knowledge and understanding of diagnoses, treatment and implications of 
the disease, among patients who needed but did not have access to interpreter services, 
which resulted in inaccurate medical history-taking and missed/incorrect diagnoses (15). 
Conversely, interpreters have been demonstrated to have a positive impact both on clinical 
outcomes and in reducing inequalities (16). Thus, interpreters are deemed to be of benefit 
from both the perspectives of social justice and of evidence-based clinical medicine. 
Studies that examine good practice in health care for migrants recommend the provision 
of interpreters and/or translated materials to overcome language barriers as a means to 
improve patients safety, the quality of health care, medical ethical practice and patient 
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outcomes (16, 17). Good practice studies of viral hepatitis screening programmes among 
at-risk migrant populations also provide translated materials and/or interpreters to improve 
screening uptake, to reach more vulnerable sub-populations (those with very limited local 
language skills) and to raise awareness in communities at risk (18–21).
There is a distinct lack of disease-specific research however, and much of the literature 
about language barriers is focused on the countries of the English speaking world (the 
United States (US), Canada, the UK and Australia) where language proficiency is defined 
as limited English proficiency. We use ‘linguistic minority’ as a more appropriate term 
for our research in the European Union (EU), specifically in Germany, Hungary, Italy, the 
Netherlands, Spain and the United Kingdom (UK) These six European countries are the 
locations of the academic and clinical teams participating in the HEPscreen project from 
which this study arose (http://www.hepscreen.eu). They also differ considerably in their 
history and experience of migration as well as the health system response to diversity. The 
proportion of the adult population defined as foreign-born varies from 4.6% in Hungary and 
9.5% in Italy to more than 10% in the Netherlands (11.5%), the UK (12.6%), Spain (13.2%) and 
Germany (13.6%) (22, 23). The UK, the Netherlands and Spain have been described as having 
a ‘difference-based’ or communitarian approach to migration and diversity, by recognising 
difference, actively adapting services to diversity and providing tailored (as opposed to 
mainstream) health care services (24). The ‘difference-blind’ or ‘republication’ systems of 
Germany, Italy and Hungary assume all citizens should be treated equally through the 
provision of mainstream (as opposed to separatist) services that are passive to diversity 
and operate with expectations of assimilation by migrants (25). The six study countries also 
vary in regard to the financing available for health care. For instance, Germany and the 
Netherlands spend around five times the amount (per capita) on health care than Hungary 
(4753.9 USD and 5456.5 USD (respectively) vs. 991.3 USD in 2012) (26).
It is likely that these differences in experience of migration, of socio-cultural value system 
response to diversity and in health care financing will affect the availability of language 
support services in the six study countries. In this exploratory study, we investigated the 
availability of language support services (interpreters and translated written materials about 
the virus/disease) for linguistic minority chronic viral hepatitis patients. We also investigated 
health care professionals’ agreement that language barriers are explanations of the lack 
of hepatitis B/C screening among people born in medium/ high prevalence countries in 
primary care, the low uptake of screening among these patients and why people diagnosed 
with a chronic infection do not reach specialist care. This study is part of HEPscreen ((http:// 
www.hepscreen.eu)), an EU Health Programme-funded project generally focused on 
screening for chronic viral hepatitis among migrants in Europe and specifically focused on 
these six countries.
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METHODS
We developed an online survey and sent it to a large convenience sample (n = 1026) of 
expert clinicians involved in screening or care for viral hepatitis in six EU countries: Germany, 
Hungary, Italy, the Netherlands, Spain and the UK (England, Wales and Scotland). Recipients 
were identified via a comprehensive snowballing method via stakeholder consultation 
within our HEPscreen project consortium, and membership of professional networks or 
clinical associations involved in five areas of health care: general practice/family medicine, 
antenatal care, health care for asylum seekers, sexual health services, and specialist secondary 
care. The aim was to reach knowledgeable experts able to reflect on the circumstances in 
their profession and country rather than use a representative sampling framework among 
individual clinicians. We took a health system approach, looking across countries rather 
than within specific health care services.
The survey measured availability of written and oral language support services (translated 
materials and telephone or face-to-face interpreters) using closed questions and a three-
point ordinal scale: ‘very common’, ‘variable or not routinely’ and ‘rarely or never’ (unsure was 
also available). We also measured clinicians’ perception, using three closed questions and 
a five-point Likert scale of agreement, of how far language barriers explain three scenarios: 
the low uptake of screening for hepatitis B/C among migrants born in medium/high 
prevalence countries; the lack of screening by primary care services among migrants with 
country of birth-related risk factors; and why people diagnosed with a chronic infection 
do not reach specialist care for further investigation and antiviral treatment. These three 
scenarios respectively reflect patient-related, health care service-related and health care 
system-related issues. The questions reported here are specific sections of a larger survey 
aimed at understanding screening, referral, treatment and clinical management of hepatitis 
B/C patients in the six countries. Findings from other sections will be and are reported 
elsewhere (27).
The survey was pre-tested five times in English in three of the study countries, each with a 
professional from each of the five professions/health care sectors: from general practice (in 
Italy), an antenatal care (in Germany), health care for asylum seekers (in Italy), sexual health 
(in the Netherlands), and specialists in hepatology/gastroenterology (in the Netherlands)). 
The method used to pre-test was influenced by cognitive interviewing techniques which 
allow for every detail, no matter how trivial, to be captured by asking subjects to ‘think 
out loud’ about the question and answer options. Interviewers can gauge how well the 
subject has interpreted and understood each aspect of the survey. These techniques also 
allow for ambiguous or unfamiliar terms and questions to be identified (28). Feedback from 
each interview was discussed within the research team and a consensus was reached on 
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each proposed amendment or addition. Several minor changes were made to each survey 
following pre-testing. Please see the Additional files available online for the final version of 
the survey.
A professional translation company was used to translate the survey into the languages 
of the study countries. To ensure the versions provided were understandable, accurate 
and professional, a native speaker (and fluent English speaker) from the HEPscreen project 
consortium checked each language translation.
The survey was sent via email in July 2012. Two further reminders were sent and the survey 
finally closed in September 2012. The reminder schedule conformed to the deadlines set 
out within our EU Health Programme milestone framework (achievement of which was 
a condition of our funding). Data were anonymised, extracted and a descriptive analysis 
was performed using SPSS 19.02. We calculated proportions at the country level for both 
questions about language support availability and about agreement with language barriers 
as explanations. To account for different numbers of respondents across each of the five 
health services, we calculated a weighted average by summing the proportions in each 
response category in each survey and dividing by five.
RESULTS
We received a total of 238 responses from 1026 recipients (23% response rate). The 
distribution across the six countries was: 17 in Spain, 21 in Hungary, 42 in the UK, 49 in the 
Netherlands, 52 in Italy and 57 in Germany. The total included representatives from each of 
the five areas of health care in all six countries, 81% of whom have a clinical role/are involved 
in the care of patients. The health care professions/areas of expertise of the 238 respondents 
were as follows: 87 (37%) from antenatal care, 64 (27%) specialists in gastroenterology/
hepatology or infectious diseases (in secondary care), 40 (17%) from general practice/family 
medicine, 29 (12%) from sexual health/genito-urinary medicine, and 18 (8%) from health 
care for asylum seekers and refugees.
Availability of language support
Of all six study countries, translated materials in languages other than the national language 
were most commonly available in the Netherlands and Germany where just over one third 
(35 and 37%) indicated very common. However, a large proportion (44 and 36% respectively) 
indicated they were variably available (Table 1). Translated materials were least commonly 
available in Italy, where 80% of respondents indicated ‘rarely or never’ along with the majority 
in Hungary (61%) and Spain (60%). Half in the UK (51%) indicated translated materials were 
175
Language support and barriers in screening and care for hepatitis B and C
8
variably or not routinely available, with the other half of respondents distributed in all of the 
other response categories. Interpreters are also very commonly available in the Netherlands 
(60%), and in the UK, where over half (54%) indicated very common and no-one indicated 
rarely or never (also Table 1). In contrast, interpreters are rarely or never available for over 
half in Italy (56%) and nearly half (45%) in Germany, along with over a third in Hungary. 
Interpreters in Spain seem to be more common than translated materials, which is a general 
trend seen in our data except for in Germany where translated materials appear to be more 
commonly available.
Table 1. Availability of translated materials (TM) and interpreters (I) in the six countries
DE (n = 57) HU (n = 21) IT (n = 52) NL (n = 49) ES (n = 17) UK (n = 42)
TM I TM I TM I TM I TM I TM I
Very 
common
35% 10% 6% 14% 5% 2% 37% 60% 15% 25% 20% 54%
Variable or 
not routinely
36% 23% 16% 40% 13% 38% 44% 24% 20% 50% 51% 36%
Rarely or 
never
17% 45% 61% 36% 80% 56% 14% 10% 60% 23% 13% 0%
Unsure 12% 22% 17% 11% 2% 4% 6% 6% 5% 3% 17% 11%
Abbreviations: DE Germany, HU Hungary, IT Italy, NL the Netherlands, ES Spain, UK United Kingdom
Language barriers as explanations
In the UK, over half agree or strongly agree that language barriers explain all three scenarios 
(screening uptake, screening offer and referral), and only a minority (between 7 and 15%) 
expressed disagreement (Table 2). Strongest agreement in the UK emerges about the role 
of language barriers in referral, where nearly three quarters (73%) strongly agree that these 
explain why cases do not reach secondary care. A similar pattern emerges in Germany, 
where three quarters of respondents agree/ strongly agree that language barriers are 
explanations. Most agreement (over 75%) in Germany is seen for the notion of language 
barriers as explanations of the lack of screening by primary care services. A less conclusive 
pattern is found in the Netherlands, where, although between 40 and 55% agree that 
language barriers are explanations of all three scenarios, a large proportion are neutral and 
a significant minority disagree/strongly disagree that language barriers explain the low 
uptake of screening (33%) and why infected patients do not reach secondary care (19%). An 
interestingly divergent pattern is seen in Hungary, especially in response to language barriers 
as explanations of low uptake and of why cases do not reach secondary care. Whilst nearly 
half in Hungary disagree/strongly disagree that language barriers explain the low uptake of 
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screening, over a third agree/strongly agree that they do explain the low screening uptake. 
Similarly, nearly half (44%) agree/ strongly agree that language barriers explain why cases of 
chronic viral hepatitis do not reach specialist care, one third in Hungary disagree/strongly 
disagree with this notion. There is agreement (77%) that language barriers explain why 
screening is not offered by primary care services in Hungary. A similarly divergent view is 
seen in Italy; 80% agree that language barriers explain the lack of screening in primary care, 
no such strong consensus emerges regarding the other two issues. Although around half 
agree/strongly agree that language barriers explain a low screening uptake and why cases 
do not reach secondary care, a significant minority disagree, especially so about the lack of 
screening offer (26%). In Spain, there is also some diversity in opinion although around two 
thirds (68%) agree that language barriers are explanations of the lack of screening in primary 
care and why hepatitis B/C cases do not reach secondary care. Variety in perception of 
language barriers as explanations of low screening uptake is seen, with 40% in agreement/ 
strong agreement and 33% in disagreement/strong disagreement.
Table 2. Scale of agreement that language barriers explain three scenarios
Scenario
Response 
option
DE
(n = 31)
HU
(n = 18)
IT
(n = 35)
NL
(n = 49)
ES
(n = 15)
UK
(n = 39)
Language barriers 
explain the low 
uptake of screening 
by people with 
country of birth-
related risk factors
Strongly disagree 3% 18% 0% 2% 13% 3%
Disagree 10% 35% 26% 31% 20% 13%
Neutral 23% 12% 26% 22% 27% 23%
Agree 52% 24% 31% 39% 33% 54%
Strongly Agree 13% 12% 17% 6% 7% 8%
A lack of translated 
materials/
interpreters 
explains the lack 
of screening in 
primary care
Strongly disagree 0% 6% 0% 0% 0% 0%
Disagree 7% 6% 6% 14% 13% 15%
Neutral 16% 12% 14% 45% 27% 33%
Agree 68% 59% 63% 37% 53% 44%
Strongly Agree 10% 18% 17% 4% 7% 8%
Language barriers 
explain why 
hepatitis B/C cases 
do not reach 
specialist secondary 
care
Strongly disagree 4% 22% 0% 0% 0% 0%
Disagree 13% 11% 15% 19% 18% 7%
Neutral 17% 22% 35% 26% 18% 20%
Agree 58% 33% 39% 41% 46% 63%
Strongly Agree 8% 11% 12% 15% 18% 10%
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DISCUSSION
European countries have differing historical experiences of migration, with the six countries 
in our study illustrative both of these differences and of the availability services to overcome 
barriers to health care, in this instance language barriers. Our first aim was to understand 
availability of language support (translated materials and interpreters) in health care 
services most involved in screening and/or treating chronic hepatitis B/C among at risk 
migrant communities. Results suggest that translated materials are rarely or never available 
in Hungary, Italy and Spain but more commonly or variably available in the Netherlands, 
Germany and the UK. Our results suggest that interpreters are quite commonly available 
in the UK, the Netherlands and Spain but more variably or rarely available in Germany, 
Hungary and Italy. Our second research aim was to investigate how far professionals agree 
that language barriers explain three scenarios: the low uptake of screening among people 
with country of birth-related risk factors; the lack of screening in primary care among these 
risk groups; and why cases of chronic viral hepatitis do not reach specialist care for clinical 
management and treatment. Three interesting results emerge from this second research 
question: one, that opinion about the role of language barriers in the three scenarios is not 
identical in each country; two, that differences of opinion within one country about each 
scenario exist; and three, that professionals in countries with the most infrequent availability 
(Hungary and Italy) disagree most that language barriers are explanations.
Our findings both mirror and contrast with those from other studies about language 
support in health services in these six study countries and about barriers to screening and 
referral for chronic viral hepatitis internationally. In an analysis of migrant health policies, the 
provision of interpreters was found to be detailed in policy goals in the UK, the Netherlands 
and Spain although actual implementation of policy was considered patchy (26), which is 
what we see in our results for these three countries. A summary study in Germany similarly 
found that the use of interpreters in health care is not well established and that availability 
is the exception not the rule (29), again in line with the variable or not routine availability 
reported by 36% of respondents here. Other studies from the Netherlands seem to suggest 
a less frequent availability of support services than we see reported in our study; studies 
found poor information exchange between migrant patients and health care professionals, 
an underreporting of poor Dutch proficiency in medical records, that family members are 
used as interpreters and that professional interpreter services are hardly used in hospital 
settings (30, 31).
In the UK, the Netherlands and Germany, migration from the former Empire (in the case of 
the UK) and from the Mediterranean region (in the Netherlands and Germany) has been 
an historic trend since the 1950s, although war, conflict and economic crisis in the Eastern 
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Mediterranean region has led to an influx of migrants presenting new challenges to health 
care systems. In contrast, migration to Spain and Italy is a relatively new phenomenon 
and it is only in the last two decades that these countries have experienced migration in 
large numbers from, for example, 2.5% in 2001 in Spain to 13.2% in 2012 (32). Migration to 
Hungary is still relatively uncommon with just 4.6% of the population foreign-born in 2012 
(23). Given these differences in the population of migrants, disagreement about the role 
that language barriers play in screening and referral could be explained by how likely it 
is that professionals encounter linguistic minority patients in their services. Disagreement 
about their role a could reflect a perception that people with country of birth-related risk 
factors are not linguistic minorities (due to speaking the same/similar languages) and/or 
can speak the national language to a good enough standard not to require support.
The results could also reflect underlying socio-cultural value systems that migrants should 
assimilate and adapt by learning the national language. Indeed, interpreters are reported to 
be less common in the three ‘difference-blind’ systems in our study, namely Germany (10%), 
Hungary (14%) and Italy (2%) compared to the ‘difference-based’ systems of the UK (54%), 
the Netherlands (60%) and Spain (25%). Agreement that language barriers exist is however 
most strong in Germany, suggesting that clinicians may not subscribe to the socio-cultural 
value system of assimilation over adaptation. Agreement in the Netherlands is surprisingly 
low across the three scenarios, which could be explained either by the common availability 
of interpreters we see in the results from our first aim (and therefore removal of language 
barriers) or by the socio-political shift from multiculturialist ‘difference-based’ policies to 
inter-culturalist policies that favour individual responsibility and encourage migrants to 
learn Dutch (24). A recent study from the Netherlands offers some support for this notion 
and found that whilst it is hospital policy to make (hospital-funded) interpreters available, 
nursing service heads rarely reference the policy, and health care providers indicated that 
it is the responsibility of patients to overcome language barriers by bringing an interpreter 
to appointments (30). Similarly, public funding for interpreters in health care was recently 
withdrawn (33).
Disagreement about the role of language barriers in the three scenarios could also reflect 
a perception of prioritisation i.e. that language barriers are not as important explanations 
when compared to other factors such as health care provider knowledge, awareness of 
country of birth as a risk factor, or a lack of time in health care appointments (34). A study 
from the US found that hepatitis C testing is rarely performed in primary care among patients 
presenting with infection risk factors, although the list in the study did not include birth 
in an endemic country, itself an indication of the lack of awareness about this important 
risk group (35). Another study in the US found frequent reports of communication barriers 
between physicians and CHC patients, including stigmatisation, assumptions of sexual 
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promiscuity or injecting drug use as the source of infection, a lack of disease-related 
explanation or post-test counselling, and an unwillingness to refer (36). The finding that 
stigmatisation and assumptions are made about patients infected with viral hepatitis, about 
people with the additional barrier of language, increases the likelihood of these patients 
receiving poor quality health care. A study in Australia about barriers faced by migrants 
in accessing health care for viral hepatitis infection found that language barriers was the 
‘chief barrier’ for 45% of patients with a migrant background (8). Studies from the UK, the 
Netherlands and Italy show that a large proportion of chronic viral hepatitis patients do not 
reach secondary care (6, 9, 37, 38) and that immigration is negatively associated with being 
on treatment (39, 40). These studies suggest multiple explanations for why screening isn’t 
offered to or taken up by at-risk migrant groups as well as why diagnosed patients do not 
reach specialist care. However, to realise the public health gains possible due to improved 
treatment regimens, screening and referral needs to be scaled up (41).
A strength of this study is the inclusion of study countries that reflect different models 
and value systems in health care delivery. Previous multi-country research among expert 
clinicians and policy makers about the provision of hepatitis B/C screening and treatment 
services for at risk populations has only been conducted in English (42, 43). The translation 
of our survey into the national languages of our study countries is a concerted effort to 
overcome language barriers, an important strength given the focus of the study on 
language barriers themselves. A further strength is the inclusion of experts across the patient 
pathway, from primary to secondary care as well as specific services for refugees and asylum 
seekers. It is notoriously challenging to yield high response rates to non-incentivised online 
surveys among busy, practising clinicians. We reached 238 knowledgeable experts in five 
areas of health care in the six countries and, although the overall response rate is low (23%), 
the results in all six countries are broadly in line with the scarce disease-specific, migrant 
population-specific and European-focused research available to compare and contrast our 
findings with.
CONCLUSIONS
Our findings show pronounced differences between countries in the availability of 
interpreters, differences that mirror the underlying socio-cultural value systems of 
‘difference-sensitive’ and ‘difference-blindness’ that have been described in literature. 
Results also suggest varying or service-/professional-specific availability of interpreters and/
or translated written materials for chronic viral hepatitis. This is despite the complexity of the 
disease, the recognised barriers to screening and care, and the large undiagnosed burden 
among (potentially) linguistic minority migrant groups. This finding is mirrored in the view 
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among many clinicians in the six study countries that language barriers are important 
explanations of low screening uptake, a lack of screening by primary care, and why 
diagnosed hepatitis B/C patients do not reach secondary care. Europe is behind the curve 
of viral hepatitis-related mortality and getting ahead requires expanding and improving 
access to screening among at-risk populations, especially among people with country 
of birth-related risk factors. Evidence shows that interpreters and translated materials 
can improve acceptance of screening, patient knowledge and understanding, and, most 
importantly, clinical outcomes. To overcome language barriers, it is important that existing 
and future screening programmes provide language support for linguistic minority patients 
at risk of or diagnosed with chronic viral hepatitis.
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ABSTRACT
Objective: Explore and develop the concept of pre-test information before HBV/HCV 
screening among at-risk migrants.
Methods: Systematic literature review/content analysis to identify pre-test information 
objectives and topics. An online survey among health care providers (HCPs) to acquiesce 
consensus on the importance of a) each objective and b) each topic across three domains 
(securing informed choice, reducing stigma and fear, and if/when time is limited).
Results: The content analysis identified six pre-test information objectives. These were 
ranked by the 43 respondents to the survey in the following order of importance: raising 
knowledge/awareness, securing informed choice, improving acceptance, preparing for a 
positive result, reducing stigma/fear and normalising testing. Ten pre-test information topics 
were consolidated from the content analysis. The five most important topics across the 
three domains were: reasons for testing, health benefits offered by treatment, implications 
of a positive test result for the individual, modes of transmission and confidentiality of test 
results.
Conclusion: HCPs see it as their role to increase screening uptake, to encourage people to 
undergo screening.
Practice Implications: We developed a ‘pre-test information checklist’ (included as a 
supplementary annex) to enable HCPs to provide pre-test information that can secure 
informed choice, reduce stigma and fear, and be delivered if/when time for a discussion is 
limited. 
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INTRODUCTION
If left untreated, chronic hepatitis B (CHB) and C (CHC) infections slowly attack the liver 
and can cause serious liver disease including cirrhosis and hepatocellular carcinoma (HCC). 
Advances in antiviral treatment have improved the scope for secondary prevention through 
suppression of viral replication, prevention of disease progression and, in the case of CHC, 
cure within 12 weeks using often side-effect free, interferon-free direct acting antivirals 
(DAAs).(1-3) As many people who are chronically infected are asymptomatic, unaware of their 
status and have not yet reached the advanced stages of the disease, attributable morbidity 
and mortality in high-income countries are predicted to at least double in the next two 
decades.(4, 5) Asymptomatic CHB/CHC cases are unlikely to be spontaneously diagnosed 
by presenting to health care services for testing.(6) To reduce the burden of CHB/CHC 
associated morbidity and mortality and to expand access to treatment, screening among 
certain populations is recommended by clinical and public health guidelines in most high-
income countries and by the World Health Organisation.(7-10) These populations include 
the baby boomer birth cohort born 1945-1965 (for HCV), migrants born in intermediate/
high prevalence countries, men who have sex with men (MSM), and people who inject(ed) 
drugs (PWID).
Screening programmes should demonstrate that the benefits outweigh the harms at 
a population level.(11) People offered screening should also be made aware of these 
benefits and harms, via the provision of unbiased information, and to choose, free from 
coercion, whether they wish to participate in screening.(12) The information exchange 
between people offered screening and health care professionals is also described as pre-
test information. This information should be of sufficient relevancy and quality to make an 
informed choice. The notion of informed choice in screening reflects the desire to respect 
individual autonomy and is based on three principal considerations: first, that it is unethical 
to provide medical interventions to people who are unaware of the consequences; second, 
that an informed choice can lead to improved health outcomes; and finally, the threat of 
litigation due to misunderstandings about the consequences of screening.(13) Much of the 
literature describing these concepts and their application in practice is focused on non-
communicable diseases like cancers (mostly in screening for breast, colorectal and lung) 
or antenatal screening for chromosomal or genetic abnormalities where the decision to 
undergo screening or not has largely individual implications. Unlike non-communicable 
disease screening, the infectious nature of viral hepatitis means that the decision to (not) 
undergo screening has a wider community health impact due to the risk of onward 
transmission and the potential for contact tracing and vaccination (for HBV).
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The field of pre-test information before screening for chronic infectious disease such as 
HBV/HCV is much less well defined and researched than the field of screening for cancers or 
of screening in pregnancy. Specifically for HBV/HCV, there is a lack of clarity about the aims 
and content of pre-test information and a lack of studies that investigate what is actually 
provided by health care professionals (HCPs) offering screening. Studies that investigate 
pre-test information provision relating to chronic hepatitis B/C across Europe are virtually 
non-existent, in part due the methodological and resource challenges posed by the 
research question.
Our study takes place within the European context and we are specifically interested in 
screening among migrants born in HBV/HCV endemic countries. Migrants to Europe from 
intermediate/high HBV/HCV prevalence countries account for around 11% of the EU/
EEA populations but are estimated to account for around a quarter of CHB infections and 
around 15% of all CHC infections.(14) Migrants from high endemic countries are therefore 
disproportionately affected by chronic viral hepatitis and a key population for HBV/HCV 
screening and linkage to care.(15) Perinatal HBV transmission and nosocomial/iatrogenic 
HCV transmission (in health care services with inadequate infection control practices) are 
responsible for the majority of HBV/HCV acquired in higher prevalence low- and middle-
income countries (LMIC).(16) These risk factors are ‘generalised’ and largely affect the general 
population.(17) In contrast in many low prevalence industrialised countries, incident cases 
of HBV/HCV are largely reported among behavioural risk groups specifically PWID, MSM or 
sex workers.(18-20) Strongly associating HBV/HCV infection with these risk factors when 
offering screening to people unlikely to have been exposed due to individual behaviour 
per se, can be stigmatising, lead to feelings of discrimination, undermine trust in HCPs, and 
limit screening uptake.(21-27)
The literature on HBV/HCV screening among migrants is scarce but we can identify four 
main ways of offering screening: 1) outreach-based offering awareness-raising and/or 
screening in community, social or civic locations (28-32); 2) invitation-based using municipal 
or patient registry data to select and invite at-risk migrants for HBV/HCV screening in health 
care services (33, 34); 3) opportunistically offering screening to at-risk migrants attending 
health care services for other issues (35-37); and 4) extending an existing migrant-focused 
screening programme to include viral hepatitis.(35, 38) These four different models also 
provide different ways of awareness-raising and exchanging information between HCPs 
and people (migrants) offered screening.
This exploratory study seeks to add knowledge and understanding to the concept of 
pre-test information before HBV/HCV screening via three main research aims: 1) to define 
the topic contents of pre-test information included in guidelines/good practice studies; 
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2) to explore perceptions among HCPs about the objectives of pre-test information; and 
3) to understand what are the ‘desirable’ and what are the ‘feasible’ aspects of pre-test 
information. We were interested in the HCP perspective and built on the work conducted 
by Gilbert et al but with a focus on at-risk migrants and in Europe.(39) Using the findings 
of this study, and others that provide some background (40-42), we developed a practical 
pre-test information checklist to enable and support HCPs providing HBV/HCV screening 
among migrants from endemic countries. Our study takes places as part of HEPscreen, an 
EU Health Programme-funded project (during 2011-2014) focused on screening for chronic 
viral hepatitis among migrants in Europe.(43)
METHODS
We utilise systematic literature review, content analysis and a DELPHI-inspired survey 
technique in this mixed methods exploratory study. Data were gathered mostly from the 
six European countries included in the HEPscreen project, namely Italy, Spain, Germany, 
Hungary, the Netherlands and the United Kingdom (UK) although European and 
international guidelines and studies were included in the literature review described below.
Literature review and content analysis
To address the first research aim, a systematic literature search of MEDLINE, EMBASE and 
Cochrane Library databases was conducted in 2012 to identify guidelines and studies 
published (in the main European languages e.g. English, Spanish, French, Italian or 
German and in Dutch and Hungarian i.e. languages of our specific study countries) about 
screening for hepatitis B/C infections. We also trawled the reference lists of included 
studies, grey literature and professional/clinical association websites for additional literature 
not retrieved via the database search. The search has been previously described.(40) We 
assessed the relevancy of retrievals specifically for this study using pre-defined inclusion/
exclusion criteria. A content analysis of documents included on the basis of full text was 
conducted to develop a comprehensive list of a) recommended topics for inclusion in 
pre-test information for people offered HBV/HCV screening and b) the objectives/aims of 
providing pre-test information.
Survey
We sought to generate in-depth elaboration (on pre-test information objectives) and gather 
consensus (on the desirability and feasibility of pre-test information) using a semi-qualitative 
survey among a small number of expert respondents to a previous survey disseminated as 
part of HEPscreen.(41, 44) The survey methodology was influenced by work on informed 
choice and uptake of screening (13, 45, 46).
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To explore the operationalisation of the tension between screening uptake and informed 
choice we asked survey recipients to rate on a five-point ordinal scale the importance of 
six pre-test information objectives derived from literature: 1) securing informed choice; 2) 
normalising testing; 3) promoting uptake; 4) reducing stigma and fear; 5) raising knowledge 
and awareness; and 6) preparing for a positive result. To develop a consensus on and distil 
a list of the most important pre-test information topics, we explored the importance/
implications of each of the topics identified in the literature search in three domains: 
1) securing informed choice; 2) reducing stigma and fear; and 3) when/if HCPs time for 
pre-test information is constrained. The importance of discussing each topic on securing 
informed choice was measured with a five point ordinal scale (very unimportant to very 
important). The impact of discussing a topic on reducing stigma and fear was measured by 
a three point ordinal scale (increases stigma/fear, neutral and decreases stigma and fear). 
The prioritisation of the topic if/when time is limited was measured by a five point ordinal 
scale (not a priority to essential). The three domains (informed choice, stigma and fear, 
and if/when time is limited) were conceptualised as a means to understand how pre-test 
information can be both ‘desirable’ and ‘feasible’.
The survey was pilot tested with an infectious disease doctor at the Rotterdam-Rijnmond 
Municipal Public Health Service (where the corresponding author is based), revised and 
uploaded into Survey Monkey. An invitation with a unique link to the survey was sent by 
email to 253 expert respondents to a previously described survey as part of the HEPscreen 
project.(40, 41, 44) The initial sample was identified by snowballing methodology and by 
membership of professional networks, clinical associations or other means. The aim was 
not to develop a representative sampling frame, but rather to reach a small number of 
knowledgeable experts across five primary and secondary health care services involved 
in the screening, clinical management and treatment of chronic viral hepatitis. The five 
areas of health care were: antenatal services (due to antenatal HBV screening), general 
practice/family medicine, sexual health services, services for asylum seekers, and secondary 
care specialists in hepatology, gastroenterology or infectious diseases. We aimed to reach 
experts able to understand and articulate at the level of their health care profession or in 
their health care service. Our study took place in 2014 across six EU/EEA countries: Hungary, 
Germany, Italy, the Netherlands, Spain and the United Kingdom.
Survey Data Analysis
Data was exported from Survey Monkey into SPSS 19.0.2 for descriptive statistical analysis. 
Differences between countries and expert groups were explored. Likert scale responses 
were measured by using the central tendency (mode and median). For the measurement 
of central tendency the median score was favoured as compared to the mean, because 
191
Pre-test information before HBV/HCV screening
9
when reflecting a convergence of opinion the data can be skewed. The mode was used to 
identify the point(s) of polarisation/clustering. Proportions were used to determine level of 
consensus and to rank the list of topics in each of the three domains (informed choice, if/
when time is limited and on stigma and fear).
RESULTS
Literature search and content analysis: pre-test information topics
The content analysis of retrievals from the previously described search (40) yielded ten pre-
test information topics: general information about viral hepatitis; reasons for testing; routes 
of transmission/risk factors; the test itself; confidentiality of results; implications of a positive 
test for the individual including onward referral; impact of a positive test on his/her family/
close contacts; health benefits of treatment; support groups available to people diagnosed 
with chronic hepatitis B/C infections; and implications of a negative test result.
Survey: Respondents
We received 46 responses from 253 recipients, equal to a response rate of 18.2%. The 
respondents included experts from all six different countries: 15 from the Netherlands, 11 
from the UK, nine from Italy, six from Germany, four from Hungary and one from Spain. They 
also included representatives from all five different areas of health care (nine experts in 
antenatal care, five from general practice/family medicine, 10 from sexual health services, 5 
from asylum seeker health care and 17 specialists in hepatology/gastroenterology/infectious 
diseases). We did not analyse differences between groups of health care providers given the 
small numbers. Three respondents were excluded from the analysis due to invalid/missing 
data. Data analysis was performed on the remaining 43 respondents.
Survey: Rating the importance of pre-test information objectives
On an importance scale of one to five (from very unimportant to very important), the median 
score and the mode for all six objectives were both four (important), implying that, on 
average, each objective was perceived as being important. ‘Securing informed choice’ was 
rated as important/very important by 40 out of 43 respondents (93%) and as unimportant 
by one (2.3%). ‘Improving acceptance’ and ‘raising knowledge and awareness’ were rated 
as important/very important by 88.4% and by none as unimportant. ‘Preparing for a 
positive result’ was rated as important/very important by 33 respondents (76.7%). Although 
‘normalising testing’ was perceived as the least important objective, the overall perception 
(using the mean and the median) was ‘important’. Using these data, the objectives can 
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be ranked in order of importance as follows: (1) improving awareness and knowledge, (2) 
securing informed choice, (3) improving acceptance, (4) preparing for a positive result, (5) 
reducing stigma and fear, and (6) normalising testing (Figure 1).
Survey: Rating the importance of pre-test information topics for securing 
informed choice
In this question, participants were provided the list of ten topics (as described above) and 
asked to rate the importance of discussing each topic before the offer of screening if the 
main aim (of information) is securing informed choice. On an importance scale of 1 to 5 
(from very unimportant to very important), the average median score for nine topics was 
4 (important), except for ‘the test itself’, which had a median score of 3 (neutral). Thus, on 
average, discussion of all topics was perceived as important in securing informed choice, 
except for ‘the test itself’, opinion on which was neutral. Based on the proportion of 
respondents that indicated very important/important in securing informed choice (Figure 
2), the topics were ranked (Table 1).
There was a strong degree of consensus (>75% agreement towards important/very 
important) between respondents on seven topics: ‘implications of a positive test result for the 
individual’, ‘reasons for testing’, ‘modes of transmission’, ‘health benefits offered by treatment’, 
‘implications of a positive test result for family/close contacts’, ‘general information about 
viral hepatitis’,  and ‘confidentiality of test results’ (Figure 2). From these results, we infer a 
consensus on these topics being the priority topics (considered very important/important) 
in securing informed choice. The remaining three topics were considered less important.
Survey: Prioritisation of topics if/when time for pre-test information is 
limited
Participants were asked to prioritise each of the 10 topics (on a five point scale: 1 = not 
a priority and 5 = essential) if/when time for pre-test information was limited. Five out of 
the ten topics (‘reasons for testing’, ‘modes of transmission’, ‘confidentiality of test results’, 
‘implications of a positive test result for the individual’ and ‘health benefits offered by 
treatment’) had a median score and a mode of 4 (high priority), except for ‘reasons for 
testing’, which had a mode of 5 (essential). The remaining five topics (‘general information 
about viral hepatitis, ‘the test itself’, ‘implications of a positive test result for his/her family/
close contacts’, ‘implications of a negative test result’ and ‘organisations and social support 
available to patient’) had a median score of 3 (medium priority). Also the mode of these 
topics were 3 (medium priority), except for ‘general information about viral hepatitis’, which 
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had two modes being 3 (medium priority) and 4 (high priority). Each topic was ranked 
(Table 1) based on the proportion of respondents indicating high priority/essential (Figure 
3).
Figure 1. Rating of the importance of each pre-test information objective
Figure 2. Importance of each topic in securing informed choice
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Figure 3. Priority of each topic in limited time
Figure 4. Effect of discussing each topic on stigma/fear.
Survey: Topics important in reducing stigma and fear
Participants were asked their opinion about the effect discussing each topic would have 
on feelings of stigma and fear when offering HBV/HCV screening to migrants. Forty-two 
respondents completed this question. ‘Confidentiality of test results’ and ‘health benefits 
offered by treatment’ had a median score of 3 (decreases stigma/fear) and the remaining 
topics had a median score of 2 (neither increases nor decreases stigma/fear). The modes for 
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the other topics were comparable with the median scores, except for ‘general information 
about viral hepatitis’ which had a mode of 3 (decreases stigma/fear) and ‘implications of 
a positive test result for family/close contacts’ which had a mode of 1 (increases stigma/
fear). Half of the respondents indicated that ‘implications of a negative test result’ decreases 
stigma/fear and the other half indicated that it neither increases nor decreases stigma/fear. 
Each topic was ranked (Table 1) based on the proportion of respondents indicating that the 
topic decreases stigma/fear (Figure 4).
Defining the content of ‘desirable’ and ‘feasible’ pre-test information
Table 1 summarises the ranking of all ten topics (based on proportion of respondents) of the 
importance of topics overall and across the three domains. The list of topics is in descending 
order of importance according to the overall rank across the three domains.
Table 1. Ranking importance topics in securing informed choice, priority in limited time and in 
decreasing effect on stigma and fear based on proportion of respondents
Informed 
choice 
(IC)
Limited 
time 
(LT)
Reducing 
stigma and 
fear (SF)
Overall rank
(IC + LT + 
SF)/3
Reasons for testing 1 1 6     2.67    (=1)
Health benefits offered by treatment 4 3 1     2.67    (=1)
Implications of a positive test result for the individual 2 2 9     4.33    (2)
Modes of transmission 3 4 7     4.67    (=3)
Confidentiality of test results 7 5 2     4.67    (=3)
General information about viral hepatitis 5 7 4     5.33    (4)
Implications of a negative test result 8 8 3     6.33    (5)
Implications of a positive test result for his/her family/
close contacts
6 6 10     7.33    (6)
Organisations and social support available to patient 9 9 5     7.67    (7)
The test itself 10 10 8     9.33    (8)
DISCUSSION
Agreement about the desired content of pre-test information can only be achieved once 
the purpose of this information is clear.(46) This is the first study to explore and understand 
the objectives and components of pre-test information before offering screening for 
HBV/HCV among migrant populations. Our survey findings show a strong consensus that 
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‘securing informed choice’, ‘improving acceptance’, ‘raising knowledge and awareness’ and 
‘preparing for a positive result’ are the most important objectives of pre-test information. 
Literature also suggests that facilitating informed choice and promoting screening uptake 
(improving acceptance) are the main purposes of information about screening.(47-51)
Interestingly ‘improving acceptance (uptake) of screening’ and ‘raising knowledge and 
awareness’ were rated as more important than ‘securing informed choice.’ This finding 
suggests that HCPs believe that the benefits of undergoing screening outweigh the harms, 
at an individual level, and that it is their role to encourage people (at risk of being infected) 
to undergo screening. Uptake of screening is also a key parameter in cost-effectiveness 
studies.(52) The notion that pre-test information is a means to improve knowledge, 
understanding, attitude and motivation and therefore uptake of screening among at-risk 
patients draws on behavioural change/health promotion theory.(39) This notion of pre-test 
information being a means to raise awareness to improve uptake is also seen in the few 
examples in literature of awareness campaigns and other interventions to promote testing 
among at-risk migrant groups.(28, 29, 31-35, 53-55) These good practice studies report that 
low levels of awareness about ill-health, viral hepatitis and risk factors, and a lack of uptake 
of health care in general, place at-risk migrants at higher risk of HBV/HCV-related morbidity 
and mortality. Low uptake and limited screening/treatment among migrants underscores 
the importance of expanding access to screening and linkage to care for at-risk migrant 
populations, and of using pre-test information/discussion opportunities to raise awareness 
and improve knowledge.(56)
The survey and the resulting checklist were specifically focused on migrants to Europe from 
endemic countries because these populations are disproportionately affected by chronic 
viral hepatitis. Furthermore, migrants are the key risk population for CHB and are estimated 
to account for almost all CHB infections in most of the low prevalence, high income 
northern and western EU/EEA Member States.(14) Migrants from high prevalence countries 
are at-risk of being chronically infected with HBV or HCV due to generalised transmission 
risk factors (mainly antenatal for HBV and iatrogenic for HCV) in the general population in 
their country of birth.(16) In contrast, most incident (acute) cases in low prevalence EU/EEA 
countries are reported among behavioural risk groups such as PWID, MSM and sex workers.
(19, 20, 57) Associating the offer of HBV/HCV screening with risky sexual behavioural or 
drug use is suspected to increase stigma, fear and shame among migrants likely to have 
been exposed through generalised risk factors.(58) It was perhaps not surprising that there 
was consensus that the topic ‘modes of transmission’ was the third most stigmatising topic 
after implications for the individual and for family/close contacts. There was also consensus 
that discussing confidentiality of test results, health benefits offered by treatment and 
implications of a negative test result before an offer of screening are important topics in 
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reducing stigma and fear. It was more surprising that there was not a strong consensus 
(almost 30% were neutral) that reducing stigma and fear was an important objective of 
pre-test information. There is however considerable implicit overlap between objectives: 
improved acceptance of screening may also be due to not feeling stigma and fear towards 
HBV/HCV screening.(59)
The central focus of screening is on early identification of chronic cases specifically to ensure 
that these patients receive the right information and appropriate treatment to prevent 
disease progression and avoidable mortality. It is therefore unsurprising that the availability 
and benefits offered by treatment was ranked as the priority topic overall across the three 
domains of informed choice, stigma and fear, and limited time. The ranking of the topics 
in this study can, to a limited extent, be compared with a 2005 study by Gilbert et al who 
reported findings among experts in viral hepatitis. Their expert participants rated sequelae, 
primary prevention and transmission routes to be the most important topics in pre-test 
information and reported a mismatch between the pre-test topic priorities of experts and 
the general public.(39) Research into the information needs from the perspective of at-risk 
or diagnosed migrants is needed.
Conclusions
We aimed to use the findings to gather consensus on the desirable and feasible aspects 
of pre-test information from HCPs perspective. The findings were then used to develop a 
short two page ‘pre-test information (discussion) checklist’ as part of the HEPscreen Toolkit 
to provide HCPs with a brief overview of evidence on the concept of pre-test information 
and enable HCPs to provide a minimum standard of pre-test information that can secure 
informed choice, reduce stigma and fear, and be delivered if/when time for a discussion 
is limited. This checklist is available in the supplementary annex to this paper. Effective 
active case finding (screening) among at-risk migrant communities will require both a 
well-designed and planned awareness campaign alongside knowledgeable HCPs able to 
discuss the relevant issues with people who take up the offer of testing.
Practice Implications
The study significantly expands the conceptual and practical understanding of the 
objectives and content of, as well as some tensions associated with providing, pre-test 
information before HBV/HCV screening. The findings reported in this study, alongside the 
subsequently developed practical pre-test information checklist, can be used to design, 
implement and evaluate screening interventions among at-risk migrant populations.
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Introduction
Chronic infection with hepatitis B or C (HBV/HCV) 
causes slowly progressive liver damage that, without 
treatment, may lead to cirrhosis and/or liver cancer 
after many years. Antiviral treatment is available, 
dramatically increasing scope for the prevention of 
related liver disease. Clinical guidelines recommend 
screening for and raising awareness of chronic viral 
hepatitis among higher risk groups. An important 
but often neglected risk group in Europe are people 
who migrated from HBV/HCV endemic areas, i.e. 
Africa, Asia, Central/Eastern Europe and other 
countries of the former USSR. 
Offering testing
GPs, community nurses and staff in public/sexual 
health services are well-placed and well-trusted 
to offer testing for hepatitis B/C to migrants. 
Opportunities include the GP registration process for 
new patients, routine or lifestyle checks and antenatal 
visits. When offering screening, health professionals 
should conduct a ‘pre-test discussion’. This is an 
important ethical issue in screening and helps to:
 Secure informed choice
 Improve acceptance of screening
 Raise awareness and improve knowledge
Information given in pre-test discussion helps to: 
 Prepare people for a positive test result
 Reduce feelings of stigma, shame and fear 
The discussion process
 The discussion is a two-way exchange where 
information is provided and questions are answered.
 The discussion need not follow a specific format 
or strict rules; every professional has their own 
communication style.
 Not all points are equally relevant to all 
individuals, but making assumptions about 
knowledge of the person offered screening 
should be avoided.
 However, there are some key issues that should 
be covered (see pre-test discussion checklist 
overleaf).
 If needed, information should be adapted to 
gender, age, literacy level and culture of the 
person offered screening.
 For example, adjusting terminology to make it 
more understandable or being aware of religious 
or cultural taboos.
 If needed, use professional interpreters to 
overcome linguistic barriers and communication 
breakdown. Informal interpreters (e.g. family 
or friends) should be avoided for reasons of 
confidentiality. 
 People from endemic areas are more likely to 
acquire HBV perinatally or as children.
 In HCV endemic areas, transmission risks 
include unsterile medical/dental procedures 
(such as vaccination or blood transfusions), 
unsterile shaving equipment and other puncture 
procedures (such as tattooing).
 Infection with such viruses is, in many cultures, 
stigmatising. Therefore linking these with 
injecting drug use or unsafe sex can increase 
stigma and fear.
The consent process
All testing must be done with informed consent. 
Local practice and professional guidance will 
determine whether this needs to be in writing. 
Usually, a clear note in the medical record that 
informed consent has been sought and obtained is 
sufficient.
Screening for hepatitis B and C in Europe:
The pre-test discussion
Recommendations for primary health care professionals 
offering screening
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Pre-test discussion topics
The box opposite contains key pre-test discussion 
points. Coverage of these issues can help to 
secure informed choice and improve acceptance of 
screening. It is important to recognise and reduce 
feelings of stigma, shame or fear about these 
viruses. Focus on topics that reassure or dispel 
myths. Avoid emphasis on topics that may give rise 
to feelings of stigma or fear
Other recommendations
 Providing written/printed information about 
hepatitis B and C in the individual’s native 
language during the pre-test discussion may 
help overcome time constraints, language 
barriers and stigma.
 Finish off with agreements on when and how the 
results will be provided.
Access to treatment
In some European countries, immigration or 
insurance status has an impact on whether 
treatment is available for people. There may be 
some populations in your country for whom access 
to antiviral treatment is significantly or completely 
restricted. If treatment entitlement is uncertain 
or restricted, it is still sensible to offer screening. 
There are benefits of knowing one’s diagnosis, 
including prevention of transmission to or from 
others, including future offspring.
 
Checklist 
pre-test discussion topics
 Reasons for testing (i.e. birth in an endemic 
country or clinical presentation). 
 Health benefits offered by treatment, 
including treatment options* 
  Confidentiality of test results*
 Implications of a negative test result 
(including HBV vaccination if indicated)* 
  Implications of a positive test result for the 
individual (i.e. referral for further tests)
  General information about viral hepatitis
 Modes of transmission. Remember - 
unprotected sexual activities or illicit 
drug taking may not be as important 
transmission routes for people from 
endemic countries and discussion of these 
in some cultures can increase feelings of 
shame, stigma and fear. Consider this on a 
case-by-case basis
  Implications of a positive test result for 
the family or close contacts (i.e. contact 
tracing). Although brief mention of this 
topic is helpful to ensure informed choice, 
it can also increase stigma and fear. Be 
sensitive. Re-emphasise confidentiality. 
 Further topics for discussion, if time 
permits: Information on the test itself (i.e. 
blood test, when and how results are to 
be provided, possibility of indeterminate 
result, etc.) 
 Organisations and social support available 
to patient (support groups, etc.), if not 
mentioned in leaflets*
*  These topics can provide reassurance and reduce 
feelings of stigma, shame and fear.
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ABSTRACT
Background: Effective linkage to specialist care following screening is crucial for secondary 
prevention of chronic viral hepatitis-related consequences.
Methods: To explore the frequency of referral of patients to secondary care from the 
health services involved in screening and to gather information on the services responsible 
for the provision of post-test counselling and contact tracing, four online surveys were 
conducted among general practitioners (GP), and experts working in sexual health services 
(SHS), antenatal care (ANC) and specialist secondary care in Germany, Hungary, Italy, The 
Netherlands, Spain and the UK.
Results: Overall, 60% of GPs report referring all patients to specialist care. Although 67% of 
specialists commonly receive patients referred by GPs, specialists in Germany rarely or never 
receive patients from ANC or from centres testing injecting drug users; and specialists in the 
Netherlands, Hungary and Germany rarely receive patients from SHS. Gastroenterologists/
hepatologists are the professionals mainly responsible for the provision of counselling 
following a positive diagnosis of viral hepatitis according to two-thirds of specialists, 14% 
of SHS providers and 11% of ANC providers. Almost half of ANC providers (45%) stated 
that gynaecologists are the professionals responsible for the provision of counselling to 
positive pregnant women; among SHS providers, only 14% identified SHS as the services 
responsible.
Conclusion: Our findings suggest the existence of complex/ineffective referral practices 
or that opportunities to screen risk groups are missed. Recommendations clarifying the 
services responsible at each step of the referral pathway are needed in order to increase the 
success of screening programmes.
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INTRODUCTION
Chronic viral hepatitis is among the top 10 fatal infectious diseases (ID) and the leading 
cause of liver cancer and cirrhosis. In the European Union (EU), the prevalence in the 
general population varies from 0.1% in the Netherlands to 5.6% in Romania for HBsAg and 
from 0.4% in Germany to 5.2% in Italy for anti HCV.(1) However the largely asymptomatic 
nature of these infections until the late stages of the disease, results in large proportions 
of infected individuals being undiagnosed.(2-4) In order to reduce the hepatitis-related 
burden of disease it is important to improve case detection by screening risk groups. In 
addition, counselling and treating (eligible) positive patients is important for limiting 
onward transmission and preventing the development of liver cirrhosis, liver failure and 
hepatocellular carcinoma. Early detection is in fact associated with improved treatment 
outcome.(5) Nonetheless, effective linkage to specialist care is crucial to maximise the 
health impact of screening. Ideally, all newly diagnosed patients should be referred for 
appropriate evaluation and management.(6, 7) However, surveys show that over half of the 
patients do not reach specialist care,(7) only up to 74% receive appropriate disease-related 
counselling(8) and up to 87% do not initiate treatment.(9,10)  The aim of this study, part of 
the EU Health Programme-funded HEPscreen project (www.hepscreen.eu), was to provide 
insight into the current referral mechanisms between primary and specialist care for newly 
diagnosed patients in Germany, Hungary, Italy, the Netherlands, Spain and the UK, and to 
gather information on the services responsible for the provision of disease-related post-test 
counselling, contact tracing and vaccination of hepatitis B negative contacts of hepatitis B 
positive patients.
METHODS
Four online surveys were developed, aimed at professionals working in four healthcare 
services: general practice (GP), sexual health services (SHS) and/or genitourinary medicine 
(SHS), antenatal care (ANC) and specialist (SP) secondary care, i.e. gastroenterology/
hepatology and ID. The survey was semi-quantitative in design, allowing professionals to 
choose either from a number of given answer options or to indicate along a given scale 
their opinion or practice, in addition to provision of text boxes for further elaboration.
Survey structure and content
Common to all questionnaires was a respondent profile where data on the type of 
organisation, job title and medical specialism were collected. The survey was extensive 
and focused on screening and testing practice, pre- and post-test counselling, referral to 
secondary care, contact tracing, vaccination of individuals found negative, treatment and 
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clinical management. This study analysed the questions concerning referral of patients, 
disease-related post-test counselling and contact tracing: there were a total of 11 questions, 
although some were conditional.
Selection process of the participants
Purposive sampling was adopted to recruit professionals most able to reflect on these 
practices: experts were identified via professional networks and board membership of 
clinical associations. The aim in each professional group was to reach 5–10 experts, deemed 
able to reflect on the practices within their specialism.
Pre-testing and translation
Each survey was pilot tested, translated into the national language of the respective study 
country and uploaded into the open source online software LimeSurvey©. Experts were 
contacted via e-mail in July 2012 and further reminded twice during data collection. The 
survey closed in September 2012. The option of ‘‘unsure’’ was available in all questions. 
Descriptive analyses were performed with SPSS Statistics 21.
Referral
To explore the role of clinical indicators in the referral of patients identified by GPs, ANCs and 
SHSs, a two-point scale was used in these three surveys (to the question: ‘Which patients 
are referred?’, the possible options included (i) All patients; (ii) A selection based on the 
clinical indicators). If clinical indicators was selected, respondents were asked to further 
specify: ‘viral load’, ‘HBe antigen status’, ‘ALT’, or ‘other’. To explore the stages in referral from 
diagnosing services into secondary care, ANC and SHS professionals were asked whether 
referral is directly to secondary care, or via GP or other services. To understand where 
specialists received referrals from, a three-point ordinal scale (‘very common’, ‘variable or not 
routinely’ and ‘rarely or never’) was used to measure how frequently patients are received 
from services most likely to screen for viral hepatitis: GPs, centres testing injecting drug 
users (IDUs), ANC, SHS and public health services (PHS) operating at the community level.
Disease-related post-test counselling
Four questions explored the roles and responsibilities of services in the provision of 
counselling: a four-point ordinal scale was used in the GP survey and a dichotomous scale 
was used in the ANC and the SHS surveys to assess whether patients are provided disease-
related counselling; a three-point scale was used to assess whether patients are referred 
from GPs and ANC to other services for disease-related counselling. If yes, we asked to 
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which health service(s) (since more than one option could be selected, the total within a 
country could sum up to>100%). Finally, we asked in the ANC, SHS and SP surveys, which 
service has the main responsibility for counselling.
Contact tracing
All surveys included a question, using a three-point scale, about the offer of screening to 
household and/or sexual contacts of hepatitis B/C patients. If yes, we asked which services 
are responsible. Experts who had stated, in a previous section of the questionnaire, that HBV 
vaccination is offered to negative contacts of hepatitis B patients, were asked to indicate the 
services responsible for immunization.
RESULTS
Respondents
We received 220 responses from 930 recipients (response rate 24%), achieving the respondent 
target of 5–10 experts in all countries but Hungary and, except for antenatal care providers, 
Spain. In Germany, the respondent target was achieved for all professional groups, except 
for GPs (n=4). Most respondents were from clinical or professional associations (34%), 
national/regional government (22%) or universities (18%) (results by country are shown in 
Supplementary Table S1, online). Around half of GP, antenatal care provider and SHS survey 
respondents see few (1–10) chronic hepatitis patients per year, whereas 95% of specialists 
see chronic viral hepatitis patients on a weekly basis.
Referral from primary to specialist care for treatment: The views of the 
diagnosing services
Referral from GPs
All patients are referred for treatment and clinical management by the majority of GPs in 
Italy (71%), the UK (60%) and by the one respondent in Hungary (Table 1). Responses in the 
other three countries were almost evenly divided between those indicating that all patients 
(response given by 56% of GPs in the Netherlands and by 50% in Germany and Spain) and 
those reporting that a selection based on clinical indicators are referred (according to 50% 
in Germany and Spain and 44% in the Netherlands). The clinical indicators possibly used to 
select patients for referral are described in Supplementary Table S2, online.
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Table 1. Referral of newly diagnosed hepatitis B or C patients to specialist care from the diagnosing 
services. The views of the diagnosing services and of specialists
Views of the diagnosing services
Referral of hepatitis B/C + patients 
by GPs
UK
(n = 10)
DE
 (n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
All patients 60% 50% 44% 100% 71% 50%
A selection based on clinical indicators 20% 50% 56% 0% 29% 50%
Unsure 20% 0% 0% 0% 0% 0%
Referral of hepatitis B+ women from 
Antenatal Care Providers 
UK
(n = 8)
DE
(n = 36)
NL
(n = 6)
HU
(n = 4)
IT
(n = 25)
ES
(n = 8)
All women 88% 53% 17% 100% 48% 63%
A selection based on clinical indicators 0% 22% 33% 0% 36% 13%
None 0% 0% 17% 0% 0% 0%
Unsure 13% 25% 33% 0% 16% 25%
Referral of hepatitis B/C + patients by 
Sexual Health Services
UK
(n = 10)
DE
(n = 5)
NL
(n = 8)
HU
(n = 3)
IT
(n = 1)
ES
(n = 2)
All patients 60% 40% 50% 100% 100% 50%
A selection based on clinical indicators 0% 0% 13% 0% 0% 50%
Referral via another service 10% 0% 25% 0% 0% 0%
Unsure 30% 60% 13% 0% 0% 0%
Referral from Antenatal Care 
Providers
UK
(n = 8)
DE
(n = 36)
NL
(n = 6)
HU
(n = 4)
IT
(n = 25)
ES
(n = 8)
Directly to gynaecologists 75% 22% 50% 0% 36% 25%
Directly to specialist secondary care 88% 56% 33% 100% 28% 38%
Referral to specialist secondary care via GP 13% 22% 33% 25% 36% 25%
Referral to specialist secondary care via 
another service
0% 0% 0% 0% 4% 13%
Unsure 0% 17% 17% 0% 4% 0%
Referral from Sexual Health Services
UK
(n = 10)
DE
(n = 5)
NL
(n = 8)
HU
(n = 3)
IT
(n = 1)
ES
(n = 2)
Directly to specialist secondary care 60% 60% 13% 67% 100% 50%
Referral to specialist secondary care via GP 20% 20% 63% 33% 0% 50%
Referral to specialist secondary care via 
another service
0% 0% 13% 0% 0% 0%
Unsure 20% 20% 13% 0% 0% 0%
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Table 1. (continued)
Views of secondary care specialists
UK
(n = 10)
DE
(n = 9)
NL
(n = 22)
HU
(n = 10)
IT
(n = 9)
ES
(n = 4)
Frequency of receiving patients from GPs
Very common 90% 78% 68% 60% 44% 50%
Variable or not routinely 0% 11% 32% 40% 56% 50%
Rarely or never 0% 11% 0% 0% 0% 0%
Unsure 10% 0% 0% 0% 0% 0%
Frequency of receiving patients from injecting drug user (IDU) Clinics
Very common 60% 33% 32% 0% 33% 75%
Variable or not routinely 30% 11% 41% 60% 33% 25%
Rarely or never 0% 56% 27% 20% 33% 0%
Unsure 10% 0% 0% 20% 0% 0%
Frequency of receiving patients from Antenatal Care
Very common 70% 0% 23% 10% 22% 50%
Variable or not routinely 20% 44% 59% 30% 33% 0%
Rarely or never 0% 56% 14% 50% 44% 50%
Unsure 10% 0% 5% 10% 0% 0%
Frequency of receiving patients from  Sexual Health Services/genito-urinary medicine
Very common 60% 11% 9% 0% 22% 25%
Variable or not routinely 30% 33% 14% 20% 33% 50%
Rarely or never 0% 56% 73% 60% 44% 25%
Unsure 10% 0% 5% 20% 0% 0%
Frequency of receiving patients from Public Health Services
Very common 10% 33% 32% 0% 0% 0%
Variable or not routinely 30% 44% 45% 30% 33% 50%
Rarely or never 50% 22% 23% 60% 67% 25%
Unsure 10% 0% 0% 10% 0% 25%
Referral from antenatal care  providers
All antenatal care experts in Hungary, nearly all in the UK (88%), two-thirds in Spain (63%) 
and nearly half in Germany (53%) and Italy (48%), indicated that HBV+ women are referred 
to specialist care for chronic viral hepatitis (Table 1). One-third in Italy (36%) and in the 
Netherlands (33%), along with a fifth in Germany (22%) stated that a subgroup of HBV+ 
women are referred. Referral is directly to specialists according to all in Hungary, and to 
the majority in the UK (88%), where; however, three quarters also reported referral to 
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gynaecologists, and Germany (56%). No majority opinion emerged about the services 
patients are mostly referred to in Italy and Spain. In the Netherlands, referral is directly to 
gynaecologists for half of the respondents, although the remaining answers (excluding the 
one unsure), were evenly distributed between ‘via GP’ and ‘directly to specialist secondary care’.
Referral from Sexual Health Services
All respondents in Hungary and Italy, 60% in the UK and 50% in the Netherlands reported that 
all patients are referred by SHS to specialists (Table 1). In Spain, one of the two respondents 
stated that all patients are referred, the other reported that referral is based on viral load. The 
majority in the UK (60%), Germany (60%), Hungary (67%) and Italy (although n =1) indicated 
that SHS directly refer all patients. However, one-third in Hungary and one-fifth in the UK 
and Germany indicated that referral is via GPs. Referral via the GP is fairly common in the 
Netherlands (reported by 63%).
Referrals to secondary care by screening services
Receiving patients from GPs was very common for a large majority of specialists in the UK 
(90%), Germany (78%) and the Netherlands (68%), and for 60% in Hungary, 50% in Spain 
and 44% in Italy (Table 1). From one-third to nearly half in Italy, Spain, Hungary and the 
Netherlands, indicated that it was variable. Referral from antenatal care and IDU clinics was 
most common in the UK and Spain, but not routine in the other countries. Referral from SHS 
was reportedly very common in the UK (60%) but rare in the Netherlands (73%), Hungary 
(60%) and Germany (56%). No majority opinion emerged in Italy. In Germany, 56% indicated 
rarely/never receiving patients from IDU clinics, SHS and antenatal care.
The provision of post-test disease-related counselling GPs
All GPs in Germany and Spain and almost all (93%) in Italy and in the Netherlands, always or 
often provide disease-related counselling (Table 2). The respondent in Hungary indicated 
GPs often provide counselling. In the UK, half indicated that GPs always or often provide 
counselling, although almost one-third reported that post-test counselling is provided by 
GPs only occasionally. The majority in all countries but the Netherlands also refer patients 
to other services for counselling. Occasional referral to other services for counselling 
occurs according to most in the Netherlands (56%), and one-fifth in the UK and Italy. In 
Spain, the UK and Germany referral for counselling by GPs is mainly to gastroenterologists/ 
hepatologists. In Italy infectious disease specialists (79%), and gastroenterologists/
hepatologists (71%) were more frequently mentioned. In the Netherlands, GPs refer patients 
to a range of services, including infectious disease specialists (67%), Public Health Services 
(56%) and gastroenterologists/hepatologists (44%). In Hungary results suggest that patients 
are referred for counselling to Public Health Services (Table 2).
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Table 2. Frequency of counselling provision following a positive test result for hepatitis B/C
Provision of post-test counselling by GPs
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Always 40% 50% 56% 0% 21% 100%
Often 10% 50% 33% 100% 71% 0%
Sometimes 30% 0% 11% 0% 7% 0%
Rarely or never 0% 0% 0% 0% 0% 0%
Unsure 20% 0% 0% 0% 0% 0%
Referral to other services for counselling?
Yes 60% 100% 44% 100% 79% 100%
Sometimes 20% 0% 56% 0% 21% 0%
Rarely or never 0% 0% 0% 0% 0% 0%
Unsure 20% 0% 0% 0% 0% 0%
Services/professionals to which patients 
are referred by their GPs
UK
(n = 8)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Gastroenterologists/hepatologists 88% 75% 44% 0% 71% 100%
Infectious disease specialists 38% 25% 67% 0% 79% 0%
Public Health Services 10% 0% 56% 100% 14% 0%
Provision of post-test-counselling by ANC 
providers
UK
(n = 8)
DE
(n = 35)
NL
(n = 6)
HU
(n = 4)
IT
(n = 24)
ES
(n = 8)
Yes 63% 57% 50% 50% 83% 100%
No 25% 6% 50% 50% 8% 0%
Unsure 13% 37% 0% 0% 8% 0%
Referral from ANC to other health 
services for counselling
UK
(n = 8)
DE
(n = 36)
NL
(n = 6)
HU
(n = 4)
IT
(n = 25)
ES
(n = 8)
Yes—mostly pre-birth 87% 50% 67% 75% 92% 63%
Yes—mostly post-birth 0% 19% 33% 25% 0% 38%
No 13% 0% 0% 0% 25% 0%
Unsure 0% 31% 0% 0% 4% 0%
Services patients are referred to by ANC 
providers
UK
(n = 7)
DE
(n = 25)
NL
(n = 6)
HU
(n = 4)
IT
(n = 23)
ES
(n = 8)
Gastroenterologists/hepatologists 86% 48% 17% 100% 44% 25%
Infectious disease specialists 57% 44% 17% 25% 52% 0%
Public Health Services 14% 4% 83% 0% 30% 13%
GPs 0% 16% 67% 0% 4% 50%
Gynaecologists 57% 12% 33% 0% 9% 38%
Others 0% 0% 0% 0% 4% 13%
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Table 2. (continued) 
Services responsible for providing 
post-test counselling according to ANC 
providers
UK
(n = 8)
DE
(n = 36)
NL
(n = 6)
HU
(n = 4)
IT
(n = 25)
ES
(n = 8)
GPs 0% 0% 0% 0% 4% 25%
Public Health Services 0% 6% 33% 25% 12% 0%
Infectious disease specialists 25% 8% 17% 0% 20% 0%
Gastroenterologists/hepatologists 25% 14% 17% 50% 12% 0%
Midwives/maternity units 13% 0% 17% 0% 4% 25%
Obstetricians/gynaecologists 13% 67% 0% 25% 36% 50%
Others 25% 3% 17% 0% 4% 0%
Unsure 0% 3% 0% 0% 8% 0%
Provision of post-test-counselling by 
SHS
UK
(n = 10)
DE
(n = 5)
NL
(n = 8)
HU
(n = 3)
IT
(n = 1)
ES
(n = 2)
Yes 80% 20% 50% 33% 100% 50%
No 20% 0% 50% 67% 0% 50%
Unsure 0% 80% 0% 0% 0% 0%
Services responsible for providing 
post-test counselling according to SHS 
providers
UK
(n = 10)
DE
(n = 5)
NL
(n = 8)
HU
(n = 3)
IT
(n = 1)
ES
(n = 2)
GPs 10% 0% 0% 0% 0% 0%
PHS 0% 0% 75% 0% 0% 0%
Infectious disease specialists 20% 20% 0% 67% 0% 50%
Gastroenterologists/hepatologists 20% 0% 0% 33% 100% 0%
SHS 30% 0% 0% 0% 0% 50%
Other 0% 40% 0% 0% 0% 0%
Unsure 0% 20% 0% 0% 0% 0%
The professional requesting the test/all of 
the above
20% 20% 25% 0% 0% 0%
Services responsible for providing post-
test counselling according to secondary 
care specialists
UK
(n = 9)
DE
(n = 10)
NL
(n = 22)
HU
(n = 10)
IT
(n = 9)
ES
(n = 4)
GPs 0% 11% 9% 0% 22% 50%
PHS 0% 0% 27% 0% 0% 0%
Infectious disease specialists 0% 11% 5% 10% 22% 0%
Gastroenterologists/hepatologists 90% 67% 50% 90% 56% 50%
Other 10% 0% 5% 0% 0% 0%
Unsure 0% 11% 5% 0% 0% 0%
Note: Responses given by GPs, ANC providers and SHS/ GUM specialists. Services identified as mainly responsible for providing 
counselling to hepatitis B/C positive patients according to ANC providers, professionals working in SHS/GUM clinics and 
secondary care specialists
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Antenatal Care Providers
The view in Spain and Italy was that antenatal care providers are involved in counselling 
HBV+ pregnant women; this was also the majority opinion in the UK and Germany. In the 
Netherlands and Hungary, the opinion was evenly divided between ‘yes’ and ‘no’. In all 
countries pre-birth referral for counselling was common practice, except in the Netherlands, 
where around two-thirds indicated mostly pre-birth, one-third indicated mostly post-birth 
referral and Public Health Services tend to be responsible (were indicated by 83%), although 
GPs were indicated by two-thirds and specialists by one third. In the UK responsibility for 
counselling is shared by infectious disease specialists, gastroenterologists/hepatologists 
and antenatal care providers, but not GPs or Public Health Services. In Germany, HBV+ 
pregnant women are referred for counselling either to gastroenterologists/hepatologists 
(48%) or infectious disease specialists (44%); however, the main responsibility for providing 
counselling lies with antenatal care providers themselves, according to two thirds of 
respondents. Half in Hungary indicated gastroenterologists/hepatologists were responsible 
for counselling. In Spain antenatal care providers seem to be responsible for post-test 
counselling; however, women are also referred to GPs, gastroenterologists/hepatologists or 
Public Health Services for counselling. In Italy the responsibility is shared between antenatal 
care providers and specialists, with little involvement of GPs or Public Health Services. 
Women are referred from antenatal care providers mostly to infectious disease specialists 
(52%) or gastroenterologists/hepatologists (44%).
Sexual Health Services
SHS are generally involved in counselling following a positive test result in the UK (80%), 
although a range of services were identified as having the main responsibility for counselling. 
In contrast, SHS are not generally involved in providing counselling in Germany: here, the 
service requesting the test, infectious disease specialists and dermatology/venereology, 
were identified as responsible. Three quarters in the Netherlands identified Public Health 
Services as responsible for providing post-test counselling, but responses were more unclear 
about the involvement of SHS. In Hungary, specialists are responsible for counselling, 
whereas SHS appear to be less involved. SHS in Italy refer patients for post-test counselling 
to gastroenterologists/hepatologists. In Spain, while some SHS provide counselling, others 
refer patients to infectious disease specialists.
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Secondary care specialists
Most specialists in all countries indicated that the main responsibility for disease-related 
counselling lies with gastroenterologists/hepatologists. However, a significant proportion 
in the Netherlands, Italy and Spain also identified other services as responsible: Public 
Health Services in the Netherlands (27%), infectious disease specialists in Italy (22%), and 
GPs in Italy (22%) and Spain (50%).
Contact tracing
In the UK, screening contacts of HBV+ patients is very frequently practiced in SHS (100% of 
SHS specialists reported that all contacts are screened for HBV infections) and commonly 
practiced in specialist care (among gastroenterologists, hepatologists and infectious disease 
specialists, 70% reported that all contacts are screened, and 20% reported that screening is 
for a selection of contacts), whereas it seems that it is not common among GPs (Tables 3). 
Varied response were obtained from specialists and SHS providers on screening of contacts 
of HCV+ patients, while GPs were mostly unsure (60%). In Germany screening contacts of 
hepatitis B/C patients appears to be frequent practice among GPs and specialists. Among 
antenatal care providers, 42% were unsure; 39% reported that antenatal care providers are 
involved in screening contacts of HBV+ women. In the Netherlands, screening contacts 
of HBV patients seems to be common practice among GPs, antenatal care providers and 
specialists, as over two-thirds of respondents in all surveys except the SHS survey (13%) 
reported that all contacts are offered hepatitis B screening. This seems not to be the case 
for contacts of HCV+ patients, for whom only 56% of the GPs and 41% of the specialists, 
but none of the SHS survey respondents, stated that it is standard practice to offer testing. 
Screening contacts of chronic hepatitis B/C patients is common practice according to the 
majority of respondents in Hungary and Italy. In Spain, screening contacts of HBV+ patients 
is recommended to all contacts according to most specialists (75%), half of the SHS and GP 
surveys’ respondents, but only to 38% of antenatal care providers. Responses on contact 
tracing for hepatitis C are divergent among professional groups (Tables 3 and 4).
The responsibility for vaccinating negative contacts of HBV+ patients lies with the Public 
Health Services in the Netherlands and in Italy, with the GPs in the UK and Spain, and is 
shared between Public Health Services and GPs in Germany and Hungary (Table 4). In 
Supplementary Figures S1–S6 online, the post-test patient’s pathway in each country is 
synthesized in a flowchart.
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Table 3. Screening practices in household or sexual contacts of HBV or HCV positive patients
Hepatitis B screening practices contacts of HBV + patients
GP
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT(n = 
14)
ES
(n = 2)
Yes—all contacts 40% 100% 89% 100% 93% 50%
Yes—a selection of contacts 10% 0% 11% 0% 0% 0%
No 0% 0% 0% 0% 7% 50%
Unsure 50% 0% 0% 0% 0% 0%
Antenatal care
UK
(n = 8)
DE
(n = 36)
NL
(n = 6)
HU
(n = 4)
IT
(n = 25)
ES
(n = 8)
Yes—all contacts 25% 39% 66% 75% 60% 37.5%
Yes—a selection of contacts 12.5% 5% 0% 0% 8% 0%
No 12.5% 14% 17% 25% 16% 12.5%
Unsure 50% 42% 17% 0% 16% 50%
Sexual Health Services
UK
(n = 10)
DE
(n = 5)
NL
(n = 8)
HU
(n = 3)
IT
(n = 1)
ES
(n = 2)
Yes—all contacts 100% 40% 12.5% 67% 100% 50%
Yes—a selection of contacts 0% 20% 50% 0% 0% 0%
No 0% 0% 12.5% 0% 0% 50%
Unsure 0% 40% 25% 33% 0% 0%
Specialists
UK
(n = 10)
DE
(n = 9)
NL
(n = 22)
HU
(n = 10)
IT
(n = 9)
ES
(n = 4)
Yes—all contacts 70% 89% 82% 70% 89% 75%
Yes—a selection of contacts 20% 0% 18% 0% 11% 25%
No 0% 0% 0% 0% 0% 0%
Unsure 10% 11% 0% 30% 0% 0%
Hepatitis C screening practices in contacts of HCV + patients
GP
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Yes—all contacts 20% 100% 56% 100% 72% 50%
Yes—a selection of contacts 10% 0% 11% 0% 7% 0%
No 20% 0% 11% 0% 7% 50%
Unsure 60% 0% 22% 0% 14% 0%
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Table 3. (continued)
Sexual Health Services
UK
(n = 10)
DE
(n = 5)
NL
(n = 8)
HU
(n = 3)
IT
(n = 1)
ES
(n = 2)
Yes—all contacts 30% 40% 0% 67% 100% 50%
Yes—a selection of contacts 40% 0% 50% 0% 0% 0%
No 0% 20% 12.5% 0% 0% 50%
Unsure 30% 40% 37.5% 33% 0% 0%
Specialists
UK
(n = 10)
DE
(n = 9)
NL
(n = 22)
HU
(n = 10)
IT
(n = 9)
ES
(n = 4)
Yes—all contacts 10% 78% 41% 70% 78% 75%
Yes—a selection of contacts 50% 11% 27% 0% 22% 25%
No 30% 0% 23% 10% 0% 0%
Unsure 10% 11% 9% 20% 0% 0%
Table 4. Health services responsible for screening contacts of HBV+/HCV+ patients and services 
identified as responsible for the vaccination of contacts of HBV+ patients
Services identified 
UK
(n = 3)
DE
(n = 16)
NL
(n = 4)
HU
(n = 3)
IT
(n = 17)
ES
(n = 3)
Survey: 
Antenatal 
Care
GPs 0% 25% 0% 33% 47% 67%
Antenatal Care 67% 31% 75% 67% 29% 0%
ID specialists 0% 12.5% 0% 0% 0% 33%
Gastroenterologists/hepatologists 33% 0% 0% 0% 6% 0%
Obstetricians/
gynaecologists
0% 19% 0% 0% 6% 0%
Other 0% 0% 25% 0% 0% 0%
Unsure 0% 12.5% 0% 0% 12% 0%
Services identified
UK
(n = 5)
DE
(n = 4)
NL
(n = 8)
HU
(n = 1)
IT
(n = 13)
ES
(n = 1)
Survey:
GP
GPs 40% 50% 25% 100% 69% 100%
PHS 20% 50% 62.5% 0% 31% 0%
SHS 20% 0% 0% 0% 0% 0%
Hospitals/clinics 0% 0% 0% 0% 0% 0%
Other 20% 0% 12.5% 0% 0% 0%
Unsure 0% 0% 0% 0% 0% 0%
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Table 4. (continued)
Services identified
UK
(n = 10)
DE
(n = 3)
NL
(n = 6)
HU
(n = 2)
IT
(n = 1)
ES
(n = 1)
Survey: 
Sexual 
Health 
Services
GPs 10% 0% 33% 0% 0% 0%
PHS 10% 67% 33% 50% 100% 0%
ID specialists 0% 0% 0% 50% 0% 0%
Gastroenterologists/hepatologists 0% 0% 0% 0% 0% 0%
SHS 20% 0% 17% 0% 0% 100%
Hospitals/clinics 0% 0% 0% 0% 0% 0%
Other 30% 0% 0% 0% 0% 0%
Unsure 30% 33% 17% 0% 0% 0%
Services identified
UK
(n = 10)
DE
(n = 8)
NL
(n = 22)
HU
(n = 8)
IT
(n = 9)
ES
(n = 4)
Survey:
Specialists
GPs 60% 62.5% 23% 0% 33% 75%
PHS 20% 0% 50% 17% 0% 0%
SHS 0% 0% 0% 0% 0% 0%
Hospitals/clinics 0% 12.5% 0% 83% 56% 0%
Other 20% 0% 18% 0% 11% 25%
Unsure 0% 25% 9% 0% 0% 0%
Vaccination of contacts of hepatitis B positive patients
Services identified as 
responsible:
UK
(n = 2)
DE
(n = 10)
NL
(n = 4)
HU
(n = 2)
IT
(n = 10)
ES
(n = 3)
Survey: 
Antenatal 
Care
GPs 0% 40% 0% 0% 10% 33%
PHS 50% 20% 100% 100% 90% 33%
ID specialists 0% 30% 0% 0% 0% 0%
Gastroenterologists/
hepatologists
50% 0% 0% 0% 0% 0%
DISCUSSION
With this study, we aimed to explore the post-test pathways for chronic viral hepatitis 
currently in place in six EU countries via an online survey of experts and representative 
healthcare professionals. Other than from GPs, referral of chronic hepatitis B and C patients 
was very varied and heterogeneity of responses within countries even within the same 
professional group were observed. Only in the Netherlands and Germany did clinical 
indicators like viral load or ALT guide patient referral.
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Clear referral pathways should be central in the design of screening interventions. 
In the guidelines on the management of hepatitis C produced by the World Health 
Organization,(11) ensuring that newly diagnosed patients are referred for appropriate care 
has been recognized as an important challenge. The concept of ‘under-treatment’ was 
introduced to refer to the disparity between the number of chronically infected individuals 
and the number of patients receiving treatment.(10) The most important limiting step to 
treatment appears to be the proper identification of chronically infected individuals. In two 
recent surveys conducted by the European Liver Patients Association among its members, 
only 21.5% of patients knew of their status at the time of their diagnosis and only 27% knew 
they were at risk.(12) However, appropriate referral to specialist care is another important 
step in the treatment cascade: probably fewer than half of chronically infected patients with 
HBV are referred for appropriate care.(10)
Not receiving disease-related counselling can have serious implications in terms of poor 
patient’s awareness and knowledge of the disease, diagnostic testing, adherence to 
treatment regimens, liver disease monitoring and onward transmission.
The recent approval of new, direct-acting antivirals, means that more effective and safer 
treatments are now available for chronic hepatitis C. As for hepatitis B, the existing drugs 
significantly decrease the risk of liver damage and many promising new drugs are being 
developed.(13,14) Nevertheless, without adequate screening programmes and linkage to 
care, mortality from chronic viral hepatitis is projected to rise and peak around 2020–30.
(15,16)
The implementation of a care pathway has been shown to reduce the variability in clinical 
practice, improve clinical outcomes and reduce health-care costs.(17,18) To our knowledge, 
the scientific literature regarding referral practices of patients in the six countries is scarce 
and studies allude to complex and non-standardized practices, often conducted as part of 
time-limited, small-scale screening programmes.(7, 19–30) This finding from the literature 
was reflected in the responses to our survey.
A limitation of the study is the sometimes small sample size, especially for Hungary and 
Spain, which greatly limits the generalizability of our findings. However, our aim was to reach 
up to 10 key experts for each professional group in each country. Given the careful selection 
of survey participants based on their affiliation to specific professional boards or clinical 
associations, and considering that professionals were specifically requested to participate 
as representatives of their respective fields in their country, it is justified to assume that 
the responses gathered convey a fair depiction of the actual referral practices in the six EU 
countries. 
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Despite some clear common practices, mainly regarding GP, heterogeneity of responses on 
how frequently patients are referred from the other well-used, well-trusted services were 
observed: specialists in Germany reported rarely or never receiving patients from ANC and 
IDU clinics and in the Netherlands, Hungary and Germany it was rare for gastroenterologists 
or ID specialists to receive patients from SHS. Furthermore, diagnosing services expressed 
a variety of opinions about the services mainly responsible for the provision of post-test 
counselling. These findings suggest either the existence of complex or ineffective referral 
practices, that not all patients reach secondary care or that services most able to offer 
screening miss opportunities to screen high-risk groups.
In the UK and in the Netherlands screening contacts of HBV+ patients seems to be common 
practice, whereas this is not the case for contacts of HCV+ patients. In Italy especially GPs 
and secondary care specialists deemed common practices screening contacts of HBV+ 
patients, while responses regarding HCV revealed diversity in practices. In Germany and 
Hungary, contact tracing seems to be frequent practice.
Discordant opinions could be partially explained by healthcare system context i.e. regional/
local referral mechanisms or differences in the role of the diagnosing services (SHS or IDU 
clinics), as opposed to quality of care or provision. In Italy, e.g. a clear denomination for SHS is 
often lacking and care for sexually transmitted diseases is provided by different professional 
groups. However, the lack of unison within countries even among experts belonging to 
the same professional group suggests a lack of clarity about responsibilities of the different 
services.
The increased scope for secondary prevention of chronic viral hepatitis can only be achieved 
with effective screening programmes that successfully detect risk groups and link all newly 
diagnosed patients to specialist care. Our findings can serve as an impetus to formulate 
guidelines targeted at specific professional groups, explicitly specifying which services are 
to be deemed responsible at each step of the referral pathway, so as to increase the success 
of screening programmes and stop the growth of this silent epidemic.
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ABSTRACT
Introduction. Chronic viral hepatitis is still a major public health concern in the EU. In 
order to halt the progression of the disease and to prevent onward transmission, timely 
recognition and accurate clinical management are crucial. The aim of the present study was 
to investigate the role of the general practitioner (GP) in the screening of persons at risk and 
in the clinical management of chronic viral hepatitis patients in six EU countries.
Methods. An online survey among GPs and secondary-care specialists was conducted in 
the UK, Germany, the Netherlands, Hungary, Italy and Spain. In the GP survey, we used a 
four-point Likert scale to find out how commonly risk groups are screened. In both surveys, 
we measured GPs involvement  in  monitoring  clinical  indicators in patients undergoing 
antiviral treatment, and explored whether patients in four clinical scenarios are referred 
back to primary care.
Results. Between five and 10 experts per professional group were surveyed, except for 
Spain (GPs: n = 2; Specialists: n = 4) and, in the case of the GP survey, Hungary (GPs: n = 1) 
and Germany (GPs: n = 4). Migrants are variably or not routinely screened for hepatitis B/C in 
the majority of cases. The majority of GPs reported that hepatitis B/C screening was routinely 
offered to people who inject drugs. In Hungary, Italy and in the Netherlands, screening sex 
workers is not a regular practice. As to whether GPs offer screening to men who have sex 
with men, responses varied; in Germany, the Netherlands and Italy, screening was “variably” 
or “commonly” implemented, while in Hungary the practice seems to be sporadic. In the 
UK, screening for hepatitis B seems to be common practice among GPs, while hepatitis 
C testing is only occasionally offered to this risk group. Most GPs (>44%) in all countries 
except Hungary reported that hepatitis B/C screening was very commonly offered to HIV 
patients. The role of GPs in monitoring hepatitis cases and the referral of cases back to 
GPs by specialists varied both within and between countries. GPs are unlikely to monitor 
clinical outcomes other than side effects in patients undergoing treatment. Patients who 
have had a sustained virological response are usually referred back to GPs, whereas patients 
undergoing antiviral treatment and those who do not respond to treatment are rarely 
referred back.
Conclusions. The GP’s decision to offer screening to risk groups often seems to be an 
individual choice of the healthcare professional. Raising GPs’ awareness of the disease, 
for example through the adoption of effective strategies for the dissemination and 
implementation of the existing guidelines for general practice, is strongly needed. The role 
of GPs and specialists involved in the management of chronically infected patients should 
also be clarified, as opinions sometimes differ markedly even within each professional group.
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INTRODUCTION
Viral hepatitis B and C are of major public health concern in the European Union, although 
there are distinct geographical variations in the prevalence and incidence of viral hepatitis 
across countries. In the EU, the burden of disease is generally low in the north-western 
countries and higher in the south-eastern region: the prevalence in the general population 
varies from 0.4% to 5.2% for anti-HCV and from 0.1% to 5.6% for HBsAg (1, 2). However, as 
there is  a  lack of representative data in higher-risk populations, such as migrants from 
countries where hepatitis is endemic (3), the true prevalence is probably higher.
In  order to halt the progression of the disease to advanced hepatic fibrosis, cirrhosis, and/
or hepatocellular carcinoma, and to prevent onward transmission, timely recognition and 
accurate clinical management of the disease are of extreme importance. Both the general 
practitioner (GP) and the secondary-care specialist are involved in the diagnosis of chronic 
viral hepatitis and in the clinical management of infected patients. Several studies have 
explored the primary-care physician’s role and experiences in treatment and shared- care 
with specialists in North America (4-6), in Australia (7-9) and in some parts of Asia (10, 11). To 
the best of our knowledge, however, the remit of the GP in the clinical management of the 
disease in the EU member states has not been extensively evaluated.
The aim of the present study, which is part of the EU funded Project “HEPscreen: Screening 
for hepatitis B and C among migrants in the European Union”, was to investigate, by means 
of a semi-quantitative online survey, the role of the GP in the screening of persons at risk and 
in the clinical management of chronic viral hepatitis patients in six EU countries: Germany, 
Hungary, Italy, the Netherlands, Spain and the United Kingdom.
METHODS
Two semi-quantitative online surveys were developed and administered, respectively, to 
general practitioners (GPs) and to secondary-care specialists (SPs), i.e. gastroenterologists, 
hepatologists and infectious disease specialists, working in the six EU countries. Both 
surveys were pilot tested, translated into the national languages of the study countries, 
uploaded into the open-source online software package LimeSurvey©, and sent by 
email to health care professionals, who were board members of clinical associations and 
professional networks. Rather than reaching a large representative sample of practising 
clinicians, the aim was to involve 5-10 experts deemed able to reflect on practices within 
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their specialty in both professional groups. Respondents were contacted via email in July 
2012 and further reminded twice during data collection, which closed in September 2012. 
Data were exported from LimeSurvey to SPSS 19.2 (Inc. Chicago, IL) for descriptive analysis.
In the GP survey, we aimed to find out how commonly population groups at higher risk, 
namely migrants from endemic countries, people who inject drugs (PWID), sex workers, 
men who have sex with men (MSM), HIV positive patients and patients with abnormal liver 
function test (LFT) results, are screened for hepatitis B/C by GPs in the six countries. To this 
end, we used a four-point Likert scale (“very common”; “variable or not routinely”; “rarely or 
never”; “unsure”). In both the GP and specialist survey, the same scale was used to determine 
whether GPs were involved in the clinical management of patients: specifically, whether 
they were involved in monitoring alanine aminotransferase (ALT), viral load and side effects 
in patients undergoing antiviral treatment. We also explored whether patients were referred 
back to primary care in four clinical/patient scenarios, i.e. i) patients not qualifying for 
treatment after the initial evaluation; ii) those undergoing antiviral treatment; iii) those who 
have a sustained virological response (SVR) due to treatment; and iv) those who are non-
responders to treatment. The replies given by the two professional groups were compared.
RESULTS
Respondent profile (Table 1)
The respondent target of between five and 10 experts per professional group was achieved, 
except in the cases of Spain (GPs: n = 2; Specialists: n = 4), Hungary (GPs:   n = 1) and 
Germany (GPs: n = 4) (Table 1). The majority of specialists (77%) were gastroenterologists/
hepatologists; 21% were infectious disease specialists and a small proportion were 
community/practice nurses. Overall, around half of the participating GPs see a few (1-10) 
chronic hepatitis patients per year, whereas more than 90% of the secondary-care specialists 
see chronic hepatitis patients on a weekly basis.
Table 1. Survey respondents by professional group and by country
UK n (%) DE n (%) NL n (%) HU n (%) IT n (%) ES n (%) Total n (%)
GPs 10 (25) 4 (10) 9 (22.5) 1 (2.5) 14 (35) 2 (5) 40 (100)
Specialists 10 (15.6) 9 (14.1) 22 (34.4) 10 (15.6) 9 (14.1) 4 (6.3) 64 (100)
Total n (%) 20 (19.2) 13 (12.5) 31 (29.8) 11 (10.6) 23 (22.1) 6 (5.8) 104 (100)
n: number of health professionals who participated in the survey.%: proportion of those invited who responded.
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Screening by GPs for groups at higher risk (Table 2)
Migrants from endemic countries
Results from the GP survey showed that 75% of respondents in Germany, 56% in the 
Netherlands, the one in Hungary and one of the two in Spain stated that it was very 
common to offer hepatitis B testing to migrants from endemic regions. On the other 
hand, approximately half of the respondents in the UK (60%) and Italy (50%) and the other 
respondent in Spain answered that this was not routine. Except for Hungary, where the one 
respondent was unsure, most GPs in the study countries stated that they either routinely or 
variably offered screening for hepatitis C to migrants from endemic regions.
People who inject drugs (PWID)
The majority of GPs from the UK, Germany and Italy, along with the one in Hungary and the 
two in Spain, reported that they routinely offered hepatitis B/C screening to PWID. In the 
Netherlands, although screening for hepatitis C appears to be commonly practised by GPs 
for PWID, screening for hepatitis B varied between very commonly (44%) or variably (44%) 
offering the test.
Sex workers
In Germany and the UK most GPs (75% and 70%, respectively) answered that it was very 
common to offer a hepatitis B test to sex workers, and the two respondents in Spain were 
also of this opinion. The single Hungarian GP stated that it was a variable practice. In the 
Netherlands, respondents were split between judgements of “very common” and “variable”. 
In Italy, no apparent trend could be discerned. The majority of GPs in the UK, Germany 
and the Netherlands, and both respondents in Spain, stated that it was very common to 
recommend hepatitis C testing to sex workers. In Italy, most replies were split between 
“very common” and “variable”. The respondent in Hungary reported that it was not routinely 
practised.
Men who have sex with men (MSM)
As to whether GPs offer screening to MSM, replies indicated that it was “variably” and 
“commonly” practised in Germany, the Netherlands and Italy, while in Hungary it seems 
to be a sporadic practice. In the UK, while screening for hepatitis B seems to be common 
practice among GPs, the majority view is that hepatitis C testing is offered only occasionally 
to MSM.
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Table 2. Frequency of screening for hepatitis B or C for population groups at higher risk by primary-
care physicians in the six countries
Migrants
HBV
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 20% 75% 56% 100% 14% 50%
Variable or not routinely 60% 25% 22% 0% 50% 50%
Rarely or never 10% 0% 22% 0% 29% 0%
Unsure 10% 0% 0% 0% 7% 0%
HCV
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 40% 75% 67% 0% 29% 50%
Variable or not routinely 30% 25% 11% 0% 57% 50%
Rarely or never 10% 0% 22% 0% 14% 0%
Unsure 20% 0% 0% 100% 0% 0%
People who inject drugs (PWID)
HBV
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 90% 75% 44% 100% 64% 100%
Variable or not routinely 0% 25% 44% 0% 14% 0%
Rarely or never 0% 0% 0% 0% 14% 0%
Unsure 10% 0% 12% 0% 8% 0%
HCV
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 50% 75% 67% 100% 72% 100%
Variable or not routinely 30% 25% 22% 0% 14% 0%
Rarely or never 0% 0% 11% 0% 14% 0%
Unsure 20% 0% 0% 0% 0% 0%
Sex workers
HBV
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 70% 75% 44% 0% 36% 100%
Variable or not routinely 0% 25% 45% 100% 29% 0%
Rarely or never 0% 0% 11% 0% 14% 0%
Unsure 30% 0% 0% 0% 21% 0%
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Table 2. (continued)
HCV
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 60% 75% 56% 0% 36% 100%
Variable or not routinely 20% 25% 33% 100% 43% 0%
Rarely or never 0% 0% 11% 0% 14% 0%
Unsure 20% 0% 0% 0% 7% 0%
Men who have sex with men (MSM)
HBV
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 60% 50% 44% 0% 36% 0%
Variable or not routinely 20% 50% 56% 100% 36% 50%
Rarely or never 0% 0% 0% 0% 21% 0%
Unsure 20% 0% 0% 0% 7% 50%
HCV
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 20% 50% 44% 0% 36% 50%
Variable or not routinely 50% 50% 45% 100% 43% 50%
Rarely or never 0% 0% 11% 0% 21% 0%
Unsure 30% 0% 0% 0% 0% 0%
1st Abnormal Liver Function Test Results
HBV
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 40% 50% 44% 100% 64% 50%
Variable or not routinely 50% 50% 45% 0% 22% 0%
Rarely or never 0% 0% 11% 0% 14% 50%
Unsure 10% 0% 0% 0% 0% 0%
2nd Abnormal Liver Function Test Results
HBV
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 60% 100% 89% 100% 64% 50%
Variable or not routinely 30% 0% 11% 0% 36% 0%
Rarely or never 0% 0% 0% 0% 0% 50%
Unsure 10% 0% 0% 0% 0% 0%
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Table 2. (continued) 
1st Abnormal Liver Function Test Results
HCV
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 40% 50% 33% 100% 64% 50%
Variable or not routinely 40% 50% 34% 0% 29% 50%
Rarely or never 0% 0% 33% 0% 7% 0%
Unsure 20% 0% 0% 0% 0% 0%
2nd Abnormal Liver Function Test Results
HCV
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 60% 100% 56% 100% 79% 50%
Variable or not routinely 20% 0% 33% 0% 22% 50%
Rarely or never 0% 0% 11% 0% 0% 0%
Unsure 20% 0% 0% 0% 0% 0%
Patients with HIV
HBV
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 80% 75% 67% 0% 79% 50%
Variable or not routinely 0% 25% 22% 100% 0% 50%
Rarely or never 0% 0% 0% 0% 7% 0%
Unsure 20% 0% 11% 0% 14% 0%
HCV
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 50% 75% 44% 0% 71% 100%
Variable or not routinely 30% 25% 22% 100% 14% 0%
Rarely or never 0% 0% 11% 0% 7% 0%
Unsure 20% 0% 23% 0% 8% 0%
Patients with HIV
Most GPs (>44%) in all countries reported that it was very common practice to offer 
hepatitis B/C screening to HIV patients, except in Hungary, where the respondent stated 
that screening was not routinely offered.
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Patients with abnormal liver function test results
A first abnormal LFT result would very commonly prompt approximately half of the GP 
respondents in each country and the one in Hungary to screen a patient for hepatitis B, 
while the others stated that this would not routinely be the case. On the other hand, a 
second abnormal LFT result would alert most GPs to recommend a hepatitis B test to their 
patients. While a first abnormal LFT result would only lead half of the GPs to request a 
hepatitis C test, apart from Italy and Hungary, where most would ask for a hepatitis C test, a 
second or repeat abnormal LFT would prompt the majority of GPs in all countries to screen 
for hepatitis C.
The involvement of GPs in the clinical management of the disease (Table 3)
ALT
In Germany, the majority of respondents indicated that it was very common for GPs to 
monitor ALT in patients undergoing antiviral treatment. A similar, but less marked, trend 
could be seen in Italy, where over half the GPs selected “very common”. GPs in Spain appeared 
to be involved in monitoring ALT variably according to the vast majority of respondents. The 
trends in these three countries contrast with that observed in the Netherlands, where nearly 
three quarters (71%) indicated that GPs were rarely or never involved in monitoring ALT. In 
the UK and in Hungary, over half (55%) indicated that GPs were rarely or never involved, the 
remaining replies being distributed across the other answer options.
Viral load
The results from both the GPs’ and specialists’ surveys show that, in the UK, the Netherlands, 
Hungary and Spain, most GPs are rarely or never involved in monitoring viral load among 
patients undergoing antiviral treatment. Also in Italy, despite the diverse spread of opinion, 
the largest proportion (39%) indicated that GPs were rarely or never involved. In Germany, a 
slight trend towards “very common” was observed.
Side effects
A diversity of opinion emerged from both surveys in most countries. The clearest picture 
emerged from Germany, where the majority view (62%) was that GPs were very commonly 
involved in monitoring side effects. The dominant view in Italy was more towards very 
common (35%) or variable (52%) monitoring of side effects by GPs, whereas the majority 
view inclined more towards variable to rarely or never in the UK, the Netherlands and 
Hungary. In Spain no majority opinion emerged.
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Table 3. GPs’ involvement in monitoring clinical indicators and side effects of antiviral treatment
GPs involvement in monitoring ALT
ACCORDING TO GPs
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 20% 75% 0% 100% 64% 50%
Variable or not routinely 40% 0% 22% 0% 21% 50%
Rarely or never 20% 0% 56% 0% 14% 0%
Unsure 20% 25% 22% 0% 0% 0%
ACCORDING TO SPECIALISTS
UK
(n = 10)
DE
(n = 9)
NL
(n = 22)
HU
(n = 10)
IT
(n = 9)
ES
(n = 4)
Very common 0% 56% 0% 10% 33% 0%
Variable or not routinely 10% 11% 23% 10% 67% 100%
Rarely or never 90% 11% 77% 60% 0% 0%
Unsure 0% 22% 0% 20% 0% 0%
COMBINED RESULTS
UK
(n = 20)
DE
(n = 13)
NL
(n = 31)
HU
(n = 11)
IT
(n = 23)
ES
(n = 6)
Very common 10% 62% 0% 18% 52% 17%
Variable or not routinely 25% 8% 23% 9% 39% 83%
Rarely or never 55% 8% 71% 55% 9% 0%
Unsure 10% 23% 6% 18% 0% 0%
GPs involvement in monitoring viral load
ACCORDING TO GPs
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 0% 50% 0% 0% 36% 0%
Variable or not routinely 30% 25% 11% 0% 43% 50%
Rarely or never 50% 25% 67% 100% 21% 50%
Unsure 20% 0% 22% 0% 0% 0%
ACCORDING TO SPECIALISTS
UK
(n = 10)
DE
(n = 9)
NL
(n = 22)
HU
(n = 10)
IT
(n = 9)
ES
(n = 4)
Very common 0% 33% 0% 0% 22% 0%
Variable or not routinely 0% 22% 0% 10% 11% 25%
Rarely or never 100% 22% 100% 70% 67% 75%
Unsure 0% 22% 0% 20% 0% 0%
COMBINED RESULTS
UK
(n = 20)
DE
(n = 13)
NL
(n = 31)
HU
(n = 11)
IT
(n = 23)
ES
(n = 6)
Very common 0% 38% 0% 0% 30% 0%
Variable or not routinely 15% 23% 3% 9% 30% 33%
Rarely or never 75% 23% 90% 73% 39% 67%
Unsure 10% 15% 6% 18% 0% 0%
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Table 3. (continued)
GPs involvement in monitoring side effects
ACCORDING TO GPs
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 10% 75% 0% 0% 50% 100%
Variable or not routinely 50% 0% 22% 100% 36% 0%
Rarely or never 20% 25% 56% 0% 14% 0%
Unsure 20% 0% 22% 0% 0% 0%
ACCORDING TO SPECIALISTS
UK
(n = 10)
DE
(n = 9)
NL
(n = 22)
HU
(n = 10)
IT
(n = 9)
ES
(n = 4)
Very common 10% 56% 0% 10% 11% 0%
Variable or not routinely 40% 11% 46% 20% 78% 50%
Rarely or never 50% 11% 55% 40% 11% 50%
Unsure 0% 22% 0% 30% 0% 0%
COMBINED RESPONSES
UK
(n = 20)
DE
(n = 13)
NL
(n = 31)
HU
(n = 11)
IT
(n = 23)
ES
(n = 6)
Very common 10% 62% 0% 9% 35% 33%
Variable or not routinely 45% 8% 39% 27% 52% 33%
Rarely or never 35% 15% 55% 36% 13% 33%
Unsure 10% 15% 7% 27% 0% 0%
Referral back to GPs/primary care from specialist secondary care (Table 4)
Patients who do not qualify for treatment after an initial evaluation
In the Netherlands and in Spain, the majority of respondents in both surveys agreed that 
patients who do not qualify for treatment after an initial evaluation are only variably or not 
routinely referred back to primary-care practitioners. Specialists’ opinion was in contrast with 
that of GPs in the UK, where 90% of specialists (vs 10% of GPs) indicated that these patients 
were rarely or never referred back to GPs. In Italy, although the majority of specialists (56%) 
selected “variable”, around one third indicated “rarely or never”, while 57% of GPs selected 
“very common”. In Germany, the majority opinion was divided between patients being very 
commonly (54%) and variably (39%) referred back to GPs. In Hungary, no dominant opinion 
could be observed.
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Table 4. Frequency of referral back to GPs for: i) patients who do not qualify for treatment after the 
initial evaluation; ii) patients undergoing antiviral treatment; iii) patients with sustained virological 
response due to treatment; and iv) patients who are non-responders to treatment
i) Patients who do not qualify for treatment after initial evaluation
ACCORDING TO GPs
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 50% 50% 33% 100% 57% 50%
Variable or not routinely 10% 50% 56% 0% 21% 0%
Rarely or never 10% 0% 11% 0% 21% 50%
Unsure 30% 0% 0% 0% 0% 0%
ACCORDING TO SPECIALISTS
UK
(n = 10)
DE
(n = 9)
NL
(n = 22)
HU
(n = 10)
IT
(n = 9)
ES
(n = 4)
Very common 10% 56% 14% 20% 11% 0%
Variable or not routinely 0% 33% 59% 30% 56% 100%
Rarely or never 90% 0% 27% 30% 33% 0%
Unsure 0% 11% 0% 20% 0% 0%
COMBINED RESULTS
UK
(n = 20)
DE
(n = 13)
NL
(n = 31)
HU
(n = 11)
IT
(n = 23)
ES
(n = 6)
Very common 30% 54% 19% 27% 39% 17%
Variable or not routinely 5% 39% 58% 27% 35% 67%
Rarely or never 50% 0% 23% 27% 26% 17%
Unsure 15% 8% 0% 18% 0% 0%
ii) Patients undergoing antiviral treatment
ACCORDING TO GPs
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 0% 75% 11% 0% 57% 0%
Variable or not routinely 40% 0% 22% 0% 14% 0%
Rarely or never 40% 25% 56% 100% 29% 100%
Unsure 20% 0% 11% 0% 0% 0%
ACCORDING TO SPECIALISTS
UK
(n = 10)
DE
(n = 9)
NL
(n = 22)
HU
(n = 10)
IT
(n = 9)
ES
(n = 4)
Very common 10% 0% 0% 10% 22% 25%
Variable or not routinely 0% 44% 5% 0% 0% 0%
Rarely or never 90% 44% 95% 60% 78% 75%
Unsure 0% 11% 0% 30% 0% 0%
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Table 4. (continued)
COMBINED RESULTS
UK
(n = 20)
DE
(n = 13)
NL
(n = 31)
HU
(n = 11)
IT
(n = 23)
ES
(n = 6)
Very common 5% 23% 3% 9% 43% 17%
Variable or not routinely 20% 31% 10% 0% 9% 0%
Rarely or never 65% 38% 84% 64% 48% 83%
Unsure 10% 8% 3% 27% 0% 0%
iii) Patients with sustained virological response due to treatment
ACCORDING TO GPs
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 10% 50% 22% 0% 57% 0%
Variable or not routinely 30% 25% 56% 0% 14% 0%
Rarely or never 20% 25% 11% 100% 29% 100%
Unsure 40% 0% 11% 0% 0% 0%
ACCORDING TO SPECIALISTS
UK
(n = 10)
DE
(n = 9)
NL
(n = 22)
HU
(n = 10)
IT
(n = 9)
ES
(n = 4)
Very common 70% 67% 59% 40% 22% 50%
Variable or not routinely 10% 22% 36% 0% 44% 25%
Rarely or never 10% 0% 5% 30% 33% 25%
Unsure 10% 11% 0% 30% 0% 0%
COMBINED RESULTS
UK
(n = 20)
DE
(n = 13)
NL
(n = 31)
HU
(n = 11)
IT
(n = 23)
ES
(n = 6)
Very common 40% 61% 49% 36% 44% 33%
Variable or not routinely 20% 23% 42% 0% 26% 17%
Rarely or never 15% 8% 6% 36% 30% 50%
Unsure 25% 8% 3% 27% 0% 0%
iv) Patients non-responders to treatment
ACCORDING TO GPs
UK
(n = 10)
DE
(n = 4)
NL
(n = 9)
HU
(n = 1)
IT
(n = 14)
ES
(n = 2)
Very common 20% 50% 11% 0% 64% 0%
Variable or not routinely 20% 25% 44% 100% 21% 0%
Rarely or never 20% 25% 22% 0% 14% 100%
Unsure 40% 0% 22% 0% 0% 0%
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Table 4. (continued)
ACCORDING TO SPECIALISTS
UK
(n = 10)
DE
(n = 9)
NL
(n = 22)
HU
(n = 10)
IT
(n = 9)
ES
(n = 4)
Very common 10% 11% 0% 0% 11% 25%
Variable or not routinely 0% 44% 0% 10% 33% 0%
Rarely or never 90% 33% 100% 50% 55% 75%
Unsure 0% 11% 0% 40% 0% 0%
COMBINED RESULTS
UK
(n = 20)
DE
(n = 13)
NL
(n = 31)
HU
(n = 11)
IT
(n = 23)
ES
(n = 6)
Very common 15% 23% 3% 0% 44% 17%
Variable or not routinely 10% 38% 13% 18% 26% 0%
Rarely or never 55% 31% 77% 46% 30% 83%
Unsure 20% 8% 7% 36% 0% 0%
Patients undergoing antiviral treatment
Overall, the majority of respondents in all countries (84% in the Netherlands, 83% in Spain, 
65% in the UK, 64% in Hungary, 48% in Italy and 38% in Germany) stated that patients 
undergoing antiviral treatment were rarely or never referred back to GPs. Only in Germany 
and Italy did the majority of GPs (75% and 57%, respectively) indicate that these patients 
were very commonly referred back to GPs, although around one quarter selected “rarely 
or never”. In Germany, although 44% of specialists reported “rarely or never” referring back 
patients undergoing antiviral treatment, the same percentage indicated that referral was 
variable. In Italy, 78% of secondary-care specialists indicated that these patients were rarely 
or never referred back to GPs (while 57% of GPs stated that it was very common).
Patients with a sustained virological response due to treatment
In the UK, despite divergent opinions from GPs, most GP and specialist respondents 
reported that referral back to GPs was very common for patients who have SVR on account 
of treatment. This was also the dominant opinion in Germany (61%) and in the Netherlands 
(49%), where, however, 42% stated that patients with these characteristics were variably 
or not routinely referred back to GPs. In Hungary, opinion was divided between “very 
commonly” and “rarely or never”. In Italy, although the majority judged referral to be very 
common, one third selected “rarely or never” and one quarter “variably or not routinely”. 
Opinion was also divided in Spain, where half of the respondents selected “rarely or never”, 
one third “very common”, and 17% “variably or not routinely”.
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Non-responders to treatment
Non-responders to treat-ment are rarely or never referred back to GPs, according to the 
majority of respondents in all countries except Italy, where 44% stated that referral back to 
GPs was very common for these patients (the percentage was higher among GPs: 64%). In 
Germany, most reported that referral back to the GP occurred variably or not routinely.
DISCUSSION
In patients with chronic viral hepatitis, shared management based on close collaboration 
between the GP and the specialist physician, through the identification of their respective 
tasks, is necessary for the appropriate diagnostic and therapeutic management of the 
patient along the care pathway. Since most people with chronic hepatitis are asymptomatic 
until cirrhosis or hepatocellular carcinoma are established, the initial  diagnosis and 
management of chronic hepatitis relies on primary-care physicians to identify and screen 
high-risk individuals (12). The GP can contribute significantly by promptly identifying and 
screening of those at risk, by providing counselling and information, by referring the patient 
to the specialist for disease staging and also by liaising/cooperating with the hospital 
services involved in the specialist management of patients.
Non-uniform practices are likely to create or exacerbate health inequalities, and might 
be an important cause of the “under-treatment” phenomenon, i.e. the disparity between 
the number of chronic hepatitis patients and the number of patients actually receiving 
treatment (13). To our knowledge, this is the first study conducted contemporarily in six EU 
countries with the aim of investigating the role of the GP in the screening practices for risk 
groups and in the clinical management of chronic viral hepatitis patients. Given the careful 
selection of the survey participants and national representatives of the experts in their 
respective fields, it may justifiably be assumed that the replies gathered provide a fair picture 
of the GP’s remit in the countries considered. However, caution is needed in interpreting 
the results where the respondent target of five to ten experts could not be reached (in 
Spain and Hungary). According to our results, the GP’s role and referral back to GPs vary 
within and between countries. What seems certain is that GPs are unlikely to monitor any 
clinical outcomes (such as viral load) other than some side effects in patients undergoing 
treatment, indicating that this is considered the remit of specialists in secondary care.
Results from a Turkish study showed that GPs were not able to follow up chronic viral 
hepatitis B and C patients because of their limited awareness of diagnostic facilities and 
treatment options (14). Indeed, while the majority of GPs had adequate knowledge of HBV 
and HCV transmission and of risk factors, a low percentage was well informed about the 
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treatment of chronic patients with elevated ALT. In particular, the Turkish study identified 
gaps in GPs knowledge of the appropriate use of diagnostic tests and interventions to 
identify and manage patients with chronic viral hepatitis. The authors concluded that 
further coordination with secondary-care specialists was warranted in order to ensure that 
patients were followed up in the primary-care setting (14).
Strategic programmes of health education and awareness-raising, for both professionals 
and risk groups, should be established. In the EU, two different strategies are used to identify 
persons with HBV or HCV infection: population screening and health care provider-initiated 
testing (based on identified risk-factors). Population screening is not cost-effective, owing 
to the low prevalence of HBV and HCV infections in the general EU population, while the 
health care provider-initiated identification of HBV or HCV infection among defined risk 
groups is a valuable instrument in secondary prevention. Making GPs aware of risk factors, 
such as demographic, behavioural, occupational and medical risk factors, and clinical signs 
or symptoms of hepatitis, may efficiently improve case identification. Patients with chronic 
HBV or HCV infection should be referred for medical care and case-management, and those 
testing negative but with risk factors for acquiring HBV or HCV infection should receive 
counselling on prevention (those at risk of HBV infection should also be offered vaccination) 
(15).
In the USA, approaches to the screening, diagnosis and management of viral hepatitis 
patients vary considerably among primary-care physicians.  Indeed,  studies in the USA have 
shown deficiencies in the way some primary-care providers diagnose, treat or refer patients 
with HCV (16-23). One such study investigated the association between the characteristics of 
the physician or practice and screening and treatment for HCV infection: more experienced 
physicians (longer in practice) and those based in affluent, suburban settings were more 
likely to order ALT  tests (16). In another study, a cross-sectional mail survey of 217 family 
physicians revealed insufficient levels of knowledge about screening and counselling for 
chronic hepatitis and hepatocellular carcinoma; in addition, around half of the physicians 
referred patients with chronic HBV or HCV to  the specialist for further management (12). 
Our results show that patients who have had a sustained virological response are generally 
referred back to the GP, while patients undergoing antiviral treatment and those who do 
not respond to treatment are rarely referred back to primary care.
As new treatment options, especially for hepatitis C, have become available in recent years, 
access and adherence to treatment are important determinants of the success of screening 
programmes (2).
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Since 2012, population-based anti-HCV screening of all adults born between 1945 and 
1965 has been recommended in the USA, where the prevalence of anti-HCV is highest in 
black non-Hispanics (6.42%) and in Mexican Americans (3.26%) (24). In the EU, particular 
attention should be paid to providing screening and treatment for hepatitis B and C for 
migrant groups at high risk of chronic infection. The adoption of a targeted screening and 
treatment programme in primary care could be an effective strategy. Results from our study 
in the UK, suggest that standard screening prac- tices are lacking, and allude to a shared 
role for GPs in the clinical monitoring of ALT, viral load and side effects. Referral back to the 
GP of patients undergoing antiviral treatment is not common, although GPs and specialists 
differed markedly in their estimates of the frequency of referral back to GPs of patients who 
do not qualify for treatment. In a recent UK study, GPs expressed concerns about screening 
and treating patients in primary care, considering their workload and also the sustainability 
of such a strategy (25). Immigrants mentioned practical barriers, such as language and 
communication difficulties, limited time on account of long working hours, and, in some 
cases, limited trust and confidence in general practice-based care (25).
Indeed, chronic hepatitis B and C infections are often undiagnosed in primary care. 
According to the ‘Hepatitis B and C surveillance in Europe – 2012’ report, in the minority 
of cases in which information on the testing facility was available, 27% of hepatitis B and 
21% of hepatitis C cases were diagnosed in general practice (26). One German study, 
involving 21,008 subjects, reported that the prevalence of HBsAg, anti-HCV and HCV-RNA 
was 0.52%, 0.95%, and 0.43%, respectively. Infections were previously unknown in 85% and 
65% of HbsAg and anti-HCV positive individuals, respectively (27). German hepatitis B and C 
treatment guidelines recommend HBsAg and anti-HCV screening in several pre-defined risk 
groups. According to the participants in our survey, most GPs in Germany report commonly 
screening population groups at higher risk. The management of patients un- dergoing 
treatment seems to be shared between GPs and specialists. Easy to apply guidelines with 
defined risk scenarios may help to diagnose previously unknown infections (27). Previous 
results from the HEPscreen Project showed that the availability of training programmes to 
improve skills and knowledge of viral hepatitis differed across the six EU countries. Among 
the experts interviewed (268 health professionals), 80% and 73% were aware of hepatitis 
B and hepatitis C guidelines, respectively, in their country (28). The findings of the present 
study could provide impetus to the formulation of precise and clear guidelines targeting 
primary-care physicians and secondary-care specialists. These should explicitly specify, in 
a shared-care model, the different responsibilities in the management of chronic hepatitis 
patients, so as to deliver more effective healthcare.
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CONCLUSIONS
Although the GP’s role in the screening and clinical management of chronic viral hepatitis 
is crucial to timely diagnosis and linkage to specialist care, the diversity of responses often 
observed suggests inadequate awareness of explicit recommendations, which results in a 
lack of uniform practices among experts. The GP’s decision to offer screening to risk groups 
often seems to be an individually motivated choice of the health care professional. The 
inconsistencies observed in screening practices may mean that many chronic infections 
remain undetected. This underscores the need to raise GPs’ awareness of this silent 
epidemic, for example through the adoption of effective strategies for the dissemination 
and implementation of the existing guidelines for general practice. The role of GPs and 
specialists involved in the management of chronically infected patients should also be 
clarified, as opinions sometimes differed markedly even within each professional group.
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ABSTRACT
Background: To investigate access to treatment for chronic hepatitis B/C among six 
vulnerable patient/population groups at-risk of infection: undocumented migrants, asylum 
seekers, people without health insurance, people with state insurance, people who inject 
drugs (PWID) and people abusing alcohol.
Methods: An online survey among experts in gastroenterology, hepatology and infectious 
diseases in 2012 in six EU countries: Germany, Hungary, Italy, the Netherlands, Spain and 
the UK. A four-point ordinal scale measured access to treatment (no, some, significant or 
complete restriction).
Results: From 235 recipients, 64 responses were received (27%). Differences in access 
between and within countries were reported for all groups except people with state 
insurance. Most professionals, other than in Spain and Hungary, reported no or few 
restrictions for PWID. Significant/complete treatment restriction was reported for all 
groups by the majority in Hungary and Spain, while Italian respondents reported no/few 
restrictions. Significant/complete restriction was reported for undocumented migrants 
and people without health insurance in the UK and Spain. Opinion about undocumented 
migrants in Germany and the Netherlands was divergent.
Conclusions:  Although effective chronic hepatitis B/C treatment exists, limited access 
among vulnerable patient populations was seen in all study countries. Discordance of 
opinion about restrictions within countries is seen, especially for groups for whom the health 
care system determines treatment access, such as undocumented migrants, asylum seekers 
and people without health insurance. This suggests low awareness, or lack, of entitlement 
guidance among clinicians. Expanding treatment access among risk groups will contribute 
to reducing chronic viral hepatitis-associated avoidable morbidity and mortality.
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INTRODUCTION
Infection with hepatitis B (HBV) virus and C virus (HCV) affects the liver and can result in 
a broad spectrum of disease outcomes. People with chronic hepatitis B (CHB) and/or C 
virus infection remain infectious and are at risk of serious liver disease such as cirrhosis or 
hepatocellular cancer (HCC). Worldwide, chronic viral hepatitis infection is responsible for 
over 70% of deaths due to HCC and nearly 60% of deaths due to cirrhosis.1,2 Around 480–
520 million people are estimated to be chronically infected with HBV/ HCV, although there 
are strong regional differences in burden of disease. The largest burden of HCV is found in 
Central/Eastern Asia and the Middle East whereas HBV prevalence is highest in SubSaharan 
Africa and Asia.3 There is also some geographical variation in HBV and HCV prevalence in 
Europe.4 Most CHB infections in Europe are detected among migrants from HBVendemic 
areas. Chronic hepatitis C is also more common among migrants (due to non-sterile health 
care, dental and shaving practices and equipment in low-and middle-income countries 
of origin), although a large proportion is found among current/past injecting drug users.5 
Differences in the proportion of chronic hepatitis C cases detected among migrants 
compared with people who inject drugs (PWID) are reported in Europe; in the United 
Kingdom (UK), e.g. PWID account for over 90% of cases,6 whereas migrants from endemic 
areas account for most infections in the Netherlands, Germany, Italy and Spain.7,8
Chronic infections are mostly asymptomatic and progress over a period of 20–30 years 
towards cirrhosis and HCC. Effective treatment exists for both chronic hepatitis B and C 
and, from 2014, highly effective direct-acting antivirals that can cure chronic hepatitis C 
are available.9,10 Early identification, before decompensation and/or development of HCC, 
is strongly associated with improved treatment outcome.11 Therefore, screening for chronic 
infection among a range of risk groups, but particularly among people born in hepatitis B/C 
endemic areas and PWID, is recommend as a form of secondary prevention.6,12 Screening 
among migrants from areas with >2% viral hepatitis prevalence has also been shown to 
be cost-effective.13 Although incident cases are decreasing, models predict that the peak 
mortality for HCVrelated causes is ahead of us and a large undiagnosed burden of disease 
exists; that the proportion of people infected that are unaware, undiagnosed and not in 
treatment is considerably larger than the proportion diagnosed and in treatment.8 For 
example, a large screening study in primary care in Germany found that 85% of HBsAg 
and 65% of anti-HCV positive individuals were unaware of their infection.14 However, 
there are few published studies of migrant-specific viral hepatitis screening programmes 
in Europe.15–18 PWID-specific studies are more common although screening among this 
high-risk group is not systematic in any European country, due to both health system and 
patient-group characteristics, including criminalisation.19 The literature also suggests that 
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migrant populations experience difficulties in accessing health care and experience worse 
health outcomes as a result.20–22 Little is known about access to treatment across Europe 
among marginalised groups at risk of hepatitis B/C infection.
We aimed to investigate access to treatment for chronic hepatitis B/C in six EU countries 
(Germany, Hungary, Italy, the Netherlands, Spain and the United Kingdom (UK)) among 
six patient/population groups. These included undocumented migrants, asylum seekers, 
people without health insurance, people with state insurance, PWID and people who abuse 
alcohol. This study is part of HEPscreen,23 an EU Health Programme-funded project focused 
on screening for chronic viral hepatitis among migrants in Europe.
METHODS
A semi-quantitative online survey was developed, pilot tested and translated into the 
national languages of the study countries and uploaded into Lime SurveyTM open source 
online survey software. The aim of the survey was to understand care pathways in clinical 
services for patients diagnosed with chronic viral hepatitis in the six study countries using 
nominal, ordinal and qualitative questions. We report here the results focused on access to 
treatment among specific patient/population groups; the more clinically focused questions 
about the use of diagnostics, referral and the role of different clinical specialists are to be 
reported elsewhere. The survey was sent to experts in hepatology, gastroenterology and 
infectious diseases based in six EU countries: Germany, Hungary, Italy, the Netherlands, 
Spain and the UK. We identified experts via board membership of clinical and professional 
associations, leadership of hepatology treatment and research centres, and authors of 
relevant scientific articles. Our objective was to reach a sample of 5–10 knowledgeable 
experts from each country rather than develop a representative sampling frame. In 
recognition of the low response rate to surveys among practising clinicians, we identified a 
large sample of 243 recipients.
We asked whether treatment for chronic hepatitis was restricted for each of the six patient/
population groups and developed a fourpoint ordinal scale to measure this: ‘no restrictions’, 
‘some restrictions’, ‘significant restrictions’ and ‘completely restricted’. An ‘unsure’ option was 
also available. We collected respondent data by asking for organisation type and whether 
they were involved in the care of patients/had a clinical role. Among those with a clinical 
role, we asked for their medical specialism and used a three-point ordinal scale to gather 
data on frequency of seeing chronic hepatitis B/C patients (weekly, monthly and annually). 
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Recipients were contacted via e-mail in July 2012 and further reminded twice during data 
collection. The survey closed in September 2012. Data was exported from Lime Survey to 
SPSS 19.0.2 for descriptive analysis of frequencies and proportions.
RESULTS
Respondents
Eight of 243 recipients actively opted out after receiving the invitation. From the remaining 
235 recipients, a total of 64 responses were received (27%). The response rate differed 
across the six study countries: 11% in Germany, 24% in the UK, 25% in Spain, 27% in 
Hungary, 48% in the Netherlands and 60% in Italy. In five of the six countries, Spain being 
the exception, we achieved the target of between 5 and 10 experts. Three of these 64 
respondents had not completed the whole survey and were excluded. All but three of the 
61 are currently involved in the care of patients and 95% of these see chronic hepatitis 
patients on a weekly basis. Due to the clinical nature of the topics, analysis was restricted 
to only data supplied by those with a clinical role (n=58). Of these, the majority (77%) are 
specialists in gastroenterology or hepatology, a fifth are specialists in infectious disease, 
and a small number (n=3) are community/practice nurses. The respondent profile pattern 
in all countries was similar to this overall pattern except in Italy and the Netherlands; in 
Italy, nearly half (44%) are specialists in infectious disease and in the Netherlands, a larger 
proportion (81%) are gastroenterologists/hepatologists. Most are based in academic (61%) 
or general hospitals (28%).
Access to treatment for undocumented migrants
Most respondents in all countries but Italy reported that antiviral treatment for chronic 
viral hepatitis is completely or significantly restricted for undocumented migrants. This 
is especially so in Hungary where three quarters reported treatment to be completely 
restricted, in the UK where two thirds indicated significant or complete restriction, and in 
Spain where three quarters selected significant or complete restriction. Over three quarters 
in Italy reported that there are no or some restrictions in place. Opinion was divided in the 
Netherlands and Germany (Table 1).
Access to treatment for asylum seekers
Two-thirds of those in Hungary and half in Spain reported significant or complete restrictions 
in treatment for chronic hepatitis patients with asylum seeker status. In contrast, all but one 
respondent in Germany, over half in the UK, and three quarters of those in the Netherlands 
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and Italy reported no or few restrictions for asylum seekers. However, there are some in the 
UK, Germany and the Netherlands who indicated that significant restrictions are in place 
(Table 2).
Access to treatment for people without health insurance and people with 
only state insurance
Over 75% in Italy reported no or few restrictions for those without health insurance whereas 
significant or complete restrictions were reported by the majority of respondents in 
Hungary (75%), Spain (75%), the UK (56%) and the Netherlands (46%). Opinion was divided 
in Germany (Table 3). We included the group ‘state insurance only’ to further explore the 
influence of (private) health insurance on access to treatment and found that the vast 
majority of respondents indicated that there are no restrictions (Table 3). In the UK, Germany, 
the Netherlands and Italy, nearly all respondents selected no restrictions. Although 50% in 
Hungary indicated that no restrictions exist for this group, one quarter selected significant 
restrictions.
Access to treatment for PWID and patients who abuse alcohol
The majority of respondents in the UK, Germany, the Netherlands and Italy indicated no 
or few restrictions in antiviral treatment for PWID infected with chronic hepatitis (table 4). 
In contrast, three quarters of professionals in Hungary reported significant or complete 
restrictions, with half reporting complete restrictions. Half in Spain reported there to be 
significant restrictions in place, although others indicated no or some restrictions. As with 
PWID, the majority of respondents in the UK, Germany, the Netherlands and Italy reported 
no or few restrictions in treatment to be in place for chronically infected patients who 
abuse alcohol. It was the opposite in Hungary, as over 75% reported complete or significant 
restrictions. Opinion was divided in Spain but suggests the existence of restrictions in access 
to treatment for patients who abuse alcohol.
Table 1. Reported treatment restrictions among undocumented migrants
UK (n=9) DE (n=6) NL (n=22) HU (n=8) IT (n=9) ES (n=4) 
No restrictions 11% 17% 14% 0% 33% 25%
Some restrictions 0% 17% 27% 13% 44% 0%
Significant restrictions 44% 17% 27% 0% 0% 25%
Complete restrictions 22% 33% 23% 75% 11% 50%
Unsure 22% 17% 9% 13% 11% 0%
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Table 2. Reported treatment restrictions among asylum seekers
UK (n=9) DE (n=6) NL (n=22) HU (n=8) IT (n=9) ES (n=4) 
No restrictions 56% 33% 50% 0% 56% 25%
Some restrictions 0% 50% 23% 0% 22% 0%
Significant restriction 22% 17% 18% 38% 0% 0%
Complete restriction 0% 0% 0% 25% 11% 50%
Unsure 22% 0% 9% 38% 11% 25%
Table 3. Reported treatment restrictions among people with no/state insurance
UK (n=9) DE (n=6) NL (n=22) HU (n=8) IT (n=9) ES (n=4)
N
o
St
at
e
N
o
St
at
e
N
o
St
at
e
N
o
St
at
e
N
o
St
at
e
N
o
St
at
e
No restrictions 11% 78% 0% 100% 18% 82% 0% 50% 44% 89% 25% 50%
Some restrictions 11% 0% 50% 0% 18% 9% 16% 25% 33% 11% 0% 50%
Significant restriction 56% 0% 33% 0% 32% 0% 0% 25% 11% 0% 25% 0%
Complete restriction 0% 0% 0% 0% 14% 0% 75% 0% 11% 0% 50% 0%
Unsure 22% 22% 17% 0% 18% 9% 13% 0% 0% 0% 0% 0%
Table 4. Reported treatment restrictions among PWID and people who :abuse alcohol (Alc.)
UK (n=9) DE (n=6) NL (n=22) HU (n=8) IT (n=9) ES (n=4)
PW
ID
A
lc
.
PW
ID
A
lc
.
PW
ID
A
lc
.
PW
ID
A
lc
.
PW
ID
A
lc
.
PW
ID
A
lc
.
No restrictions 22% 22% 33% 17% 55% 36% 0% 13% 44% 33% 25% 0%
Some restrictions 56% 56% 50% 67% 36% 59% 25% 13% 33% 44% 25% 50%
Significant restriction 11% 11% 17% 17% 5% 5% 25% 38% 11% 0% 50% 25%
Complete restriction 0% 0% 0% 0% 5% 0% 50% 38% 11% 22% 0% 25%
Unsure 11% 11% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
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DISCUSSION
Although effective treatment for chronic hepatitis B/C exists and even cure for chronic 
hepatitis C, results from this study show that access to treatment is limited for a number of 
vulnerable populations at risk of chronic infection in most countries we studied. Restrictions 
were most often reported by experts in Hungary and Spain, while as a group, undocumented 
migrants have the most limited access to treatment. We also found discordance of opinion 
about restrictions within countries, especially for groups for whom the health care system 
defines access to treatment, such as undocumented migrants, asylum seekers and people 
without health insurance.
For screening to be considered ethical and appropriate and to result in health gain, there 
should be treatment available for diagnosed patients.24 The Wilson and Jungner criteria list 
availability of effective treatment and an agreed policy on who to treat as two of 10 principles 
that should be met to conduct screening. Treatment availability and eligibility are often 
seen from a biomedical perspective, in terms of clinical or prognostic factors only. As the 
six study countries organise their health care differently, eligibility and availability can also 
be understood from a health system perspective. We were interested to find out whether 
there are population-group specific restrictions in place as understood by clinicians most 
involved in providing it. The profile of our respondents indicates that this aim was fulfilled; 
nearly all respondents are clinical specialists in gastroenterology, hepatology or infectious 
diseases and see infected patients on a weekly basis.
As in many parts of the world, there are differences in health system organisation between 
EU countries that make it an interesting environment in which to conduct health systems 
and health services research; in our EU-funded project, we adopted a European perspective 
and sought to compare six Member States. In Bismarckian-based welfare states, like the 
Netherlands and Germany, citizens must ‘buy’ health insurance provision from insurance 
companies who cannot discriminate on the basis of individual health conditions or risk 
factors and contributions depend on an individual’s financial resources.25,26 It is, therefore, 
not surprising that we do observe some or significant restrictions in access to treatment 
among people without health insurance here (table 3). In Beveridge-style welfare states, like 
Italy, Spain and the UK, the notion of national insurance as collective contributions towards 
social and health service provision is familiar and a national health service with associated 
universal free access is in place.27 Other than a small minority who purchase private health 
insurance coverage, the concept of ‘buying’ health insurance as a means to entitlement 
in these universal health systems is undesirable and alien to most. This universalism is 
mirrored in responses from Italy where no or only some restrictions exist for all six patient/ 
population groups. It is, however, somewhat surprising that restriction to treatment among 
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those without insurance is reported in Spain and the UK, countries with health systems 
where insurance is not expected to play a role. However, both systems rely on some form of 
registration to receive social support, such as a National Insurance/NHS number in the UK or 
a residence permit in Spain. Access to health care would be limited without this registration, 
not because patients do not have health insurance coverage but because those without 
state insurance cover are effectively considered undocumented migrants or persons for 
whom health care entitlement is uncertain.28 As a result of the financial crisis affecting Spain 
from 2008, various austerity and cost-containment measures were introduced into the 
health and social welfare system. One change, introduced after our survey was conducted, 
was the restriction of access to health care among undocumented migrants (and others 
considered to be uninsured under the universal, residence permitbased system) to 
emergency and ante- and post-natal care only.29 The implication is likely to be more severe 
restrictions than the already significant restrictions we observe in our results. In Hungary, 
the health care system is a hybrid of a Semashko-style Soviet system and a Bismarckian-
influenced model where (social) health insurance coverage is key to access but the legacy 
of out-ofpocket payments remains.30 In fact, respondents from Hungary reported the most 
restrictions among population groups, especially among undocumented migrants, asylum 
seekers and people without insurance.
Another surprising finding was the discordance about restrictions within each country, 
especially for population groups for whom the health care system or policy context 
defines access to treatment, such as undocumented migrants, asylum seekers and people 
without health insurance. We suggest that this lack of consensus about restrictions in 
access to treatment may either be an important explanation of, or in fact caused by, the 
limited existence of screening programmes that target these higher risk populations. 
Undocumented migrants and asylum seekers are rarely screened for viral hepatitis and, 
if found chronically infected, do not actually reach secondary care.31 Previous studies also 
found lower preventative health care usage and poorer health outcomes from viral hepatitis 
among migrant groups.32,33
This lack of consensus also suggests that specific guidance about health care entitlement is 
either not available, unclear or not known to medical professionals most involved in treating 
viral hepatitis. In the absence of clear guidance about access to specific services/ provision 
in the health care system, professional discretion when treating patients is likely to be 
applied.34 To deal with ambiguous health care entitlement criteria, two professional coping 
strategies have been suggested: ‘functional ignorance’ where the legal status of somebody 
who needs health care is neither asked for nor monitored; and ‘partial acceptance’, where, 
e.g. specific sub-groups of migrants without permission to stay may have the right to 
certain limited hospital and outpatient treatment in the case of sickness or accidents, as 
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well as to preventive care.35 The extent to which the adoption of either strategy influences 
health outcomes, in terms of screening and referral to specialist care for treatment, warrants 
further investigation.
Discordance of opinion could be explained by other health system factors. For example, 
within the Dutch health care system, there are only a selected number of hospitals that 
are able to provide antiviral treatment to patients without health insurance.36 The regional 
organisation of municipal and other public services in Germany (Länder) and Spain 
(Comunidad Autónoma) may also be reflected in differing arrangements of health care 
including entitlement, especially for marginalised groups like undocumented migrants. In 
the case of Spain, regional authorities define the benefits package for the local population 
according to local preferences and needs and are responsible for public health service 
planning.37
For PWID patients and patients who abuse alcohol, restricted treatment is less likely to 
be explained by the health system or policy context and more likely due to associated 
clinical implications.9,10 Most professionals in most study countries, other than in Spain and 
Hungary, reported no or few restrictions for PWID. Case detection, treatment and clinical 
management of PWID is an important public health issue given the high risk of HCV 
transmission associated with injecting drug use as well as the large proportion of current/
past injecting drug users among the burden of chronic hepatitis C cases in the European 
population.4,7 However, previous studies suggest that many PWID remain undetected and 
if screened, do not reach specialist secondary care.19,32,38 Over half in all study countries 
(table 4) reported the existence of some restrictions for patients who abuse alcohol. 
Alcohol use among people infected with chronic viral hepatitis affects disease progression 
and increases the risk of cirrhosis and HCC. Alcohol intake is, therefore, undoubtedly a key 
treatment consideration among chronic viral hepatitis patients and although it is not an 
explicit contraindication for treatment,9 alcohol and drug use are identified as the reason for 
ineligibility of treatment by 83% of treating clinicians in the UK.39
The current climate of economic austerity has led to restrictions access to both health and 
social welfare provision among vulnerable populations and to the effective new treatments 
that can potentially cure chronic hepatitis C infection.40 It is, therefore, possible that access 
to treatment among the populations investigated here has become more restricted 
since the time of this study. The significant health gains possible through our expanded 
understanding of viral hepatitis and the scope for secondary prevention can only be realised 
through expanded access to screening and antiviral treatment to urgently find those most 
affected.8
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ABSTRACT
Background/Aims: Advances in viral hepatitis treatment have increased the scope 
for secondary prevention although differential availability of antivirals across Europe is 
suggested. We investigated restrictions in treatment and use of diagnostics in six European 
countries: Germany, Hungary, Italy, the Netherlands, Spain and the United Kingdom.
Methods: An online survey among experts in gastroenterology, hepatology and infectious 
diseases in 2012 investigated diagnostics and antivirals approved up to 2012. An updated 
survey sent to the same sample investigated 2014-approved hepatitis C drugs. Frequency 
of diagnostic test usage and scale of antiviral restrictions were both measured using three-
point ordinal scales.
Results: Of 243 recipients, 61 responses to the 2012 survey and 29 responses to the 2015 
survey were received. Few differences across countries were found in diagnostics used in 
initial patient assessments; blood markers and non-invasive tests are more common than 
invasive and expensive diagnostics (e.g. biopsy and genotyping). Differences between 
countries were observed in the use of first- and second-generation protease inhibitors for 
chronic hepatitis C treatment. Complete restriction of first-generation drugs were reported 
in Hungary, Italy and Spain. Sofosbuvir, simeprevir, daclatasivr and simeprevir/ledipasvir 
were restricted to severely fibrotic/cirrhotic (F3/F4) patients in the United Kingdom, the 
Netherlands and Italy.
Conclusions: This study among practising clinicians directly involved in treating patients 
provides insight into actual clinical management of chronic viral hepatitis, specifically 
antiviral treatment availability and diagnostic testing, in six European countries. Widespread 
availability of antivirals for chronic hepatitis B further strengthens the rationale to expand 
access to screening. However, despite European approval and guidelines, differential 
availability of chronic hepatitis C treatment regimens exists across Europe, suggesting that 
national health care system resourcing, alongside clinical effectiveness, influence treatment 
availability. Realising the possible health gains from treatment will require expansion both 
in geographic availability and in the patients considered eligible for treatment.
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INTRODUCTION
Chronic hepatitis B and C virus infections are mostly asymptomatic and, if untreated, 
can progress over 20-30 years towards cirrhosis and hepatocellular carcinoma (HCC) 
(1). Between 480 and 520 million people, mostly in Asia and Africa, are estimated to be 
chronically infected, although there are regional differences in burden of disease (2, 3). 
Antiviral treatment for hepatitis B/C has the potential to prevent associated morbidity and 
mortality (4, 5). As early identification, before progression to liver decompensation and/
or development of HCC, is associated with improved treatment outcome, screening for 
chronic infection is recommended among risk groups as a cost-effective form of secondary 
prevention (6-9). Yet, most chronic infections are undiagnosed (10), many patients do not 
reach secondary care (11, 12) and only a minority of chronically infected individuals are on 
treatment (13, 14).
The centralised approval system for pharmaceutical innovations for viral diseases in Europe, 
the European Medicines Agency (EMA), appraises applications for marketing authorisation in 
all EU countries. Decisions on pricing and reimbursement are generally made at the national 
level however, and differences between Member States in availability of new medication, 
especially for chronic hepatitis C, have been suggested (15). Epidemiological, health system, 
clinical and economic factors offer some explanation of this variation, although limited data 
hamper a systematic understanding (16, 17).
Highly sensitive and specific diagnostics, for blood markers and the severity of liver disease, 
are recommended in referral and clinical management (4, 5, 18, 19). Despite the European-like 
nature of these recommendations, studies into current referral pathway mechanisms across 
Europe are scarce. Recent international and national strategies highlight the importance 
of strengthening health systems to respond to the public health challenge of chronic viral 
hepatitis in an era when eradication is a possibility. The proceedings from the first World 
Hepatitis Summit, convened in response World Health Assembly resolution 67.6 on viral 
hepatitis, highlight that many nations have been slow to make new treatments available at 
the clinical level and that pricing affects expanded access to affected populations
The Summit also sought to strengthen global and national responses to the public health 
challenge for viral hepatitis, a key component of which is expanded access to diagnostics 
and antiviral treatment (20). To support knowledge-driven eradication efforts and as of part 
of the 2011-2014 EU Health Programme-funded HEPscreen project (21), we investigated 
current practices in chronic viral hepatitis treatment in Germany, Hungary, Italy, the 
Netherlands, Spain and the United Kingdom (UK). We posed two specific research questions: 
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how common are eight diagnostic tools used in the initial assessment of patients; are there 
restrictions in the use of antiviral treatment options for chronic hepatitis B/C approved in 
Europe and, if so, what are these restrictions.
METHODS
The field of chronic hepatitis C treatment rapidly evolved during our study period (2012-
2015), and in response we developed two semi-quantitative online surveys. The first (in 
2012) was based on the EASL HBV (4) and HCV (22) guidelines; the second (2015) was based 
on the 2014 EASL HCV guideline (5). Both surveys were sent to experts in viral hepatitis 
treatment identified via boards of clinical/professional associations, leadership of hepatology 
treatment/research centres and scientific literature. Our objective was to reach 5-10 experts 
in each study country deemed able to report on practices in their country, among their 
peers, rather than just at their individual practice level. In recognition of the historically low 
response to surveys among practising clinicians, we identified a large sample of 243. The 
same sample was then used for the second survey about 2014-approved antivirals. Both 
surveys collected other data including organisation type and whether respondents are 
involved in the care of patients/have a clinical role. Among those with a clinical role, we 
collected data on their medical specialism and how often they see hepatitis B/C patients 
(weekly, monthly, annually). According to the CCMO (the Central Committee on Research 
Involving Human Subjects) guidelines to which the coordinating institute adheres, research 
which requires filling in a questionnaire just once generally does not fall under the scope 
of the Medical Research Involving Human Subjects Act (WMO)(23) and specific ethical 
approval from a medical ethical committee was therefore not required.
Diagnostics
For the first survey, a list was prepared of all diagnostics recommended in the EASL guidelines 
to confirm chronic infection and assess liver disease severity, including: HBeAg, ALT, other 
biochemical markers (such as AST, GGT, serum albumin etc), viral load, genotype, ultrasound, 
liver biopsy, and elastography. Respondents were asked to indicate how commonly each 
diagnostic was used in the initial evaluation of patients using a three-point ordinal scale: 
‘very common’, ‘variable/not routinely’, and ‘rarely/never’ (‘unsure’ was also available).
Treatment options
For the first survey, we included conventional or pegylated interferon α and five nucleoside/
nucleotide analogues (NAs) (entecavir, tenofovir, lamivudine, telbivudine and adefovir), as 
treatment options for chronic hepatitis B (4). The 2011 HCV guideline recommends the use 
of pegylated interferon α with oral ribavirin as first-line treatment for chronic hepatitis C. 
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Other treatment options at this time point were limited to telaprevir and boceprevir, in 
combination with pegylated interferon α and ribavirin. EMA approval was granted relatively 
recently (boceprevir in August 2011; telaprevir in October 2011). The second survey included 
the four 2014-approved options (sofosbuvir, simeprevir, daclatasivr and a combination drug 
simeprevir/ledipasvir) (5).
Treatment restrictions
Respondents were asked to indicate if each treatment option was restricted using a three-
point ordinal scale: ‘no limitations’, ‘some limitations’ and ‘complete limitation/cannot 
be prescribed’ (‘unsure’ was also available). If ‘some limitations’ was selected, five specific 
restrictions were then available to select all those that apply, ‘can only be prescribed…’: ‘if 
resistance to another drug has developed’; ‘for a limited duration’; ‘by selected hospitals (e.g. 
tertiary centres)’; and ‘in selected geographic areas’. The fifth was ‘other restrictions’, with a 
request to give details in a text field.
Data collection
The first survey was pilot tested, revised, translated into the national languages of the study 
countries and uploaded into the online survey software Lime Survey™. Recipients were 
contacted via email in July 2012 and further reminded twice during data collection. The 
survey closed in September 2012. The second survey was also translated into the national 
languages and uploaded into Lime Survey™.  Recipients were contacted via email in March 
2015 and further reminded twice during data collection. The survey closed in May 2015. 
Data from both surveys were exported from Lime Survey to SPSS 19.0.2 for analysis.
RESULTS
Respondents
We received 64 responses to the first survey, achieving the respondent target of between 
5-10 experts in all countries but Spain. Although five respondents did not complete the 
questions related to restrictions in antiviral therapy, there was information about diagnostic 
markers. All but three of 64 are currently involved in the care of patients and 95% of these 
see chronic hepatitis patients on a weekly basis. Due to the clinical nature of the topics, 
analysis was restricted to those with a clinical role (n=61). The majority of clinicians (77%) 
are specialists in gastroenterology/hepatology, a fifth are infectious disease specialists and 
three are community/practice nurses. Mostly the pattern in countries was similar to this 
except in Italy and the Netherlands; in Italy, nearly half (44%) are infectious disease specialists 
whereas in the Netherlands, 81% are gastroenterology/hepatology specialists. Most are 
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based in academic teaching hospitals (61%) or general hospitals (28%). A similar profile was 
seen among the 30 respondents (overall response rate of 13%) to the 2015 survey, although 
only in Hungary and the Netherlands was the target of 5-10 respondents achieved. All 30 
have a clinical role, 90% are gastroenterologists/hepatologists, 93% see chronic hepatitis 
B/C patients on a weekly basis, and most are based in academic (63%) or general hospitals 
(27%). Interestingly, the one respondent from Spain is a prison health specialist.
Diagnostic testing in initial patient evaluations (Table 1)
HBeAg, ALT, viral load and other diagnostic markers (such as AST, GGT or serum albumin) are 
generally very commonly measured in initial patient evaluations in all countries; most, if not 
all, respondents selected ‘very common’ for each diagnostic and no-one indicated ‘rarely/
never’. Opinion about genotyping is divided in all countries, except Spain and Germany 
where it is very commonly tested. Although three quarters in the UK and around two thirds 
in the Netherlands and Italy also indicated genotype testing was ‘very common’, some 
indicated ‘variable’ (22% in the UK and Italy, 14% in the Netherlands) or that it is ‘rarely/never’ 
tested (18% in the Netherlands, 11% in Italy). There was no clear majority about genotyping 
in Hungary. Of the three recommended diagnostics for cirrhosis, ultrasound is most 
common and liver biopsy is least common in initial patient evaluations. For ultrasound, 
most in all countries indicated ‘very common’ and no-one selected ‘rarely/never’. Opinion 
within countries, especially Germany and Hungary, varied about liver biopsy. Most indicated 
it is not routinely used and a notable proportion in the Netherlands (23%), along with two in 
Hungary and one in Germany indicated liver biopsy was ‘rarely/never’ used in initial patient 
evaluations. For elastography, opinion is divided between very common and variable 
except in the Netherlands, where a third indicated elastography was ‘rarely/never’ used. 
Comparable results emerge from Germany and Hungary; around half indicated ‘variable’ 
use of elastography but around a third selected ‘very common’.
Hepatitis B treatment
The results for entecavir and tenofovir are presented together as both are potent HBV 
inhibitors with a high barrier to resistance and recommended as first line mono-therapies. 
Lamivudine, telbivudine and adefovir are recommended where more potent drugs with a 
higher barrier to resistance are unavailable or inappropriate. Three of the 61 respondents 
that did not answer these questions were excluded (thus, n=58).
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Table 1. Reported use of diagnostics in initial patient evaluations
HBeAg UK (n=9) DE (n=7) NL (n=22) HU (n=10) IT (n=9) ES (n=4)
Very common 100% 57% 95% 80% 89% 100%
Variable/not routinely 0% 29% 5% 0% 11% 0%
Rarely/never 0% 0% 0% 0% 0% 0%
Unsure 0% 14% 0% 20% 0% 0%
ALT UK (n=9) DE (n=7) NL (n=22) HU (n=10) IT (n=9) ES (n=4)
Very common 100% 86% 95% 70% 100% 100%
Variable/not routinely 0% 0% 0% 0% 0% 0%
Rarely/never 0% 0% 0% 0% 0% 0%
Unsure 0% 14% 5% 30% 0% 0%
Other biochemical 
markers
UK (n=9) DE (n=7) NL (n=22) HU (n=10) IT (n=9) ES (n=4)
Very common 100% 86% 95% 80% 78% 100%
Variable/not routinely 0% 0% 0% 0% 22% 0%
Rarely/never 0% 0% 0% 0% 0% 0%
Unsure 0% 14% 5% 20% 0% 0%
Viral load UK (n=9) DE (n=7) NL (n=22) HU (n=10) IT (n=9) ES (n=4)
Very common 100% 86% 91% 70% 100% 75%
Variable/not routinely 0% 0% 9% 10% 0% 25%
Rarely/never 0% 0% 0% 0% 0% 0%
Unsure 0% 14% 0% 20% 0% 0%
Genotype UK (n=9) DE (n=7) NL (n=22) HU (n=10) IT (n=9) ES (n=4)
Very common 78% 86% 68% 20% 67% 100%
Variable/not routinely 22% 0% 14% 30% 22% 0%
Rarely/never 0% 0% 18% 30% 11% 0%
Unsure 0% 14% 0% 20% 0% 0%
Ultrasound UK (n=9) DE (n=7) NL (n=22) HU (n=10) IT (n=9) ES (n=4)
Very common 78% 71% 95% 80% 100% 75%
Variable/not routinely 22% 14% 5% 0% 0% 0%
Rarely/never 0% 0% 0% 0% 0% 0%
Unsure 0% 14% 0% 20% 0% 25%
Liver biopsy UK (n=9) DE (n=7) NL (n=22) HU (n=10) IT (n=9) ES (n=4)
Very common 33% 14% 5% 20% 22% 0%
Variable/not routinely 67% 43% 73% 40% 78% 100%
Rarely/never 0% 14% 23% 20% 0% 0%
Unsure 0% 29% 0% 20% 0% 0%
Elastography UK (n=9) DE (n=7) NL (n=22) HU (n=10) IT (n=9) ES (n=4)
Very common 44% 29% 9% 30% 56% 50%
Variable/not routinely 44% 57% 59% 50% 44% 50%
Rarely/never 0% 0% 32% 0% 0% 0%
Unsure 11% 14% 0% 20% 0% 0%
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Pegylated interferon α
The majority in all countries but Italy reported no limitations in the use of pegylated 
interferon α. Two thirds in Italy along with around a quarter in the Netherlands and Hungary, 
and one respondent in both Germany and the UK indicated ‘some restrictions’, specifically: 
‘for a limited duration’ in all countries, and ‘selected hospitals only’ in, Hungary, Italy, the 
Netherlands and the UK . Other restrictions included clinical indications such as genotype, 
ALT and the non-suitability for patients with cirrhosis.
Entecavir and tenofovir
The results for entecavir and tenofovir are the same in Germany, Italy, the Netherlands and 
the UK: most indicated no restrictions and no-one indicated that either cannot be prescribed. 
In Hungary, whilst entecavir can generally be used without restriction, over a third indicated 
that tenofovir is completely restricted. In Spain, tenofovir is available without restriction. In 
Spain and Italy, ‘resistance to other drugs’ was a restriction for entecavir. One respondent 
in the Netherlands, two in Hungary and three in Italy reported ‘some restrictions’ for both 
options, specifically ‘selected hospitals’. Restrictions for tenofovir included ‘resistance to 
other drugs’ (Hungary) and the contra-indications/side effects of kidney disease or renal 
failure (the Netherlands and Italy) (Table 2).
Table 2. Reported restrictions in the use of entecavir (E*) or tenofovir (T**)
Level of 
restriction
UK (n=9) DE (n=6 NL (n=22) HU (n=8) IT (n=9) ES (n=4)
E* T** E* T** E* T** E* T** E* T** E* T**
None 89% 89% 83% 83% 96% 96% 75% 25% 67% 67% 75% 100%
Some 0% 0% 17% 17% 5% 5% 25% 25% 33% 33% 25% 0%
Complete 0% 0% 0% 0% 0% 0% 0% 38% 0% 0% 0% 0%
Unsure 11% 11% 0% 0% 0% 0% 0% 13% 0% 0% 0% 0%
Lamivudine
In Spain, all respondents indicated there are no restrictions in the use of lamivudine. 
Although most in the UK (50%), Germany (60%) and the Netherlands (82%) also reported 
no restrictions, a minority reported some or complete restriction. Results in Italy are divided 
between ‘no’ and ‘some restrictions’. Among those selecting ‘some restrictions’, these include 
‘for a limited duration only’ in Germany and Italy, and ‘selected hospitals only’ in Hungary, 
Italy and the Netherlands. Lamivudine was also described as rarely used (the UK), non-first 
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line drug choice (Hungary) associated with a high risk of resistance (the Netherlands) and 
use only as a pre-emptive prophylaxis in selected immuno-compromised patients (Italy) or 
for those with cirrhosis and a low viral load (UK).
Telbivudine
Of all the CHB antivirals, complete restriction was reported most often for telbivudine, 
except in Spain where all indicated no restrictions. Although the majority in Germany and 
the Netherlands selected no restrictions, a third in Germany and 14% in the Netherlands, 
along with half in Hungary and over a third in the UK, reported that telbivudine is completely 
restricted. Among those selecting ‘some restrictions’ (Italy, the Netherlands, Spain and the 
UK), these include: ‘limited duration’ (Italy); ‘selected hospitals only’ (the Netherlands and 
Italy); formulary/drug agency limitations (the UK); and use only in patients with a low viral 
load (Italy and the Netherlands).
Adefovir
Most respondents in all countries indicated there are no restrictions for adefovir. However, 
one respondent in the UK, Germany and Italy, and three in the Netherlands, indicated 
complete restriction. Among those that reported ‘some restrictions’ (Germany, Hungary, 
Italy and the Netherlands), ‘selected hospitals only’ was reported in all but Germany. Other 
restrictions included it not being a first line option (Germany and Hungary) and having 
limited efficacy compared to other antivirals (Italy and the Netherlands).
Hepatitis C treatment
As for CHB treatment, analysis of hepatitis C treatment options was restricted to those who 
have clinical responsibilities and completed the relevant section (n=58).
Pegylated interferon α
All respondents in Spain and the UK, and most in all but Italy reported no restrictions in 
the use of pegylated interferon α. Over half in Italy, around a quarter in the Netherlands, 
two respondents in Hungary and one in Germany indicated that ‘some restrictions’ exist 
including ‘selected hospitals’ (Germany, Hungary, Italy and the Netherlands) and ‘for a 
limited duration’ (all but Germany). In Italy and the Netherlands restrictions were reported 
for patients with co-morbidities, especially psychiatric disorders. No-one selected complete 
limitation or unsure.
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Ribavirin
The same results as interferon α were observed for ribavirin in Germany, Hungary, Spain 
and the UK. Results are also comparable in Italy; although over half reported no restrictions, 
the remainder indicated ‘some limitations’, along with nearly a fifth in the Netherlands, two 
in Hungary and one in Germany. Specific restrictions included ‘selected hospitals’ (all four 
countries) and ‘for a limited duration’ (Hungary, Italy and the Netherlands). Cardiac disease, 
anaemia and renal impairment were mentioned indications for stoppage in Italy and the 
Netherlands.
Boceprevir and telaprevir
Results are the same for both options in Hungary, Italy, Spain and the Netherlands whereas 
results in Germany and the UK suggest that telaprevir is less restricted (Table 3). All but one 
respondent in Hungary indicated that both cannot be prescribed at all. In the Netherlands, 
73% reported no limitations and no-one indicated complete restriction. In Italy, although 
two thirds selected ‘some restrictions’, the remainder indicated telaprevir was completely 
restricted. Although half in the UK selected some restrictions, a third indicated no restrictions 
are in place for boceprevir; for telaprevir, more respondents (50%) indicated that there are 
no restrictions. Two thirds in Germany reported no restrictions in the use of boceprevir, 
rising to 83% for telaprevir; one respondent selected ‘some restrictions’ for both options. All 
in Spain selected ‘some restrictions’. Specific restrictions are almost identical in all countries 
and are reported together below.
Table 3. Reported restrictions in the use of boceprevir (B*) and telaprevir (T**)
Level of 
restriction
UK (n=9) DE (n=6 NL (n=22) HU (n=8) IT (n=9) ES (n=4)
B* T** B* T** B* T** B* T** B* T** B* T**
None 33% 44% 67% 83% 73% 73% 0% 0% 0% 0% 0% 0%
Some 56% 44% 17% 17% 27% 27% 0% 0% 67% 67% 100% 100%
Complete 0% 0% 0% 0% 0% 0% 88% 88% 33% 33% 0% 0%
Unsure 11% 11% 17% 0% 0% 0% 13% 13% 0% 0% 0% 0%
Specific restrictions for boceprevir and telaprevir
‘Restriction to selected hospitals’ was selected in all countries and ‘for a limited duration’ was 
reported in the Netherlands (though only for telaprevir), Italy and Spain. ‘Resistance to other 
drugs’ was selected in Spain. A diverse mix of other restrictions were also reported including 
variable approval rates (UK), clinical indications such as genotype (the Netherlands) and the 
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degree of liver disease/damage (Spain), side effects such as anaemia and allergic reactions 
(Italy and the Netherlands), drug interactions (the Netherlands), patient response to past 
treatment (Spain), the need for considerable professional knowledge (the Netherlands) and, 
interestingly, the prohibited use in prisoners (Spain). In the UK, one respondent described 
boceprevir as more expensive than telaprevir and that it should only be used if telaprevir is 
contra-indicated.
Sofosbuvir, simeprevir, daclatasvir and simeprevir/ledipasvir (Table 4)
In Spain, all four options are reported to be completely limited. All in Germany report that 
there are no restrictions in the use of sofosbuvir or simeprevir/ledipasvir. All in Italy and the 
UK and the majority in Hungary and the Netherlands report that there are some restrictions 
in sofosbuvir, notably restriction to certain hospitals (all four countries), limited duration 
(Italy and Hungary) and only if resistance to another drug has developed (Hungary). One 
in Hungary reported that sofosbuvir cannot be prescribed. There was at least one in each 
country who indicted simeprevir cannot be prescribed. There was diversity of opinion in 
all countries but Spain, with respondents in each response category in the Netherlands 
and the UK, a split between ‘none’ and ‘complete’ in Germany and a split between ‘some’ 
and ‘complete’ in Hungary and Italy. In Hungary, all four who indicated ‘some’ restrictions 
exist specified that simeprevir is restricted for use in certain hospitals. Restriction to patients 
infected with genotype 1 or 4 was reported in the Netherlands. All in the UK and most in 
Hungary, Italy and the Netherlands indicated that there are ‘some’ restrictions in the use of 
daclatasvir. These were diverse for Hungary and Italy, with drug resistance, time and only 
certain hospitals selected in both. Restriction to certain hospitals was also mentioned in 
the UK and Netherlands along with genotype (the Netherlands). All in Italy and most of 
those in the UK and Hungary indicated ‘some’ restrictions exist for simeprevir/ledipasvir; 
specifically, restriction to certain hospitals (Hungary, Italy and the UK), time (Hungary and 
Italy) and drug resistance (Hungary). In contrast, most of those in the Netherlands (53%) 
and one in Hungary and the UK indicated that simeprevir/ledipasvir cannot be prescribed. 
Further restrictions reported included: the need for national guidelines for simeprevir and 
daclatasvir in the UK; a no reimbursement for all four antivirals as part of national health 
insurance arrangements in the Netherlands; and most significantly, frequent mention of 
restriction of use only in patients with advanced disease, specifically F3/4 stage cirrhosis in 
Italy, the Netherlands and the UK.
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DISCUSSION
The first aim of our study was to understand which diagnostics are used when patients 
reach specialist care and to see if there are differences between study countries. The second 
aim was to find out whether there are restrictions in the availability of antivirals approved 
for chronic hepatitis B/C treatment in six EU countries as understood by practising clinical 
specialists providing treatment. The profile of our respondents indicates this goal was met; 
nearly all respondents are gastroenterology, hepatology or infectious disease specialists 
who see chronic hepatitis B/C patients on a weekly basis. These clinicians are likely to know 
what antiviral options available, under what circumstances and for which patients.
We found there are remarkably few differences between countries in the use of diagnostic 
tests in initial patient evaluations; blood markers and non-invasive tests for liver disease 
(ultrasound) are used before more invasive and expensive (biopsy, elastography and 
genotype) diagnostics. The only discernible differences are in the use of genotyping, which 
is more common in Spain and Germany than in the other four countries, and in HBeAg 
testing, which is less common in Germany than in the other countries. Commonality in 
use of diagnostics suggests fairly consistent implementation of recommendations detailed 
in clinical guidelines and other studies of specific diagnostics (4, 5, 24). The phrase ‘initial 
patient evaluation’ is of course open to interpretation. A stepwise evaluation is the most 
likely scenario with an initial evaluation of HBeAg (for chronic hepatitis B patients), ALT and 
viral load, with ultrasound or biopsy done for a subset. Clinical markers including cirrhosis, 
genotype, contra-indications (mostly psychological and nephrological), co-morbidities and 
previous treatment response are used to assess eligibility for treatment.
We were also able to compare availability of antiviral drug options in the six countries. In 
general, CHB treatment is more widely available than treatment for chronic hepatitis C. With 
the exception of all the newer hepatitis C antivirals, most specialists in most countries can 
use all treatment options with few serious restrictions. Restriction to use in certain hospitals 
was commonly identified, especially in Hungary, Italy and the Netherlands which would 
perhaps explain why within-country differences are observed. However, there is remarkable 
homogeneity in responses within countries about each option. Homogeneity also suggests 
success in reaching expert clinicians able to reflect on the circumstances in their profession 
in their country.
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The differences between countries in the availability of both first-generation protease 
inhibitors boceprevir/telaprevir and 2014-approved innovations are especially interesting. 
This finding provides some insight into the differential speed at which pharmacological 
innovations approved in Europe cascade to the national level and become available to 
clinicians. In four of the six countries, the latest innovations appear to be limited to certain 
hospitals but, most significantly, to patients with advanced disease, specifically F3/4 cirrhosis. 
While these patients are most urgently in need of treatment, to maximise the health gains 
from secondary prevention, these highly effective options would need to become available 
for patients without cirrhosis.
Our research provides a snap shot of clinical perspectives at one specific point in time 
in six EU/EEA countries, and the results are not generalizable outside these six countries. 
Treatment availability can also be subject to change as new policy directives, funding or 
guidelines expand access to different patients. As our research was conducted soon after 
the European-level approval of most HCV medications, the severity of reported restrictions 
could have reduced over time. Further, the low response rate may undermine wider 
generalisability within the specific study country and introduce selection bias, specifically 
that the most motivated and interested clinicians respond. The aim was to reach expert 
clinicians involved in treating patients chronically infected with viral hepatitis and, whilst 
the response rate is indeed a weakness, the profile of the respondents indicates that our 
sample is representative of the clinicians we sought to reach.
There are few studies to compare these results with, especially for the newer therapies. 
News reports suggest that complete restriction of new hepatitis C antivirals have provoked 
protest in Spain (25). The  innovative 2015-published ‘Strategic Plan for Tackling Hepatitis C 
in the Spanish National Health System’ supports the findings in this study that the priority for 
treatment with the newest DAAs are fibrotic patients, among other severely affected patients 
with multi-morbidity (Type-2 diabetes, lymphoma etc.), although there is a commitment 
to review the treatment indications at periodic intervals (26).  Some studies suggest that 
most CHB patients who reach specialist care are treated with first line nucleotides (24, 27, 
28). Studies also suggest restrictions related to patient characteristics, including compliance 
with the treatment regimen (8), age and gender (28), immigration status, and awareness of 
treatment options (29). Even before the possibility to undergo diagnostic evaluation and 
treatment, there is evidence that diagnosed patients are not reaching secondary care, not 
being clinically managed effectively or not on treatment (12, 13, 30, 31). The large burden 
of disease in populations that may have difficulty accessing health care, such as migrants 
or people who inject drugs, is also suggested to explain the lack of detection, referral and 
treatment initiation (32).
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Most of the burden of viral hepatitis remains undiagnosed and Europe is still behind the 
peak in the related mortality curve (10, 14). There is an urgent need to identify people 
eligible for treatment through screening and referral to specialist care.  However, maximising 
possible health gains from treatment, especially the potential cure of chronic hepatitis 
C, will require expansion in both geographic availability and the clinical characteristics of 
patients considered eligible for treatment. The rapid publication and adoption of global 
and national strategies during and after this study was conducted illustrate how far the field 
of viral hepatitis research and policy are evolving. Notable within this global governance 
context are the first World Health Organisation (WHO) strategy on Hepatitis C (33), the WHO 
Global Strategy on Viral Hepatitis (34), and the first World Hepatitis Summit (20). These set 
ambitious and far-reaching targets and goals for nations to work towards the eradication 
of hepatitis B and C, including those related to treatment initiation, access to diagnostic 
testing and strengthening health systems. Findings in this study can serve as useful baseline 
measures in these areas to the member states included and assist other member states 
to understand the clinical realities diagnosing and treating patients infected with chronic 
hepatitis B and C through similar research.
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The aims of this thesis were twofold: 1) to understand the epidemiology of CHB/CHC in the 
EU/EEA; and 2) to understand the conditions at the health system level and the characteristics 
of screening interventions that effectively diagnose and retain at-risk migrants in a cascade 
of care. The discussion adopts a public health perspective on the cascade of care to answer 
the following three research questions.
1) To what extent are migrants from endemic countries a risk group for chronic 
hepatitis B and C in Europe?
2) What can be learned from different migrant-focused models of HBV/HCV 
screening?
3) How can the impact of screening among migrants be maximised?
A schematic representation of a cascade of care for viral hepatitis produced by the World 
Health Organisation for the Global Health Sector Strategy for Viral Hepatitis 2016-2021 is 
shown in Figure 1.(1) 
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The cascade of care perspective provides a strategic organising framework to conceptualise 
three things: 1) the need for ‘upstream’ and ‘downstream’ interventions to achieve elimi ation; 
2) the movement of people through the cascade; and 3) the more specific interventions 
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become moving downstream. A public health level cascade perspective also provides a 
framework for monitoring progress towards elimination.(1) The aim is to populate each 
stage of the cascade with estimated or modelled data to understand the overall burden 
of disease at the population level and what proportion of that total (estimated) caseload is 
diagnosed, in care, on treatment or cured/suppressed.(2)
Figure 2 builds on this strategic perspective and highlights specific interventions that 
maximise impact at each stage. This schematic representation can also be used by screening 
and treatment interventions at the planning stage to envisage linkage between different 
services and what a patient journey might look like. It can also be used to evaluate the 
efficacy and efficiency of screening and linkage to care programmes by reporting successful 
referral or attrition through the stages of care, as reported by the HEPscreen pilot studies in 
Chapter 6.
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Figure 2. An intervention-based conceptualisation of a continuum of care (3)
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RESEARCH QUESTION 1: TO WHAT EXTENT ARE MIGRANTS FROM 
ENDEMIC COUNTRIES A RISK GROUP FOR CHRONIC HEPATITIS B 
AND C IN EUROPE?
Migrants from endemic countries account for 10% of the EU/EEA population yet account 
for an estimated 25% of all CHB and 14% of all CHC infections in the EU/EEA. Thus, from both 
an epidemiological and public health equity perspective, migrants are a disproportionately 
affected risk group for chronic viral hepatitis infection.
To expand this discussion, we see three conceptualisations of the notion of ‘extent’. Extent 
can be conceptualised as in the short answer above in terms of relative magnitude i.e. the 
relative contribution of migrants to the overall number of cases in each EU/EEA Member 
State and in the EU/EEA as whole. The second conceptualisation is related to this notion of 
relative magnitude but involves a comparison of migrants in relation to other risk groups 
for CHB/CHC – so, how does the expected prevalence among migrants compare to that 
in other key risk groups?  We can also conceptualise extent based on how far migrants are 
the focus of existing secondary prevention interventions, encasing the notion of ‘extent’ in 
issues of distributive justice, fairness and equality. 
Expanding the short answer of ‘extent’ in terms of relative contribution, we show in Chapters 
4 and 5 that migrants comprise a minority of the population but contribute significantly to 
the estimated caseload of chronic viral hepatitis in most EU/EEA countries, although more 
so for CHB than for CHC. We also find there are clear differences in the relative contribution 
across the 31 EU/EEA Member States (Figure 3 in both Chapter 4 (for CHB) and Chapter 
5 (CHC)). These differences at Member State-level depend on four key parameters: the 
prevalence in the host EU/EEA country; the size of the total population of the host country; 
the number of migrants from endemic countries; and the prevalence in countries of birth 
of migrants. In general, migrants from endemic countries account for more of the burden 
of CHB/CHC in the low prevalence countries in the Northern and Western EU/EEA Member 
States than in the higher prevalence Member States in Central, Eastern and Southern Europe. 
The second conceptualisation of ‘extent’ – how does the expected prevalence among 
migrants compare to other risk groups – is addressed throughout Part I of this thesis. There 
are two components to this: how reliable is country of birth-derived prevalence as a proxy 
for the prevalence in migrants and secondly, what is the prevalence among other at-risk 
groups. In Chapters 4 and 5, we conclude via a systematic review and epidemiological 
analysis that the prevalence in country of birth is a reliable proxy for the prevalence among 
migrants for both CHB and CHC. However, we found there to be very few studies that report 
on the prevalence among migrants representative of the general population and even 
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fewer specifically designed as sero-prevalence studies. Prevalence can be understood as a 
measure of exposure risk – the higher the prevalence, the higher the exposure risk. Equally, 
the greater the risk of exposure in the general population, the higher the prevalence. The 
distribution and frequency of transmission risks in the general population in different 
countries differ for the two viruses. These differences influence the extent to which migrants 
are a risk group, as we now explain. 
Perinatal and childhood exposure to HBV are the key drivers of transmission in hepatitis B 
endemic countries and these risk factors broadly affect the general population.(4-6) It is to 
be expected therefore that migrants born in HBV endemic countries are at higher risk of 
CHB infection due to the high(er) risk of perinatal HBV exposure. 
It is less clear to what extent birth in a high HCV prevalence country is a risk factor for 
exposure given the drivers and dynamics of HCV over time. Specifically, there has been 
a significant decline in prevalence over time in most middle and high income countries 
that has led to a strong birth cohort effect worldwide with the baby boomer generation 
(born between 1945 - 1965) the most affected cohort in North America and Europe.(2, 
7-9) Furthermore, HCV exposure risk factors differ from country to country, especially the 
contribution of health-care acquired HCV infection compared to behaviourally-acquired 
HCV, specifically unsafe/unsterile drug injecting practices. In higher prevalence low and 
middle income countries (LMIC), HCV is largely acquired via parenteral procedures in 
health-care services with inadequate infection control practices. This is described by the 
WHO as a generalised pattern of infection and the act of migrating to a low prevalence 
country largely removes the risk of health-care acquired (generalised) HCV infection.(10) 
The primary difference between a “birth cohort” pattern and a generalised pattern of 
infection is the duration of time that the generalised exposure has existed and whether it 
has been removed or mitigated. In (lower prevalence) middle and higher income countries, 
infection control practices introduced over the last ~20 years have largely controlled health-
care acquired HCV infection (11) and injecting drugs using unsterile equipment is the key 
driver of HCV transmission. In most middle and high income countries therefore, the risk of 
exposure to HCV is low in the general population and mostly related to participation in high 
risk behavioural practices. Recent studies, especially from the US, highlight that people are 
still acquiring blood-borne viruses (BBVs) via unsafe drug injecting, and that the incidence 
of new HCV infections is increasing as a result especially in sub-populations of the general 
population such as rural women of reproductive age.(12) There is similar evidence from the 
EU/EEA that injecting drug use (IDU)-acquired HCV continues, that harm reduction services 
are sub-optimal and that limited data on people who inject drugs (PWID) across the cascade 
of care may hamper elimination efforts.(13, 14) Given the decades of knowledge and 
experience we have in public health about the harms associated with unsafe IDU practises 
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and how to prevent IDU-acquired BBVs, ongoing BBV transmission especially among young 
adults should be an urgent matter of concern and a call to action for countries to invest in 
effective harm reduction services. 
We can compare country of birth-derived estimates (the proxy for the prevalence among 
migrants used in Chapter 4 and 5) to that derived from other risk groups described in 
Chapter 3. We would argue that from this perspective of ‘extent’ as a function of comparative 
prevalence across risk groups, PWID and people incarcerated in prison are the key risk 
population for CHC infection given the high prevalence, the dynamic interaction/overlap 
between the two populations (due to criminalisation of high transmission risk behaviours 
specifically IDU and sex work) and the efficacy of IDU in transmitting HCV.(15, 16) We 
conclude, based on the evidence in Chapters 3, 4 and 5, that migrants born in HBV endemic 
countries are the key population for CHB infection in most EU/EEA countries, but especially 
in the lower prevalence Northern and Western countries. We would also argue that the 
overrepresentation of migrants among the incarcerated population in some countries is a 
driver of the high prevalence of HBsAg in the prison population.(17, 18)
The final conceptualisation draws on theories of distributional justice, specifically equity 
and prioritisation (19), to discuss to what ‘extent’ migrants are a risk group. From this 
philosophical perspective, we can define a risk group based on how likely they are to 
experience final (poor) health outcomes as a consequence of CHB/CHC infection through 
being unable to access or being underserved by secondary prevention interventions to 
avoid these final consequences of morbidity and mortality. We argue that based on the 
findings in this thesis and in wider literature, migrants are currently underserved by existing 
screening and treatment programmes in the EU/EEA and as such, we argue for further 
investment in, and scaling up of, interventions that specifically reach, diagnose and retain 
migrants from endemic countries in a care pathway for chronic viral hepatitis. Evidence 
for this position comes firstly from the results from the systematic search for migrant-
derived prevalence estimates in Chapters 4 and 5. Here, our findings suggest that screening 
among at risk migrant populations is limited in time, scope and geographical coverage. 
These findings chime with those found by another systematic review which found very few 
published screening studies among at-risk migrants in Europe.(20) Immigration status is 
also independently associated with not reaching specialist care and not receiving treatment 
for chronic viral hepatitis.(21) Previous studies also found lower usage of preventative 
health care services among migrants and poorer health outcomes in general for chronically 
infected migrants compared to non-migrants.(22, 23)
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Turning back to the cascade of care perspective, the evidence highlighted in this thesis and 
in the discussion of this specific research question can help to define at a strategic level the 
population(s) for targeted action. More specifically, it can help to understand the extent to 
which migrants born in endemic countries should be a focus of prevention activities (steps 
one/two in the cascade) in a specific EU/EEA Member State. It can also help to understand 
(existing/potential) barriers affecting the smooth transition of chronic cases through the 
cascade. This latter point is now expanded on in research questions two and three.
RESEARCH QUESTION 2: WHAT CAN BE LEARNED FROM 
DIFFERENT MIGRANT-FOCUSED MODELS OF HBV/HCV 
SCREENING?
We identified five key learning points for effective HBV/HCV screening: 1) a simple care 
pathway; 2) the involvement/partnership with secondary care to facilitate referral; 3) offering 
on site screening together with awareness-raising/pre-test information; 4) the availability of 
interpreters/translated materials to reduce language barriers; and 5) the use at the planning 
stage of country of birth prevalence to define the migrant communities at highest risk of 
chronic viral hepatitis infection. 
The first two learning points (a simple care pathway and a partnership between primary 
and secondary care services) are related to each other and aim specifically to minimise 
participant attrition across the cascade of care. Findings described in Chapter 6 show 
how more complex care pathways lead to higher participant drop out. We also found (in 
Chapter 10) via a survey among practising clinicians that standard referral practices in the 
six EU countries included in this study are complex involving multiple stages and multiple 
services. These characteristics are likely to exacerbate the findings in wider literature that 
many patients do not receive their diagnosis, do not reach secondary care and are not on 
treatment for their CHB/CHC infection.(23-27) We found in Chapter 6 and in other literature 
(28-30) that a partnership between primary care/public health services and secondary 
care can facilitate smooth referral and to ensure that diagnosed cases reach specialist care 
for further investigation and treatment. Further, a centralised coordinated referral system 
that can ensure individual patients are followed up seemed more conducive to successful 
retention in the cascade of care compared to larger, more dispersed referral mechanisms 
involving multiple hospitals and multiple referral pathways. 
The third leaning point relates to screening uptake. Uptake is also sensitive to the number 
of steps an individual is required to take in order to actually take up the offer of HBV/
HCV screening. It is clear from the experience in Chapter 6 that more complex pathways 
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involving a number of steps leading to screening is likely to increase the attrition of 
migrant participants who may also drop out due to language and other barriers (such as 
insecure employment and other socio-economic disadvantages). Uptake seems highest 
in individual-focused models offering screening in one-to-one confidential health care 
encounters.(31) This is partly because uptake is easier to measure in models offering one-
on-one screening than in outreach models where, for instance, an entire workforce (as in 
the Grampian pilot described in Chapter 6), anyone attending a civic or social centre (in the 
Barcelona outreach pilot described in Chapter 6) or an entire local population (28, 30) could 
be considered to be part of the target population. Indeed, none of the studies of outreach 
screening among migrants we know of measure or report screening uptake (28, 30, 32-35) 
the manner in which we attempt to in Chapter 6. 
With regard to learning point 4, we investigated the availability of language support services 
in six EU countries in Chapter 8. Findings from the pilot studies described in Chapter 6 
also highlight the importance of providing translated materials/interpreters to overcome 
language barriers experienced by linguistically diverse migrants. Findings across these 
chapters and in wider literature suggest that language support services can improve the 
quality of clinical care provided to linguistically diverse migrants, improve retention in the 
cascade of care and reduce inequalities in health outcomes.(26, 36, 37) 
The final learning point is related to the potential for the screening model to successfully 
detect cases of chronic HBV/HCV infection. Expected prevalence of the target population 
is an important characteristic in weighing the ethical considerations (harms vs. benefits at 
the population level) of offering screening.(38-40) Prevalence is also a key input in cost-
effectiveness models.(41-45) We demonstrate via a systematic review in Chapters 4 and 5 
in Part I that the prevalence of HBsAg and anti-HCV in a country of birth are both a reliable 
proxy for the prevalence of these virological markers in migrants born in these countries. We 
also see from experience in Chapter 6 that offering screening among migrants born in low 
prevalence countries (such as those in Latin America) does not successfully diagnose cases 
of chronic viral hepatitis. Therefore, we suggest the greatest utility is to offer screening to 
migrants born in high(er) prevalence countries; and to use demographic and epidemiological 
information at the national/local (most appropriate) level to determine which communities 
these are at the planning stage. Furthermore, defining the migrant communities of interest 
can then allow for further specific tailoring of screening interventions according to the 
linguistic and other socio-cultural characteristics of the target population(s). 
Our experience gained throughout the HEPscreen project highlights the fragmented 
nature of knowledge about offering HBV/HCV screening among migrants born in endemic 
countries. The models described in Chapter 6 and in other studies (28, 32, 34, 35, 46-57) can 
291
General Discussion
14
be broadly grouped into four types: 1) outreach-based offering awareness-raising and/or 
screening in community, social or civic locations or in workplaces (such as the innovative 
pilot in Grampian, Scotland described in Chapter 6); 2) invitation-based using municipal or 
patient registry data to select and invite at-risk migrants for HBV/HCV screening in health 
care services; 3) opportunistically offering screening to at-risk migrants attending health care 
services for other issues; and 4) extending an existing migrant-focused screening programme 
to include viral hepatitis. Our experience underlines the need for more implementation 
studies of screening among migrants, especially studies that compare different models of 
screening, report results across the cascade of care and report costs across the cascade of 
care (such as cost per person screened, diagnosed and started on treatment). It is to these 
key measures of impact that this discussion now turns.
RESEARCH QUESTION 3: HOW CAN THE IMPACT OF SCREENING 
AMONG MIGRANTS BE MAXIMISED?
There are two key conditions needed to maximise the impact of screening among 
migrants: 1) good data across the cascade of care; and 2) scaling up key interventions and 
good practices as part of a strategic approach. Good data across the cascade of care is 
necessary to understand (national) progress towards elimination. Scaling up good practices 
in designing and delivering screening to at-risk migrants as part of a strategic plan improves 
population health and makes effective use of scarce health care resources.
Data at the first stage of the cascade of care, specifically good epidemiological data about 
the distribution and scale of CHB/CHC across the population, is necessary to determine 
in the first instance to what extent migrants from endemic countries are a key risk group 
for chronic viral hepatitis in a specific country (or area). National/local (public) health 
planners can draw on demographic and epidemiological data (country of birth prevalence 
and population size) to identify which migrant communities are most at risk of being 
chronically infected with HBV/HCV, and to target interventions for these communities. We 
show in Chapters 4 and 5 that the contribution of migrants to the overall burden of chronic 
viral hepatitis differs greatly across EU/EEA Member States. The data from these chapters 
can assist public health decision makers to prioritise health conditions, populations and 
interventions given that (public) health care resources are finite. In most Northern and 
Western EU/EEA Member States, migrants from endemic countries account for at least a 
quarter of CHC infections and are the priority population for CHB infection. However, in 
countries where migrants account for a minimal number of infections and the prevalence of 
HBV/HCV in the general population is intermediate or high (≥2%), there may be more utility 
in prioritising national birth cohort screening (especially for HCV) or offering screening to 
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behavioural high (transmission) risk groups such as PWID. Results from such programmes, 
especially results related to prevalence, can then be used to further update and refine our 
epidemiological understanding of chronic viral hepatitis. 
Other key data for elimination planning include the number (and proportion) diagnosed, 
the number (and proportion) of people on treatment and the number (and proportion) 
of people reporting viral suppression/SVR/cure. To support collection of data across the 
cascade of care, the WHO have defined 10 key indicators in the Monitoring and Evaluation 
Framework for Viral Hepatitis B and C (shown in Figure 3 below).(58) Along with monitoring 
progress towards elimination, reliable estimates for each of these indicators can also be 
politically motivating and should be used to inform (public) health care planning and 
investment. A national viral hepatitis registry is suggested in the World Health Organisation 
Global Elimination Strategy as the most effective method in which to capture this data.
(1) Some European countries are making progress towards establishing a national registry, 
most notably in literature is Denmark.(53) This data can also be used to further calibrate and 
refine elimination forecast modelling.(2) Data can also allude to breaks in the cascade of 
care to stimulate investment and improvement in reducing barriers to referral and retention 
in treatment. 
Secondly, good practice screening and treatment interventions must be scaled up to have 
a significant impact public health.(59) Scaling up screening and treatment is also highly 
time sensitive and urgent due to the global concentration of chronic viral hepatitis infection 
in working age adult populations born (1945-1965) prior to the introduction of key primary 
prevention interventions.(2, 60) Models predict that the crucial time period for action to 
prevent mortality due to CHB/CHC-related causes is between now and 2030.(59) There is 
much to be done in this 15 year window.(14) 
Scaling up requires a strategic approach. Establishing a national/local viral hepatitis strategy, 
investment plan and partnership that brings together key stakeholders can help to ensure 
that resources are effectively distributed and that interventions are coherently scaled 
up, accurately targeted, based on good practices and properly evaluated.(14) A strategic 
partnership can be an effective mechanism to plan and monitor action, to identify gaps in 
provision, aggregate and analyse data and to evaluate progress towards elimination. 
National/local strategies and partnerships should also set out specific strategic actions 
focused on migrants from endemic countries. These strategic actions should follow the 
cascade of care approach to determine how and where people (migrants) born in endemic 
countries can access/be reached by screening interventions, how a diagnosis will be 
communicated, and, crucially, what efforts will be made to ensure people with evidence of 
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CHB/CHC infection reach specialist care for clinical monitoring, treatment (if indicated) and 
contact tracing. To maximise the proportion diagnosed, it is important to provide numerous 
conduits into the cascade of care by offering screening via a combination of the four models 
(set out in research question 2) in a range of health services. A suite of interventions can 
provide comprehensive and diverse screening coverage to reach heterogeneous groups 
of migrants in community locations, primary health care services and workplaces, and via 
existing screening programmes.
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10	key	indicators	in	the	Monitoring	and	Evaluation	Framework	for	Viral	Hep titis	B	and	C	(shown	in	Figure	3	
below).(99)		
Figure	3:	The	ten	key	indicators	across	the	cascade	of	care:	the	World	Health	Organisation’s	monitoring	
and	evaluation	framework	for	hepatitis	B	and	hepatitis	C	virus	elimination	2016–2021		
	
Along	with	monitoring	progress	towards	elimination,	reliable	estimates	for	each	of	these	indicators	can	also	
be	 politically	 motivating	 and	 should	 be	 used	 to	 inform	 (public)	 health	 care	 planning	 and	 investment.	 A	
national	viral	hepatitis	registry	is	suggested	in	the	World	Health	Organisation	Global	Elimination	Strategy	as	
the	most	effective	method	in	which	to	capture	this	data.(19)	Some	European	countries	are	making	progress	
towards	establishing	a	national	 registry,	most	notably	 in	 literature	 is	Denmark.(94)	 This	data	 can	also	be	
used	to	further	calibrate	and	refine	elimination	forecast	modelling.(57)	Data	can	also	allude	to	breaks	in	the	
cascade	of	care	to	stimulate	investment	and	improvement	in	reducing	barriers	to	referral	and	retention	in	
treatment.		
	
Figure 3. The ten key indicators across the cascade of care: the World Health Organisation’s 
monitoring and evaluation framework for hepatitis B and hepatitis C virus elimination 2016–2021
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Specific screening interventions should also draw on the good practice resources in pre- 
and post-test counselling, in contact tracing and vaccination, and referral and retention 
alluded to throughout this thesis, contained within the HEPscreen Toolkit (61) and reported 
as part of the HEPscreen scientific output, (37, 62-64) or elsewhere.(3)
Alongside these two key conditions, the impact of screening on resources both from the 
health system perspective and the individual/patient level should be considered. Health 
planners need evidence on how the cost-effectiveness of HBV/HCV screening among 
migrants can be maximised and on how to offer screening if human and financial health 
care resources are limited. To maximise the cost-effectiveness of screening, interventions 
should seek to:
a. Maximise the case yield (number of chronic cases) by focusing on intermediate/
high prevalence migrant communities, especially for HBV screening (42);
b. Minimise the resources required to deliver a good practice intervention through 
prudent (financial) planning, strong project management and a partnership 
approach drawing on existing resources (related to infrastructure and human 
capital).
Interventions should therefore consider two key questions in advance. First, what is the 
expected case yield in the target population using country of birth prevalence as a proxy 
(Chapters 4 and 5), or how likely is it that chronic HBV/HCV infections will be detected 
by screening in this specific migrant community? And secondly, where are and what are 
the opportunities for attrition in the cascade of care, and how can these be avoided or 
minimised? Whilst cost-effectiveness analyses (CEAs) of screening are heterogeneous in 
design (41, 42), and an all parameter sensitivity analysis is not always conducted, prevalence 
and attrition across the cascade of care (including referral and treatment adherence) are key 
parameters in (modelled) cost-effectiveness studies.(42, 45) 
A more challenging policy question, one that is not easily answered in research, is what 
would elimination actually cost for countries? Screening and treatment interventions among 
specific/generalised cohorts and groups may be cost-effective in terms of acceptable costs 
per QALY gained, but what would be the net budgetary impact of planning, implementing, 
coordinating and evaluating all required for elimination? This is largely unknown, although 
a recent modelling study in France showed that treating all CHC-infected people with new 
DAAs regardless of fibrosis stage is cost-effective but would add €3.5–7.2 billion, depending 
on the specific DAA combination, to the health care budget.(65) This cost does not include 
efforts required to identify these infections through screening, nor does it include CHB. 
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Consideration of the financial impact on health systems of HBV/HCV screening among 
migrants is especially relevant in the global economic and political climate from which 
this thesis emerged. A policy of austerity in public finances has been adopted by many 
industrialised high income countries in the decade since the financial crash of 2007/8.
(66) Specifically, the reduction of funding for prevention activities (such as harm reduction 
services (67)) and in health care entitlement for migrants (68-71) will impact public health 
decision-makers abilities to design and implement HBV/HCV screening for migrants. We 
demonstrate as part of the HEPscreen Toolkit produced alongside this thesis how HBV/
HCV screening among migrants can be delivered when human and financial resources are 
limited. All of the various models of screening described (in the Toolkit, in Chapter 6 and in 
the discussion of research question two) can be adapted according to resource limitations 
in the health care system. 
Screening interventions should also consider how to minimise the time/resource impact 
of attending screening on the target population, for instance the costs incurred for 
appointments (such as travel costs, work-related absence and short-notice adjustment of 
family/carer responsibilities) especially for migrants reached via outreach screening rather 
than in health care settings. We demonstrate via the Grampian pilot that workplace-based 
outreach screening is a feasible means to offer screening to migrants during working 
hours. The success this pilot study had in detecting chronic viral hepatitis, in reaching a 
large number of migrants and in engaging employers (who were willing to provide time, 
logistics and space to support screening) presents a good practice example that others can 
replicate in future. We describe in Chapter 6 that socio-economic vulnerability is a barrier 
to attending follow up appointments for viral hepatitis-related care. Offering screening in 
outreach settings can reach people without access to the health care system (a lack of 
insurance, undocumented status), as described in Chapter 6 and in wider literature.(46, 47, 
72, 73) Arranging health care entitlement as part of the planning for outreach screening is 
thus both ethically prudent and crucial to maximise impact.
Research and practice implications
Throughout this discussion, we allude to the key findings and learning points from the 
work conducted in the thesis. In the following section, we make explicit mention of how 
future research and public health practice can make use of, build on and take further the 
work conducted as part of HEPscreen and as part of this thesis. The recommendations are 
split into four themes: A) screening; B) cost-effectiveness; C) epidemiology; and D) national 
policy. Most of these recommendations come directly from our experience in this thesis; 
some come from limitations and future priority issues arising from key literature informing 
and shaping the work contained in this thesis.
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Recommendations for future research and practice
A) Screening
1. There is clear and urgent need for more implementation studies of screening strategies 
among risk populations that includes both HBV and HCV, especially among migrants 
from endemic countries.
2. We need more examples of workplace-based outreach HBV/HCV screening among 
migrants to determine that, as in our experience, this model of screening is acceptable 
to the target population, is feasible, has utility and is supported by employers.
3. Future screening studies should adopt the good practices in linkage to care described 
in this thesis, elsewhere (3) and as part of HEPscreen (37, 61-64) to minimise attrition 
and maximise health impact.
4. There is a need for a standardised reporting framework for screening interventions 
to set out the key outcomes. This should include as a minimum: uptake, prevalence, 
costs per person screened, costs per case and proportion of cases reaching the various 
stages of care (progress through the cascade).
5. Screening interventions should provide, where required, additional social and 
administrative support to integrate migrants living with high levels of socio-economic 
vulnerability into society and the health care system.
B) Cost-effectiveness
6. Cost-effectiveness modelling studies should recalibrate the key parameters of uptake, 
attrition and intervention costs (specifically running screening interventions) using 
‘real world’ measures using, for instance, those in Chapter 6.
7. In future modelling studies, the intervention costs related to screening should 
encompass staff time, consumables and logistical resources (as well as the commonly 
included costs related only to blood/serum sample-taking and serological testing) 
required to recruit/bring people to health services for screening.
8. There is a need for more cost-effectiveness studies of screening and treatment for HCV 
but focused only on interferon-free DAAs. Most of the CEAs of screening and treatment 
conducted prior to the availability of interferon-free DAAs for HCV treatment arguably 
are redundant.
C) Epidemiology
9. The development and consistent application of an EU/EEA or international standard 
for the design and quality assessment of seroprevalence studies to inform pooling 
and/or statistical comparison of data across studies and populations would greatly 
improve understanding of prevalence across countries and populations.
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10. Future seroprevalence studies of HCV should measure both anti-HCV and HCV RNA 
to ensure data relate to viraemic chronic infections and not simply report evidence of 
anti-HCV exposure or a resolved infection.
D) National policy
11. Countries should (continue to) invest in harm reduction strategies and services to 
prevent IDU-acquired HBV/HCV. Injecting drug use should be seen primarily from the 
policy perspective of protecting and promoting public health (and not criminalisation).
12. Countries where general population anti-HCV prevalence is estimated to be high 
should explore the feasibility and utility (and costs) of birth cohort screening among 
people born 1945-1965. Much can be learned from studies in the United States (31, 
41, 74, 75) and France.(76) Birth cohort (HCV) screening has been demonstrated to be 
good value for money.(41)
13. Low HBsAg prevalence, Northern/Western European Union Member States should 
focus (non-antenatal) screening efforts on migrants born in HBV endemic countries.
Recommendations and Implications for EU Policy:
This research took place within and across the EU/EEA landscape and the included studies 
were funded through EU Agencies. This perspective and experience has generated some 
wider policy implications and insights. These recommendations seek to influence the 
continuation of EU funding for research and action around the key themes and topics 
explored in this thesis.
1. The European Medicines Agency and other joint medical procurement mechanisms 
should utilise the combined purchasing power of the EU to negotiate better value 
access to interferon-free DAA regimens.
2. Chronic viral hepatitis infection should be explicitly mentioned as a priority area for 
action as part of a future EU Cross Border Threats framework for action.
3. Future and existing EU Frameworks, Agencies and other policy mechanisms should 
aim to build the epidemiological capacity in middle income MS specifically in Central 
and Eastern Europe where there are gaps in data and a likely high burden of CHB/CHC.
4. The EU should, on humanitarian grounds, reduce systemic barriers to health care for 
undocumented migrants, asylum seekers and other vulnerable populations. Universal 
access to health care should also be considered as a cornerstone of a successful Cross 
Border Threats programme.
5. EU level funding for public health projects, especially those that aim to develop tools 
for practice/a toolkit such as HEPscreen, should provide a follow up tranche of budget 
and funded staff time for dissemination and awareness raising. This funding should 
298
Chapter 14
only be available following completion of the tools/toolkit to ensure it is ring-fenced 
for dissemination of practice-focused outcomes. This could improve adoption and use 
of tools/toolkits produced as part of EU health funding.
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SUMMARY
This thesis focuses on chronic viral hepatitis infection in the EU/EEA through work 
conducted as part of the EU Health Programme funded HEPscreen project and two large 
scale systematic reviews and meta-analysis/epidemiological analysis in collaboration with 
the European Centre for Disease Control (ECDC). The strategic aim of this work is to inform 
future efforts towards the WHO-led goal to eliminate chronic viral hepatitis as a health threat 
in Europe by 2030. Whilst progress has been made and incident infections are declining 
in most EU/EEA countries, there is much to do to achieve this ambitious goal within this 
narrow timeframe. The research is focused around the first three strategic pillars of the WHO 
elimination strategy: 1) the who and where; 2) the what; and 3) the how. There are two 
broad aims:
1. To understand the epidemiology of chronic viral hepatitis in the general 
population and among key risk groups in the EU/EEA;
2. To understand the health system conditions and screening interventions that 
effectively reach, diagnose and retain at-risk migrants in health care for viral 
hepatitis.
In Chapter 1, provides an introduction to the aetiology, sequelae, transmission routes, 
global epidemiology and broader public health context of how we can eliminate hepatitis 
B (HBV) and C (HCV) virus infections. HBV and HCV are remarkably successful blood-borne 
infections transmitted through contact with infected blood/blood products and other 
bodily fluids (although latterly more for HBV than for HCV). Infections can spontaneously 
resolve and lead to immunity or they can fail to resolve and progress to chronic infection. 
Chronic infections can, if left untreated, progress over decades to serious liver disease 
specifically fibrosis, cirrhosis and hepatocellular carcinoma (HCC).
However, we have the ability to prevent both incident cases (via primary prevention 
measures) and to address the burden of chronic infection (through screening and 
treatment). Chapter 1 explains how patchy implementation of primary prevention in some 
parts of the world and at historic periods has led to an unequal global distribution of HBV 
and HCV as well as to a birth cohort effect in most middle and high-income countries. 
We also elucidate the different drivers of infection for the two viruses and from region to 
region. Perinatal transmission is responsible for around a third of chronic hepatitis B (CHB) 
cases and is thus the key driver of infection in HBV endemic areas. Interrupting transmission 
through antenatal screening, maternal antiviral treatment (to reduce viral load) and birth 
dose vaccination is crucial to control the spread of HBV. In low prevalence areas, most 
HBV transmission is via risk behaviour, specifically unprotected sexual contact or sharing 
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drug injecting equipment with HBsAg carriers. Risk group vaccination and harm reduction 
interventions are therefore key primary prevention measures. Past/current shared injecting 
drug practices are also key driver of HCV infection, placing people who inject(ed) drugs 
(PWID) at increased risk of both HBV and HCV infection. Prior to the introduction of stringent 
hospital and health care infection control measures (in the late 1980s/early 1990s in most 
high income countries), including blood/blood product screening, both HBV and HCV were 
also acquired via unscreened blood transfusions and contaminated percutaneous medical 
equipment. However, in many resource-poor countries, transmission via the use of unsafe 
medical tools remains a key driver of incident infections.
Encouragingly, prevalence of both HBsAg and anti-HCV/HCV RNA has decreased over 
time in most countries. Many countries now face a dichotomy: a declining incidence of 
new infections due to the success of primary prevention alongside a projected increase in 
chronic viral hepatitis-related mortality due to ageing and disease progression in the most 
affected birth cohort (born 1945-1965).
Expanded scope in antiviral treatment has the potential to suppress viral replication, halt 
disease progression and even cure chronic (HCV) infection. These potential public health 
benefits of effective treatment can only be realised by finding (through screening), retaining 
in care and treating people with a chronic hepatitis B/C infection. Our understanding of 
transmission risks allows us to define key risk groups for case finding (screening). In low 
prevalence middle and high-income countries, migrants born in endemic countries are 
one population subgroup in which the likelihood of being chronically infected is higher. 
Migrants born in HBV endemic countries may have been exposed to HBV perinatally or 
parenterally as children (and therefore may be at high risk of CHB infection). Migrants from 
HCV endemic countries are suspected to be at risk of CHC infection due to nosocomial/
iatrogenic exposure where health care infection control practices are substandard.
Drawing on a range of methodological techniques from epidemiology, public health and 
the social sciences, this thesis seeks to answer the following three research questions:
1. To what extent are migrants from endemic countries a risk group for chronic 
hepatitis B and C in Europe?
2. What can be learned from different migrant-focused models of HBV/HCV 
screening?
3. What are the key conditions to maximise the impact public health of HBV/HCV 
screening among migrants?
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We begin in Chapter 2 with a systematic review and meta-analysis to retrieve, analyse and 
describe prevalence estimates for the general population and in two low risk populations 
often used as a proxy for the general population (first time blood donors and pregnant 
women). We found considerable heterogeneity in HBsAg/anti-HCV prevalence and in the 
availability and quality of data across the EU/EEA. The findings from this study can assist 
Member States in elimination planning and progress monitoring as well as to highlight 
priority areas for epidemiological capacity-building. We show in this study how HBsAg/anti-
HCV prevalence increases in an Eastern and Southern direction in the EU/EEA. We also show 
how using the prevalence in first time blood donors or pregnant women is an unreliable 
proxy for the general population due to inherent bias in these selective groups.
We further expand on the work to understand the epidemiology of chronic HBV/
HCV infection in the EU/EEA in Chapter 3, turning here to the prevalence in three key 
behavioural risk groups: men who have sex with men (MSM), PWID and people incarcerated 
in prison. Data were gathered via a systematic review and meta-analysis (for MSM and 
people in prison) and via an epidemiological analysis of data systematically collected by 
the European Monitoring Centre for Drug Dependency and Addiction (EMCDDA). This 
study found that PWID and people in prison are the priority populations for CHB/CHC 
screening and treatment in most EU/EEA countries given the high prevalence of infection 
and dynamic interaction between the two sub-populations. We aimed, as in Chapter 2, to 
control for key sources of selection bias for each population via the development of study 
quality assessment frameworks. This systematic study found a paucity of studies across the 
three risk groups, especially high quality studies with a low risk of bias. This underlines the 
need for epidemiological capacity building across the EU/EEA to enable and equip Member 
States to measure and monitor the prevalence in key risk populations.
We turn in Chapters 4 and 5 to the burden of chronic viral hepatitis among migrants from 
endemic countries to the EU/EEA. We conducted a systematic review and epidemiological 
analysis to estimate the burden of CHB (Chapter 4) and CHC (Chapter 5) attributable to 
migrants to all 31 EU/EEA Member State and across the EU/EEA as a whole. We searched for 
systematic reviews of the prevalence of virological markers of chronic infection to develop 
a global, national prevalence data set. We then retrieved demographic information on 
population size of all 31 EU/EEA Member State, and on the size and country of birth of all 
(registered) migrants to each EU/EEA Member State. We then developed estimates for the 
number of (potential) cases of CHB and CHC in both the general population in each (and 
across all) EU/EEA Member State and among migrants from endemic countries. We found 
that migrants from endemic countries account for around 10% of the EU/EEA population 
but are disproportionately affected by CHB/CHC, accounting for a quarter of all (estimated) 
CHB infections and 14% of all CHC infections. We also found that in low prevalence Northern/
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Western EU/EEA Member States, migrants from endemic countries account for almost all 
estimated CHB infections and from a third to a half of all CHC infections. To validate the use 
of country of birth prevalence as a proxy for migrants, we also compared the prevalence 
found in studies among migrants (living in EU/EEA Member States and representative of 
the general population) with the prevalence retrieved for the corresponding country of 
birth. This analysis showed that, whilst there are limited data points for the prevalence in 
migrants, country of birth prevalence can be used as a proxy for the prevalence in migrants.
Chapters 2-5 aim to answer research question 1. In Part 2, we turn to questions 2 and 3 
and focus on ‘the how’ of secondary prevention. Chapters 6 - 13 describe the key scientific 
work conducted as part of the EU Health Programme funded project HEPscreen: screening 
for chronic viral hepatitis among migrants in Europe. This consortium project funded during 
2011-2014 aimed to define the tools and conditions for effective screening and linkage to 
care for chronic viral hepatitis among migrants in Europe. Alongside the scientific output 
reported in this thesis, we also translated and synthesised the knowledge and findings 
gathered into a practical online toolkit aimed at supporting policy makers, public health 
practitioners and clinicians to implement and evaluate the impact of screening among 
migrants from endemic countries. This toolkit is available in multiple EU languages at 
http://www.hepscreen.eu and is an accessible repository of good practices consisting of 
epidemiological tools, practical checklists, animated videos to improve knowledge and 
awareness, and short documentary videos of models of good practice screening to assist 
in replication.
Chapter 6 describes the six screening pilot studies that were at the core of the HEPscreen 
project. In this study, we report on the implementation, outcomes and costs of six models 
of screening for CHB/CHC among migrants. We pilot tested two outreach screening models 
(one in community locations in Barcelona, Spain; one in workplaces in Grampian, Scotland), 
an opportunistic model (also in Barcelona) and an invitation-based model (in London, the UK) 
both in primary care, and two extension models (adding HBV/HCV screening to university-
based tuberculosis screening in Grampian, Scotland; extending antenatal HBV screening 
to include HCV in Budapest/Pest County, Hungary). We collected and compared data on 
cascade of care outcomes, screening uptake, prevalence and costs. Five of the six screening 
models were completed, screening 1203 people for HBV and HCV. Uptake varied from 
33% in workplace outreach screening to 78% in opportunistic screening in primary care. 
The invitation-based model in primary care ceased prematurely due to low uptake (2.3%). 
Attrition was seen in the community outreach where testing was not offered at the first 
point of contact. The highest HBsAg prevalence (12.9%) was detected among South-East 
Asian migrants. The highest anti-HCV prevalence was found in migrants from Central 
(10.3%) and South (8.3%) Asia, and Eastern Europe (5.3%). Costs per person screened ranged 
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from €48 (tuberculosis screening extension model) to €111 (community outreach model). 
We conclude that at-risk migrants can be effectively reached via screening models in 
health care and community settings. Uptake in community-based outreach screening may 
be improved by offering testing at the first point of contact. HBV/HCV screening should 
prioritise migrants born in intermediate/high prevalence countries to maximise public 
health impact.
Chapters 7 to 13 focus on understanding the health system conditions that facilitate 
implementation of screening among migrants. Chapter 7 describes a systematic literature 
search for guidelines related to screening, counselling, clinical management and treatment 
for chronic viral hepatitis. We further supplemented this search with a survey among policy 
makers and clinicians to identify guidelines not retrieved by the search. The online survey 
retrieved 40 national guidelines in addition to the 12 retrieved by the systematic scientific 
database search. This study suggests that scientific databases are not the most important 
source to disseminate good practice guidelines to clinicians.
Language barriers are the focus of Chapter 8. Via an online survey among clinicians involved 
in screening and/or clinical management and treatment of viral hepatitis, we investigate 
the availability of interpreters and translated materials for chronic viral hepatitis patients 
in the six HEPscreen study countries (Germany, Hungary, Italy, the Netherlands, Spain and 
the United Kingdom). We also investigate how far clinicians feel that language barriers 
explain three scenarios: why screening is not offered to culturally and linguistically diverse 
(CALD) migrants with country of birth-related risk factors; why the uptake of screening is 
low among at-risk CALD migrants; and why CALD migrants with evidence of a chronic viral 
hepatitis infection do not reach secondary care for clinical investigation and treatment. 
We found that support to overcome language barriers (interpreters/translated materials) is 
more common in the ‘difference-sensitive’ health systems of the Netherlands, Spain and the 
UK and less common in the ‘difference-blind’ health systems of Germany, Hungary and Italy. 
We also found that in ‘difference-blind’ countries, where migrants are (largely) expected to 
assimilate to the language and culture of the host country, clinicians disagree that language 
barriers explain the three scenarios despite the reported infrequent availability of services 
that overcome language barriers. This finding highlights that wider social and cultural 
norms and values around assimilation (the expectation that migrants adapt to the host 
country) exists in health care. Conversely, in ‘difference-sensitive’ health systems, clinicians 
agree that language barriers are important explanations for the three scenarios despite the 
frequent availability of interpreters and translated materials.
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We turn to pre-test information prior to HBV/HCV screening among migrants in Chapter 9. 
We set out via a systematic literature search, content analysis and a DELPHI-inspired online 
survey among clinicians to add explore and expand the concept of pre-test information 
before HBV/HCV screening. The study first defines the objectives and discussion topics of 
pre-test information before HBV/HCV screening as reported in good practice guidelines 
retrieved via the search and content analysis. Secondly, we explored clinicians’ perceptions 
of the objectives of pre-test information and the importance of each discussion topic 
towards achieving each objective. Finally, we consolidate findings into a consensus on the 
desirable and feasible aspects of pre-test information – what can be delivered topic-wise 
that assures key objectives (securing informed choice, achieving a high uptake, reducing 
stigma and improving knowledge) when time in health care encounters is limited. We 
then further synthesise these findings (as an annex to the study) into a practical ‘pre-test 
information’ checklist aimed at clinicians offering screening among migrants. The checklist 
outlines the priority discussion topics if time is limited as well as which topics can increase 
feelings of stigma, fear and shame among at-risk migrants offered screening.
Chapters 10 to 13 focus on current pathways for patients with evidence of chronic viral 
hepatitis infection in referral, clinical management and access to treatment in the six 
HEPscreen countries. All four studies utilise online survey methodology among practising 
clinicians, with Chapters 12 and 13 specifically focused among secondary care specialists 
(in infectious diseases, gastroenterology or hepatology). In Chapter 10, we explore current 
practices in referral of patients with evidence of a CHB/CHC infection and findings allude 
to the existence of complex and unclear referral pathways within countries and to the 
variability in the role of primary care. Secondary care specialists report variably or rarely 
receiving patients with evidence of a CHB/CHC infection from services likely to be involved 
in screening such as antenatal care, sexual health services and harm reduction/PWID testing 
facilities/services in Germany, Hungary, Italy and the Netherlands. Most commonly across all 
six study countries is the referral from or via GPs to specialist care, highlighting the pivotal 
‘gate-keeper’ role of GP services in these countries but especially so in Spain, the Netherlands 
and the UK. Findings from this study suggest that strengthening and systematising referral 
between screening/diagnosing services and clinical management/treatment services is a 
key part improving progression through a cascade of care.
We build on these findings in Chapter 11, focusing on the role of the GP in screening and 
clinical management for CHB/CHC, with data gathered also via an online survey among 
GPs and specialists in secondary care. We first focus on how common it is for GPs to offer 
screening to key risk groups including migrants born in endemic countries, PWID, MSM, 
sex workers and people with abnormal liver function tests. Results show variability in 
the offer of screening across all groups across all countries. Most relevant for this thesis 
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is the finding that HBV/HCV screening among migrants born in endemic countries is not 
systematically offered by GPs in any of the six study countries. We suggest that systematising 
and expanding the offer of HBV/HCV screening to migrants from endemic areas by GPs 
can contribute significantly to increasing the diagnosed fraction and can be achieved via 
electronic patient prompts, invitation-based screening using country of birth selection 
criteria and interventions to improve GP knowledge and awareness.
In Chapter 12, we set out to determine if restrictions in access to antiviral treatment for CHB/
CHC exist for six vulnerable populations: undocumented migrants, asylum seekers, people 
without health insurance, people with only state insurance, PWID and people abusing 
alcohol. We used a four point Likert scale (complete, significant, some or no restriction) 
to measure clinicians’ perceptions of restrictions in their country. Most notable was the 
discordance of opinion about restrictions within countries, especially for groups for whom 
the health care system defines access to treatment, such as undocumented migrants, 
asylum seekers and people without health insurance. This study adopts a health system 
perspective and the six countries in our study represent different types: in Germany and the 
Netherlands, a Bismarkian system exists where state insurance is crucial for access to health 
care. It is, therefore, not surprising that we do observe some or significant restrictions in 
access to treatment among people without health insurance. Italy, Spain and the UK operate 
a Beveridge-style system where health care coverage is free and universal, and funded 
through collective national insurance payments. This universalism is mirrored in responses 
from Italy where no or only some restrictions exist for all six patient/population groups. It 
is, however, somewhat surprising that restriction to treatment among those without health 
insurance is reported in Spain and the UK where insurance is not expected to play a role. 
However, both systems require registration to receive social support and access to health 
care would be limited without this registration, not because patients do not have health 
insurance coverage per se but because those without (state) insurance cover are effectively 
considered undocumented migrants or persons for whom health care entitlement is 
uncertain. Hungary operates a hybrid of a Semashko-style Soviet system and a Bismarckian-
influenced model where individual (social) health insurance coverage is key to access but 
the legacy of out-of- pocket payments remains. Most restrictions are reported in Hungary, 
especially among undocumented migrants, asylum seekers and people without insurance.
Chapter 13 examines access to antiviral treatment options in the six countries. We investigate 
via a three point Likert scale (no, some, complete) the level of restriction for each treatment 
option approved for use in Europe (by the European Medicines Agency) up to summer of 
2014. We deployed two surveys – one in 2012 and a follow up in 2015 about interferon-free 
direct acting antivirals (DAAs) (sofosbuvir, simeprevir, declatasvir and simeprevir/ledipasvir) 
approved in 2014. We find that most options for CHB treatment are widely available for 
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use by specialists in all six countries. This further strengthens the rationale for expanding 
access to HBV screening. For HCV treatment, clinical and health system factors restrict and 
ration the use of the latest antiviral innovations in Hungary, Italy, the Netherlands, Spain, and 
the UK. The latest innovations in HCV treatment appear to be limited to certain hospitals 
but, most significantly, to patients with advanced disease, specifically F3/4 cirrhosis. While 
these patients are most urgently in need of treatment, to maximise the health gains from 
secondary prevention, highly effective DAAs would need to become available for patients 
without cirrhosis.
Finally we discuss the three research questions and the research, policy and practice 
implications arising out of this thesis in Chapter 14. We open the discussion on research 
question one with three conceptualisations of to what ‘extent’ migrants born in endemic 
countries are a key risk group: 1) ‘extent’ in terms of relative magnitude; 2) ‘extent’ in terms of 
relative prevalence and 3) ‘extent’ seen through the lens of distributional justice. We conclude 
based on these conceptualisations that migrants from endemic countries are the key risk 
group for HBV in most low prevalence, high income Member States in the North and West of 
the EU/EEA. We draw a slightly more nuanced conclusion for HCV: migrants from endemic 
countries are one key risk group based on their higher prevalence (compared to the host 
population) and relatively high contribution (in relation to population size). However, PWID 
and people (formerly) incarcerated in prison are the key HCV risk group due to the very 
high (>50%) prevalence in these two populations. What this epidemiology underlines is the 
need for a more sensitive approach to the discussion of risk factors when offering screening 
to migrants from endemic countries and specifically to avoid stigmatisation of (people 
with) viral hepatitis infection through avoiding emphasis on illicit drug use, sexual contact 
and criminality as the source of infection.
We synthesize the learning from the HEPscreen Project in discussion of research question 
2 summarising five key learning points for effective HBV/HCV screening among migrants:
1. A simple care pathway;
2. Involvement of/partnership with secondary care to facilitate referral;
3. Offering on site screening with awareness-raising/pre-test information;
4. The availability of interpreters/translated materials to reduce language barriers; 
5. The use at the planning stage of country of birth prevalence and demographic 
information to define the migrant communities at highest risk of chronic viral 
hepatitis infection.
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There is an urgent need for more implementation studies of screening among migrants, 
specifically studies that compare different models of screening and report outcomes and 
costs across the cascade of care.
The discussion turns to the question of how to maximise the impact of screening among 
and linkage to care of at-risk migrant groups (research question 3). We elucidate two key 
conditions required for maximise impact:
1. Good data across the cascade of care; 
2. Scaling up key interventions and good practices as part of a strategic approach.
Good data across the cascade of care are necessary to understand (national) progress towards 
elimination. We refer to the WHO led elimination strategy and action plan, specifically the 
key indicator set, as important strategic tools and frameworks available to assist countries/
regions in data collection and elimination planning. Scaling up good practices in designing 
and delivering screening to at-risk migrants as part of a strategic approach improves 
population health and makes effective use of scarce health care resources.
The key term here is strategic – the notion of making effective use of existing resources; of 
mapping existing interventions and looking both for gaps in provision and for unexplored 
synergy; of building partnerships between layers and levels within health systems; of 
adopting project management techniques when implementing multiple interventions 
within a defined area/for a defined population; appropriately targeting interventions; of 
using evidence to guide intervention/project development; of prudent financial planning 
to maximise delivery and minimise waste; and of including evaluation in the cycle of 
intervention/strategy development and implementation.
We conclude the discussion by summarising a series of recommendations – for research 
and practice, for national policy and for EU policy.
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Dit proefschrift gaat over chronische virale hepatitis infecties in de EU/EER en beschrijft werk 
uitgevoerd in het kader van het door het EU Health Programme gefinancierde HEPscreen 
project, en twee grootschalige systematische reviews en meta-analyse/epidemiologische 
analyse voor het European Centre for Disease Control (ECDC). Het strategische doel van 
dit werk is om richting te geven aan de toekomstige inspanningen om het door de World 
Health Organisation (WHO) gestelde doel, om chronische virale hepatitis als een bedreiging 
voor de gezondheid in Europa te elimineren voor 2030, te bereiken. Hoewel er vooruitgang 
is geboekt en het aantal nieuwe infecties daalt in de meeste EU/EER-landen, is er nog veel te 
doen om dit ambitieuze doel te bereiken in dit smalle tijdsbestek. Het onderzoek is gericht 
op de eerste drie strategische pijlers van de eliminatie strategie van de WHO: 1) ‘het wie en 
waar’; 2) ‘het wat’; en 3) ‘het hoe’. Er zijn twee overkoepelende doelen:
1. Inzicht krijgen in de epidemiologie van chronische virale hepatitis in de algemene 
bevolking en onder belangrijke risicogroepen in de EU/EER;
2. Inzicht krijgen in de gezondheidszorg organisatorische voorwaarden en 
screeningsinterventies die migranten met virale hepatitis effectief bereiken, 
diagnosticeren en in zorg houden.
Hoofdstuk 1 geeft een inleiding op de etiologie, de gevolgen, de transmissie routes, 
wereldwijde epidemiologie en bredere volksgezondheid context van de manier waarop we 
hepatitis B (HBV) en C (HCV) virusinfecties kunnen elimineren. HBV en HCV zijn opmerkelijk 
besmettelijke infecties die kunnen worden overgedragen door contact met besmet bloed/
bloedproducten en andere lichaamsvloeistoffen (hoewel dit laatste meer voor HBV dan 
HCV). Infecties kunnen spontaan herstellen en leiden tot immuniteit of ze kunnen overgaan 
in een chronische infectie. Chronische infecties kunnen, indien onbehandeld, na tientallen 
jaren ernstige leverziekten zoals cirrose en hepatocellulair carcinoom (HCC) veroorzaken.
We hebben echter de mogelijkheid om zowel nieuwe gevallen te voorkomen (via primaire 
preventiemaatregelen) als ook de ziektelast van chronische infectie aan te pakken (door 
screening en behandeling). In hoofdstuk 1 wordt uitgelegd hoe gebrekkige implementatie 
van primaire preventie in sommige delen van de wereld en in specifieke periodes heeft 
geleid tot een ongelijke wereldwijde verdeling van HBV en HCV, evenals een geboortecohort 
effect in de meeste midden en hoog inkomen landen. We verhelderen ook de verschillende 
onderliggende factoren voor de verspreiding van de twee virussen en van regio tot regio. 
Perinatale transmissie is verantwoordelijk voor ongeveer een derde van de chronische 
hepatitis B (CHB) en is de belangrijkste drijvende kracht in HBV endemische gebieden. Het 
onderbreken van transmissie door prenatale screening en antivirale behandeling tijdens de 
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zwangerschap (waardoor de viral load afneemt) en een geboortedosis vaccinatie is cruciaal 
om de verspreiding van HBV tegen te gaan. In lage prevalentie gebieden vindt de meeste 
HBV transmissie plaats via risicogedrag zoals onbeschermd seksueel contact of het delen 
van drug injectiemateriaal met HBsAg dragers. Risicogroep vaccinatie en harm reduction zijn 
dan ook belangrijke primaire preventie maatregelen. (Ex)druggebruik is ook een belangrijke 
oorzaak van HCV-infectie, wat mensen die drugs injecteren (PWID) een verhoogd risico 
geeft op zowel HBV als HCV-infectie. Voorafgaand aan de invoering van strenge controle 
maatregelen (o.a. bloed/bloedproduct screening) in het ziekenhuis en de gezondheidszorg 
(in de late 1980/begin jaren 1990 in de meeste rijke landen), werden zowel HBV en HCV 
ook overgedragen via ongescreende bloedtransfusies en besmet percutane medische 
apparatuur. In vele resource-arme landen, blijft transmissie via het gebruik van onveilige 
medische hulpmiddelen een belangrijke motor bij het ontstaan van nieuwe infecties.
Het is bemoedigend dat de prevalentie van zowel HBsAg als anti-HCV/HCV RNA in de loop 
der tijd is verminderd in de meeste landen. Veel landen staan nu voor een dichotomie: een 
dalende incidentie van nieuwe infecties als gevolg van het succes van de primaire preventie 
en tegelijkertijd een verwachte toename van chronische virale hepatitis gerelateerde 
sterfte als gevolg van de vergrijzing en de progressie van de ziekte in het zwaarst getroffen 
geboortecohort (geboren 1945-1965).
Verbeterde antivirale behandeling heeft het vermogen om virale replicatie te onderdrukken, 
progressie van de ziekte te stoppen en zelfs chronische (HCV) infectie te genezen. Deze 
potentiële voordelen voor de volksgezondheid van een effectieve behandeling kunnen 
alleen worden gerealiseerd door het opsporen (via screening), in zorg brengen en het 
behandelen van mensen met een chronische hepatitis B/C-infectie. Ons begrip van 
transmissie risico's stelt ons in staat om belangrijke risicogroepen voor case-bevinding 
(screening) te definiëren. In midden en hoge-inkomenslanden met een lage prevalentie 
zijn migranten geboren in endemische landen een bevolkingsgroep waarin de kans om 
chronisch geïnfecteerd te zijn hoger is. Migranten geboren in HBV endemische landen 
kunnen perinataal of parenteraal zijn blootgesteld aan HBV als kinderen (en hebben daarom 
een hoog risico op CHB infectie). Migranten uit HCV endemische landen kunnen risico op 
CHC infectie hebben gelopen als gevolg van nosocomiale/iatrogene blootstelling, daar 
waar de gezondheidszorg infectie controle praktijken ondermaats zijn.
Op basis van een aantal methodologische technieken uit de epidemiologie, volksgezondheid 
en de sociale wetenschappen, wil dit proefschrift de volgende drie onderzoeksvragen 
beantwoorden:
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1. In welke mate zijn migranten uit endemische landen een risicogroep voor 
chronische hepatitis B en C in Europa?
2. Wat kan geleerd worden uit verschillende op migranten gerichte modellen voor 
HBV/HCV screening?
3. Wat zijn de belangrijkste voorwaarden om de volksgezondheid impact van HBV/
HCV-screening onder migranten te maximaliseren?
In hoofdstuk 2 worden met een systematische review en meta-prevalentie schattingen 
voor de algemene bevolking en twee laag risico populaties die vaak gebruikt worden als 
een proxy voor de algemene bevolking (bloed donoren en zwangere vrouwen) verzameld, 
geanalyseerd en beschreven. Wij vonden een aanzienlijke heterogeniteit in HBsAg/anti-HCV-
prevalentie en in de beschikbaarheid en de kwaliteit van de gegevens in de hele EU/EER. 
De bevindingen van deze studie kunnen EU/EER-lidstaat helpen bij de eliminatie planning 
en voortgangsbewaking alsmede gebieden voor epidemiologische capaciteitsopbouw te 
prioriteren. Wij tonen in deze studie aan hoe HBsAg/anti-HCV-prevalentie toeneemt in een 
oostelijk en zuidelijk richting in de EU/EER. Wij laten ook zien dat de prevalentie in de bloed 
donoren en zwangere vrouwen een onbetrouwbare proxy is voor de algemene bevolking 
als gevolg van inherente bias in deze selectieve groepen.
In hoofdstuk 3 draait het om de prevalentie in drie belangrijke gedragsgebonden 
risicogroepen: mannen die seks hebben met mannen, injecterende druggebruikers (PWID) 
en gedetineerden. De gegevens werden verzameld via een systematische review en meta-
analyse (MSM en gedetineerden) en via een epidemiologische analyse van gegevens die 
systematisch worden verzameld door het European Monitoring Centre for Drug Dependency 
and Addiction (EMCDDA). Deze studie bleek dat PWID en gedetineerden de prioriteit 
populaties zijn voor CHB/CHC screening en behandeling in de meeste EU/EER-landen, gezien 
de hoge prevalentie van infectie en dynamische interactie tussen de twee subpopulaties. 
Wij streven ernaar, zoals in hoofdstuk 2, voor belangrijke bronnen van selectiebias voor elke 
populatie te corrigeren via de ontwikkeling van studiekwaliteitsbeoordelingsraamwerken. 
Deze systematische studie vond een gebrek aan studies over de drie risicogroepen, vooral 
van studies van hoge kwaliteit met een laag risico op bias. Dit onderstreept de noodzaak 
voor epidemiologische capaciteitsopbouw in de hele EU/EER om EU/EER-lidstaten in staat 
te stellen om de prevalentie in de verschillende risicogroepen te meten te monitoren.
Wij richten ons in hoofdstukken 4 en 5 op de ziektelast van chronische virale hepatitis 
onder migranten uit endemische landen in de EU/EER. Wij voerden een systematische 
review en epidemiologische analyse om het aandeel van migranten aan de ziektelast van 
CHB (hoofdstuk 4) en CHC (hoofdstuk 5) te schatten migranten voor alle 31 EU/EER-lidstaten 
en in de hele EU/EER als geheel. Wij hebben gezocht naar systematische reviews van de 
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prevalentie van virologische markers van chronische infectie om een nationale prevalentie 
dataset te ontwikkelen voor alle landen in de wereld. Vervolgens hebben we demografische 
informatie over de omvang van de populatie van alle 31 EU/EER-lidstaten verzameld, en van 
de grootte en het land van geboorte van alle (geregistreerde) migranten in elke EU/EER-
lidstaat. Vervolgens hebben we het aantal (potentiële) gevallen van CHB en CHC geschat, 
zowel in de algemene bevolking in elke EU/EER-lidstaten (en in totaal) en onder migranten 
uit endemische landen. Wij vonden dat migranten uit endemische landen ongeveer 10% 
van de EU/EER-bevolking uitmaken, maar dat ze onevenredig worden getroffen door CHB/
CHC aangezien een kwart van de (geschatte) CHB infecties en 14% van alle CHC infecties bij 
migranten gevonden wordt. Wij vonden ook dat in lage prevalentie landen in het noorden 
en westen van de EU/EER, migranten uit endemische landen bijna alle geschatte CHB 
infecties en tussen een derde tot de helft van alle CHC infecties vertegenwoordigen. Om 
de validiteit van het gebruik van de prevalentie in het geboorteland als een proxy voor de 
prevalentie onder migranten te toetsen, hebben we deze waar beschikbaar vergeleken. 
Deze analyse toonde aan dat, hoewel er beperkte data zijn over de prevalentie onder 
migranten, de prevalentie in het geboorteland kan worden gebruikt als een proxy voor de 
prevalentie onder migranten.
In de hoofdstukken 2-5 wordt vraagstelling 1 beantwoord. In deel 2, richten we ons op 
de vragen 2 en 3 en ligt de focus op 'het hoe' van secundaire preventie. Hoofdstukken 
6 - 13 beschrijven het wetenschappelijke werk dat is uitgevoerd als onderdeel van het EU-
gezondheidsprogramma gefinancierde project HEPscreen: screening voor chronische virale 
hepatitis onder migranten in Europa. Dit consortiumproject,  met looptijd 2011-2014, had 
als doel de instrumenten en voorwaarden te definiëren voor effectieve screening en toe 
geleiding tot zorg voor chronische virale hepatitis onder migranten in Europa. Naast de 
wetenschappelijke output die in dit proefschrift wordt beschreven, hebben we ook de 
kennis en de bevindingen verzameld en gesynthetiseerd in een praktische online toolkit, 
gericht op het ondersteunen van beleidsmakers, volksgezondheidsprofessionals en clinici 
om de impact van screening onder migranten uit endemische landen te implementeren 
en te evalueren. Deze toolkit is beschikbaar in meerdere talen via http://www.hepscreen.
eu en is een toegankelijke verzameling van goede praktijkvoorbeelden, bestaande uit 
epidemiologische instrumenten, praktische checklists, animatiefilmpjes om de kennis en 
het bewustzijn te verbeteren, en korte documentaire video's van screeningsprojecten in de 
praktijk om implementatie te vergemakkelijken.
Hoofdstuk 6 beschrijft de zes pilot screeningprojecten die de kern van de HEPscreen 
project vormden. In deze studie rapporteren we over de uitvoering, de resultaten en de 
kosten van de zes manieren van screening voor CHB/CHC onder migranten. Er zijn twee 
outreach screening modellen getest (één in de gemeenschap locaties in Barcelona, Spanje, 
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één in werkplaatsen in Grampian, Schotland), een opportunistisch model (ook in Barcelona) 
en een model met persoonlijke uitnodiging (in Londen, het Verenigd Koninkrijk), beide 
in de eerste lijn, en twee uitbreidingsmodellen (toevoegen van HBV/HCV screening aan 
tuberculosescreening in Grampian, Schotland; uitbreiding van de prenatale HBV-screening 
met HCV in Budapest/Pest regio, Hongarije). Wij verzamelden en vergeleken gegevens 
op uitkomsten in de cascade van de zorg, screening deelname, prevalentie en kosten. Vijf 
van de zes screeningsmodellen werden voltooid, waarbij 1203 mensen voor HBV en HCV 
werden gescreend. De deelname varieerde van 33% in de screening op de werkplek tot 
78% bij opportunistische screening in de eerstelijn. Het op uitnodiging-gebaseerde model 
vanuit de huisarts stopte voortijdig door een lage deelname (2,3%). Uitval werd gezien in de 
gemeenschap-outreach waar het testen niet bij het eerste contactpunt werd aangeboden. 
De hoogste HBsAg prevalentie (12,9%) werd gevonden onder Zuidoost-Aziatische 
migranten. De hoogste anti-HCV prevalentie werd gevonden onder migranten uit 
Centraal (10,3%) en Zuid (8,3%) Azië en Oost-Europa (5,3%). Kosten per gescreend persoon 
varieerde van €48 (tuberculose screening uitbreidingsmodel) tot €111 (gemeenschap-
outreach model). Wij concluderen dat een migranten met een verhoogd risico effectief via 
screening modellen kunnen worden bereikt in de gezondheidszorg en maatschappelijke 
instellingen. Deelname in gemeenschap-outreach screening kan worden verbeterd door 
het aanbieden van testen bij het eerste contactpunt. HBV/HCV screening moet prioriteit 
geven aan migranten geboren in intermediaire/hoge prevalentie landen om te impact op 
de volksgezondheid te maximaliseren.
Hoofdstukken 7 - 13 richten zich op het begrijpen van de aspecten van het 
gezondheidszorgsysteem die de implementatie van screening onder migranten 
bevorderen. Hoofdstuk 7 beschrijft een systematisch literatuuronderzoek naar richtlijnen 
met betrekking tot screening, counseling, patiëntmanagement en de behandeling van 
chronische virale hepatitis. Wij hebben deze zoekopdracht verder aangevuld met een 
onderzoek onder beleidsmakers en clinici om richtlijnen te identificeren die niet met de 
zoekopdracht zijn gevonden. De online-enquête identificeerde 40 nationale richtlijnen in 
aanvulling op de 12 die waren gevonden in het systematische literatuuronderzoek. Deze 
studie suggereert dat wetenschappelijke databanken niet de belangrijkste bron zijn om 
goede praktijkrichtlijnen onder clinici te verspreiden.
Taalbarrières zijn de focus van hoofdstuk 8. Via een online enquête onder clinici die 
betrokken zijn bij het screenen en/of patiëntmanagement en de behandeling van virale 
hepatitis,  onderzoeken we de beschikbaarheid van tolken en vertaalde materialen 
voor chronische virale hepatitis patiënten in de zes HEPscreen studie landen (Duitsland, 
Hongarije, Italië, Nederland, Spanje en het Verenigd Koninkrijk). Wij onderzoeken ook 
in hoe verre clinici vinden dat taalbarrières drie scenario's verklaren: waarom screening 
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niet aan cultureel en taalkundig diverse (CALD) migranten met aan het geboorteland-
gerelateerde risicofactoren wordt aangeboden; waarom de deelname aan screening 
laag is bij CALD-migranten; en waarom CALD migranten een chronische virale hepatitis 
infectie de secondaire zorg niet bereiken voor klinisch onderzoek en behandeling. Wij 
vonden dat ondersteuning bij het overwinnen van taalbarrières (tolken/vertaald materiaal) 
vaker beschikbaar is in de 'verschil-gevoelige' gezondheidsstelsels van Nederland, Spanje 
en het Verenigd Koninkrijk en minder vaak in de 'verschil-blinde' gezondheidsstelsels 
van Duitsland, Hongarije en Italië. Wij vonden ook dat in 'verschil-blinde' landen, waar 
migranten (grotendeels) verwacht worden te assimileren aan de taal en cultuur van het 
gastland, clinici er niet mee eens zijn dat taalbarrières een rol spelen in de drie scenario's, 
ondanks de gerapporteerde sporadische beschikbaarheid van diensten om taalbarrières 
te overkomen. Deze bevinding wijst erop dat de bredere sociale en culturele normen 
en waarden rond assimilatie (de verwachting dat migranten zich aanpassen aan het 
gastland) ook bestaat in de gezondheidszorg. Omgekeerd, zijn clinici in 'verschil-gevoelige' 
gezondheidszorgsystemen het erover eens dat taalbarrières belangrijke verklaringen zijn 
voor de drie scenario's, ondanks de veelvuldige beschikbaarheid van tolken en vertaalde 
materialen.
In hoofdstuk 9 gaan we in op pre-test counseling voorafgaand aan HBV/HCV screening 
onder migranten. Via een systematisch literatuuronderzoek, inhoudsanalyse en een DELPHI 
geïnspireerde online enquête onder clinici is  het concept van pre-test counseling voor 
HBV/HCV screening verkend en uitgebreid. We rapporteren over de wenselijkheid en 
haalbaarheid van aspecten van pre-test counseling - wat kan worden per onderwerp 
worden meegenomen dat de belangrijkste doelstellingen veiligstelt (geïnformeerde 
keuze, het bereiken van een hoge deelname, een vermindering van stigmatisering en 
verbetering van kennis) wanneer de tijd in de gezondheidszorg beperkt is. Wij hebben deze 
bevindingen vervolgens verder gesynthetiseerd (als bijlage bij de studie) in een praktische 
'pre-test counseling' checklist gericht op clinici die screening onder migranten aanbieden. 
De checklist schetst welke gespreksonderwerpen prioriteit hebben als tijd beperkt is, en 
welke onderwerpen gevoelens van stigmatisering, angst en schaamte kunnen verhogen 
onder migranten die screening aangeboden krijgen.
Hoofdstukken 10 - 13 richten zich op de huidige trajecten voor patiënten met 
chronische virale hepatitis-infectie bij doorverwijzing, klinische behandeling en toegang 
tot behandeling in de zes HEPscreen landen. Alle vier studies maken gebruik van online 
enquêtes onder clinici, waarbij hoofdstuk 12 en 13 specifiek gericht zijn op specialisten 
in de tweede lijn (in infectieziekten, gastro-enterologie en hepatologie). In hoofdstuk 
10 onderzoeken we de huidige praktijken in de verwijzing van patiënten met bewijs 
van een CHB/CHC infectie. De bevindingen suggereren het bestaan van complexe en 
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onduidelijke verwijstrajecten binnen landen en variabiliteit in de rol van de eerstelijns 
gezondheidszorg. Secondaire zorg specialisten melden wisselend of zelden patiënten met 
CHB/CHC besmetting te ontvangen vanuit diensten die zijn betrokken bij screening, zoals 
antenatale zorg, seksuele gezondheid en harm reduction/PWID testfaciliteiten/services in 
Duitsland, Hongarije, Italië en Nederland. Het meest gebruikelijk in alle zes studie landen is 
de verwijzing vanuit de huisarts naar specialistische zorg, wat de cruciale 'poortwachter' rol 
van de huisartsen in deze landen onderstreept, vooral in Spanje, Nederland en het Verenigd 
Koninkrijk. Bevindingen uit deze studie suggereren dat de versterking en systematisering 
van doorverwijzing van screening/diagnosticerende diensten naar klinische behandeling/
behandelde diensten is een belangrijk onderdeel is bij het verbeteren van de doorstroom 
in de cascade van de zorg.
Wij bouwen voort op deze bevindingen in hoofdstuk 11, met de nadruk op de rol van de 
huisarts in screening en klinische behandeling voor CHB/CHC, met gegevens verzameld 
via een online enquête onder huisartsen en specialisten in de secondaire zorg. Wij richten 
ons eerst op hoe gebruikelijk het is voor huisartsen om de belangrijkste risicogroepen, zoals 
migranten geboren in endemische landen bieden, pwid, MSM, sekswerkers en mensen 
met abnormale lever functies te screenen. De resultaten tonen variatie aan in het aanbod 
van screening in alle groepen in alle landen. Het meest relevant voor dit proefschrift is de 
bevinding dat HBV/HCV screening voor migranten geboren in endemische landen niet 
systematisch wordt aangeboden door huisartsen in de zes studie landen. Wij stellen voor dat 
systematiseren en het uitbreiden van het aanbod van HBV/HCV screening voor migranten 
uit endemische gebieden door huisartsen aanzienlijk kan bijdragen  aan het verhogen 
van de gediagnosticeerde fractie en kan worden bereikt via prompts in het elektronisch 
patiëntendossier, screening-uitnodiging op basis van het geboorteland en interventies om 
kennis en bewustzijn van de huisarts te verbeteren.
In hoofdstuk 12, pogen we te bepalen of er beperkingen in de toegang tot antivirale 
behandeling voor CHB/CHC bestaan voor zes kwetsbare groepen: ongedocumenteerde 
migranten, asielzoekers, mensen zonder ziektekostenverzekering, mensen met alleen een 
overheidsverzekering, PWID en mensen die misbruik maken van alcohol. Wij gebruikten 
een vier-punt Likert-schaal (totale, significante, enkele of geen beperking) om percepties 
van beperking onder clinici te meten in hun land. Het meest opvallend was de discordantie 
van meningen over beperkingen binnen landen, in het bijzonder voor groepen voor wie de 
gezondheidszorg toegang tot behandeling bepaalt, zoals ongedocumenteerde migranten, 
asielzoekers en mensen zonder ziektekostenverzekering. Deze studie hanteert een 
gezondheidszorgstelsel perspectief en de zes landen in onze studie vertegenwoordigen 
verschillende types: Duitsland en Nederland hebben een Bismarkian systeem waarin een 
zorgverzekering van cruciaal belang is voor de toegang tot de gezondheidszorg. Het is 
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dan ook niet verwonderlijk dat we enkele of belangrijke beperkingen in de toegang tot 
behandeling waarnemen onder mensen zonder ziektekostenverzekering. Italië, Spanje 
en het Verenigd Koninkrijk hebben een Beveridge-stijl systeem waar de dekking van de 
gezondheidszorg gratis en universeel is en gefinancierd wordt door middel van collectieve 
nationale verzekering uitkeringen. Dit universalisme wordt weerspiegeld in de reacties 
van respondenten uit Italië, waar geen of enkele beperkingen bestaan voor alle zes 
patiëntengroepen. Het is echter enigszins verrassend dat restrictie op de behandeling onder 
degenen zonder ziektekostenverzekering werd gemeld in Spanje en het Verenigd Koninkrijk, 
waar de zorgverzekering niet wordt verwacht een rol te spelen. Echter, beide systemen 
vereisen registratie voor het ontvangen van sociale steun en toegang tot gezondheidszorg 
zou worden beperkt zonder registratie, niet omdat patiënten geen ziektekostenverzekering 
hebben per se, maar omdat mensen zonder verzekering effectief gezien beschouwd 
worden als gedocumenteerde migranten of personen voor wie recht op verzekerde zorg 
onzeker is. Hongarije hanteert een hybride van een Semashko-stijl Sovjet-systeem en een 
Bismarckiaanse - beïnvloed model waarin individuele (sociale) ziektekostenverzekering 
de sleutel is tot toegang, maar de erfenis van out-of-pocket betalingen blijft. De meeste 
beperkingen worden gerapporteerd in Hongarije, vooral onder ongedocumenteerde 
migranten, asielzoekers en mensen zonder verzekering.
Hoofdstuk 13 onderzoekt de toegang tot antivirale behandeling opties in de zes landen. 
Wij onderzoeken via een drie-punt Likert-schaal (geen, sommige, volledig) het niveau van 
de beperking voor elke behandeling optie die is goedgekeurd voor gebruik in Europa 
(door de European Medicines Agency) tot en met de zomer van 2014. Wij hebben twee 
onderzoeken ingezet - een in 2012 en een follow-up in 2015 over interferon-vrij direct 
werkende antivirale DAAs (sofosbuvir, simeprevir, declatasvir en simeprevir/ledipasvir) 
goedgekeurd in 2014. Wij vonden dat de meeste opties voor CHB-behandeling op grote 
schaal beschikbaar zijn voor gebruik door specialisten in alle zes landen. Dit versterkt 
verder de onderbouwing voor uitbreiding van de toegang tot HBV screening. Voor HCV 
behandeling, beperken klinische en gezondheidszorg factoren het gebruik van de nieuwste 
antivirale innovaties in Hongarije, Italië, Nederland, Spanje en het Verenigd Koninkrijk. De 
laatste innovaties in HCV-behandeling lijken beperkt te zijn tot bepaalde ziekenhuizen, 
maar vooral voor patiënten met geavanceerde ziekte, met name F3/4 cirrose. Hoewel deze 
patiënten het meest dringend behoefte hebben aan behandeling, om de gezondheid 
voordelen van secundaire preventie te maximaliseren, zouden de zeer effectieve DAAs ook 
beschikbaar moeten zijn voor patiënten worden zonder cirrose.
Tot slot bespreken we de drie onderzoeksvragen en de onderzoek, beleid en praktijk 
implicaties die voortkomen uit dit proefschrift in hoofdstuk 14. Wij openen de discussie 
over onderzoeksvraag één met drie conceptualiseringen van in welke ‘omvang’ migranten 
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geboren in endemische landen een belangrijke risicofactor groep zijn: 1) 'omvang' qua 
relatieve grootte; 2) ‘omvang’ in termen van relatieve prevalentie en 3) 'omvang' gezien 
door de lens van herverdelende rechtvaardigheid. Wij concluderen op basis van de 
verschillende conceptualiseringen dat migranten uit endemische landen de belangrijkste 
risicogroep zijn voor HBV in de meeste lage prevalentie, hoog inkomen lidstaten in het 
noorden en westen van de EU/EER. Wij trekken een iets genuanceerder conclusie over HCV: 
migranten uit endemische landen zijn een belangrijke risicogroep op basis van de hogere 
prevalentie (vergeleken met de (algemene) bevolking) en relatief grote aandeel (met 
betrekking tot populatiegrootte). Echter, PWID en (ex)gedetineerden zijn de belangrijkste 
HCV risicogroep als gevolg van de zeer hoog (> 50%) prevalentie in deze twee populaties. 
Wat de epidemiologie onderstreept is de noodzaak van een gevoeliger benadering van 
risicofactoren bij het aanbieden screening aan migranten uit endemische landen, specifiek 
wat betreft het voorkomen van stigmatisering van (mensen) met virale hepatitis door het 
vermijden van nadruk op illegaal drugsgebruik, seksueel contact en criminaliteit als bron 
van besmetting.
We synthetiseren de lessen uit het HEPscreen Project bij het bespreken van onderzoeksvraag 
2 en vaten de vijf belangrijke leerpunten voor een effectieve HBV/HCV screening bij 
migranten samen:
1. een eenvoudige zorgpad;
2. betrekken van/samenwerken met de tweedelijnszorg om verwijzing te 
vergemakkelijken;
3. het aanbieden van screening op locatie met bewustwordings/pre-test informatie;
4. beschikbaarheid van tolken/vertaalde materialen om taalbarrières op te heffen; 
5. in het planningsstadium gebruik maken van de prevalentie in het geboorteland 
en demografische informatie om de migrantengemeenschappen met het 
grootste risico op chronische virale hepatitis infectie vast te stellen.
Er is een dringende behoefte aan meer implementatie studies naar screening onder 
migranten, in het bijzonder studies die verschillende modellen van screening vergelijken 
en  de resultaten en de kosten over de cascade van zorg beschrijven.
De discussie richt zich op de vraag hoe de impact van screening en toegeleiding tot zorg 
van migrantengroepen met een verhoogd risico te maximaliseren is (onderzoeksvraag 3). 
Wij verhelderen twee belangrijke voorwaarden voor een optimale impact:
1. goede gegevens over de gehele cascade van de zorg; 
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2. het opschalen van de belangrijkste interventies en goede praktijken in het kader 
van een strategische aanpak.
Goede gegevens over de verschillende fases in de cascade van de zorg zijn nodig om 
(nationale) vooruitgang richting eliminatie te monitoren Wij verwijzen naar de eliminatie 
strategie en het actieplan van de WHO, met name de essentiële indicator set, als belangrijke 
strategische tools en frameworks die beschikbaar zijn voor landen/regio’s als hulp bij het 
verzamelen van gegevens en de eliminatie planning. Opschaling van goede praktijken 
in het ontwerpen en aanbieden van screening aan risicogroepen migranten in het kader 
van een strategische aanpak verbetert de gezondheid van de bevolking en maakt effectief 
gebruik van schaarse middelen de gezondheidszorg.
De belangrijkste term hier is strategisch - het idee van het effectief gebruik maken van 
bestaande middelen; het in kaart brengen van bestaande interventies en op zoek gaan naar 
tekortkomingen in de dienstverlening en naar onontdekte synergie; van het opbouwen 
van partnerschappen tussen de lagen en niveaus binnen gezondheidssystemen; het 
gebruik van project management technieken bij de implementeren van verschillende 
interventies; het op de passende  doelgroep richten van interventies; het gebruik maken 
van wetenschappelijk bewijs bij de interventie/projectontwikkeling; van een zorgvuldige 
financiële planning om de uitvoering te maximaliseren en verspilling te minimaliseren; en 
het opnemen van een evaluatie in de cyclus van de interventie/strategieontwikkeling en 
implementatie.
De discussie wordt afgesloten met een reeks aanbevelingen - voor onderzoek en praktijk, 
voor nationaal beleid en voor het EU-beleid. Deze zijn hieronder weergegeven:
Aanbevelingen voor toekomstig onderzoek en praktijk
A) Screening
1. Er is duidelijk en dringend behoefte aan meer implementatie studies van screening 
strategieën in risico populaties die zowel HBV als HCV bevatten, vooral onder migranten 
uit endemische landen.
2. Wij hebben meer voorbeelden nodig van workplace-based outreach HBV/
HCV-screening onder migranten om te bepalen of, zoals in onze ervaring, dit 
screeningsmodel aanvaardbaar is voor de doelgroep, haalbaar is, nut heeft en wordt 
ondersteund door werkgevers.
3. Toekomstige screening studies moeten de goede praktijken voor toegeleiding tot zorg 
beschreven in dit proefschrift, elders (1) en als onderdeel van HEPscreen (2-6) gebruiken 
om het uitval te minimaliseren en het de gezondheid impact te maximaliseren.
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4. Er is behoefte aan een gestandaardiseerd rapportagekader voor de belangrijkste 
resultaten van screening interventies. Dit zou minimaal moeten omvatten: deelname, 
prevalentie, kosten per persoon die wordt gescreend, kosten per opgespoord geval 
en het aantal gevallen dat de verschillende stadia van zorg bereikt (voortgang door 
het continuum).
5. Screening interventies moeten, waar nodig, bijkomende sociale en administratieve 
ondersteuning bieden aan sociaal-economische kwetsbare migranten om integratie 
in de samenleving en het gezondheidszorgsysteem te bevorderen.
B) Kosten efficiëntie
6. Kosteneffectiviteit modelstudies moeten de belangrijkste parameters met betrekking 
tot deelname, uitval en interventie kosten (in het bijzonder het uitvoeren van screening 
interventies) opnieuw kalibreren op basis  van 'echte wereld' uitkomsten met behulp 
van bijvoorbeeld die uit hoofdstuk 6.
7. In toekomstige modelleringsstudies moeten de interventiekosten van screening de 
personeelskosten, verbruiksgoederen en logistieke middelen omvatten (evenals de 
vaak opgenomen kosten die alleen betrekking hebben op bloed/serummonstering 
en serologisch testen) die nodig zijn om mensen te werven/brengen naar 
gezondheidsdiensten voor screening.
8. Er is behoefte aan meer kosten-effectiviteitsstudies van screening en behandeling 
voor HCV maar alleen gericht op interferon-vrije DAA's. De meeste van de KEA's van 
screening en behandeling die zijn uitgevoerd voorafgaand aan de beschikbaarheid 
van interferonvrije DAA's voor HCV-behandeling, zijn waarschijnlijk overbodig.
C) Epidemiologie
9. De ontwikkeling en consistente toepassing van een EU/EER of internationale 
standaard voor het ontwerp en de kwaliteitsbeoordeling van seroprevalentiestudies 
om pooling en/of statistische vergelijking van gegevens tussen studies en populaties 
te ondersteunen zou inzicht in de prevalentie tussen landen en bevolkingsgroepen 
sterk verbeteren.
10. Toekomstige seroprevalentie onderzoeken naar HCV moeten tenminste HCV RNA 
meten om ervoor te zorgen dat de gegevens betrekking hebben op viraemische 
chronische infecties en niet alleen op blootstelling aan HCV of geklaarde infectie .
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D) Nationaal beleid
11. Landen moeten (blijven) investeren in harm reduction strategieën en diensten om 
te IDU-verworven HBV/HCV te voorkomen. Injecterend drugsgebruik moet in de 
eerste plaats worden gezien vanuit het beleidsperspectief van de bescherming en 
bevordering van de volksgezondheid (en niet vanuit criminalisering).
12. Landen waar de anti-HCV-prevalentie in de algemene bevolking hoog wordt geschat, 
moeten de haalbaarheid en het nut (en kosten) van geboortecohort screening 
onderzoeken onder mensen geboren in de periode 1945-1965. Er is veel te leren van 
studies in de Verenigde Staten (7-10) en Frankrijk.(11) Van geboorte-cohort (HCV) 
screening is aangetoond dat het waar voor het geld is.(9)
13. Noord/West-Europese EU-Lidstaten met een lage HBsAg prevalentie moeten zich 
richten op (niet-prenatale) screening van migranten geboren in HBV endemische 
landen.
Aanbevelingen en implicaties voor het EU-beleid:
Dit onderzoek vond plaats in het gebied van de EU/EER en de studies die hierin werden 
opgenomen, werden gefinancierd via EU-agentschappen. Dit perspectief en de opgedane 
ervaring heeft geleid tot een aantal bredere beleidsimplicaties en inzichten. Deze 
aanbevelingen hebben tot doel de voortzetting van EU-financiering voor onderzoek en 
actie rond kernthema's en onderwerpen in dit proefschrift te beïnvloeden.
1. De European Medicines Agency en andere gezamenlijke medische 
aanbestedingsmechanismen moeten de gecombineerde koopkracht van de EU te 
gebruiken om te onderhandelen over een betere prijs voor toegang tot interferon-
vrije DAA regimes.
2. Chronische virale hepatitis-infectie moeten expliciet worden genoemd als een van 
de prioriteiten voor actie in het kader van een toekomstig EU-Cross Border Threats 
actiekader.
3. Toekomstige en bestaande EU-Frameworks, agentschappen en andere 
beleidsmechanismen moeten erop gericht zijn de epidemiologische capaciteit in het 
midden inkomen Lidstaten met name in Centraal- en Oost-Europa op te bouwen waar 
er lacunes zijn in data en een waarschijnlijke hoge last van CHB/CHC.
4. De EU zou, op humanitaire gronden, systemische belemmeringen tot zorg moeten 
verminderen voor ongedocumenteerde migranten, asielzoekers en andere kwetsbare 
groepen. Universele toegang tot gezondheidszorg moet ook worden beschouwd als 
een hoeksteen van een succesvol Cross Border Threats programma.
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5. EU financiering voor volksgezondheid projecten, vooral degenen die gericht zijn op de 
ontwikkeling van een toolkit/instrumenten voor de praktijk zoals HEPscreen, moeten 
een follow-up tranche van de begroting en gefinancierde personeelsinzet bieden voor 
de verspreiding en bewustwording. Deze financiering moet alleen beschikbaar zijn na 
de voltooiing van de instrumenten/toolkit om te zorgen dat het geoormerkt is voor 
de verspreiding van praktijkgerichte resultaten. Dit kan de goedkeuring en het gebruik 
van instrumenten/toolkits geproduceerd als onderdeel van EU health financiering 
verbeteren.
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Amsterdam, Netherlands (Poster)
Holland Fuse: "How to get practice into science?”, Noordwijkhout, Netherlands 
(Elevator Pitch)
European Public Health Association (EUPHA) Annual Conference, Brussels 
(Poster)
European Public Health Association (EUPHA) Annual Conference, Brussels (Oral 
Poster Presentation)
EUPHA Migrant and Ethnic Minority Health, Granada, Spain (Poster)
EUPHA Migrant and Ethnic Minority Health, Granada, Spain (Oral Poster 
Presentation)
HEPscreen Final Conference (project summary presentation), (Satellite to 
HepHIV in Europe) Barcelona, Spain
2013
2013
2013
2013
2014
2014
2014
0.2 ECTS
0.4 ECTS
0.2 ECTS
0.3 ECTS
0.2 ECTS
0.3 ECTS
0.5 ECTS
(Inter)national conferences
European Association for the Study of the Liver (EASL) Annual Conference
Holland Fuse: "How to get practice into science?”, Noordwijkhout, Netherlands
European Public Health Association (EUPHA) Annual Conference, Brussels, 
Belgium
EUPHA Migrant and Ethnic Minority Health, Granada, Spain
HepHIV in Europe, Barcelona, Spain
HEPscreen Final Conference
2013
2013
2013
2014
2014
2014
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
1 ECTS
Supervising Master’s theses
VUMC MSc. thesis supervision 2014 100 hours
TOWARDS
THE ELIMINATION
OF CHRONIC VIRAL
HEPATITIS IN EUROPE
Prevalence, Risk Groups and Screening Strategies
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INVITATION 
To attend the public defence 
of my PhD thesis entitled:
TOWARDS
THE ELIMINATION
OF CHRONIC VIRAL
HEPATITIS IN EUROPE
Prevalence, Risk Groups and 
Screening Strategies
Friday 20th April 2017 at 11.30am 
Senaatszaal, Woudestein Campus 
Erasmus University Rotterdam
Burgemeester Oudlaan 50 
3062 PA Rotterdam
Please also join me at a
reception following the defence:
Cum Laude Room
(two floors below the room where 
the defence is to be held)
12.45pm to 2.15pm
ABBY FALLA
Rubensstraat 98 3e
1077 NB Amsterdam
am.falla@rotterdam.nl
abby.falla@gmail.com
+31 (0) 6 43 25 78 50
PARANIMFEN
Matt Webster 
mr.matt.webster@gmail.com
+31 (0) 6 21 10 82 32
Christine Raiswell
christineraiswell@gmail.com
MAPS NOT ONLY 
REPRESENT THE WORLD,
THEY SHAPE THE 
WAY WE SEE IT
The map used here is the Gall-Peters 
projection of the world. The Gall-Peters 
World Map is an equal area, equal axis, 
equal proportion cylindrical projection 
of Earth with standard parallels at 45 
degrees. This results in a distortion of 
shape; the Earth seems stretched at 
the equator and squashed towards the 
poles. This map has the great advantage 
that all countries are correct in size in 
relation to each other. 
Most modern world maps are based on 
a projection created by the sixteenth-
century cartographer Gerardus Mercator, 
created largely for use in navigation. 
Traditional maps tended to show 
countries incorrectly in proportion to 
one another, exaggerating the size of 
high latitude countries (in North America 
and Europe) and making sub-equator 
regions such as Africa and South Asia 
appear much too small. The Gall-Peters 
projection restores poorer, less powerful 
nations, especially in the global south, to 
their rightful proportions. 
Maps are political.
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